
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" encoding="utf-8"?-->


     <title></title>
<meta http-equiv="Content-Type" content="text/html">

<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_CLCS_cellsource.com_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20210101_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001569340 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->

<div style="display: none">
<ix:header>
 <ix:hidden>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityCentralIndexKey" inside-table="false" id="fact-identifier-0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0001569340</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag" inside-table="false" id="fact-identifier-1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">false</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentFiscalPeriodFocus" inside-table="false" id="fact-identifier-2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span>
  <ix:nonfraction id="xdx2ixbrl0063" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0120" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0129" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0165" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0247" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0251" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0253" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0281" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0289" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0294" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0295" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0297" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0309" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0310" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0311" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0313" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0316" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0317" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0320" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0325" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0326" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0327" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0329" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0332" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0333" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0336" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0341" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0342" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0343" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0345" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0348" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0349" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0352" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0357" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0358" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0359" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0361" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0364" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0365" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0367" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0368" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0380" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0381" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0384" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0389" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0390" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0391" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0393" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0396" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0397" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0398" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0400" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0405" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0406" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0411" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0419" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0424" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0432" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0436" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0440" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0447" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0449" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0451" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0463" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0464" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0465" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0467" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0470" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0471" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0474" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0488" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0489" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0490" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0492" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0495" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0496" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0497" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0499" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0502" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0503" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0504" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0506" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0509" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0513" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0514" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0520" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0521" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0522" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0524" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0527" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0528" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0531" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0543" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0544" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0547" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0552" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0553" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0554" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0556" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0559" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0560" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0561" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0563" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0566" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0567" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0568" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0569" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0608" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0615" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0620" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0624" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0674" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0683" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0686" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0696" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0698" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0722" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0731" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0735" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0747" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0750" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0752" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0756" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0759" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0762" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0765" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0768" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0771" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0776" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0779" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0782" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0785" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0788" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0791" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0794" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0919" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0923" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0929" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0931" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0937" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0939" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0945" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0947" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0959" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0971" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0975" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0977" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0987" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0999" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1001" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1007" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1009" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1017" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonnumeric id="xdx2ixbrl1113">P5Y</ix:nonnumeric>
  <ix:nonfraction id="xdx2ixbrl1171" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1257" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1265" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1273" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1280" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonnumeric format="ixt-sec:duryear" id="xdx2ixbrl1320">5</ix:nonnumeric>
  <ix:nonnumeric id="xdx2ixbrl1335">P5Y</ix:nonnumeric>
  <ix:nonnumeric format="ixt-sec:duryear" id="xdx2ixbrl1349">5</ix:nonnumeric>
  <ix:nonnumeric format="ixt-sec:duryear" id="xdx2ixbrl1365">5</ix:nonnumeric>
  <ix:nonnumeric id="xdx2ixbrl1384">P5Y</ix:nonnumeric>
  <ix:nonnumeric id="xdx2ixbrl1392">P5Y</ix:nonnumeric>
  <ix:nonnumeric id="xdx2ixbrl1400">P5Y</ix:nonnumeric>
  <ix:nonnumeric id="xdx2ixbrl1409">P5Y</ix:nonnumeric>
  <ix:nonfraction id="xdx2ixbrl1529" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1530" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1569" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1578" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1579" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1826" unitref="USDPShares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1842" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1850" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1941" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1943" unitref="USDPShares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1955" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1963" unitref="USD" xs:nil="true"></ix:nonfraction>
  </ix:hidden>
 <ix:references>
  <link:schemaref xlink:href="clcs-20211231.xsd" xlink:type="simple">
  </link:schemaref></ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesAConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesAConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesCConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesCConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesPayableRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">CLCS:ConvertibleNotesPayableRelatedPartiesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleNotesPayableRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">CLCS:ConvertibleNotesPayableRelatedPartiesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesAConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesCConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesAConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesCConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesAConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesCConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesAConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesCConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesAConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesCConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-04-15_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2022-01-01</xbrli:startdate>
        <xbrli:enddate>2022-04-15</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_OptionPricingMethodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">CLCS:OptionPricingMethodMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionPricingMethodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">CLCS:OptionPricingMethodMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_IsraeliShekelMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">CLCS:IsraeliShekelMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_IsraeliShekelMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">CLCS:IsraeliShekelMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_IsraeliShekelMember_custom_WeightedAveragesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">CLCS:IsraeliShekelMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RestatementAxis">CLCS:WeightedAveragesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_IsraeliShekelMember_custom_WeightedAveragesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">CLCS:IsraeliShekelMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RestatementAxis">CLCS:WeightedAveragesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_IsraeliShekelMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">CLCS:IsraeliShekelMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_IsraeliShekelMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">CLCS:IsraeliShekelMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_IsraeliShekelMember_custom_WeightedAveragesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">CLCS:IsraeliShekelMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RestatementAxis">CLCS:WeightedAveragesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_IsraeliShekelMember_custom_WeightedAveragesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:ConsolidatedEntitiesAxis">CLCS:IsraeliShekelMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RestatementAxis">CLCS:WeightedAveragesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CLCS:StockOptionsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CLCS:StockOptionsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CLCS:ConvertibleNotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CLCS:ConvertibleNotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">CLCS:AccruedInterestMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">CLCS:AccruedCompensationMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">CLCS:AccruedInterestMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">CLCS:AccruedCompensationMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">CLCS:AccruedInterestMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">CLCS:AccruedCompensationMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">CLCS:AccruedInterestMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">CLCS:AccruedCompensationMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">CLCS:AccruedInterestMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">CLCS:AccruedCompensationMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-052020-05-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-05-05</xbrli:startdate>
        <xbrli:enddate>2020-05-06</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:NotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:NotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NoteholderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">CLCS:NoteholderMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">CLCS:NotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_NotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">CLCS:NotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-15_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:PromissoryNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-142020-04-15_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:PromissoryNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-04-14</xbrli:startdate>
        <xbrli:enddate>2020-04-15</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:PromissoryNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:PromissoryNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:PromissoryNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-15_custom_PromissoryNoteOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:PromissoryNoteOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-142020-04-15_custom_PromissoryNoteOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:PromissoryNoteOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-04-14</xbrli:startdate>
        <xbrli:enddate>2020-04-15</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_PromissoryNoteOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:PromissoryNoteOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-282020-07-29_custom_PromissoryNoteOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:PromissoryNoteOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-28</xbrli:startdate>
        <xbrli:enddate>2020-07-29</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-09_custom_NotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:NotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-072021-11-09_custom_NotesPayableMember_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:NotesPayableMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesCConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-07</xbrli:startdate>
        <xbrli:enddate>2021-11-09</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotesPayableMember_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:NotesPayableMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesCConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-03_custom_NotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:NotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-24_custom_ThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ThreeConvertibleNotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-202020-02-24_custom_ThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ThreeConvertibleNotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-02-20</xbrli:startdate>
        <xbrli:enddate>2020-02-24</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-11_custom_ConvertibleNotePurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">CLCS:ConvertibleNotePurchaseAgreementsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-082021-03-11_custom_ConvertibleNotePurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">CLCS:ConvertibleNotePurchaseAgreementsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-03-08</xbrli:startdate>
        <xbrli:enddate>2021-03-11</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-29_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-282020-07-29_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-28</xbrli:startdate>
        <xbrli:enddate>2020-07-29</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-28_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-272021-01-28_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-27</xbrli:startdate>
        <xbrli:enddate>2021-01-28</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-28_custom_ConvertibleNotesPayableNewNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNotesPayableNewNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-15_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-20_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-27_custom_TwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:TwoConvertibleNotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-252021-04-27_custom_TwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:TwoConvertibleNotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-04-25</xbrli:startdate>
        <xbrli:enddate>2021-04-27</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-27_custom_TwoConvertibleNotesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:TwoConvertibleNotesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-27_custom_TwoConvertibleNotesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:TwoConvertibleNotesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-11_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-102020-12-11_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-12-10</xbrli:startdate>
        <xbrli:enddate>2020-12-11</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-15_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-102020-12-15_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-12-10</xbrli:startdate>
        <xbrli:enddate>2020-12-15</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-15_custom_ConvertibleNotesPayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNotesPayableOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-102020-12-15_custom_ConvertibleNotesPayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNotesPayableOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-12-10</xbrli:startdate>
        <xbrli:enddate>2020-12-15</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesPayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNotesPayableOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ConvertibleNotesPayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNotesPayableOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-04-15_custom_ConvertibleNotesPayableOneMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNotesPayableOneMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2022-01-01</xbrli:startdate>
        <xbrli:enddate>2022-04-15</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-152020-01-03_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-12-15</xbrli:startdate>
        <xbrli:enddate>2020-01-03</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-03_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-01_custom_ConvertibleNotesPayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNotesPayableOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-10_custom_ConvertibleNotesPayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNotesPayableOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-01-10</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-06_custom_ConvertibleNotesPayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNotesPayableOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2020-07-06</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-06_custom_ConvertibleNotesPayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNotesPayableOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesPayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNotesPayableTwoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ConvertibleNotesPayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNotesPayableTwoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ConvertibleNotesPayableTwoMember_custom_AccruedInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNotesPayableTwoMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">CLCS:AccruedInterestMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesPayableTwoMember_custom_AccruedInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNotesPayableTwoMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">CLCS:AccruedInterestMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesPayableTwoMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:ConvertibleNotesPayableTwoMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-012020-03-02_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-03-01</xbrli:startdate>
        <xbrli:enddate>2020-03-02</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-02_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-012020-03-02_custom_SoaveNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:SoaveNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-03-01</xbrli:startdate>
        <xbrli:enddate>2020-03-02</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-152020-06-18_custom_SoaveNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:SoaveNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-06-15</xbrli:startdate>
        <xbrli:enddate>2020-06-18</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-152020-06-18_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-06-15</xbrli:startdate>
        <xbrli:enddate>2020-06-18</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-18_custom_SoaveNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">CLCS:SoaveNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-03_custom_MsSoaveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLCS:MsSoaveMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-12-01</xbrli:startdate>
        <xbrli:enddate>2020-12-03</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-03_custom_MsSoaveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLCS:MsSoaveMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-03_custom_MsSoaveMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLCS:MsSoaveMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-03_custom_MsSoaveMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLCS:MsSoaveMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">CLCS:BoardOfDirectorsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MsSoaveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLCS:MsSoaveMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MsSoaveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLCS:MsSoaveMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotesIssuedOnMarch26TwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NotesIssuedOnMarch26TwoThousandFifteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NotesIssuedOnMarch26TwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NotesIssuedOnMarch26TwoThousandFifteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NoteIssuedOnMay15TwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NoteIssuedOnMay15TwoThousandFifteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NoteIssuedOnMay15TwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NoteIssuedOnMay15TwoThousandFifteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NoteIssuedOnMay10TwoThousandSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NoteIssuedOnMay10TwoThousandSixteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NoteIssuedOnMay10TwoThousandSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NoteIssuedOnMay10TwoThousandSixteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotesIssuedOnVariousDatesFromJuly20TwoThousandSixteenToOctober13TwoThousandSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NotesIssuedOnVariousDatesFromJuly20TwoThousandSixteenToOctober13TwoThousandSixteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NotesIssuedOnVariousDatesFromJuly20TwoThousandSixteenToOctober13TwoThousandSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NotesIssuedOnVariousDatesFromJuly20TwoThousandSixteenToOctober13TwoThousandSixteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NoteIssuedOnFebruaryTwentySixTwoThousandEightteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NoteIssuedOnFebruaryTwentySixTwoThousandEightteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NoteIssuedOnFebruaryTwentySixTwoThousandEightteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NoteIssuedOnFebruaryTwentySixTwoThousandEightteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NoteIssuedOnJulyTwentyNineTwoThousandNinteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NoteIssuedOnJulyTwentyNineTwoThousandNinteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NoteIssuedOnJulyTwentyNineTwoThousandNinteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NoteIssuedOnJulyTwentyNineTwoThousandNinteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NoteIssuedOnNovemberTwentySixTwoThousandFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NoteIssuedOnNovemberTwentySixTwoThousandFourteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NoteIssuedOnNovemberTwentySixTwoThousandFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NoteIssuedOnNovemberTwentySixTwoThousandFourteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotesIssuedOnJuly202015TwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NotesIssuedOnJuly202015TwoThousandFifteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NotesIssuedOnJuly202015TwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:NotesIssuedOnJuly202015TwoThousandFifteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesIssuedOnOctober7TwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedOnOctober7TwoThousandFifteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleNotesIssuedOnOctober7TwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedOnOctober7TwoThousandFifteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesIssuedOnMay18TwoThousandSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedOnMay18TwoThousandSeventeenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleNotesIssuedOnMay18TwoThousandSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedOnMay18TwoThousandSeventeenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNoteIssuedOnJulyTwentyNineTwentyTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNoteIssuedOnJulyTwentyNineTwentyTwentyMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleNoteIssuedOnJulyTwentyNineTwentyTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNoteIssuedOnJulyTwentyNineTwentyTwentyMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesIssuedBetweenOctoberElevenandOctoberFifteenTwentyTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedBetweenOctoberElevenandOctoberFifteenTwentyTwentyMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleNotesIssuedBetweenOctoberElevenandOctoberFifteenTwentyTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedBetweenOctoberElevenandOctoberFifteenTwentyTwentyMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesIssuedBetweenDecemberElevenandDecemberFifteenTwentyTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedBetweenDecemberElevenandDecemberFifteenTwentyTwentyMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleNotesIssuedBetweenDecemberElevenandDecemberFifteenTwentyTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedBetweenDecemberElevenandDecemberFifteenTwentyTwentyMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesIssuedBetweenJulyEightandDecemberFifteenTwentyTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedBetweenJulyEightandDecemberFifteenTwentyTwentyOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleNotesIssuedBetweenJulyEightandDecemberFifteenTwentyTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedBetweenJulyEightandDecemberFifteenTwentyTwentyOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesIssuedOnMayEighteenTwoThousandSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedOnMayEighteenTwoThousandSeventeenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleNotesIssuedOnMayEighteenTwoThousandSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedOnMayEighteenTwoThousandSeventeenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesIssuedOnOctoberTwentyEightTwoThousandNineteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedOnOctoberTwentyEightTwoThousandNineteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleNotesIssuedOnOctoberTwentyEightTwoThousandNineteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">CLCS:ConvertibleNotesIssuedOnOctoberTwentyEightTwoThousandNineteenMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ConsultingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">CLCS:ConsultingServicesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-26_custom_YedaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">CLCS:YedaMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-02_custom_YedaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">CLCS:YedaMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-252020-11-02_custom_YedaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">CLCS:YedaMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-25</xbrli:startdate>
        <xbrli:enddate>2020-11-02</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">CLCS:ConsultantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NoteholderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">CLCS:NoteholderMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-292020-03-31_custom_SeriesAConvertiblePreferredStockMember_custom_PrivatePlacementMemorandumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesAConvertiblePreferredStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">CLCS:PrivatePlacementMemorandumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-29</xbrli:startdate>
        <xbrli:enddate>2020-03-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_SeriesAConvertiblePreferredStockMember_custom_PrivatePlacementMemorandumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesAConvertiblePreferredStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">CLCS:PrivatePlacementMemorandumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesAConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesAConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-26_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesCConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-26_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-242021-07-26_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesCConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-07-24</xbrli:startdate>
        <xbrli:enddate>2021-07-26</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesCConvertiblePreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember24399703">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_WarrantMember24399828">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-13_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-20_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-182020-05-20_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-05-18</xbrli:startdate>
        <xbrli:enddate>2020-05-20</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-19_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-172020-08-19_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-08-17</xbrli:startdate>
        <xbrli:enddate>2020-08-19</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-20_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-172020-08-20_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-08-17</xbrli:startdate>
        <xbrli:enddate>2020-08-20</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-15_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-132020-10-15_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-13</xbrli:startdate>
        <xbrli:enddate>2020-10-15</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-19_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-012020-11-19_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-11-01</xbrli:startdate>
        <xbrli:enddate>2020-11-19</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-172020-11-19_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-11-17</xbrli:startdate>
        <xbrli:enddate>2020-11-19</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_DecemberOneTwoThousandTwentyMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">CLCS:DecemberOneTwoThousandTwentyMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_DecemberOneTwoThousandTwentyMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">CLCS:DecemberOneTwoThousandTwentyMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-12-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-05_custom_JanuaryFiveTwoThousandTwentyOneMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">CLCS:JanuaryFiveTwoThousandTwentyOneMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-032021-01-05_custom_JanuaryFiveTwoThousandTwentyOneMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">CLCS:JanuaryFiveTwoThousandTwentyOneMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-03</xbrli:startdate>
        <xbrli:enddate>2021-01-05</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_DecemberThirtyFirstTwoThousandTwentyOneMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">CLCS:DecemberThirtyFirstTwoThousandTwentyOneMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DecemberThirtyFirstTwoThousandTwentyOneMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">CLCS:DecemberThirtyFirstTwoThousandTwentyOneMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-31_custom_AugustTwoThousandTwentyOneMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">CLCS:AugustTwoThousandTwentyOneMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_AugustTwoThousandTwentyOneMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">CLCS:AugustTwoThousandTwentyOneMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-08_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-08_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember24401546">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockOptionsMember24401578">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">CLCS:StockOptionsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">CLCS:ExercisePriceOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">CLCS:ExercisePriceOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">CLCS:ExercisePriceTwoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">CLCS:ExercisePriceTwoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">CLCS:ExercisePriceThreeMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">CLCS:ExercisePriceThreeMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember24401984">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockOptionsMember_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">CLCS:StockOptionsMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">CLCS:ExercisePriceOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockOptionsMember_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">CLCS:StockOptionsMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">CLCS:ExercisePriceOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockOptionsMember_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">CLCS:StockOptionsMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">CLCS:ExercisePriceTwoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockOptionsMember_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">CLCS:StockOptionsMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">CLCS:ExercisePriceTwoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">CLCS:StockOptionsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_MinimumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_MaximumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_YedaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">CLCS:YedaMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_YedaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">CLCS:YedaMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_YedaResearchAndLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">CLCS:YedaResearchAndLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_YedaResearchAndLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">CLCS:YedaResearchAndLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_YedaResearchAndLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">CLCS:YedaResearchAndLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_YedaResearchAndLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">CLCS:YedaResearchAndLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-28_custom_SponsoredResearchAgreementMember_custom_FromJanuaryOneTwoThousandNineteenToDecemberThirtyOneTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">CLCS:SponsoredResearchAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">CLCS:FromJanuaryOneTwoThousandNineteenToDecemberThirtyOneTwoThousandTwentyOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SponsoredResearchAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">CLCS:SponsoredResearchAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SponsoredResearchAgreementMember_custom_FromJanuaryOneTwoThousandNineteenToDecemberThirtyOneTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">CLCS:SponsoredResearchAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">CLCS:FromJanuaryOneTwoThousandNineteenToDecemberThirtyOneTwoThousandTwentyOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SponsoredResearchAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">CLCS:SponsoredResearchAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">CLCS:SponsoredResearchAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MDAndersonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">CLCS:MDAndersonMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MDAndersonSponsoredResearchAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">CLCS:MDAndersonSponsoredResearchAgreementsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_MDAndersonSponsoredResearchAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">CLCS:MDAndersonSponsoredResearchAgreementsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MDAndersonSponsoredResearchAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">CLCS:MDAndersonSponsoredResearchAgreementsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-01-01</xbrli:startdate>
        <xbrli:enddate>2019-01-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2019-10-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CourtOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">CLCS:CourtOfficerMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-282022-03-31_custom_SeriesCConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">CLCS:SeriesCConvertiblePreferredStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2022-03-28</xbrli:startdate>
        <xbrli:enddate>2022-03-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-282022-03-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2022-03-28</xbrli:startdate>
        <xbrli:enddate>2022-03-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-10_us-gaap_SubsequentEventMember_custom_MrVerstraeteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">CLCS:MrVerstraeteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-15_us-gaap_SubsequentEventMember_custom_MrVerstraeteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">CLCS:MrVerstraeteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-15_us-gaap_SubsequentEventMember_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-04-15_us-gaap_SubsequentEventMember_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2022-01-01</xbrli:startdate>
        <xbrli:enddate>2022-04-15</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-15_us-gaap_SubsequentEventMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001569340</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitnumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitnumerator>
        <xbrli:unitdenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitdenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromrefs="Fact000867" torefs="Footnote000878 Footnote000881"></ix:relationship>
  <ix:relationship fromrefs="Fact000869" torefs="Footnote000878 Footnote000881"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington
D. C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_907_edei--DocumentType_c20210101__20211231_zeUaR3ntD5Nj"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentType" inside-table="false" id="fact-identifier-3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_90B_edei--DocumentAnnualReport_c20210101__20211231_zHnN5oUMm30f"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport" inside-table="true" id="fact-identifier-4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
    OF 1934</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">For the year ended <span id="xdx_909_edei--DocumentPeriodEndDate_c20210101__20211231_zZPH3baUS749"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" inside-table="true" id="fact-identifier-5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span id="xdx_904_edei--CurrentFiscalYearEndDate_c20210101__20211231_zP3kqi4V5q37"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" inside-table="true" id="fact-identifier-6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">December
    31</ix:nonnumeric></span></span>, <span id="xdx_909_edei--DocumentFiscalYearFocus_c20210101__20211231_zjoAxeFhMOi8"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentFiscalYearFocus" inside-table="true" id="fact-identifier-7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span></span></ix:nonnumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--DocumentTransitionReport_c20210101__20211231_zpkwMJQbxSHa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" inside-table="true" id="fact-identifier-8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the transition period from _____________ to _____________</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number <span id="xdx_901_edei--EntityFileNumber_c20210101__20211231_zEqKipyam6oh"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityFileNumber" inside-table="false" id="fact-identifier-9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">000-55413</ix:nonnumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_903_edei--EntityRegistrantName_c20210101__20211231_zwPWahG5l8A9" style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityRegistrantName" inside-table="false" id="fact-identifier-10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Cell
Source, Inc.</ix:nonnumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20210101__20211231_z97TG5V34LGk"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" inside-table="true" id="fact-identifier-11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Nevada</ix:nonnumeric></span></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20210101__20211231_zBpeGVCMIv4h"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityTaxIdentificationNumber" inside-table="true" id="fact-identifier-12" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32-0379665</ix:nonnumeric></span></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction</span></p>
                                                         <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
                                            incorporation or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
                                                         <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
                                            No.)</span></p></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_903_edei--EntityAddressAddressLine1_c20210101__20211231_zer4P3ybBES6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine1" inside-table="false" id="fact-identifier-13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57
West 57<sup>th</sup> Street</ix:nonnumeric></span></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20210101__20211231_z6LZL3hChOy2"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine2" inside-table="false" id="fact-identifier-14" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Suite
400</ix:nonnumeric></span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_90C_edei--EntityAddressCityOrTown_c20210101__20211231_zxHwZVTxYBv4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressCityOrTown" inside-table="false" id="fact-identifier-15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">New
York</ix:nonnumeric></span></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20210101__20211231_zi32NnfKnBJ4"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressStateOrProvince" inside-table="false" id="fact-identifier-16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">NY</ix:nonnumeric></span>
</span></span></b><b><span id="xdx_903_edei--EntityAddressPostalZipCode_c20210101__20211231_z6gz5ZiEAY0a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressPostalZipCode" inside-table="false" id="fact-identifier-17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10019</ix:nonnumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<span id="xdx_903_edei--CityAreaCode_c20210101__20211231_zeiGxAyYAsEd"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:CityAreaCode" inside-table="false" id="fact-identifier-18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">646</ix:nonnumeric></span></span>)
</b></span><b><span id="xdx_90B_edei--LocalPhoneNumber_c20210101__20211231_zMdnLuu32AUg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:LocalPhoneNumber" inside-table="false" id="fact-identifier-19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">416-7896</ix:nonnumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Issuer’s
telephone number)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    symbol(s)</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; width: 2%"></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(g) of the Act: Common stock, $0.001 par value</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act. ☐&nbsp;Yes ☒&nbsp;<span id="xdx_90B_edei--EntityWellKnownSeasonedIssuer_c20210101__20211231_z6ouqkLYcQi8"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityWellKnownSeasonedIssuer" inside-table="false" id="fact-identifier-20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ☐&nbsp;Yes
☒&nbsp;<span id="xdx_906_edei--EntityVoluntaryFilers_c20210101__20211231_z1SHG9Bi2aV7"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityVoluntaryFilers" inside-table="false" id="fact-identifier-21" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. ☒&nbsp;<span id="xdx_90A_edei--EntityCurrentReportingStatus_c20210101__20211231_zv47QI62xuyk"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityCurrentReportingStatus" inside-table="false" id="fact-identifier-22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">☐&nbsp;No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). ☒&nbsp;<span id="xdx_90E_edei--EntityInteractiveDataCurrent_c20210101__20211231_zpCxiasgK5m5"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityInteractiveDataCurrent" inside-table="false" id="fact-identifier-23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">☐&nbsp;No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer ☐</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer ☐</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--EntityFilerCategory_c20210101__20211231_znDwBxLeoqKh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" inside-table="true" id="fact-identifier-24" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Non-accelerated
    filer</ix:nonnumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">☒</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_905_edei--EntitySmallBusiness_c20210101__20211231_zeXMzvMachW1"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness" inside-table="true" id="fact-identifier-25" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_907_edei--EntityEmergingGrowthCompany_c20210101__20211231_zQTewrg9AtUj"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" inside-table="true" id="fact-identifier-26" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for completing
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;☐</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by the check mark whether the registration has filed a report on and attestation to its management’s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.&nbsp;<span id="xdx_904_edei--IcfrAuditorAttestationFlag_c20210101__20211231_zEyv2sVGMeKe"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag" inside-table="false" id="fact-identifier-27" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act) ☐&nbsp;Yes ☒&nbsp;<span id="xdx_90C_edei--EntityShellCompany_c20210101__20211231_zk45R944NZH7"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany" inside-table="false" id="fact-identifier-28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2021, the aggregate market value of the issued and outstanding common stock held by non-affiliates of the registrant was
$<span id="xdx_907_edei--EntityPublicFloat_iI_c20210630_z1Sreb1kYlca"><span><ix:nonfraction name="dei:EntityPublicFloat" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45,701,873</ix:nonfraction></span></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">based
on the closing sale price as reported on the OTCQB Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 11, 2022, there were <span id="xdx_903_edei--EntityCommonStockSharesOutstanding_iI_c20220411_z4oRCsvqPug7"><span><ix:nonfraction name="dei:EntityCommonStockSharesOutstanding" contextref="AsOf2022-04-11" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,437,076</ix:nonfraction></span></span> shares of common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOCUMENTS
INCORPORATED BY REFERENCE -</b> <span id="xdx_904_edei--DocumentsIncorporatedByReferenceTextBlock_c20210101__20211231_zYJ35jZvoXT2" title="Documents Incorporated by Reference"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">None</ix:nonnumeric></span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CELL
SOURCE, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
10-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE FISCAL YEAR ENDED DECEMBER 31, 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_001" tabindex="18">PART
    I</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002" tabindex="18">Business.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003" tabindex="18">Risk
    Factors.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004" tabindex="18">Unresolved
    Staff Comments.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005" tabindex="18">Properties.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006" tabindex="18">Legal
    Proceedings.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007" tabindex="18">Mine
    Safety Disclosures.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_008" tabindex="18">PART
    II</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009" tabindex="18">Market
    for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010" tabindex="18">[Reserved]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011" tabindex="18">Management’s
    Discussion and Analysis of Financial Condition and Results of Operations.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012" tabindex="18">Quantitative
    and Qualitative Disclosures About Market Risk.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013" tabindex="18">Financial
    Statements and Supplementary Data.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014" tabindex="18">Changes
    in and Disagreements With Accountants on Accounting and Financial Disclosure.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015" tabindex="18">Controls
    and Procedures.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016" tabindex="18">Other
    Information.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017" tabindex="18">Disclosure
    Regarding Foreign Jurisdictions that Prevent Inspections.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_018" tabindex="18">PART
    III</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019" tabindex="18">Directors,
    Executive Officers and Corporate Governance.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020" tabindex="18">Executive
    Compensation.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021" tabindex="18">Security
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022" tabindex="18">Certain
    Relationships and Related Transactions, and Director Independence.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023" tabindex="18">Principal
    Accounting Fees and Services.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_024" tabindex="18">PART
    IV</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_025" tabindex="18">Exhibits,
    Financial Statement Schedules.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_026" tabindex="18">Form
    10-K Summary.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_027" tabindex="18">Signatures</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTE REGARDING FORWARD LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K contains forward-looking statements regarding, among other things, our anticipated financial and operating
results. Forward-looking statements reflect our management’s current assumptions, beliefs, and expectations. Words such as “anticipate,”
“believe,” “estimate,” “seek,” “expect,” “intend,” “could,” “plan,”
and similar expressions are intended to identify forward-looking statements. While we believe that the expectations reflected in our
forward-looking statements are reasonable, we can give no assurance that such expectations will prove correct. Forward-looking statements
are subject to risks and uncertainties that could cause our actual results to differ materially from the future results, performance,
or achievements expressed in or implied by any forward-looking statement we make. Some of the relevant risks and uncertainties that could
cause our actual performance to differ materially from the forward-looking statements contained in this report are discussed below under
the heading “Risk Factors” and elsewhere in this Annual Report on Form 10-K. We caution investors that these discussions
of important risks and uncertainties are not exclusive, and our business may be subject to other risks and uncertainties which are not
detailed there. Investors are cautioned not to place undue reliance on our forward-looking statements. We make forward-looking statements
as of the date on which this Annual Report on Form 10-K is filed with the U.S. Securities and Exchange Commission (“SEC”),
and we assume no obligation to update the forward-looking statements after the date hereof whether as a result of new information or
events, changed circumstances, or otherwise, except as required by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Principal Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business operations are subject to numerous risks, factors and uncertainties, including those outside our control that could cause our
actual results to be harmed, including risks regarding the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Business and Industry</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not receive regulatory approvals for our product candidates or there may be a delay in
                                            obtaining such approvals.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
                                            trials for our product candidates are expensive and time consuming and their outcome is uncertain.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be required to suspend or discontinue clinical trials due to unexpected side effects
                                            or safety risks.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delays
                                            in our clinical trials could delay our ability to obtain regulatory approval and our ability
                                            to commercialize our products.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            results of our clinical trial are uncertain and could substantially delay or prevent us from
                                            bringing products to market.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
                                            studies and Phase 1 or 2 clinical trials of our product candidates may not predict the results
                                            of subsequent human trials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            clinical trials may fail to demonstrate evidence substantial evidence of the safety and efficacy
                                            of our product candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are subject to various government regulations, may become subject to increased government
                                            regulation and may fail to comply with regulatory requirements.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
                                            approval of our product candidates may be withdrawn at any time.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
                                            if approved, our products may not gain market acceptance.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            do not own any patents and rely on the patents we license from Yeda Research and Development
                                            Company Limited.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            success will depend in part on our ability to obtain and maintain patent protection for the
                                            patents we license.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidentiality
                                            agreements may not prevent unauthorized disclosure of trade secrets or proprietary information.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are dependent on collaborative partners and service providers.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will be unable to operate profitability if we are unable to keep up with rapid technological
                                            developments.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to sell products will depend to a large extent upon reimbursement from insurance
                                            companies.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may expend our limited resources to pursue a particular product candidate or indications
                                            and fail to capitalize on more profitable products or indications.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
                                            trial data that we publish may change as more patient data becomes available.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            rely on key personnel.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be subject to foreign exchange fluctuations.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be subject to potential product and clinical trials liability and liabilities related
                                            to working with hazardous materials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            we conduct clinical trials outside of the United States, the FDA may not accept data from
                                            such trials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            outbreak of COVID-19 could adversely affect our pre-clinical studies and subsequent clinical
                                            trials.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Capital Resources and Impairments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have a limited operating history and a history of operating losses and expect to incur significant
                                            additional losses.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will need to secure additional financing.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            is substantial doubt about our ability to continue as a going concern.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are an early stage company with an unproven business strategy.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are in default of payment obligations under promissory notes.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may issue additional shares of preferred stock in the future.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            is not an active liquid trading market for our Common Stock.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not be able to attract the attention of brokerage firms because we became a public company
                                            by means of a reverse acquisition.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting
                                            power of our shareholders is highly concentrated in insiders.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            do not intend to pay dividends on our Common Stock for the foreseeable future.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
                                            may be diluted by future issuances of Common Stock.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            an issuer of “penny stock”, protection provided by federal securities laws relating
                                            to forward looking statements does not apply to us.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to use net operating loss carryforwards may be limited.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            issuance of Common Stock upon exercise of warrants or options may depress the price of our
                                            Common Stock.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
General Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable
                                            regulatory requirements may make it difficult to retain or attract qualified directors and
                                            officers.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            stock price could be adversely affected if we fail to maintain effective internal controls
                                            over financial reporting.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
                                            to comply with the Sarbanes-Oxley Act of 2002 could harm our business and stock price.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            stock price may decline or be volatile, regardless of our operating results.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            quarterly operating results may fluctuate significantly or fall below expectations of investors
                                            or securities analysts.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            a result of reduced disclosure requirements applicable to a “smaller reporting company,”
                                            the information we provide to investors may be different than information provided by other
                                            public companies.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            could be subject to securities class action litigation.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>ITEM
1. BUSINESS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Overview</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
Business</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a cell therapy company focused on immunotherapy. Since our inception, we have been involved with the development of proprietary immune
system management technology (“Cell Source technology”) licensed from Yeda Research &amp; Development Company Limited
(“Yeda”), the commercial arm of the Weizmann Institute of Science (“Weizmann Institute”) in Israel. The current
focus of our Research and Development efforts is at the University of Texas MD Anderson Cancer Center (“MD Anderson”) in
Houston, Texas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
technology addresses one of the most fundamental challenges within human immunology: how to tune the immune response such that it tolerates
selected desirable foreign cells, but continues to attack all other (undesirable) targets. In simpler terms, a number of potentially
life-saving treatments have limited effectiveness today because the patient’s immune system rejects them. For example, while HSCT
- hematopoietic stem cell transplantation (e.g. bone marrow transplantation) has become a preferred therapeutic approach for treating
blood cell cancer, most patients do not have a matched family donor. Although matched unrelated donors and cord blood can each provide
an option for such patients, haploidentical stem cell transplants (sourced from partially mismatched family members) are rapidly gaining
favor as a treatment of choice. This is still a risky and difficult procedure primarily due to potential conflicts between host and donor
immune systems and as well as viral infections that often follow even successful HSCT while the compromised new immune system works to
reconstitute itself by using the transplanted stem cells. Today, rejection is partially overcome using aggressive immune suppression
treatments that leave the patient exposed to many dangers by compromising their immune system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unique advantage of Cell Source technology lies in the ability to induce sustained tolerance of transplanted cells (or organs) by the
recipient’s immune system in a setting that requires only mild immune suppression, while avoiding the most common transplant related
complications. The scientific term for inducing such tolerance in a transplantation setting is chimerism, where the recipient’s
immune system tolerates the co-existence of the (genetically different) donor type and host (recipient) type cells. Attaining sustained
chimerism is an important prerequisite to achieving the intrinsic GvL (graft versus leukemia) effect of HSCT and supporting the
reconstitution of normal hematopoiesis (generation of blood cells, including those that protect healthy patients from cancer) in blood
cancer patients. Preclinical data, as well as initial clinical data show that Cell Source’s Veto Cell technology (currently in
a trial in the US) can provide superior results in allogeneic (donor-derived) HSCT by allowing for haploidentical stem cell transplants
under a mild conditioning regimen, while avoiding the most common post-transplant complications. Combining this with CAR (Chimeric Antigen
Receptor) T cell therapy employing Veto Cells, as a VETO CAR-T treatment, we will be able to treat patients in relapse as well as those
in remission and use the cancer killing power of CAR-T to protect the patient while their immune system fully reconstitutes, thus providing
an end-to-end solution for blood cancer treatment by potentially delivering a fundamentally safer and more effective allogeneic HSCT:
prevention of relapse; avoidance of graft versus host disease (GvHD); prevention of viral infections; and enhanced persistence of GvL
effect. This means that the majority of patients will be able to find a donor, and will have access to a potentially safer procedure
with higher long term survival rates than what either donor-derived HSCT or autologous CAR-T each on their own currently provide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability to induce permanent chimerism (and thus sustained tolerance) in patients – which allows the transplantation to overcome
rejection without having to compromise the rest of the immune system - may open the door to effective treatment of a number of severe
medical conditions, in addition to blood cancers, which are characterized by this need. These include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            broader set of cancers, including solid tumors, that can potentially be treated effectively
                                            using genetically modified cells such as CAR-T cell therapy, but also face efficacy and economic
                                            constraints due to limited persistence based on immune system issues (i.e., the need to be
                                            able to safely and efficiently deliver allogeneic CAR-T therapy). Inducing sustained tolerance
                                            to CAR-T cells may bring reduced costs and increased efficacy by allowing for off-the-shelf
                                            (vs. patient-derived) treatments with more persistent cancer killing capability.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organ
                                            failure and transplantation. A variety of conditions can be treated by the transplantation
                                            of vital organs. However, transplantation is limited both by the insufficient supply of available
                                            donor organs and the need for lifelong, daily anti-reject treatments post-transplant. Haploidentical
                                            organ transplants, with sustained chimerism, have the potential to make life saving transplants
                                            accessible to the majority of patients, with the prospect of improved life quality and expectancy.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-malignant
                                            hematological conditions (such as type one diabetes and sickle cell anemia) which could,
                                            in many cases, also be more effectively treated by stem cell transplantation if the procedure
                                            could be made safer and more accessible by inducing sustained tolerance in the stem cell
                                            transplant recipient.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Corporate
History</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
Source, Inc. (the “Company”) is a Nevada corporation formed on June 6, 2012 under the name Ticket to See, Inc. (“TTSI”).
Cell Source Ltd. (“Cell Source Israel”) was founded in 2011 in order to commercialize a suite of inventions that were the
result of over ten (10) years of research at the Weizmann Institute. Pursuant to a Research and License Agreement by and between Cell
Source Israel and Yeda, dated October 3, 2011, as amended in April, 2014, November, 2016, March, 2018, August 2019, December, 2019, November,
2020, and December, 2021 (the “Yeda License Agreement”), Yeda, the commercial arm of the Weizmann Institute, granted Cell
Source Israel an exclusive, worldwide license to certain patents, discoveries, inventions, and other intellectual property generated
(together with others) by Yair Reisner, Ph.D. (“Dr. Reisner”), former head of the Immunology Department at the Weizmann Institute.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Implications
of being a Smaller Reporting Company</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a company with less than $100 million in revenue during our last fiscal year and a public float of less than $250 million, we qualify
as a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K. A “smaller reporting company”
may take advantage of reduced reporting requirements and disclosure obligations that are otherwise applicable to public companies. These
provisions include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.27in"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
                                            permitted to present only two years of audited financial statements and only two years of
                                            related Management’s Discussion &amp; Analysis of Financial Condition and Results of
                                            Operations in this report on Form 10-K;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
                                            being required to comply with the auditor attestation requirements of Section 404 of the
                                            Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
                                            disclosure obligations regarding executive compensation in our periodic reports, proxy statements
                                            and registration statements.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have elected to take advantage of certain of the reduced disclosure obligations and may elect to take advantage of other reduced reporting
requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might receive
from other public reporting companies in which you hold equity interests. Decreased disclosures in our SEC filings due to our status
as a “smaller reporting company” may make it harder for investors to analyze our results of operations and financial prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Hematological
Malignancies</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hematological malignancies (blood cancers) comprise
a variety of lymphomas and leukemias. A very important treatment protocol for these malignancies involves the use of HSCT. To the best
of our knowledge, over 1,500,000 HSCT have been performed worldwide with the annual number of procedures approaching 100,000 (table below).
Our technology has immediate relevance for, at a minimum, the roughly 40,000 worldwide stem cell transplants that are allogeneic (using
cells taken from another individual, not the patient). According to the Center for International Blood and Marrow Transplant Research
(“CIMBTR”), there were 8,326 allogeneic stem cell transplants in the US in 2020.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 7; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" style="height: 348.75pt; width: 464.25pt" data-src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_001.jpg" src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_001.jpg"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source:
American Society of Hematology</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">HSCT often has a curative effect when successful.
However, it is very risky. HSCT typically involves destroying the patient’s native immune system with radiation or chemotherapy
(myeloablation) before the transplantation, and then suppressing immune response (immunosuppression) with drugs to manage the conflicts
between host and donor cells. The majority of patients are unable to find a matched family donor. Over 50% of all adult haploidentical
transplant patients in the US suffering from AML (the most common indication for allogeneic HSCT) die within three years of transplantation.
Among adult patients receiving haploidentical HSCT, of those who die in the first 100 days post-transplant, 35% die from either infections
(associated with a compromised immune system), graft rejection or GvHD (Graft versus Host Disease).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 8; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_011.jpg" src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_011.jpg"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Myeloablation
and immunosuppression are dangerous and difficult to tolerate, especially in patients over age 50. Therefore, HSCT has been used mainly
with younger patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Another
very important treatment protocol for blood cancers is CAR-T cell therapy. This novel approach uses the patient’s own immune system
cells to directly attack cancer cells. CAR-T cells are made by removing a specific set of cells from the blood, genetically modifying
them in order to intensify the immune system’s natural response to cancer, and then re-injecting them into the patient. This form
of cellular therapy has produced exceptional near term results in blood cancer patients and is currently being tested against a variety
of different cancer types.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAR
T-cell therapy has been approved by the U.S. Food and Drug Administration as standard therapy for some patients with lymphoma (drug names
Yescarta, Kymriah, Tecartus and Breyanzi), leukemia (drug name Kymriah) and multiple myeloma (drug names Abecma and Carvykti).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
approved treatments use the patient’s own cells in order to create CAR-T cells, which involves high cost (between $373,000 and
$475,000 per infusion) and significant safety risks (e.g. high rate of relapse, significant incidence of Cytokine Release Syndrome (CRS)).
While a number of companies are attempting to develop allogeneic or “off-the-shelf” CAR-T, they face several challenges including
rejection by the host’s immune system and GvHD. The currently approved CAR-T treatments, while showing high early response rates,
have not shown long term survival results for blood cancer that exceed those of allogeneic HSCT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
means that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">many
                                            blood cancer patients are not candidates for the primary treatment (HSCT) that represents
                                            a potential cure;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
                                            is high mortality among those patients who are candidates for HSCT and do undergo the procedure;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAR-T
                                            cell therapy, which is currently used in limited indications and has had relatively slow
                                            adoption, has yet to demonstrate long term survival that substantively exceeds that of HSCT.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is widespread awareness of the need for improved immune-system management technologies for HSCT - both to improve outcomes of transplantations
for the traditional target set of patients and to expand the use of the procedure by making transplantation safe enough to become appropriate
for a broader set of patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is also a strong awareness for the need of an off-the-shelf approach to CAR-T that overcomes rejection, avoids GvHD, and has increased
persistence so as to deliver longer-term efficacy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 9; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
aspire to use VETO CAR-T, combining Veto Cell technology with allogeneic CAR-T cell therapy, to dramatically improve the outcomes of
the allogeneic transplantations already being performed, and thereby to rapidly penetrate the current market. However, our target population
greatly exceeds those patients who currently undergo HSCT or CAR-T, as the firm’s tolerizing technology could potentially make
allogeneic transplantation and off-the-shelf CAR-T an option for a much larger proportion of the diseased population. The following table
shows the incidence of the specific hematological malignancies on which we will focus:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><br>Initial
                                            Malignancy Indications</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(note
                                            estimates for North America and EU only)</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incidence</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Annual
                                            New Cases)</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Annual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HSCT</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Lymphoma</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">225,241</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,505</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Leukemia</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">156,898</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,423</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Multiple
    Myeloma</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">83,868</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38424</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">466,007</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">87,352</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source:
National Cancer Institute, World Health Organization, Leukemia &amp; Lymphoma Society, Lymphoma</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coalition
Europe, EMBT, HRSA, CIMBTR</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of this document, it is assumed that the immediate candidates for Cell Source-enabled HSCT will be the subset of cancer
patients that today receive transplantations as part of their cancer treatment (rightmost column in table above). We believe that a portion
of these patients will benefit from Veto Cell adjunct therapy, as such therapy aspires to improve the success and reduce the risk and
mortality of a procedure that they are having anyway. With time, as Veto Cell treatment becomes more widespread and data is accumulated,
we believe that the percentage of patients that will be referred for Veto Cell enabled HSCT will increase significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is also important to note that incidence of these diseases is increasing. The global market for blood cancer therapeutics was estimated
at $41 billion in 2020 and is projected to increase in size to over $90 billion by 2028 according to <i>Polaris Market Research Blood
Cancer Drugs Market Share, Size, Trends, Industry Analysis Report June</i>. The aging of the US population and the increased incidence
of hematologic malignancies are expected to significantly increase the number of older patients who receive allogeneic HSCT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">HSCT
Market Trends</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are four important market trends affecting the hematological malignancies market:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            noted above, increasing incidence of these disorders, largely driven by the aging population.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improvement
                                            and proliferation of HSCT treatments.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            “virtuous circle” of lowered death rate due to better transplantations leading
                                            to more aggressive focus on HSCT.</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            growing use of milder conditioning regimens, which makes the procedure more survivable for
                                            older patients (see table below).</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_012.jpg" src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_012.jpg"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
despite the above trends, the use of HSCT, especially allogeneic, remains limited because of the risks associated with the myeloablative
treatments required to reduce the host immune response, viral infections and GvHD. This means that the “gold-standard” of
treatment is largely unavailable to an age cohort that constitute a significant proportion of sufferers of these diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company aspires to address this issue in a distinctive manner by significantly reducing the need for myeloablative treatment while avoiding
the risk of GvHD, thereby improving the outlook for allogeneic transplantations and enabling their use in a much larger population set.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 10; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">CAR-T
cell therapy</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the most promising new approaches to treating hematological malignancies is by using genetically modified T cells in treatments such
as CAR-T and TCR. CAR-T cell therapy for blood cancers, which has already been approved by the FDA, has shown the ability to attain remissions
in a significant proportion of those patients treated. That said, the number of patients treated has been relatively low, in part due
to the significant costs associated with this treatment. Since the approved treatment products rely on autologous (patient derived) production
of the CAR-T cells, the costs can run into the hundreds of thousands of dollars for a single treatment, with the cost of the infusion
alone ranging between $373,000 and $475,000 in the US. The broader hope for CAR-T cell therapy is for an allogeneic or “off the
shelf” version that is expected to significantly lower the treatment costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
Source has completed a preclinical proof-of-concept in collaboration with Professor Zelig Eshhar, the inventor of CAR-T cell technology,
combining CAR-T and Veto Cell technology so as to allow for a successful allogeneic approach to CAR-T cell therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Relevant
Non-Malignant Diseases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
Hematological malignancies represent the Company’s initial focus, the Company’s selective immune response blocking technology
may also be effective in treating certain non-malignant organ diseases as well as blood and immune system disorders. This would represent
an additional growth opportunity for the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
target non-malignant diseases are widespread. The Company’s first non-malignant disorder target is expected to be is support of
organ transplantations (kidney, liver, etc.). Approximately 100,000 kidney and 35,000 liver transplants are conducted worldwide
each year. As with bone marrow transplantations, organ transplantations require substantial and ongoing immunosuppression to prevent
rejection. This ongoing treatment is dangerous, quality-of-life and life expectancy reducing, and costly. The Company’s Veto Cell
technology can potentially be used to selectively reduce immune response to the transplanted organ, thus broadening the donor pool and
reducing or possibly eliminating the need for daily, life-long immunosuppression post transplantation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
second target within non-malignant disorders are blood diseases such as sickle cell disease, aplastic anemia, beta thalassemia
and scleroderma. Sickle cell anemia, for example, can be effectively treated by HSCT. However, because of HSCT’s riskiness, the
procedure is currently used only in extreme cases. If successful in enabling safer HSCT, the Company can make this treatment available
to a broader set of sickle cell anemia sufferers. Preclinical data have also shown the potential effectiveness of Veto Cells in preventing
the development of Type 1 Diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Market
Access and Channels</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for stem cell transplantation is relatively concentrated. There are over 1,700 transplantation centers worldwide, of which some
700 are in North America and Western Europe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
relatively small subset of these (often termed “Centers of Excellence”) tends to set the practice standards for the entire
transplantation community. Therefore, as discussed in the “Strategy” section, the Company plans to focus its initial penetration
strategy on a relatively small group of influential centers. There are over 150 centers in the US today that provide CAR-T cell therapy
treatments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimbursement
issues for our therapies are expected to be relatively straightforward. Once clinical effectiveness and regulatory approval are established,
the value-proposition for payors and providers is expected to be clear and compelling. Issues connected with immunosuppression and rejection
constitute a major component of bone marrow transplantation costs, and significant improvement in this area is expected to bring substantive
cost-savings for payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Sector
Focus</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the overall arena of immunotherapy. The cancer immunotherapy market was estimated at approximately $85 billion for 2021 and projected
to grow to over $277 billion by 2030, according to Precedence Research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
the immunotherapy field, our initial focus is on allogeneic therapies (treatments using donor derived-as opposed to patient derived-cells),
with a focus on haploidentical transplantations (transplantations that use cells from partially matched-as opposed to fully matched-donors
and recipients). While potentially valuable, allogeneic therapies are relatively complex, risky, and expensive. A key driver of this
complexity and associated costs is the conflict between host and donor immune systems, as discussed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
technology, which in preclinical studies, as well as in a first-in-human proof of concept, has shown the ability to enable tolerance
of donor cells without affecting other immune processes, is fundamentally enabling. We expect it to significantly increase the safety,
reduce the overall treatment cost, and therefore broaden the scope of indications for such procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 11; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
delivery method for Veto Cell treatments would take the form of a non-invasive cell suspension treatment administered intravenously.
For HSCT treatments, Veto Cells are derived from stem cells taken from the same donor who is providing the stem cells for the transplantation
itself. In the case of VETO CAR-T cell therapy, this will initially be combined with HSCT, but a more generic “off the shelf”
modality offering is planned, which would eventually be marketed as a pre-packaged suspension of cells and medium, prepared and stored
in advance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
Value Drivers</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current positioning in the cancer immunotherapy value chain is typical of an early clinical stage company: developing, validating and
attaining regulatory approvals for the various applications of our technology platforms. Going forward, once the products are commercialized,
physician and patient interest in these treatments is expected to drive insurer reimbursement for patients - a key demand lever. The
generic value chain for biotechnology development commences with an invention which is formulated, patented and successful in pre-clinical
animal trials. We have already passed this stage with our Veto Cell technology platform, for which we have an exclusive license to use
from Yeda, the owner of these patents. We are currently at the stage of human trials (testing both safety and efficacy). Finally, the
offering earns regulatory approval and patient treatment, along with the ensuing revenues, can commence. This can be a particularly lengthy
process in the United States and therefore some medical treatments are approved in Europe or Asia and generate revenues there prior to
commencing U.S. sales. Recently expanded “fast track” regulation in the U.S. is aimed at getting critical treatments for
life threatening conditions to patients more quickly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
successful preclinical validation of the Veto Cell treatment involved basic laboratory research including both in-vivo (live) animal
trials and in-vitro (in a glass dish) human cell trials. This validated the protocol prior to commencing human clinical trials. Human
clinical trials fine-tune the treatment protocol and confirm both safety and efficacy in treating patents. In parallel, the patents on
the core technology go into the national phase in various countries and are emended with claims associated with exact treatment protocols,
bolstering the protection afforded by already issued patents on the base technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, successful biotech companies have been able to capitalize on positive human clinical results (even prior to full approval
for patient treatment) by either signing lucrative non-dilutive distribution option deals or by being partially or fully acquired by
larger market participants. KITE Pharmaceuticals, a CAR-T cell therapy company, was acquired outright by Gilead Sciences in 2017 for
$11.9 billion in cash, prior to having attained FDA approval and prior to commencing any product sales. In 2018, Juno Therapeutics was
acquired by Celgene Corporation for approximately $9 billion, also without having FDA approval for its CAR-T cell therapy technology.
There is no indication or assurance that we are currently under consideration for any option or acquisition deal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently conducting a human clinical trial for approval for the Veto Cell based treatments in the United States. We have
had positive preclinical results for three of our cell therapy treatments. Yeda, the proprietary owners of the patents underlying our
technologies from whom we license our patents, has been granted patents for its original Veto Cell. The revised versions of the Veto
Cell are the subject of patent applications which have been granted in some jurisdictions and are pending in others. These newer patent
applications both leverage the priority of the already granted patents and extend the protection period for more advanced versions. We
are currently engaged in our first human clinical trial. If such trials are successful, they will demonstrate both safety (the patients
survived and were not harmed) and initial indications of efficacy (there are signs of successful engraftment under a mild conditioning
regimen, with a reduction in GvHD, and in the case of cancer patients prolonging the progression free period).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Science
and Technology Overview</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent portfolio that we license from Yeda includes a variety of cell therapy applications. The portfolio includes both granted and pending
patents. The total relevant patent portfolio consists of 15 patent “families” (i.e. grouping of similar patent applications
in different territorial jurisdictions) which currently include: 56 granted patents; 5 allowed/accepted patents; and a
further 43 pending patents. The key terms of the agreement pursuant to which we license all of Yeda’s patents related to
our technology is set forth in the section entitled “Intellectual Property” herein. The license period (per product, per
country) is for the full life of the patents and expires at the later of the patent expiration date in that country or 15 years after
the date that the FDA or local equivalent regulatory authority in each country approves that particular product for sale in that country.
Provided that Cell Source either sponsors research or pays either a nominal license fee of $50,000 per year (total for use of all the
products), or pays royalties on product sales on at least one product as per the license agreement, the license will remain in effect
continuously and expire only with the expiration of the patent or 15 years after regulatory approval (later of the two) per product per
country as described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professor
Yair Reisner, the inventor of Veto Cell technology, left the Weizmann Institute and relocated to MD Anderson in Houston, Texas. He has
been awarded a $6 million grant from the Cancer Research and Prevention Institute of Texas. This, coupled with research funding from
the University itself, provides him with a total funding commitment of $10 million for five years. Professor Reisner is now the Head
of Stem Cell Research at the Department of Stem Cell Transplantation &amp; Cellular Therapy as well as the Reisner Laboratory at MD Anderson.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 12; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
Source is currently sponsoring ongoing research by Professor Reisner and his team, many of whom have also relocated from the Weizmann
Institute to MD Anderson, for developing existing and new applications for Veto Cell technology and plans to license any new intellectual
property developed there on an exclusive basis, as it does from Yeda. MD Anderson is the largest HSCT center in the United States, performing
over 850 transplantations per year. MD Anderson is currently conducting a human clinical trial sponsored by Cell Source for its Anti-Viral
Veto Cell. Professor Richard Champlin (who Chairs their Department of Stem Cell Transplantation and Cellular Therapy and is a longtime
associate and collaborator of Professor Reisner) serves as Principal Investigator for this trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
Yeda has applied for and been granted various patents related to our technology, a granted patent only provides Yeda, and the Company
by virtue of its exclusive license, the right to use the underlying invention. However, in order for our cell therapy and cancer therapy
to be legally sold and administered to patients, the FDA or similar regulatory agencies must approve its use. In other words, having
a patent provides legal “freedom to operate” for a certain technology, and may provide the ability to prevent others from
using the same technology without the patent holder’s permission. However, in order to legally manufacture and distribute products,
a company must go through all of the typical approval steps delineated in the “Overview” section above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following sections provide an overview of each platform. Further information on the underlying science is available upon written request
and the execution of an appropriate nondisclosure agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
licensed technology portfolio consists of 15 patent families, 56 granted patents, 5 allowed/accepted patents and a further 43 pending
patents. The following table lists the patents and patent applications that Yeda holds and which we have a license to use in each of
the below-referenced countries:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Anti Third Party
    Central Memory T Cells, Methods of Producing Same and Use of Same in Transplantation and Disease Treatment</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Country</td>
    <td style="text-align: left; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Patent Number</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Filed</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Expires</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Status</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Assignee</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; width: 12%; text-align: left">USA</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">9,738,872</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">29-Oct-2009</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">29-Oct-2029</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">Granted</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 30%; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Europe</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2365823</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">29-Oct-2009</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">29-Oct-2029</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">China</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">ZL200980153053.4</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">29-Oct-2009</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">29-Oct-2029</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Israel</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">212587</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">29-Oct-2009</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">29-Oct-2029</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">India</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">285832</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">29-Oct-2009</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">29-Oct-2029</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Russian Federation</td>
    <td>&nbsp;</td>
    <td style="font-weight: normal; vertical-align: top; font-style: normal; text-align: left">2506311</td><td style="font-weight: bold">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">29-Oct-2009</td><td style="font-weight: bold">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">29-Oct-2029</td><td style="font-weight: bold">&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Use of Anti
    Third Party Central Memory T Cells for Anti-Leukemia/Lymphoma Treatment</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Country</td>
    <td style="text-align: left; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Patent Number</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Filed</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Expires</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Status</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Assignee</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; width: 12%; text-align: left">USA</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">9,421,228</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">08-Sep-2011</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">08-Sep-2031</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">Granted</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 30%; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">USA <br>(Continuation)</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2016-0354410-A1</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2011</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2031</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Europe</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2613801</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2011</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2031</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Canada</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2,810,632</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2011</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2031</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">China</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">ZL201180053858.9</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2011</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2031</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Israel</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">225102</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2011</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2031</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Japan</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">5,977,238</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2011</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2031</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Hong Kong</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">HK1187528</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2011</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2031</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Republic of Korea</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">10-1788826</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2011</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2031</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Singapore</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">188473</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2011</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2031</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Mexico</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">357746</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2011</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">08-Sep-2031</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 13; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Anti Third Party
    Central Memory T Cells, Methods of Producing Same and Use of Same in Transplantation and Disease Treatment</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Country</td>
    <td style="text-align: left; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Patent Number</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Filed</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Expires</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Status</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Assignee</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">USA <br>(Divisional)</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2018-0193384-A1</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Allowed</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; width: 12%; text-align: left">Europe</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">2753351</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">06-Sep-2012</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">06-Sep-2032</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">Granted</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 30%; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Canada</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2,848,121</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Allowed</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">China</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">ZL201280054739.X</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Israel</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">231397</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Australia</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2012305931</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">New Zealand</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">622749</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Japan</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">6,196,620</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Hong Kong</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">HK1200099</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Republic of Korea</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">10-2073901</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Singapore</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">11201400513P</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Brazil</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">BR 11 2014 005355 3</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Allowed</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Mexico</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">351226</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">South Africa</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2014/01993</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">India</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">375463</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Russian Federation</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2636503</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Sep-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Use of Anti
    Third Party Central Memory T Cells</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Country</td>
    <td style="text-align: left; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Patent Number</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Filed</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Expires</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Status</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Assignee</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; width: 12%; text-align: left">Europe</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">3322424</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">14-Jul-2016</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">16-Jul-2036</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">Pending</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 30%; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">China</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">CN 108025026 A</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">14-Jul-2016</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">16-Jul-2036</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 14; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Methods Of Transplantation
    And Disease Treatment</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Country</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Patent Number</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Filed</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Expires</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Status</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Assignee</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; width: 12%; vertical-align: top">USA</td><td style="text-decoration: none; width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">10,933,124</td><td style="width: 2%">&nbsp;</td>
    <td style="text-align: left; width: 12%; vertical-align: top">14-Jul-2016</td><td style="width: 2%">&nbsp;</td>
    <td style="text-align: left; width: 12%; vertical-align: top">14-JuL-2036</td><td style="width: 2%">&nbsp;</td>
    <td style="text-align: left; width: 12%; vertical-align: top">Granted</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 30%; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  </tbody></table>



<p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Genetically
    Modified Anti-Third Party Central Memory T Cells and Use of Same in Immunotherapy</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Country</td>
    <td style="text-align: left; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Patent Number</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Filed</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Expires</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Status</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Assignee</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; width: 12%; text-align: left">USA</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">11,179,448</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">14-July-2016</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">16-Jul-2036</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">Granted</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 30%; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">USA (Continuation)</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">17/531,897</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">14-July-2016</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">16-Jul-2036</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Europe</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">3322425</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">14-July-2016</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">16-Jul-2036</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Canada</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2,991,690</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">14-July-2016</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">16-Jul-2036</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">China</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">CN 108135938 A</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">14-July-2016</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">16-Jul-2036</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">China (Divisional)</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">62/193,229</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">14-July-2016</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">16-Jul-2036</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Israel</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">256916</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">14-July-2016</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">16-Jul-2036</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Australia</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2016291825</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">14-July-2016</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">16-Jul-2036</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Japan</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2018-501339</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">14-July-2016</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">16-Jul-2036</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Allowed</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Hong Kong</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">1255063A</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">14-July-2016</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">16-Jul-2036</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  </tbody></table>


<p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<!-- Field: Page; Sequence: 15; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Veto Cells Generated
    from Memory T-Cells</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Country</td>
    <td style="text-align: left; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Patent Number</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Filed</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Expires</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Status</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Assignee</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; width: 12%; text-align: left">USA</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">10,961,504</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">27-Jun-2017</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">27-Jun-2037</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">Granted</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 30%; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">USA (Continuation)</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2021-0214687-A1</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2017</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2037</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Europe</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">3475414</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2017</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2037</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Canada</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">3,029,001</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2017</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2037</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">China</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">CN 109661463 A</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2017</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2037</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Israel</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">263924</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2017</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2037</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Australia</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2017289879</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2017</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2037</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Japan</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2018-567129</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2017</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2037</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Hong Kong</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">40007502A</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2017</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2037</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Singapore</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">11201811563R</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2017</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2037</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Republic of Korea</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">10-2019-7002824</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2017</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2037</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Mexico</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">MX/a/2019/000022</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2017</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2037</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">India</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">201927002672</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2017</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2037</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Russian Federation</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2019101826</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2017</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">27-Jun-2037</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
</tbody></table>

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Methods of Transplantation
    and Disease Treatment</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Country</td>
    <td style="text-align: left; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Patent Number</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Filed</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Expires</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Status</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Assignee</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; width: 12%; text-align: left">USA</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">10,751,368</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">18-Jan-2018</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">18-Jan-2038</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">Granted</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 30%; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  </tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Genetically
    Modified Veto Cells and Use of Same in Immunotherapy</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Country</td>
    <td style="text-align: left; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Patent Number</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Filed</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Expires</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Status</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Assignee</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">USA</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2019-0338247-A1</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">18-Jan-2018</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">18-Jan-2038</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; width: 12%; text-align: left">Europe</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">3571295</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">18-Jan-2018</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">18-Jan-2038</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">Pending</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 30%; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">China</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">CN 110392736 A</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">18-Jan-2018</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">18-Jan-2038</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Israel</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">268126</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">18-Jan-2018</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">18-Jan-2038</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 16; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Anti-Viral
    Central Memory CD8+ Veto Cells in Haploidentical Stem Cell Transplantation</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Country</td><td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Patent Number</td><td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Filed</td><td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Expires</td><td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Status</td><td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Assignee</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; width: 12%; text-align: left">Canada <br> NP</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">3,149,379</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">06-Aug-2020</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">06-Aug-2040</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">Pending</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 30%; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Japan</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2022-506965</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2020</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2040</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Brazil</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">62/883,164</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2020</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2040</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Israel</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">290337</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2020</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2040</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Mexico</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">62/883,164</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2020</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2040</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">USA</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">17/633,294</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2020</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2040</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Australia</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">62/883,164</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2020</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2040</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">India</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">202227011269</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2020</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2040</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Europe</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20850208.8</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2020</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2040</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">China</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">62/883,164</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2020</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2040</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Russian Federation</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2022105687</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2020</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">06-Aug-2040</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Veto CAR-T Cells</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 12%; font-weight: bold; text-align: left">Country</td><td style="text-align: left; width: 2%; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 12%; font-weight: bold; text-align: left">Patent Number</td><td style="text-align: left; width: 2%; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 12%; font-weight: bold; text-align: left">Filed</td><td style="text-align: left; width: 2%; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 12%; font-weight: bold; text-align: left">Expires</td><td style="text-align: left; width: 2%; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 12%; font-weight: bold; text-align: left">Status</td><td style="text-align: left; width: 2%; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 30%; font-weight: bold; text-align: left">Assignee</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">PCT</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">WO2022/034593</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">11-Aug-2020</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">11-Aug-2021</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Use of Veto
    Cells for the Treatment of Sickle Cell Disease</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 12%; font-weight: bold; vertical-align: bottom">Country</td><td style="text-align: left; padding-bottom: 1pt; width: 2%; font-weight: bold; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 12%; font-weight: bold; text-align: left">Patent Number</td><td style="text-align: left; padding-bottom: 1pt; width: 2%; font-weight: bold; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 12%; font-weight: bold; vertical-align: bottom">Filed</td><td style="text-align: left; padding-bottom: 1pt; width: 2%; font-weight: bold; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 12%; font-weight: bold; vertical-align: bottom">Expires</td><td style="text-align: left; padding-bottom: 1pt; width: 2%; font-weight: bold; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 12%; font-weight: bold; vertical-align: bottom">Status</td><td style="text-align: left; padding-bottom: 1pt; width: 2%; font-weight: bold; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 30%; font-weight: bold; vertical-align: bottom">Assignee</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">PCT</td><td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">WO2021/090320</td><td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">05-Nov-2020</td><td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">05-Nov-2040</td><td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  </tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Use of Veto
    Cells in Treatment of T Cell Mediated Autoimmune Diseases</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 12%; font-weight: bold; vertical-align: bottom">Country</td><td style="text-align: left; width: 2%; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 12%; font-weight: bold; text-align: left">Patent Number</td><td style="text-align: left; width: 2%; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 12%; font-weight: bold; vertical-align: bottom">Filed</td><td style="text-align: left; width: 2%; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 12%; font-weight: bold; vertical-align: bottom">Expires</td><td style="text-align: left; width: 2%; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 12%; font-weight: bold; vertical-align: bottom">Status</td><td style="text-align: left; width: 2%; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 30%; font-weight: bold; vertical-align: bottom">Assignee</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">PCT</td><td style="font-weight: bold">&nbsp;</td>
    <td style="vertical-align: top; font-weight: bold; text-align: left"><b style="text-decoration: none; font-style: normal; font-weight: normal">WO2021/090321</b> <br></td><td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">05-Nov-2020</td><td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">05-Nov-2040</td><td>&nbsp;</td>
    <td style="text-align: left; vertical-align: top">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 17; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">A Combination
    Therapy for a Stable and Long Term Engraftment</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Country</td>
    <td style="text-align: left; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Patent Number</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Filed</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Expires</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Status</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Assignee</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; width: 12%; text-align: left">USA</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">10,369,172</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">20-Dec-2012</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">20-Dec-2032</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">Granted</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 30%; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">USA <br> (Continuation)</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2019-0328793-A1</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Europe</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2793914</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Israel</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">233303</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Australia</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2012355990</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">New Zealand</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">627272</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Hong Kong</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">HK1202810</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Republic of Korea</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2109643</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Singapore (Divisional)</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">10201801905W</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Mexico</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">370404</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Russian Federation</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2657758</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">A Combination
    Therapy for a Stable and Long Term Engraftment Using Specific Protocols for T/B Cell Depletion</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Country</td>
    <td style="text-align: left; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Patent Number</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Filed</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Expires</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Status</td><td style="text-align: left; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Assignee</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; width: 12%; text-align: left">USA</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">10,434,121</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">20-Dec-2012</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">20-Dec-2032</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 12%; text-align: left">Granted</td><td style="width: 2%">&nbsp;</td>
    <td style="vertical-align: top; width: 30%; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">USA <br> (Continuation)</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2019-0358269-A1</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Europe</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2797421</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Canada</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2,859,952</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Israel</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">233302</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Australia</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2012355989</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Australia (Divisional)</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2016259415</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">New Zealand</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">627549</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Japan</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">6,313,219</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Hong Kong</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">1202775</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Singapore</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">11201403456U</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Brazil</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">BR 11 2014 015959 9</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Pending</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Mexico</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">372502</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">South Africa</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2014/05298</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">Russian Federation</td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">2648354</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2012</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">20-Dec-2032</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Granted</td><td>&nbsp;</td>
    <td style="vertical-align: top; text-align: left">Yeda Research and Development Co. Ltd.</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 18; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Veto
Cell Technology Platform</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Background</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Veto Cell technology is a next generation immunotherapy technology that enables the selective attenuation of the immune system. In other
words, pre-clinical studies as well as initial human clinical trial results suggest that the treatment has the ability to reduce the
immune response to selective “threats,” with low risk for adverse side effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">What
makes the Veto Cell approach distinctive is the degree to which it leverages the inherent specificity of the human immune system. The
immune system defends the body by creating a specific stream of T-cell clones for each of millions of possible individual threats. A
given T-cell will attack only its specific target, ignoring all other threats. Our technology might enable the physician to selectively
attenuate immune response, thus effectively “switching-off” an individual stream of T-cell clones without affecting any other
such streams of T-cell clones dispatched by the immune system to attack unwanted incursions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
technology is based on the discovery that certain T-cells can acquire the property of attracting and proactively neutralizing immune
attacks on them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
technology has achieved distinctive results in animal live trial models. <i>See, e.g.</i>, Eran Ophir et al. <i>Murine anti-third party
central-memory CD8+ promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells</i>,
BLOOD, Feb. 14, 2013, at 1220; <i>Towards off-the-shelf genetically modified T cells: prolonging functional engraftment in Mice by CD8
veto T cells,</i> Leukemia 32, 2018; 1038-1040. <i>Veto cells for safer nonmyeloablative haploidentical HSCT and CAR T cell </i></span><i>therapy
</i>Seminars in Hematology 56, 2019; 173-182. It has also demonstrated both safety and efficacy thus far in human clinical trials.
If it continues to succeed in human clinical trials, we believe that it may have meaningful and potentially broad impact on the field
of stem cell transplantation:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i>&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significantly
                                            improve outcomes of transplantations by reducing the host (transplant recipient) rejection
                                            rate of T-cell depleted stem cells (e.g. from bone marrow) – thus supporting successful
                                            engraftment of the transplanted cells, which is the treatment for the blood cancer itself.
                                            In order to improve the safety of this cancer treatment, Veto Cell technology has shown in
                                            both preclinical studies and initial clinical data that it can markedly reduce both the risk
                                            of GvHD and the need for using aggressive amounts of immunosuppression medications, as well
                                            as, in preclinical studies and anticipated to be shown as clinical studies progress, preventing
                                            viral infections that typically threaten patients post transplantation. This safer means
                                            of deliver stem cell transplants would significantly reduce the HSCT mortality rate and therefore
                                            lead to broader use of this treatment. Furthermore, by adding CAR-T to the HSCT protocol,
                                            we can bridge between the initial transplantation and the conclusion of immune reconstitution,
                                            thus providing both short-term and ongoing protection against remission. This has the potential
                                            to significantly improve efficacy beyond that of the current outcomes of either CAR-T or
                                            HSCT on their own.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantively
                                            increase the number of transplantations by enabling successful engraftment under lower levels
                                            of immune suppression and therefore making the therapy accessible to older and sicker patients
                                            (who today may not survive ablation).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
                                            increase the number of transplantations by making transplantation appropriate for other indications
                                            (for which today transplantation would be considered an inappropriately risky treatment).</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our Veto Cell technology may possibly play a role in the treatment of a number of serious and currently poorly treated non-malignant
diseases. Finally, based on preclinical studies using genetically modified cells, we believe that Veto Cells will be able to act as critical
enabler for other cell therapies, most notably CAR-T cell therapy, which has recently shown strong initial indications of being effective
in the near term in treating blood cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 19; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeda
filed two patent applications that extend the usage of Veto Cell technology as a critical enabler for other cell therapy treatments.
One patent application highlights, based on preclinical data, the ability of Veto Cells to accompany other cell therapy treatments and
help them overcome rejection and avoid GvHD in an allogeneic treatment setting. The other patent application involves a genetically modified
Veto Cell that can have sustained survival in the patient’s body while avoiding rejection and GvHD. These patents have both
been granted in the United States Both of these, as well as a more recent patent application filed showing data which combines Veto Cells
with CAR-T cells, highlight the potential to make CAR-T cells, which to date have been effective primarily in an autologous (patient’s
own cells) setting, succeed in an allogeneic setting. What follows is a description of the significance of these two new patent applications:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gene
                                            modified cell therapy is considered to be one of the most promising cancer treatment approaches
                                            in decades, with companies like Kite Pharma and JUNO Therapeutics having recently been acquired
                                            at multi-billion-dollar valuations after having successfully treated relatively small
                                            numbers of patients in clinical trials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
                                            gene modified treatments such as CAR-T have shown remarkable results in cancer treatment
                                            trials, their published successes to date have been mostly limited to “autologous”
                                            blood cell cancer treatments using the patient’s own cells. There are concerns that
                                            this type of “personalized” treatment may not have favorable economics on a large-scale
                                            basis.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            ideal, more lucrative commercial path for CAR-T and similar genetically engineered cell therapies
                                            is to become allogeneic or off the shelf product with drug-like distribution economics and
                                            to treat a broad spectrum of cancers including solid tumors. Allogene Therapeutics, an early-stage
                                            clinical company focused on allogeneic CAR-T, has attained a valuation of $6 billion,
                                            whereas Legend Biotech valuation reached $8 billion and Fate Therapeutics valuation attained
                                            the $10B level, underlining the importance of off-the-shelf CAR as a potential cancer treatment.
                                            Cell Source licenses Yeda’s patent applications for combining Veto Cells with genetically
                                            modified T cells and is currently exploring active collaboration with CAR-T cell providers
                                            to move Veto and CAR-T combined cell therapy towards the clinic.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            the case of blood cancer treatment, we believe that a VETO CAR-T combined treatment will
                                            provide sustained protection for patients in relapse as well as a fundamentally superior
                                            approach for those in remission</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
Source has completed a collaboration, through its licensing agreement with Yeda, with Professor Zelig Eshhar, the inventor of CAR-T cells.
Professor Eshhar has served as both a scientist at the Weizmann Institute and on the Scientific Advisory Board of KITE Pharma. This collaboration
confirmed the strength of combining Veto Cell technology with CAR-T cell therapy. Cell Source plans to introduce allogeneic VETO CAR-T
HSCT combined cell treatment for lymphoma and leukemia and, eventually, off the shelf VETO CAR-T for these and other cancers, including
solid tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
Yeda has filed a patent application, licensed to Cell Source, which was recently granted in the United States, as well as a new patent
based on more advanced data, for an Anti-Viral Veto Cell. Below is an explanation of the potential for this application:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            than primary disease (typically blood cell cancer) the leading causes of death in unrelated
                                            donor bone marrow transplants are rejection, GvHD, where the donor bone marrow rejects the
                                            host or recipient), and infections, which collectively are responsible for 35%-40%
                                            of deaths after haploidentical donor transplants within the first 100 days post-transplant.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            is well established that GvHD can be prevented by T cell depletion of the bone marrow transplant.
                                            However, this procedure is also associated with an increased rate of graft rejection. Preclinical
                                            studies and initial clinical results suggest that this problem can be overcome by adding
                                            Veto Cells to the bone marrow transplant, as well as allowing for a reduced intensity conditioning
                                            (RIC) regimen. However, viruses such as CMV and EBV remain a major threat to patients post-transplant.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
                                            Source has developed a next generation Veto Cell that not only facilitates mismatched transplants
                                            but also protects the transplant recipient against these common viruses. During the initial
                                            period after a stem cell transplantation the patient’s body undergoes an immune system
                                            reconstitution period. While the “new” immune system is building up, the patient
                                            is particularly vulnerable to viral infections, which develop in over 90% of bone marrow
                                            transplant recipients during the first 100 days post transplantation. Veto cells can fend
                                            off CMV and similar viral infection until such time as the patient’s own immune system
                                            reconstitutes to the point that it can fight off the infection on its own.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Combining
                                            GvHD prevention by using T cell depleted transplants with anti-rejection action, under a
                                            mild conditioning regimen, as well as virus prevention, Veto Cell could potentially significantly
                                            increase survival rates post-transplant. Further adding the short-term cancer killing of
                                            CAR-T can combine to deliver even better long-term survival outcomes.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on preclinical data, Veto Cells can also be used to facilitate organ transplants (e.g. kidney
                                            transplant combined with a bone marrow transplant) with partially mismatched donors and either
                                            reduce or eliminate the need for lifelong daily anti-rejection treatment currently given
                                            to even fully matched donor organ recipients.</span></td></tr></tbody></table>

<p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>


<!-- Field: Page; Sequence: 20; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify; text-indent: -27pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Mechanism</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Veto Cell is a CD8 central memory anti-3rd party T-cell that has five critical properties:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            has an outer surface coating that triggers attack by specific host T-cells (and only those
                                            specific T-cells).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            can annihilate an attacking T-cell without itself being damaged (specifically, it exposes
                                            or releases a death-signaling molecule when an attacking T-cell binds to it).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            has been oriented to attack cells of a simulated third party (i.e., neither host nor donor),
                                            or a set of viral peptides, and thus exhibits markedly reduced risk of GvHD or graft rejection.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            is long-lived and endures in the body for extended periods.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            migrates to the thymus and lymph nodes.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outcome is that when a large number of these cells are introduced into the body, they effectively eliminate the T-cell clones that the
immune system dispatches to attack the desirable, transplanted stem cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thus,
for example, if a population of Veto Cells is derived from a donor, they will express the same peptide as do the donor’s cells.
Therefore, the specific stream of host T-cells that would ordinarily attack the donor stem cells, are instead directed to “decoy”
Veto Cells and disabled before they reach the transplantation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Described
in a <i>Blood</i> editorial as a “substantial advance in Cell Therapy,” a notable characteristic of our Veto Cell is that
this mechanism is quite specific. Only those specific T-cell clones that were generated to attack cells from this specific donor are
disabled. The rest of the immune system essentially remains intact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is in marked contrast with conventional immunosuppression which degrades the entire immune system and is therefore associated with severe
risk of infection and, in the case of stem cell transplantations, high mortality.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
effect is long-lived. Firstly, the Veto Cells themselves are long-lived memory cells. Secondly, when infused with stem cells the latter
migrate to the thymus where, over time, they create a new “identity” in the host and initiate chimerism where the host and
donor cells peacefully co-exist. This chimerism has the effect of “educating” new T-cells being generated by the thymus to
tolerate donor cells and this tolerance can become permanent. Furthermore, by inducing permanent tolerance to donor cells, Veto Cells
may be able to enable both acceptance (i.e. mitigate both host rejection and GvH rejection) and thus persistence (i.e. extended survival
resulting in enhanced efficacy) of important cell therapy treatments such as CAR-T cells, TCRs and NK cells in treating both blood cell
and solid tumor cancers. Beyond this, Veto Cells can be directed not only to kill host anti-donor rejecting cells, but also common viruses
such as EBV and CMV that are a common cause of post-transplantation morbidity and mortality.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Target
Indications</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Veto Cell technology, an intravenously administered cell suspension, if successful, could initially be used in stem cell (e.g. bone marrow)
transplantations and other treatments associated with malignant disorders (i.e., cancers). Veto Cell technology may also be applied to
selected non-malignant conditions. The following sections provide a brief overview of the use of the Veto Cell technology in both of
these scenarios.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<span style="text-decoration: underline">Stem Cell Transplantation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to describe the effect of Veto Cells in transplantation, it is helpful to first briefly review the state of the art:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a conventional stem cell transplant, the recipient first receives myeloablative conditioning - powerful chemotherapy and/or radiation
therapy intended to destroy his/her own bone marrow cells. This has a threefold purpose:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            destroys the host T-cells so they will not attack (reject) the donor bone marrow cells.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            makes space in the host bone marrow for the new donor cells.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            destroys diseased host blood cells so that they do not proliferate and cause relapse following
                                            the procedure.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 21; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
practice however, there are three major problems:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Host
                                            rejection - the myeloablative conditioning does not destroy all of the host T-cells. Those
                                            that remain may aggressively attack the donor bone marrow cells before they can engraft.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GvHD
                                            - the transplanted cells include donor T-cells which recognize the host’s body as foreign
                                            and attack it.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Infections
                                            are a common complication from HSCT and result in 26% of early patients deaths in
                                            haploidentical transplants of adult patients in the US.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rejection,
GvHD and viral infections are all potentially life-threatening complications in and of themselves and also lead to the use of dangerous
and costly immunosuppression medications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<span style="text-decoration: underline">Veto Cell in Transplantation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Veto Cell technology addresses not only rejection but also GvHD and infections. In a transplantation scenario, a population of donor
Veto Cells is created to “escort” the stem cells when they are transplanted. This population is created by identifying donor
cells with Veto Cell properties, exposing them to simulated 3rd party cells (e.g., selecting only those that react to a third person
and therefore by definition will not react to either host or donor) or to viral peptides, and expanding their population in the lab.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Veto Cells are then introduced into the host following the transplantation of the stem cells. The host mounts its normal immune response
to the donor cells by generating a population of T-cell clones that will bind to any cells expressing markers from this specific donor.
In a conventional transplantation, these T-cells would bind to and destroy donor stem-cells thus causing rejection of the transplant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
when the transplantation treatment involves a large number of Veto Cells, this rejection mechanism is “ambushed.” Since the
Veto Cells express the same donor markers as the stem cells, the host T-cell clones will attempt to bind to the donor-derived Veto Cells
as noted above, which act as decoys by attracting and then counterattacking and killing the clones before they ever reach the stem cell
transplantation. These same Veto Cells concurrently attack viruses such as CMV and EBV which are a common source of infections that threaten
HSCT patients. Based on additional preclinical data, in June of 2016 Yeda filed a U.S. provisional patent application, which has since
been granted, and in 2019 a further patent application based on additional data, also licensed by Cell Source, which show the ability
of Veto Cells to be directed against these types of viruses that typically cause infections in bone marrow transplant patients. This
additional functionality, when combined with attacking host anti-donor rejecting cells, may even further enhance survival rates for patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<span style="text-decoration: underline">VETO CAR-T combined therapy</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSCT
are well known to be an effective treatment for hematological malignancies. Making these treatments safer and more accessible by reducing
the need for harmful immune suppression, avoiding GvHD and fending off common post-transplantation viruses are expected to facilitate,
through successful Veto Cell treatments, a broader and more successful use of HSCT for not only the most severe cases, but also for older
or weaker patients who are not capable of tolerating high intensity conditioning (high levels of radiation and chemotherapy). This is
expected to significantly increase the number of patients who can receive successful cancer treatments that require allogeneic HSCT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAR-T
cell therapy has shown strong cancer killing efficacy in the near term, mainly in an autologous setting. Longer term efficacy to date
has been significantly lower, and to date there has been little success in establishing a successful approach to allogeneic CAR-T therapy.
Having worked with Zelig Eshhar, the inventor of CAR-T therapy, to combine the CAR-T cell and the Veto Cell in to single cell which both
directly attacks cancer cells and facilitates T cell depleted HSCT under RIC, Cell Source intends to combine Veto Cell powered HSCT with
CAR-T cell therapy for blood cell cancers into a single treatment, thus providing a comprehensive end-to-end solution which addresses
both short-term cancer killing (via CAR-T) and long term relapse prevention (through a more safely delivered reconstituted immune system).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<span style="text-decoration: underline">Enabling Third Party Cell Therapies</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on preclinical studies using genetically modified cells, in July of 2015 Yeda filed two U.S. provisional patent applications, both of
which have since been granted in the United States, which are also licensed exclusively by Cell Source on a worldwide basis. These patent
applications show the ability of Veto Cells to enhance the performance of cell therapy treatments involving genetically modified receptors.
When combined with CAR-T or TCR cell therapy for example, these would potentially greatly enhance the ability of these treatments to
be used in an allogeneic or “off the shelf” setting, and also increase their efficacy by avoiding both rejection and GvHD,
thus increasing their persistence (survival in the patient’s body). A new patent, based on the Cell Source collaboration with Dr.
Zelig Eshhar, the inventor of CAR-T technology, showing the effectiveness of Veto Cells combined with CAR-T cell therapy, was filed by
Yeda, under license to Cell Source, in 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
combined VETO CAR-T or similar treatment (e.g. combining Veto with NK cells) is expected to result in broadly applicable effective treatments
for both blood cell cancers and, eventually, a variety of solid tumor cancers as well.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 22; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<span style="text-decoration: underline">In Non-Malignant Diseases</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are two major categories of non-malignant disorders that the Veto Cell technology aspires to address: organ transplantation and non-malignant
hematological disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of organ transplantations and congenital non-malignant hematological disorders, the goal of the Veto Cells is to enable transplantation
(stem cell or organ) by reducing host/donor immune system conflicts. This could potentially allow for mismatched (partial vs. full identity
match between donor and host) kidney transplants, for example, and also obviate the need for lifelong daily anti-rejection medication
which is the current standard of care. Such an outcome could improve quality of life, reduce cost of care and significantly increase
life expectancy for a broader audience of prospective transplant recipients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of congenital non-malignant diseases such as sickle cell disease and aplastic anemia, the body’s bone marrow produces
“flawed” cells. An effective treatment is HSCT which replaces the flawed host bone marrow with healthy donor cells. These
cells then produce healthy blood cells, basically curing the anemia. As noted elsewhere however, today HSCT is a risky procedure because
of the graft/host immune conflicts. It is therefore used infrequently to treat sickle cell disease. The Veto Cell tolerizing technology
would increase the target population for this treatment by significantly reducing these conflicts and by extension the procedure’s
risk. Yeda has filed patent applications, licensed to Cell Source, based on preclinical data that show Veto Cells’ effectiveness
in reversing Sickle Cell Disease and their use in the treatment of T-cell mediated auto immune diseases such as preventing the development
of Type 1 Diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Development
Status</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Veto Cell platform has been extensively tested by in vitro studies (on both human and mouse disease) and confirmed in animal trials.
The results appear to be consistently effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Inducing chimerism:</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following images show some example data from the Veto Cell animal studies. Skin of black mice has been grafted onto the backs of white
mice. The data show that T-cells from host and donor mice are fully coexisting in the treatment group using the Veto Cells (“chimerism”).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" style="height: 172.5pt; width: 99.75pt" data-src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_009.jpg" src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_009.jpg"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Successful bone marrow transplantation under reduced levels of immune suppression:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
anti-rejection effect in the data below shows mice with lymphoma treated with Veto Cell therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
control group mice (left side) all die by day 27. By contrast, the Veto Cell treatment group (right side) show far better results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 23; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" style="height: 213.75pt; width: 282.75pt" data-src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_003.jpg" src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_003.jpg"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Administration</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
envision that Veto Cell therapy will be administered in an in-patient setting, typically as part of the existing procedures involved
with stem cell transplantations. Blood will be taken from the donor. The blood will be sent to a regional Company center where the Veto
Cells will be developed and expanded - a process that lasts up to two weeks. The Veto Cells will then be sent to the transplantation
center where they will be infused to the patient intravenously along with the transplantation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Patent
Status</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
Source’s CD8 TcM (central memory T-cells) Veto Cell, are protected by granted patents in the US, Mexico, Europe, China, Japan,
Hong Kong, Korea, Singapore, Israel, India and the Russian Federation as well as Canada, Australia, New Zealand and South Africa. More
recent patent applications, including those for the Genetically Modified Veto Cell and the Anti-Viral Veto Cell have been granted in
the US and are in the national phase in a broad set of jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Development
Roadmap</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Veto Cell platform roadmap comprises two main programs as outlined in the table below. The specific clinical trials planned for each
are detailed in the Clinical Trials section of this document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Offering</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Objective</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Major
    Activities</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 21%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
    timing</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VETO
    CAR-T (with and without HSCT) </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validate
    and introduce new commercial treatment to deliver safer and more successful haploidentical HSCT combined with CAR-T cell therapy</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
                                            Establish initial safety and efficacy for Anti-viral Veto Cell, then</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">augment
    existing trial protocol with CAR-T 2. Commence multi-center registration study</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
    Introduce approved</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    to high profile</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    HSCT centers</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●2023</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●2025-2026</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●2027-2028</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Veto
    Cell Organ Transplantation</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validate
    efficacy of Veto Cells in attaining engraftment and reducing need for ongoing post-transplant anti-rejection treatment for haploidentical
    kidney transplants</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
                                            Finalize treatment</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">protocol
    and</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commence
    Phase 1/2</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">study</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    Show sustained</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tolerance
    post-</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transplant
    without need for daily</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">anti-rejection
    therapy</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●2022-2023</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●2023-2024</span></p></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 24; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Products
and Services</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we do not have any products, and there is no assurance that we will be able to develop any products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following products are currently planned:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>VETO
                                            CAR-T HSCT cell therapy for donor mismatched allogeneic stem cell transplantations for treatment
                                            of blood cancer</i>.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20.25pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20.25pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is our flagship (as an initial platform for increasing transplantation success) and is focused on haploidentical allogeneic stem cell
transplantations. Treatment will comprise infusion of VETO CAR-T cells derived from the donor and processed in a Company (or subcontracted)
facility that will be accessible to the transplantation center at the time of transplantation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Veto
                                            Cell based haploidentical organ transplantation initially for kidney and then also for liver
                                            transplants</i>.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20.25pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20.25pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
therapy will involve a partially mismatched donor organ transplant followed by an Anti-Viral Veto powered HSCT using stem cells derived
from the same donor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Off
                                            the shelf VETO CAR-T cell therapy</i>.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20.25pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
treatment would be use Veto Cells to increase persistence and hence efficacy of CAR-T cell therapy, without the use of HSCT, for blood
cancers and eventually solid tumors as well.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>4.</i></span></td>
  <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Veto
  Cell tolerance therapy for non-malignant disorders.</i></span></td></tr>
</tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is the application of Veto Cell technology to treatment of non-malignant (i.e., non-cancerous) diseases, as discussed in the Technology
section. Target indications for Veto Cell therapy for nonmalignant disorders are likely to be: tolerizing therapy for allogeneic transplantations
for sickle cell anemia and aplastic anemia (by using stem cell transplantations as referenced in no. 2 above) and tolerizing therapy
for a broader range of congenital immune system related disorders, possibly including preventing the development of Type 1 Diabetes in
Diabetes prone or early onset Diabetes patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
Overall Development Status and Future Development Program</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to commercializing its products, the Company must conduct human clinical trials and obtain FDA approval and/or approvals from comparable
foreign regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally
speaking, as a preclinical biotechnology firm, Cell Source needs to go through several necessary steps in order to commercialize its
products and commence revenue generation. These steps are per product, but can run in parallel for multiple products, which are each
in different stages of the development “pipeline”, so that, for example, when a certain product is already in a human clinical
trial, another product may still be in preclinical development and a third may be awaiting regulatory approval to commence human trials.
These can also take place in parallel, and varied stages, for the same product in different geographic jurisdictions. The typical steps
per product (and range of time frame for each) are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
                                            development of human treatment protocol (2-5 years)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apply
                                            for and receive approval to commence human trials (9-18 months)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recruit
                                            patients (1-6 months)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
                                            Phase 1 trials showing safety of product (1-2 years)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apply
                                            for and receive approval to conduct trials showing product efficacy (6-12 months)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
                                            collecting and analysis (6-12 months)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
                                            Phase 2 efficacy trials (2-3 years)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
                                            collecting and analysis (6-12 months)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apply
                                            for and receive approval to conduct trials showing efficacy in larger numbers of patients
                                            (6-12 months)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
                                            Phase 3 efficacy trials with larger numbers of patients (2-4 years)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
                                            collecting and analysis (6-12 months)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apply
                                            for and receive approval for production scale manufacturing facilities (6-12 months)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
                                            third party or establish own production facilities (6-30 months)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
                                            third party or establish own distribution platform (6-18 months)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commence
                                            manufacturing and distribution (6-12 months)</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 25; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notably,
steps 12-15 can be conducted in parallel with some of the steps above. In the case of Cell Source and other firms that treat terminal
patients with either rare diseases or those for which there is currently no effective treatment, or where preclinical studies indicate
a reasonable expectation to increase life expectancy and survival rates by a substantive margin, several of these steps can be combined
and or shortened, subject to regulatory discretion. For example, Phase 1 and 2 (safety and efficacy) can be combined in a single concurrent
step; approvals for subsequent steps can be accelerated; in some countries patients can already be treated commercially after the end
of Phase 2, foregoing the requirement for Phase 3 data prior to commencing commercial treatments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
specific detailed next steps the company must take to get the treatments or products to market include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of the Megadose Drug Combination, the Hematology and Bone Marrow Transplantation Unit of the University of Parma in Italy on
May 14, 2014 requested and on October 23, 2014 obtained approval from the Italian Medicine Association (the Italian equivalent of the
U.S. FDA) to conduct human clinical trials using the “Megadose + Drug Combination.” While we are not mentioned in the application
nor in the approval, we may indirectly benefit from the outcome of the trial, if successful, although we are not the sponsor of this
trial. There are no written or verbal agreements between the hospital and Cell Source regarding the use of the technology. That said,
Cell Source is aware and in favor of the hospital’s plans to use the technology and would of course find a positive initial outcome
encouraging. Since the treatment is being done on compassionate grounds as a non-commercial clinical trial, there is no legal requirement
for the hospital to obtain approval to use the treatment protocol. The hospital successfully treated the first cancer patient using the
Megadose Drug Combination technology that Cell Source exclusively licenses from Yeda. The patient who was suffering from late-stage multiple
myeloma, was released from hospital within a month of being treated and has since been cancer free for over seven years, with
no GvHD, as initially reported in <i>Blood Advances</i>, vol. 1 no. 24 2166-2175 which was published online October 27, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
Cell Source was not a sponsor of the trial, the results provide a positive initial indication with respect to the technology. The patient
received a bone marrow transplantation from a haploidentical or “mismatched” donor under a RIC regimen (i.e., a relatively
low level of immune suppression treatment). There was successful initial engraftment of the transplantation in the absence of GvHD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2018, we executed a sponsored research
agreement with MD Anderson, which was amended in December 2020 and in October 2021. The Company engaged MD Anderson to perform research
services in the amount of approximately $1,500,000 from January 1, 2019 to December 31, 2021 (approximately $500,000 each year for three
years). The agreement was amended in December 2020 in order to increase the research budget for the year ending December 31, 2021 from
approximately $500,000 to $800,000. In October 2021, the agreement was amended to extend the agreement by one year to November 27, 2022
and define the budget during such one-year period to be approximately $1,300,000.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February  2019, we executed a second agreement with MD Anderson for the production of Veto Cells and the conducting of a Phase
1/2 FDA trial for the Anti-Rejection, Anti-Viral Veto Cell. The treatment protocol was submitted to the FDA by MD Anderson in February
of 2019. Cell Source has conducted Veto Cell production development in cooperation with the Medical Center at the Julius Maximilian University
of Würzburg in Germany.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Anti-Viral Veto Cell product candidate, MD Anderson is currently conducting a Phase 1/2 human clinical trial, sponsored by Cell Source.
The trial has successfully completed the first treatment cohort, with 3 patients each receiving a haploidentical HSCT under reduced intensity
conditioning with Veto Cells. This first in human dose optimization trial has thus far shown that the initial dose is in fact the optimal
dose, as all three patients had successful stem cell engraftment after 42 days, in the absence of GvHD. Cell Source is now continuing
the trial as it proceeds with additional cohorts of patients, using the same dose level. Cell Source anticipates that the US Phase 1/2
trial, once augmented with CAR-T cancer killing capability in the anticipated VETO CAR-T cell HSTC combined therapy, will last through
2023 or 2024. This would be followed by completion of a Phase 2 trial and Phase 3 trial, which could each last another 2-3 years. While
under a fast track FDA program such as RMAT initial marketing approval could potentially be attained after a Phase 2 registration study
as early as in 2025 or 2026, full approval, if successful, may not be attained until 2027 or later. Cell Source has concluded an initial
proof-of-concept collaboration with Professor Zelig Eshhar, the inventor of CAR-T cell therapy, with respect to combining CAR-T cell
therapy with Veto Cells. This is expected to lead to the augmentation of the existing Veto Cell treatment protocol at MD Anderson to
include VETO CAR-T cells in 2022 or 2023, which may lead to fast track approval by 2025 or 2026 but may last until 2027 or 2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
referenced above, it is possible that Cell Source treatments could qualify for any or all of Fast Track, Breakthrough Therapy, Accelerated
Approval, RMAT or Priority Review designation under the FDA, which would hasten their approval if successful. The estimated costs for
each step of development, in terms of clinical trials, are delineated below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
Source estimates the cost of clinical trials alone to be at least $5 million over the coming two years and overall company financing
requirements of at least $50 million in order to reach commercialization for the Veto Cell products. This would mean that Cell Source
will need to secure one or more significant capital infusions in order to reach the point that meaningful revenues could be generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 26; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the development plan through 2026:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" style="width: 660px" data-src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_004.jpg" src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_004.jpg"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Competition</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the area of allogeneic HSCT and related GvHD and virus management, our competitors include: the so-called “Baltimore” protocol,
which employs a T-cell replete approach under RIC; companies who which have been focused on reducing GvHD in a T-cell depleted setting,
with high intensity conditioning (e.g. Bellicum); companies working to treat GvHD after it occurs (e.g. Abbvie, Incyte and Kadmon); and
finally cell therapy companies developing anti-viral treatments (e.g. Atara, Allovir). In the area of CAR-T cell therapy, our competitors
include allogeneic CAR-T companies (e.g. Allogene, Legend, Fate) and autologous CAR-T focused players (e.g. Novartis, Gilead (KITE),
BMS/Celgene (JUNO)).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haploidentical
HSCT is gaining popularity in the US, outflanking UCB (umbilical cord blood) and growing more quickly than MUD (matched unrelated donor)
based transplants. In the US, the majority of haploidentical HSCT are performed under RIC, mostly using T- cell replete transplants with
post-transplant cyclophosphamide treatment. While this “Baltimore” RIC approach has gained popularity (mainly due to safety
reasons) – as a <b><i>T-cell replete</i></b> approach it carries the risk of marked GvHD. Although some <b><i>T-cell depleted</i></b>
approaches have shown reductions in GvHD, they face significant safety issues due to their aggressive use of immune suppression. Similarly,
while currently approved CAR-T therapy for blood cancer has shown compelling short-term efficacy, the initial longer term data
have shown a marked drop off in overall survival rates. Cell Source’s planned distinctive combination of a <b><i>T-cell depleted
</i></b>HSCT <b><i>with RIC</i></b>, complemented by anti-viral activity and enhanced by CAR-T short-term cancer killing, aims to provide
the “best of both worlds” with safer, more effective HSTC leading to a reconstituted immune system, supported by “bridging”
CAR-T remission induction and relapse prevention during the immune reconstitution period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical
testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Earlier stage companies
may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. While
our commercial opportunities may be reduced or eliminated if our competitors develop and commercialize products that are safer, more
effective, have fewer side effects or are less expensive than our own products, we believe that if our human trials show efficacy at
the same levels of our animal trials, we would have the potential to develop at least a niche market share. Also, a number of large US
cancer centers such as Johns Hopkins in Baltimore, Fred Hutchinson in Seattle, City of Hope in Duarte, CA and Dana Farber in Boston are
conducting clinical trials and providing treatments on a compassionate care basis that can be funded on a not for profit basis and provide
competition to Cell Source.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 27; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our ability to compete effectively will depend upon our capacity to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
                                            complete adequate and well-controlled clinical trials that demonstrate statistically significant
                                            safety and efficacy and to obtain all requisite regulatory approvals in a timely and cost-effective
                                            manner;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively
                                            use patents and possibly exclusive partnership agreements with important third-party treatment
                                            providers and collaboration partners to maintain a stable competitive stance for our Technology;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
                                            and retain appropriate clinical and commercial personnel and service providers; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
                                            adequate distribution relationships for our products.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
in efficiently developing and executing these capabilities may have an adverse effect on our business, financial condition or results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Strategy
Overview</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy is based on two underlying drivers: (a) that animal studies (supported by initial human data) show Veto Cell technology to be
consistently effective and have advantages over competitors; and (b) that the lead indications (the most common blood cancers) are relatively
common, have high mortality and have limited treatment options today.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing drivers, we have developed a business plan with the objective of obtaining regulatory approvals and subsequently launching
product sales with a focus on the United States, Europe and Asia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Key
Strategy Elements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are pursuing a staged entry strategy. The first several years will be narrowly focused, both in terms of market segments (blood cancers,
kidney disease) and products (VETO CAR-T and VETO Organ Transplants).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequently,
we plan to broaden the segmentation strategy to include, stand-alone cancer treatments without HSCT (e.g. for solid tumors) and additional
HSCT indications (e.g. selected genetic non-malignant diseases).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy can be summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 12%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strategy
    Element</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 45%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Introductory
                                            period <br>
                                            (years 1 -3 post FDA approval)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 3%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years
    4+</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    Segments</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
                                            Lymphoma and leukemia</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
    Multiple myeloma</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
    Kidney disease</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
    Same as before plus solid tumor cancer targets, liver failure, sickle cell anemia beta thalassemia, diabetes and other non-malignant
    hematological disorders; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
    Rollout</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
                                            VETO CAR-T (with or without HSCT) for B-cell malignancies</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
    Veto Cell Kidney transplants</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
                                            VETO CAR-T for solid tumors</span></p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
                                            Veto Cell liver transplants</span></p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
                                            Veto HSCT for non-malignant disorders</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer/
    Geographic Focus</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
                                            United States</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
    Western Europe</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">●&nbsp;&nbsp;
    <span style="font-size: 10pt">China</span></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
    Major markets worldwide</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Channels/Go
    to Market</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
                                            Direct relationships with leading transplantation centers</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif">●&nbsp;&nbsp;
    <span style="font-size: 10pt">Partnerships with global pharma players</span></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
                                            Out-licensing to, or outright acquisition by, global pharma players</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
    Consistent with other cell therapy offerings currently associated with transplantations and immuno-oncology</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
    Potentially higher volume, lower cost for “off the shelf” offerings</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;Three
                                            production centers:</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
    US</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
    Western Europe</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
    Far East</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
    Initial capacity leased from or situated adjacent to major transplantation center.</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●&nbsp;&nbsp;
                                            Regional production centers owned outright or JV with partners</span></p></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>


<!-- Field: Page; Sequence: 28; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Segment
Selection</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
the general market for immune therapies, we have selected target market segments (i.e., medical conditions) for initial focus based on
two (2) key criteria:	</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severity
                                            of unmet medical need: degree of severity of the indication and the effectiveness of existing
                                            treatments. These criteria help determine the proper regulatory pathway.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technology
                                            relevance: relative value of the ability to manage immune response to the treatment of a
                                            given indication.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will initially focus on indications that score highly with respect to both criteria (e.g., blood cancers, kidney failure). These conditions
may qualify for Fast Track status with the FDA, and, due to the cost and relative efficacy of current treatment alternatives, could potentially
support profitable price points for effective new treatments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Product
Rollout</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
Source plans to seek approval initially in the US and Europe and, in parallel but with a delayed start, in China and possibly Japan.
A successful first-in-human Phase 1/2 trial in the US, which could be concluded by 2023 or 2024, would serve as a strong foundation for
trials in other countries. Limited sales on a “compassionate grounds” basis may, depending on qualification for Breakthrough
Therapy or other Accelerated Approval designation, commence as early as 2025 or 2026. Full approval by the FDA in the U.S. can take as
long as 8 years, or until 2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
products may include VETO CAR-T HSCT combined cell therapy for allogeneic stem cell transplantations as well as Veto Cell based organ
transplantation. Following the initial market penetration and establishment of solid market positioning, we plan to broaden the product
offering to address a wider variety of indications which may include custom Veto Cell developments for specific collaborations with other
cell therapy treatments. For example, we believe that one area in which we could broaden our product offerings is to utilize our Veto
Cell technology, if successful in humans, to address the rejection problems being faced by companies developing NK, TCR and similar cell
therapy products, as an enabler for these treatments to help them overcome some of the rejection and persistence related performance
issues their technology currently seems to be facing. If our Veto Cell technology proves to be successful in humans, we plan to continue
to explore such potential applications in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Customer/Geographic
Focus</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
positive clinical trials, we will initially focus our sales efforts of Veto Cell anti-rejection therapy on centers dealing with late-stage
B-cell malignancies. High profile, high volume HSCT facilities can be targeted to market this treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
plans are to introduce the products first in North America and Western Europe, and, perhaps concurrently, in China. Focusing on key transplantation
facilities in target geographic markets will allow us to both refine the administration of our products and bolster our reputation in
both these and a broader set of geographic markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the introductory period, we plan to expand activities in these initial markets while simultaneously broadening geographic coverage. In
Stage 2, we plan to initiate active marketing efforts in the remaining Western European countries, Japan, Australia, and possibly Russia
and India.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Marketing
Strategy</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial target market is concentrated and networked. It comprises the approximately 100 leading transplantation centers in the target
geographies. As discussed in the “Market Access” and “Channels” section, these centers are well connected to
each other and tend to quickly share innovations and best practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
planned penetration strategy is to introduce Veto Cell into the best-known and most influential centers in North America and Western
Europe, and benefit from the exposure and industry leadership provided by these centers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
initial penetration strategy includes incorporating some of these centers into clinical trials so as to expose and involve their medical
leadership.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the longer term, we plan to drive use and awareness within and across the broader oncology community in order to encourage oncologists
to refer their patients to centers that already use our products and therapies and to encourage pull-influence on additional centers
to adopt our products and therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
broader provider community will be addressed both through a presence in leading peer-reviewed publications and by attending conferences
where research and best clinical practices are shared, seminars are conducted, and networking opportunities are provided for the physicians.
Furthermore, a dedicated sales force will approach leading bone marrow transplant physicians in the United States, as well as other key
points of contact at the leading HSCT centers in the US as referenced above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 29; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Operating
Strategy</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Veto
Cell doses are to be prepared by Cell Source facilities or qualified production partners. This is to both protect trade secrets and directly
control quality during the initial stages.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
graphic below outlines the general operating model in each geographic market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" style="width: 660px" data-src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_005.jpg" src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_005.jpg"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
care facilities send frozen cells to a Cell Source processing center. Most likely, the first processing center will consist of lab space
leased from or adjacent to a large transplantation center, such as MD Anderson in Texas. Such a transplantation center has appropriate
equipment and infrastructure, along with available production capacity, and will also represent an immediate market for our offerings
for use in their own procedures. The Cell Source processing center processes the cells and sends the treated cells and appropriate protocols
back to the caregiver for infusion at time of transplantation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the introductory post regulatory approval phase, we plan on establishing one center in the U.S., one in Western Europe (most likely Germany),
and one in the Far East. Specific locations and timing are to be determined. Initially, we plan to outsource production capacity from
existing facilities operated by Contract Manufacturing Organizations (CMO) adjacent to large hospitals, or, where capacity is available,
contract directly with major cancer treatment centers who have accredited GMP facilities and experienced cell production staff for Veto
Cell production. Subsequently, sales from these centers can justify and fund stand-alone facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
general goal of the initial centers is to support the FDA process, provide full coverage for the North American and European markets,
and provide access to the Chinese market. Following the introductory period in each respective market, we may elect to migrate the production
facilities from leased space in transplantation center laboratories or contract services with specialized CMOs to company-owned stand-alone
facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, we assume a capital cost per stand-alone production facility of at least $10 million. This estimate is based, in part, on the
projected high costs of GMP “clean rooms,” each of which can cost $1 million to set up. We will need to obtain financing
in order to fund the setup of such facilities. There can be no assurance that financing will be available in amounts or on terms acceptable
to us, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 30; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Clinical
Trials Overview</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will initially focus our clinical trials on stem cell transplantation for patients suffering from blood cancers (lymphoma, leukemia,
myeloma), for which our Veto Cell technology constitutes a potential breakthrough. These indications have unmet needs as evidenced by
the valuations of leading CAR-T players who thus far have chiefly presented data treating these diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
commenced our first Phase 1/2 clinical trial in late 2019. This trial combines traditional Phase 1 safety with Phase 2 efficacy inasmuch
as it is a safety trial conducted on sick patients, so as to both establish safety and show initial indications of efficacy concurrently.
The goal is to demonstrate safety and initial efficacy in several indications. Management has structured the trials such that an additional
goal of showing initial markers pointing to successful engraftment, in the absence of GvHD, while preventing viral infections, already
within Phase 1/2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
chart below provides an overview of the current trials plan, which can of course vary based on both finalization of human protocols and
timing or regulatory approvals:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" style="height: 303.75pt; width: 539.25pt" data-src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_004.jpg" src="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/form10-k_004.jpg"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Trial
Plans</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trials
are planned for the US and Europe. The current initial US trial plans to treat 24 patients. We plan to focus on haploidentical (donor
mismatched) stem cell bone transplantation under reduced intensity conditioning (reduced levels of immune suppression treatment) for
B-cell malignancies and possibly non-malignant indications (e.g. sickle cell disease). We are currently conducting preclinical trials
for VETO CAR-T cell therapy. Once we complete a proof of concept, we plan to augment the current clinical trial protocol for blood cell
cancer to include VETO CAR-T cells, and to develop an Off-the-shelf VETO CAR-T treatment, without a stem cell transplant, for patients
in relapse. In the future, we plan to conduct clinical trials for solid tumor patients as well. Also, once we have shown safety and efficacy
for Veto Cell based stem cell transplants, we plan to combine these with haploidentical kidney transplants in patient trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Regulatory
Issues Overview</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are seeking regulatory approval from the U.S. FDA, the European Medicines Agency (“EMA”) in Europe and plan to approach similar
agencies elsewhere for approvals to both produce and sell our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
commenced a 24 patient human clinical trials for Anti-Viral Veto Cells, our lead product candidate, in the US in late 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 31; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Regulatory
Process and Expectations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed and will continue to develop our clinical trial protocols with the support of highly experienced medical practitioners
who have vast experience in working with their local regulators. MD Anderson, for example, as the largest stem cell transplantation center
and leading cancer treatment facility in the US, has a thoroughgoing internal protocol approval process which serves to refine every
aspect of each patient protocol, in great detail, in anticipation of any potential issues that the FDA would typically wish to see addressed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trials outlined in the previous section are designed to lead to regulatory approval for Veto Cell-based therapy in treating
blood cancers and stem cell transplantation applications and, thereafter, solid organ transplantations and, eventually, solid tumor cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Interim
Revenue Opportunities</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our focus is to conclude Phase 3 approval for cancer treatments, the Company is also exploring complementary shorter-term opportunities
for generating revenue before additional FDA approvals are received, namely:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treating
                                            patients after the end of Phase 2 (based on US Fast Track approvals and/or European Marketing
                                            Authorization Approvals) with either partial or full insurance reimbursement available);
                                            and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
                                            upfront and milestone driven licensing revenues from collaborations with third parties.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Intellectual
Property</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Yeda License Agreement, Yeda granted the Company an exclusive worldwide license to certain patents, discoveries, inventions and
other intellectual property generated (together with others) by Professor Yair Reisner at the Immunology Department at the Weizmann Institute.
Under the Yeda License Agreement, the Company grants Yeda a 4% royalty on sales of patented products. Cell Source is required
to pay Yeda a $50,000 annual license fee until such time as payment of royalties commences. The Yeda License Agreement also requires
the Company to proceed with the development of the technologies on a timely basis. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
license period (per product, per country) is for the full life of the patents and expires at the later of the patent expiration date
in that country or 15 years after the date that the FDA or local equivalent regulatory authority in each country approves that particular
product for sale in that country. As long as Cell Source sponsors research or pays either a nominal license fee of $50,000 per year (total
for use of all the products) or royalties on product sales on at least one product as per the license agreement, the license will remain
in effect continuously and expire only with the expiration of the patent or 15 years after regulatory approval (later of the two) per
product per country as described above. Cell Source voluntarily sponsors Research at the Weizmann Institute for the sake of developing
its products and treatments from initial invention through to finalization of human treatment protocols.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement with Yeda, as amended most recently on December 2, 2021, includes certain development milestones. If the Company fails
to achieve any one of the milestones set forth in the Yeda License Agreement (as per the current amended version) which are listed below,
then Yeda will be entitled to (i) modify the related license such that it will become non-exclusive or (ii) terminate the Yeda License
Agreement upon thirty (30) days written notice:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 157.5pt; text-align: justify; text-indent: -2.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            January 1, 2025, to have commenced Phase 2 clinical trials with respect to a Product;
                                            provided that in the interim the company continues to substantively sponsor research and
                                            clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            January 1, 2028, to have either commenced Phase 3 clinical trials or to have received FDA
                                            or EMA marketing approval in a respect of a Product (“Marketing Approval”);</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">within
                                            12 (twelve) months from the date of Marketing Approval, to have made a First Commercial Sale
                                            of a Product; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            case commercial sale of any Product having commenced, there shall be a period of 12 (twelve)
                                            months or more during which no sales of any Product shall take place by the Company or its
                                            Sublicensees (except as a result of force majeure or other factors beyond the control of
                                            the Company).</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Yeda License Agreement also provides that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">○</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title.
                                            </b>All right, title and interest in and to the Licensed Information and the Patents (as
                                            those terms are defined in the Yeda License Agreement) and all right, title and interest
                                            in and to any drawings, plans, diagrams, specifications, other documents, models, or any
                                            other physical matter in any way containing, representing or embodying any of the foregoing,
                                            vest and shall vest in Yeda and subject to the license granted in the Yeda License Agreement.<br>
                                            <br></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">○</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patents.
                                            </b>Both Yeda and the Company shall consult with one another on the filing of patent applications
                                            for any portion of Licensed Information and/or corresponding to patent application existing
                                            at the time the Yeda License Agreement was executed. Yeda shall retain outside patent counsel
                                            that will be approved by Cell Source, to prepare, file and prosecute patent applications.
                                            All applications will be filed in Yeda’s name.</span></td></tr></tbody></table>

<p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>


<!-- Field: Page; Sequence: 32; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
  <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt; width: 0.75in"></td>
  <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><br>
  <br></b></span></td></tr>
</tbody></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">○</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Patents;
                                            Patent Infringements. Where the Company determines that a third party is infringing one or
                                            more of the Patents or is sued, in prosecuting or defending such litigation, the Company
                                            must pay any expenses or costs or other liabilities incurred in connection with such litigation
                                            (including attorney’s fees, costs and other sums awarded to the counterparty in such
                                            action). The Company agreed to indemnify Yeda against any such expenses or costs or other
                                            liabilities.</span></td></tr>
                                                                                                                                      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
                                                                                                                                      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">○</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License.
                                            </b>With regard to the expiration of Patents, a Product is deemed to be covered by a Patent
                                            so long as such Product is protected by “Orphan Drug” status (or the like). The
                                            Company has an exclusive worldwide license under the Licensed Information and the Patents
                                            for the development, manufacture and sales of the Products. License remains in force in each
                                            country with respect to each Product until the later of (i) the expiration of the last Patent
                                            in such country covering such Product or (ii) the expiration of a 15-year period commencing
                                            the day FDA New Drug Approval is received for a Product in such country.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may grant a Sublicense only with Yeda’s prior written consent, which shall not be withheld unreasonably provided that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            proposed Sublicense is for monetary consideration only;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            proposed Sublicense is to be granted in a bona fide arm’s length commercial transaction;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            copy of the agreement granting the Sublicense and all amendments thereof shall be made available
                                            to Yeda, 14 days before their execution and Cell Source shall submit to Yeda copies of all
                                            such Sublicenses and all amendments thereof promptly upon execution thereof; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            proposed Sublicense is made by written agreement, the provisions of which are consistent
                                            with the terms of the License and contain, inter alia, the following terms and conditions,
                                            including: the Sublicense shall expire automatically on the termination of the License for
                                            any reason.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
Yeda’s prior written consent is not needed if the sublicense is limited to China, and the Company grants it to a Chinese affiliated
entity of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">○</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Termination.
                                            </b>The Yeda License Agreement terminates on the later of: (i) the expiration of the last
                                            of the Patents or (ii) the expiry of a continuous period of 20 years during which there shall
                                            not have been a First commercial sale of any product in any country. Yeda may terminate by
                                            written notice, effective immediately, if the Company challenges the validity of any of the
                                            Patents. If a challenge is unsuccessful, then in addition to Yeda’s right to termination,
                                            the Company shall pay to Yeda liquidated damages in the amount of $8,000,000. Either the
                                            Company or Yeda may terminate the Yeda License Agreement and the License by serving a written
                                            notice upon (i) occurrence of a material breach or (ii) the granting of a winding-up order.
                                            Additionally, Yeda may terminate for failure to reimburse Yeda for patent application and/or
                                            prosecution expenses.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
technology portfolio includes a patented platform termed “Veto Cell” (more formally described as “Anti 3rd party central
memory T cell”), which is an immune tolerance biotechnology that enables the selective blocking of immune responses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a list of all the patents and pending patents that Yeda holds and which we have a license to use, please refer to the table in the section
entitled “<i>Science and Technology Overview</i>” above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Patents
&amp; Proprietary Rights</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in part on our ability to protect our existing product candidates and the products we acquire or license by obtaining
and maintaining a strong proprietary position. To develop and maintain our position, we intend to continue relying upon patent protection,
orphan drug status, Hatch-Waxman exclusivity, trade secrets, know-how, continuing technological innovations and licensing opportunities.
We intend to seek patent protection whenever available for any products or product candidates and related technology we acquire in the
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also seek orphan drug status whenever it is available. If a product which has an orphan drug designation subsequently receives the
first regulatory approval for the indication for which it has such designation, the product is entitled to orphan exclusivity, meaning
that the applicable regulatory authority may not approve any other applications to market the same drug for the same indication, except
in very limited circumstances, for a period of seven years in the U.S. and Canada, and 10 years in the EU. Orphan drug designation does
not prevent competitors from developing or marketing different drugs for the same indication or the same drug for a different clinical
indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 33; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute
confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all
confidential information made known to the individual during the course of the individual’s relationship with us is to be kept
confidential and may not be disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide
that all inventions conceived by the individual shall be our exclusive property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Government
Regulation and Product Approval</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
submitted our first IND application to the FDA, which was done on our behalf by MD Anderson, in February 2019. Cell Source itself has
not had any contact with any regulator anywhere regarding treatment approvals or clinical trials associated with regulatory approvals.
We are aware that a hospital in Italy has independently requested and received approval to conduct a trial with a treatment protocol
the patents for which we license from Yeda, which today forms part of the broader protocol that we plan to use in the US and European
clinical trials, but we are not mentioned in the application nor in the approval. However, we may indirectly benefit from the outcome
of the trial, if successful, although we are not the sponsor of this trial. There are no written or verbal agreements between the hospital
and Cell Source regarding the use of the technology. That said, Cell Source is aware and in favor of the hospital’s plans to use
the technology and would find a positive initial outcome encouraging. Since the treatment is being done on compassionate grounds as a
non-commercial clinical trial, there is no legal requirement for the hospital to obtain approval to use the treatment protocol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
Source commenced a human clinical trial, conducted on its behalf by MD Anderson, in 2019 to show initial safety, and possibly efficacy,
results in the US.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
by governmental authorities in the U.S. and other countries is a significant factor, affecting the cost and time of our research and
product development activities, and will be a significant factor in the manufacture and marketing of any approved products. All of our
products require regulatory approval by governmental agencies prior to commercialization. In particular, our products are subject to
rigorous pre-clinical and clinical testing and other approval requirements by the FDA and similar regulatory authorities in other countries.
Various statutes and regulations also govern or influence the manufacturing, safety, reporting, labeling, transport and storage, record
keeping and marketing of our products. The lengthy process of seeking these approvals, and the subsequent compliance with applicable
statutes and regulations, require the expenditure of substantial resources. Any failure by us to obtain, or any delay in obtaining, the
necessary regulatory approvals could harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulatory requirements relating to the testing, manufacturing and marketing of our products may change from time to time and this may
impact our ability to conduct clinical trials and the ability of independent investigators to conduct their own research with support
from us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical development, manufacturing and marketing of our products are subject to regulation by various authorities in the U.S., the EU
and other countries, including, in the U.S., the FDA, in Canada, Health Canada, and, in the EU, the EMA. The Federal Food, Drug, and
Cosmetic Act, the Public Health Service Act in the U.S. and numerous directives, regulations, local laws and guidelines in Canada and
the EU and elsewhere govern the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and
promotion of our products. Product development and approval within these regulatory frameworks takes a number of years and involves the
expenditure of substantial resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
approval will be required in all the major markets in which we seek to develop our products. At a minimum, approval requires the generation
and evaluation of data relating to the quality, safety, and efficacy of an investigational product for its proposed use. The specific
types of data required and the regulations relating to this data will differ depending on the territory, the treatment candidate involved,
the proposed indication and the stage of development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, new cell compositions are tested in animals until adequate evidence of safety is established to support the proposed clinical
study protocol designs. Clinical trials for new products are typically conducted in three sequential phases that may overlap. In Phase
1, the initial introduction of the pharmaceutical into either healthy human volunteers or patients with the disease (typically 20 to
50 subjects), the emphasis is on testing for safety (adverse effects), dosage tolerance, metabolism, distribution, excretion and clinical
pharmacology. Phase 2 involves studies in a limited patient population (typically 50 to 200 patients) to determine the initial efficacy
of the pharmaceutical for specific targeted indications, to determine dosage tolerance and optimal dosage and to identify possible adverse
side effects and safety risks. Once a treatment protocol shows preliminary evidence of some efficacy and is found to have an acceptable
safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to more fully evaluate clinical outcomes in a larger patient population
in adequate and well-controlled studies designed to yield statistically sufficient clinical data to demonstrate efficacy and safety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 34; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., specific pre-clinical data, manufacturing and chemical data, as described above, need to be submitted to the FDA as part of
an IND application, which, unless the FDA objects, will become effective thirty (30) days following receipt by the FDA. Phase 1 studies
in human volunteers may commence only after the application becomes effective. Prior regulatory approval for human healthy volunteer
studies is also required in member states of the EU. Currently, in each member state of the EU, following successful completion of Phase
1 studies, data are submitted in summarized format to the applicable regulatory authority in the member state in respect of applications
for the conduct of later Phase 2 studies. In many places in Europe, a two-tiered approval system mandates approval at the regional level
prior to applying for national approval. Regional approval cycle times, including multiple iterations where questions are answered and
the specific details of the protocol may be fine-tuned, can last several months prior to applying to the national (federal government
level) regulator. The national regulatory authorities in the EU typically have between one and three months in which to raise any objections
to the proposed study, and they often have the right to extend this review period at their discretion. In the U.S., following completion
of Phase 1 studies, further submissions to regulatory authorities are necessary in relation to Phase 2 and 3 studies to update the existing
IND. Authorities may require additional data before allowing the studies to commence and could demand that the studies be discontinued
at any time if there are significant safety issues. In addition to the regulatory review, a study involving human subjects has to be
approved by an independent body. The exact composition and responsibilities of this body will differ from country to country. In the
U.S., for example, each study will be conducted under the auspices of an independent institutional review board at each institution at
which the study is conducted. This board considers among other things, the design of the study, ethical factors, the privacy of protected
health information as defined under the Health Insurance Portability and Accountability Act, the safety of the human subjects and the
possible liability risk for the institution. Equivalent rules to protect subjects’ rights and welfare apply in each member state
of the EU, where one or more independent ethics committees, which typically operate similarly to an institutional review board, will
review the ethics of conducting the proposed research. These ethical review committees typically exist at the regional level, where approval
is required prior to applying for national approval. Other regulatory authorities around the rest of the world have slightly differing
requirements involving both the execution of clinical trials and the import/export of pharmaceutical products. It is our responsibility
to ensure we conduct our business in accordance with the regulations of each relevant territory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
leveraging existing pre-clinical and clinical data, we are seeking to build upon an existing pre-clinical safety and efficacy database
to accelerate our research. In addition, our focus on an end-stage population which has limited current treatment options may result
in relatively shorter approval cycle times. Approval by the FDA in this category generally has been based on objective response rates
and duration of responses rather than demonstration of survival benefit. As a result, trials of drugs to treat end-stage refractory cancer
indications have historically involved fewer patients and generally have been faster to complete than trials of drugs for other indications.
We are aware that the FDA and other similar agencies are regularly reviewing the use of objective endpoints for commercial approval and
that policy changes may impact the size of trials required for approval, timelines and expenditures significantly. The trend over the
past few years has been to shorten approval cycles for terminal patients in the U.S. by employing a “fast track” approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to gain marketing approval, we must submit a dossier to the relevant authority for review, which is known in the U.S. as an NDA
and in the EU as a marketing authorization application, or MAA. The format is usually specific and laid out by each authority, although
in general it will include information on the quality of the chemistry, manufacturing and pharmaceutical aspects of the product as well
as the non-clinical and clinical data. Once the submitted NDA is accepted for filing by the FDA, it undertakes the review process that
takes ten (10) months, unless an expedited priority review is granted which takes six (6) months to complete. Approval can take several
months to several years, if multiple ten (10) month review cycles are needed before final approval is obtained, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
approval process can be affected by a number of factors. The NDA may be approvable requiring additional pre-clinical, manufacturing data
or clinical trials which may be requested at the end of the ten (10) month NDA review cycle, thereby delaying marketing approval until
the additional data are submitted and may involve substantial unbudgeted costs. The regulatory authorities usually will conduct an inspection
of relevant manufacturing facilities, and review manufacturing procedures, operating systems and personnel qualifications. In addition
to obtaining approval for each product, in many cases each drug manufacturing facility must be approved. Further inspections may occur
over the life of the product. An inspection of the clinical investigation sites by a competent authority may be required as part of the
regulatory approval procedure. As a condition of marketing approval, the regulatory agency may require post-marketing surveillance to
monitor for adverse effects or other additional studies as deemed appropriate. After approval for the initial indication, further clinical
studies are usually necessary to gain approval for any additional indications. The terms of any approval, including labeling content,
may be more restrictive than expected and could affect the marketability of a product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA offers a number of regulatory mechanisms that provide expedited or accelerated approval procedures for selected drugs in the indications
on which we are focusing our efforts. These include accelerated approval under Subpart H of the agency’s NDA approval regulations,
fast track drug development procedures and priority review. At this time, we have not determined whether any of these approval procedures
will apply to any of our current treatment candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
US, EU and other jurisdictions may grant orphan drug designation to drugs intended to treat a “rare disease or condition,”
which, in the US, is generally a disease or condition that affects no more than 200,000 individuals. In the EU, orphan drug designation
can be granted if: the disease is life threatening or chronically debilitating and affects no more than fifty (50) in 100,000 persons
in the EU; without incentive it is unlikely that the drug would generate sufficient return to justify the necessary investment; and no
satisfactory method of treatment for the condition exists or, if it does, the new drug will provide a significant benefit to those affected
by the condition. If a product that has an orphan drug designation subsequently receives the first regulatory approval for the indication
for which it has such designation, the product is entitled to orphan exclusivity, meaning that the applicable regulatory authority may
not approve any other applications to market the same drug for the same indication, except in very limited circumstances, for a period
of seven years in the U.S. and ten (10) years in the EU. Orphan drug designation does not prevent competitors from developing or marketing
different drugs for the same indication or the same drug for different indications. Orphan drug designation must be requested before
submitting an NDA or MAA. After orphan drug designation is granted, the identity of the therapeutic agent and its potential orphan use
are publicly disclosed. Orphan drug designation does not convey an advantage in, or shorten the duration of, the review and approval
process; however, this designation provides an exemption from marketing authorization (NDA) fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 35; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to numerous environmental and safety laws and regulations, including those governing the use and disposal of hazardous
materials. The cost of compliance with and any violation of these regulations could have a material adverse effect on our business and
results of operations. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards
prescribed by state and federal regulations, accidental contamination or injury from these materials may occur. Compliance with laws
and regulations relating to the protection of the environment has not had a material effect on our capital expenditures or our competitive
position. However, we are not able to predict the extent of government regulation, and the cost and effect thereof on our competitive
position, which might result from any legislative or administrative action pertaining to environmental or safety matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
various countries, animal rights activism has led to either formal or informal boycotting of certain types of animal trials. This may
have an adverse impact on our business as we rely on animal experiments as precursors to human trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Employees</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than our Chief Executive Officer, we currently do not have any full-time employees, but retain the services of independent contractors/consultants
on a contract-employment basis. Our ability to manage growth effectively will require us to continue to implement and improve our management
systems and to recruit and train new employees. Although we have done so in the past and expect to do so in the future, there can be
no assurance that we will be able to successfully attract and retain skilled and experienced personnel. We anticipate that in the near
future, other key personnel will enter into employment agreements with the Company on customary terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>ITEM
1A. RISK FACTORS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in the Company’s Common Stock involves a high degree of risk. You should carefully consider the risks described below
as well as other information provided to you in this Annual Report on Form 10-K, including information in the section of this document
entitled “Information Regarding Forward Looking Statements.” The risks and uncertainties described below are not the only
ones facing us. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also impair
our business operations. If any of the following risks actually occur, our business, financial condition or results of operations could
be materially adversely affected, the value of our Common Stock could decline, and you may lose all or part of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
related to our Business and our Industry</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
may not receive regulatory approvals for our product candidates or there may be a delay in obtaining such approvals.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products and our ongoing development activities are subject to regulation by regulatory authorities in the countries in which we or our
collaborators and distributors wish to test, manufacture or market our products. For instance, the FDA will regulate the product in the
U.S. and equivalent authorities, such as the EMA, will regulate in Europe. Regulatory approval by these authorities will be subject to
the evaluation of data relating to the quality, efficacy and safety of the product for its proposed use, and there can be no assurance
that the regulatory authorities will find our data sufficient to support product approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain regulatory approval varies between countries. In the U.S., for products without “Fast Track” status,
it can take up to eighteen (18) months after submission of an application for product approval to receive the FDA’s decision. Even
with Fast Track status, FDA review and decision can take up to twelve (12) months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Different
regulators may impose their own requirements and may refuse to grant, or may require additional data before granting, an approval, notwithstanding
that regulatory approval may have been granted by other regulators. Regulatory approval may be delayed, limited or denied for a number
of reasons, including insufficient clinical data, the product not meeting safety or efficacy requirements or any relevant manufacturing
processes or facilities not meeting applicable requirements as well as case load at the regulatory agency at the time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 36; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Clinical
trials for our product candidates are expensive and time consuming, and their outcome is uncertain.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining and maintaining regulatory approvals for new therapeutic products is expensive, lengthy and uncertain. Costs and
timing of clinical trials may vary significantly over the life of a project owing to any or all of the following non-exclusive reasons:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    duration of the clinical trial;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of sites included in the trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    countries in which the trial is conducted;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    length of time required and ability to enroll eligible patients;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of patients that participate in the trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of doses that patients receive;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    drop-out or discontinuation rates of patients;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
    patient trial costs;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third
    party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    final product candidates having different properties in humans than in laboratory testing;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    need to suspend or terminate our clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
    or inadequate supply of quality of necessary materials to conduct our trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    additional safety monitoring, or other conditions required by FDA or comparable foreign regulatory authorities regarding the scope
    or design of our clinical trials, or other studies requested by regulatory agencies;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">problems
    engaging institutional review boards (“IRB”) to oversee trials or in obtaining and maintaining IRB approval of studies;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    duration of patient follow-up;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    efficacy and safety profile of a product candidate;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of obtaining regulatory approvals; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in enforcing or defending patent claims or other intellectual property rights.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Late-stage
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical trials are especially expensive, typically
requiring tens of millions of dollars, and take years to reach their outcomes. Such outcomes often fail to reproduce the results of earlier
trials. It is often necessary to conduct multiple late-stage trials, including multiple Phase 3 trials, in order to obtain sufficient
results to support product approval, which further increases the expense. Sometimes trials are further complicated by changes in requirements
while the trials are underway (for example, when the standard of care changes for the disease that is being studied in the trial). Accordingly,
any of our current or future product candidates could take a significantly longer time to gain regulatory approval than we expect, or
may never gain approval, either of which could delay or stop the commercialization of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude approval
of our product candidates.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trials may be suspended at any time for a number of reasons. For example, we may voluntarily suspend or terminate our clinical
trials if at any time we believe that they present an unacceptable risk to the clinical trial patients. In addition, the FDA or other
regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe that the
clinical trials are not being conducted in accordance with applicable regulatory requirements or that they present an unacceptable safety
risk to the clinical trial patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 37; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administering
any product candidate to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials
of our product candidates and could result in the FDA or other regulatory authorities denying further development or approval of our
product candidates for any or all targeted indications. Ultimately, some or all of our product candidates may prove to be unsafe for
human use. Moreover, we could be subject to significant liability if any volunteer or patient suffers, or appears to suffer, adverse
health effects as a result of participating in our clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Delays
in our clinical trials could result in us not achieving anticipated developmental milestones when expected, increased costs and delay
our ability to obtain regulatory approval and commercialize our product candidates.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delays
in our ability to commence or enroll patients for our clinical trials could result in us not meeting anticipated clinical milestones
and could materially impact our product development costs and delay regulatory approval of our product candidates. We do not know whether
planned clinical trials will be commenced or completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in the development of manufacturing capabilities for our product candidates to enable their consistent production at clinical trial
    scale;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in the commencement of clinical trials as a result of clinical trial holds or the need to obtain additional information to complete
    an Investigational New Drug Application (IND);</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 86%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining regulatory approval to commence new trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 86%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    safety events experienced during our clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
    efficacy during trials leading to withdrawal of product candidate;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 84%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining clinical materials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower
    than expected patient recruitment for participation in clinical trials; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching agreement on acceptable clinical trial agreement terms with prospective sites or obtaining institutional review board
    approval.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not successfully commence or complete our clinical trials on schedule, the price of our common stock may decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
product candidates must undergo rigorous clinical testing, the results of which are uncertain and could substantially delay or prevent
us from bringing them to market.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
we can obtain regulatory approval for a product candidate, we must undertake extensive clinical testing in humans to demonstrate safety
and efficacy to the satisfaction of the FDA or other regulatory agencies. Clinical trials of new drug candidates sufficient to obtain
regulatory marketing approval are expensive and take years to complete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain of successfully completing clinical testing within the time frame we have planned, or at all. We may experience numerous
unforeseen events during, or as a result of, the clinical trial process that could delay or prevent us from receiving regulatory approval
or commercializing our product candidates, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional
    clinical and/or preclinical testing or to abandon programs;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results obtained in earlier stage clinical testing may not be indicative of results in future clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trial results may not meet the level of statistical significance required by the FDA or other regulatory agencies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enrollment
    in our clinical trials for our product candidates may be slower than we anticipate, resulting in significant delays and additional
    expense;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
    or regulators, may suspend or terminate our clinical trials if the participating patients are being exposed to unacceptable health
    risks; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 87%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            effects of our product candidates on patients may not be the desired effects or may include
                                            undesirable side effects or other characteristics that may delay or preclude regulatory approval
                                            or limit their commercial use, if approved.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 38; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
of clinical trials depends, among other things, on our ability to enroll a sufficient number of patients, which is a function of many
factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 83%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    therapeutic endpoints chosen for evaluation;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 83%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    eligibility criteria defined in the protocol;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 84%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    perceived benefit of the investigational drug under study;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    size of the patient population required for analysis of the clinical trial’s therapeutic endpoints;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 10%"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 3%"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 87%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to recruit clinical trial investigators and sites with the appropriate competencies
                                            and experience;</span></p></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 83%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain patient consents; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 86%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    for patients by clinical trial programs for other treatments.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience difficulties in enrolling patients in our clinical trials, which could increase the costs or affect the timing or outcome
of these clinical trials. This is particularly true with respect to diseases with relatively small patient populations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Preclinical
studies and Phase 1 or 2 clinical trials of our product candidates may not predict the results of subsequent human clinical trials.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
studies, including studies of our product candidates in animal models, may not accurately predict the result of human clinical trials
of those product candidates. In particular, promising animal studies suggesting the efficacy of our products may not predict the ability
of these products to treat humans. Our technology may be found not to be efficacious when studied in human clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
satisfy FDA or foreign regulatory approval standards for the commercial sale of our product candidates, we must demonstrate in adequate
and controlled clinical trials that our product candidates are safe and effective. Success in early clinical trials, including Phase
2 trials, does not ensure that later clinical trials will be successful. Our initial results from Phase 1/2 clinical trials also may
not be confirmed by later analysis or subsequent larger clinical trials. A number of companies in the pharmaceutical industry have suffered
significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates or any future product
candidates, which would prevent or delay or limit the scope of regulatory approval and commercialization</span><b>.</b></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain the requisite regulatory approvals to market and sell any of our product candidates and any other future product candidates, we
must demonstrate through clinical trials that our product candidates are safe and effective for use in each targeted indication. Clinical
testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during
the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for
commercialization. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically
meaningful, and a clinical trial can fail at any stage of testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials, and
can vary substantially based upon the type, complexity, and novelty of the product candidates involved, as well as the target indications,
patient population, and regulatory agency. Prior to obtaining approval to commercialize our product candidates and any future product
candidates in the United States or abroad, we or our potential future collaborators must demonstrate with substantial evidence from adequate
and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product
candidates are safe and effective for their intended uses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials that we conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates.
In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product
candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of
the patient populations, changes in and adherence to the clinical trial protocols, and the rate of dropout among clinical trial participants.
If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of our product candidates, if we
do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated
with our product candidates, we may be delayed in obtaining marketing approval, if at all. Additionally, any safety concerns observed
in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates
in those and other indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 39; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if the trials are successfully completed, clinical data are often susceptible to varying interpretations and analyses, and we cannot
guarantee that the FDA or comparable foreign regulatory authorities will interpret the results as we do, and more trials could be required
before we submit our product candidates for approval. We cannot guarantee that the FDA or comparable foreign regulatory authorities will
view our product candidates as having efficacy even if positive results are observed in clinical trials. The FDA or comparable foreign
regulatory authorities may not agree with our manufacturing strategy or find comparability between our clinical trial product candidates
and proposed commercial product candidates even if positive results are observed in clinical trials, which may result in regulatory delays
or a need to perform additional clinical studies. Moreover, results acceptable to support approval in one jurisdiction may be deemed
inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results
of the trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, approval
of our product candidates and any future product candidates may be significantly delayed, or we may be required to expend significant
additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product
candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of
the specific product candidate, which may also limit its commercial potential.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
are subject to various government regulations.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacture and sale of human therapeutic and diagnostic products in the U.S., Canada and foreign jurisdictions are governed by a variety
of statutes and regulations. These laws require approval of manufacturing facilities, controlled research and testing of products and
government review and approval of a submission containing manufacturing, preclinical and clinical data in order to obtain marketing approval
based on establishing the safety and efficacy of the product for each use sought, including adherence to current Good Manufacturing Practice
(or cGMP) during production and storage, and control of marketing activities, including advertising and labeling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
products we are currently developing will require significant development, preclinical and clinical testing and investment of substantial
funds prior to their commercialization. The process of obtaining required approvals can be costly and time-consuming, and there can be
no assurance that future products will be successfully developed and will prove to be safe and effective in clinical trials or receive
applicable regulatory approvals. Markets other than the U.S. and Canada have similar restrictions. Potential investors and shareholders
should be aware of the risks, problems, delays, expenses and difficulties which we may encounter in view of the extensive regulatory
environment which controls our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
may become subject to increased government regulation.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increased
government regulation could: (i) reduce any future revenues; (ii) increase our operating expenses; and (iii) expose us to significant
liabilities. We cannot be sure what effect any future material noncompliance by us with any future laws and regulations or any material
changes in current laws and regulations could have on our business, operating results and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
may fail to comply with regulatory requirements</span></i><span style="text-decoration: underline">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will be dependent upon our ability, and our collaborative partners’ abilities, to maintain compliance with regulatory requirements,
including cGMP, and safety reporting obligations. The failure to comply with applicable regulatory requirements can result in, among
other things, fines, injunctions, civil penalties, total or partial suspension of regulatory approvals, refusal to approve pending applications,
recalls or seizures of products, operating and production restrictions and criminal prosecutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Regulatory
approval of our product candidates may be withdrawn at any time.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
regulatory approval has been obtained for medicinal products, the product and the manufacturer are subject to continual review, including
the review of adverse experiences and clinical results that are reported after our products are made available to patients, and there
can be no assurance that such approval will not be withdrawn or restricted. Regulators may also subject approvals to restrictions or
conditions or impose post-approval obligations on the holders of these approvals, and the regulatory status of such products may be jeopardized
if such obligations are not fulfilled. If post-approval studies are required, such studies may involve significant time and expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturer and manufacturing facilities we use to make any of our products will also be subject to periodic review and inspection by
the FDA or EMA, as applicable. The discovery of any new or previously unknown problems with the product, manufacturer or facility may
result in restrictions on the product or manufacturer or facility, including withdrawal of the product from the market. We will continue
to be subject to the FDA or EMA requirements, as applicable, governing the labeling, packaging, storage, advertising, promotion, recordkeeping,
and submission of safety and other post-market information for all of our product candidates, even those that the FDA or EMA, as applicable,
had approved. If we fail to comply with applicable continuing regulatory requirements, we may be subject to fines, suspension or withdrawal
of regulatory approval, product recalls and seizures, operating restrictions and other adverse consequences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 40; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Even
if approved, our products may not gain market acceptance, in which case we may not be able to generate product revenues, which will materially
adversely affect our business, financial condition, and results of operations</span></i><span style="text-decoration: underline">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if the FDA or any comparable foreign regulatory authority approves the marketing of any product candidates that we develop, physicians,
healthcare providers, patients, or the medical community may not accept or use them. Additionally, the product candidates that we are
developing are based on our proprietary platforms, which are new technologies. If these products do not achieve an adequate level of
acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of any of
our product candidates will depend on a variety of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of market introduction;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms of any approvals and the countries in which approvals are obtained;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and clinical profile of competing products;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to provide acceptable evidence of safety and efficacy;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of any side effects;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
    convenience and ease of administration;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effectiveness;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    diagnostics and screening infrastructure in each market;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">marketing
    and distribution support;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    publicity about our product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of coverage, adequate reimbursement and sufficient payment from health maintenance organizations and other insurers, both public
    and private, for our product candidates, or the procedures utilizing our product candidates, if approved;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors and government authorities; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    potential advantages over alternative treatment methods.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, although we are not utilizing replication competent vectors, adverse publicity due to the ethical and social controversies
surrounding the therapeutic use of such technology, and reported side effects from any clinical trials using these technologies or the
failure of such trials to demonstrate that these therapies are safe and effective may limit market acceptance of our product candidates.
If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment
centers or others in the medical community, we will not be able to generate significant revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our product candidates fail to gain market acceptance, this will have a material adverse impact on our ability to generate revenues to
provide a satisfactory, or any, return on our investments. Even if some products achieve market acceptance, the market may prove not
to be large enough to allow us to generate significant revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
do not own any patents and rely on the patents we license from Yeda Research and Development Limited.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently own any patents and only have an exclusive worldwide license to certain intellectual property owned by Yeda pursuant
to a license agreement between us and Yeda. Under the license agreement with Yeda, Yeda retains ownership of the licensed patents. If
we were to default under the license agreement, then our rights to Yeda’s intellectual property would be extinguished and we would
lose all rights to operate the license. In such an event, we would effectively cease to operate unless we re-obtained licensing with
Yeda.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 41; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
are dependent on protecting our proprietary rights.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success and competitive position and future overall revenues will depend in part on our ability to obtain and maintain patent protection
over the patents that we have an exclusive license to use for our product candidates, methods, process and other technologies to preserve
our trade secrets, to prevent third parties from infringing on our proprietary rights and to operate without infringing the proprietary
rights of third parties. Although our patents and related technologies are owned by Yeda, under our exclusive license agreement, we are
required to pay all patent related expenses for applications, renewals, etc., as well as any and all legal or other costs associated
with the defending and protecting such proprietary rights. However, we cannot predict:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    degree and range of protection any patents will afford us against competitors, including whether third parties will find ways to
    invalidate or otherwise circumvent the patents that we license;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    or not others will obtain patents claiming aspects similar to those covered by the patents that we license; or</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we will need to initiate litigation or administrative proceedings, which may be costly whether we win or lose.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a complete list of the patents that we license from Yeda, please see the section entitled “<i>Science and Technology Overview</i>”
of this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be required to obtain licenses from third parties to avoid infringing patents or other proprietary rights. No assurance can be given
that any licenses required under any such patents or proprietary rights would be made available, if at all, on terms we find acceptable.
If we do not obtain such licenses, we could encounter delays in the introduction of products, or could find that the development, manufacture
or sale of products requiring such licenses could be prohibited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of pharmaceutical, biopharmaceutical and biotechnology companies and research and academic institutions have developed technologies,
filed patent applications or received patents on various technologies that may be related to or affect our business. Some of these technologies,
applications or patents may conflict with our technologies or patent applications. Such conflict could limit the scope of the patents,
if any, that we may be able to obtain. Such conflict may also result in the denial of our patent applications. In addition, if patents
that cover our activities are issued to other companies, there can be no assurance that we would be able to obtain licenses to these
patents at a reasonable cost or be able to develop or obtain alternative technology. If we do not obtain such licenses, we could encounter
delays in the introduction of products, or could find that the development, manufacture or sale of products requiring such licenses could
be prohibited. In addition, we could incur substantial costs in defending ourselves in suits brought against us on patents that our products
might infringe or in filing suits against others to have such patents declared invalid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
applications in the U.S. are maintained in secrecy and not published if either: i) the application is a provisional application or, ii)
the application is filed and we request no publication and certify that the invention disclosed “has not and will not” be
the subject of a published foreign application. Otherwise, U.S. applications or foreign counterparts, if any, publish 18 months after
the priority application has been filed. Since publication of discoveries in the scientific or patent literature often lag behind actual
discoveries, we cannot be certain that we or any licensor were the first creator of inventions covered by pending patent applications
or that we or such licensor was the first to file patent applications for such inventions. Moreover, we might have to participate in
interference proceedings declared by the U.S. Patent and Trademark Office to determine priority of invention, which could result in substantial
cost to us, even if the eventual outcome were favorable to us. There can be no assurance that our patents, if issued, would be held valid
or enforceable by a court or that a competitor’s technology or product would be found to infringe such patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Much
of our know-how and technology may not be patentable. To protect our rights, we require employees, consultants, advisors and collaborators
to enter into confidentiality agreements. There can be no assurance, however, that these agreements will provide meaningful protection
for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure. Further, our business
may be adversely affected by competitors who independently develop competing technologies, especially if we obtain no, or only narrow,
patent protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Confidentiality
agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect
proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and
any other elements of our product candidates, technology and product discovery and development processes that involve proprietary know-how,
information, or technology that is not covered by patents. Any disclosure, either intentional or unintentional, by our employees, the
employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research,
clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade
secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our
competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates,
we must, at times, share trade secrets with them. Our reliance on third parties requires us to share our trade secrets, which increases
the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 42; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
are dependent on our collaborative partners and service providers the loss of which would hurt our business.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy is to enter into various arrangements with corporate and academic collaborators, licensors, licensees, service providers and
others for the research, development, clinical testing and commercialization of our products. We intend to or have entered into agreements
with academic, medical and commercial organizations to research, develop and test our products. In addition, we intend to enter into
corporate partnerships to commercialize the Company’s core products. There can be no assurance that such collaborations can be
established on favorable terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any collaborative partner or service provider fail to appropriately research, develop, test or successfully commercialize any product
to which the Company has rights, our business may be adversely affected. Failure of a collaborative partner or service provider to successfully
conduct or complete their activities or to remain a viable collaborative partner or commercial enterprise for any particular program
could delay or halt the development or commercialization of any products arising out of such program. While management believes that
collaborative partners and service providers will have sufficient economic motivation to continue their activities, there can be no assurance
that any of these collaborations or provisions of required services will be continued or result in successfully commercialized products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notably,
we maintain an exclusive worldwide license to certain intellectual property owned by Yeda pursuant to the Yeda License Agreement, as
further discussed in the “Intellectual Property” section hereinafter. If we should default under the License Agreement, then
our rights to Yeda’s intellectual property would extinguish, and we would lose all rights to operate the licenses. In such event,
we would effectively cease to operate unless we re-obtained licensing with Yeda.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there can be no assurance that the collaborative research or commercialization partners will not pursue alternative technologies
or develop alternative products either on their own or in collaboration with others, including our competitors, as a means for developing
treatments for the diseases or conditions targeted by our programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">If
we are unable to keep up with rapid technological changes in our field or compete effectively, we will be unable to operate profitably.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are engaged in a rapidly changing field. Other products and therapies that will compete directly with the products that we are seeking
to develop and market currently exist or are being developed. Competition from fully integrated pharmaceutical companies and more established
biotechnology companies is intense and is expected to increase. Most of these companies have significantly greater financial resources
and expertise in discovery and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing
than us. Smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical
and established biopharmaceutical or biotechnology companies. Many of these competitors have significant products that have been approved
or are in development and operate large, well-funded discovery and development programs. Academic institutions, governmental agencies
and other public and private research organizations also conduct research, seek patent protection and establish collaborative arrangements
for therapeutic products and clinical development and marketing. These companies and institutions compete with us in recruiting and retaining
highly qualified scientific and management personnel. In addition to the above factors, we will face competition based on product efficacy
and safety, the timing and scope of regulatory approvals, availability of supply, marketing and sales capability, reimbursement coverage,
price and patent position. There is no assurance that our competitors will not develop more effective or more affordable products, or
achieve earlier patent protection or product commercialization, than our own.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
companies may succeed in developing products earlier than ourselves, obtaining Health Canada, European Medicines Agency (the “EMA”)
and FDA approvals for such products more rapidly than we will, or in developing products that are more effective than products we propose
to develop. While we will seek to expand our technological capabilities in order to remain competitive, there can be no assurance that
research and development by others will not render our technology or products obsolete or non-competitive or result in treatments or
cures superior to any therapy we develop, or that any therapy we develop will be preferred to any existing or newly developed technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
ability and our collaborators’ ability to sell therapeutic products will depend to a large extent upon reimbursement from health
care insurance companies.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success may depend, in part, on the extent to which reimbursement for the costs of therapeutic products and related treatments will be
available from third-party payers such as government health administration authorities, private health insurers, managed care programs,
and other organizations. Over the past decade, the cost of health care has risen significantly, and there have been numerous proposals
by legislators, regulators and third-party health care payers to curb these costs. Some of these proposals have involved limitations
on the amount of reimbursement for certain products. Similar federal or state health care legislation may be adopted in the future and
any products that we or our collaborators seek to commercialize may not be considered cost-effective. Adequate third-party levels that
are sufficient for realization of an appropriate return on investment in product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 43; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates
or indications that may be more profitable or for which there is a greater likelihood of success.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and managerial resources, we focus on research programs, therapeutic platforms, and product candidates that
we identify for specific indications. Additionally, we have contractual commitments under our collaboration agreements to use commercially
reasonable efforts to develop certain programs and, thus, do not have unilateral discretion to vary from such agreed to efforts. In addition,
we have contractual commitments to conduct certain development plans, and thus may not have discretion to modify such development plans,
including clinical trial designs, without agreement from our collaboration partners. As a result, we may forego or delay pursuit of opportunities
with other therapeutic platforms or product candidates or for other indications that later prove to have greater commercial potential.
Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.
Our spending on current and future research and development programs, therapeutic platforms, and product candidates for specific indications
may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular
product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements
in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Interim,
topline, or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes
available or as we make changes to our manufacturing processes and are subject to audit and verification procedures that could result
in material changes in the final data</span><b>.</b></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publicly disclose interim, topline, or preliminary data from our preclinical studies and clinical trials, which
is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change
following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations,
and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate
all data. Further, modifications or improvements to our manufacturing processes for a therapy may result in changes to the characteristics
or behavior of the product candidate that could cause our product candidates to perform differently and affect the results of our ongoing
clinical trials. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions
or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject
to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously
published. As a result, topline data should be viewed with caution until the final data are available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may also disclose preliminary or interim data from our preclinical studies and clinical trials. Preliminary or interim
data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment
continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly
harm our business prospects. Additionally, disclosure of preliminary or interim data by us or by our competitors could result in volatility
in the price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability
or commercialization of the particular product candidate, and our company in general. If the interim, topline, or preliminary data that
we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability
to obtain approval for, and commercialize, any of our potential product candidates may be harmed, which could harm our business, operating
results, prospects, or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
rely on key personnel and, if we are unable to retain or motivate key personnel or hire qualified personnel, we may not be able to grow
effectively.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on our Chief Executive Officer, Itamar Shimrat, our Executive Chairman, Dennis Brown, and on scientific and drug development
consultants, the loss of services of one or more of whom could materially adversely affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than our Chief Executive Officer, we currently do not have full-time employees, but we retain the services of independent contractors/consultants
on a contract-employment basis. Our ability to manage growth effectively will require us to continue to implement and improve our management
systems and to recruit and train new employees. Although we have done so in the past and expect to do so in the future, there can be
no assurance that we will be able to successfully attract and retain skilled and experienced personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
may be subject to foreign exchange fluctuation.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain our accounts in both U.S. dollars and Israeli Shekels. A portion of our expenditures are in foreign currencies, most notably
in Israeli Shekels, and therefore we are subject to foreign currency fluctuations, which may, from time to time, impact our financial
position and results. We may enter into hedging arrangements under specific circumstances, typically through the use of forward or futures
currency contracts, to minimize the impact of increases in the value of the Israeli Shekel. In order to minimize our exposure to foreign
exchange fluctuations we may hold sufficient Israeli Shekels to cover our expected Israeli Shekel expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 44; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
may be exposed to potential product and clinical trials liability.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to potential product liability risks, which are inherent in the testing, manufacturing, marketing and sale of therapeutic
products. Human therapeutic products involve an inherent risk of product liability claims and associated adverse publicity. While we
will continue to take precautions we deem appropriate, there can be no assurance that we will be able to avoid significant product liability
exposure. We do not currently maintain liability insurance coverage as such insurance is expensive and difficult to obtain. As we move
forward with our own clinical trials, we plan to obtain liability insurance coverage in the jurisdictions applicable to such clinical
trials. However, when we seek such insurance, it may not be available on acceptable terms, if at all. The inability to obtain sufficient
insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit our
ability to conduct clinical trials in certain jurisdiction or the commercialization of our current or potential products. A product liability
claim brought against us in a clinical trial or a product withdrawal could have a material adverse effect upon us and our financial condition.
Should the insurance coverage be insufficient in amount or scope to address multiple and diverse claims, liabilities not covered by insurance
could represent a significant financial liability for Cell Source. Since Yeda does not conduct human trials, there is no need for Cell
Source to have insurance for trials there. As Cell Source continues to contract facilities at hospitals to conduct human trials on its
behalf, it will ensure that full and proper insurance coverage will be in place with respect to such clinical facilities. Cell Source
plans to insure its direct participation in clinical trials, above and beyond whatever insurance coverage is already held by the institutions
and facilities providing services with respect to such clinical trials, as may be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
may become subject to liabilities related to risks inherent in working with hazardous materials.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
discovery and development processes involve the controlled use of hazardous and radioactive materials. We are subject to federal, state,
provincial and local laws and regulations governing the use, manufacture, storage, handling and disposal of such materials and certain
waste products. Although we believe that our safety procedures for handling and disposing of such materials comply with the standards
prescribed by such laws and regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated.
In the event of such an accident, we could be held liable for any damages that result and any such liability could exceed our resources.
We are not specifically insured with respect to this liability. Although we believe that we are in compliance in all material respects
with applicable environmental laws and regulations and currently do not expect to make material capital expenditures for environmental
control facilities in the near-term, there can be no assurance that we will not be required to incur significant costs to comply with
environmental laws and regulations in the future, or that our operations, business or assets will not be materially adversely affected
by current or future environmental laws or regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
may in the future conduct clinical trials for our products or product candidates outside the United States and the FDA may not accept
data from such trials.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may in the future choose to conduct one or more of our clinical trials outside the United States. Although the FDA may accept data from
clinical trials conducted outside the United States, acceptance of such study data by the FDA is subject to certain conditions. For example,
the study must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The study
population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical
practice in ways that the FDA deems clinically meaningful. Generally, the patient population for any clinical studies conducted outside
of the United States must be representative of the population for whom we intend to label the product in the United States. In addition,
such studies would be subject to the applicable local laws and FDA acceptance of the data would be dependent upon its determination that
the studies also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials
conducted outside of the United States. If the FDA does not accept any such data, it would likely result in the need for additional trials,
which would be costly and time consuming and delay aspects of our business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">The
outbreak of the novel coronavirus disease, COVID-19, could materially and adversely affect our preclinical studies and development, any
clinical trials we subsequently commence, and our business, financial condition, and results of operations</span><b>.</b></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the coronavirus disease, COVID-19, was identified in Wuhan, China. Since then, COVID-19 has spread globally. In March
2020, the World Health Organization declared COVID-19 a global pandemic and the United States declared a national emergency with respect
to COVID-19. In response to the COVID-19 pandemic, “shelter in place” orders and other public health guidance measures were
implemented across much of the United States, including in the locations of our offices and those of key vendors and partners. As a result
of the COVID-19 pandemic, or similar pandemics, and related “shelter in place” orders and other public health guidance measures,
we have and may in the future experience disruptions that could materially and adversely impact our preclinical studies and clinical
trials, and our business, financial condition, and results of operations. Potential disruptions to our preclinical development efforts
include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff, limited or no access to
    animal facilities, and unforeseen circumstances at contract research organizations (CROs) and vendors;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 45; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    on employee or other resources that would otherwise be focused on the conduct of our preclinical work and any clinical trials we
    subsequently commence, including because of sickness of employees or their families, the desire of employees to avoid travel or contact
    with large groups of people, an increased reliance on working from home, school closures, or mass transit disruptions;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in necessary interactions with regulators, ethics committees, and other important agencies and contractors due to limitations in
    employee resources or forced furlough of government or contractor personnel; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    in maintaining our corporate culture that facilitates the transfer of institutional knowledge within our organization and fosters
    innovation, teamwork, and a focus on execution.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection,
    processing and analyses, due to limitations on travel imposed or recommended by federal, state, or local governments, employers and
    others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical
    study endpoints;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting
    clinical site investigators and clinical site staff;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or difficulties in enrolling and retaining patients in our clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions
    or being forced to quarantine;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages,
    production slowdowns, or stoppages and disruptions in materials and reagents;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial
    sites and hospital staff supporting the conduct of our clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    or delays in the operations of the FDA and comparable foreign regulatory agencies;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials
    are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because
    of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages,
    production slowdowns or stoppages and disruptions in delivery systems;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA or comparable regulatory authorities to accept data from clinical trials in affected geographies; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    delays, difficulties or interruptions as a result of current or future shutdowns due to the COVID-19 pandemic in countries where
    we or our third-party service providers operate.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 global pandemic continues to rapidly evolve. Although many countries, including certain countries in Europe and the United States,
have re-opened, rises in new cases have caused certain countries to re-initiate restrictions. The extent to which the outbreak may affect
our preclinical studies, clinical trials, business, financial condition, and results of operations will depend on future developments,
which are highly uncertain and cannot be predicted at this time, such as the ultimate geographic spread of the disease, the duration
of the outbreak, travel restrictions, and actions to contain the outbreak or treat its impact, such as social distancing and quarantines
or lock-downs in the United States and other countries, business closures, or business disruptions and the effectiveness of actions taken
in the United States and other countries to contain and treat the disease. Additionally, we are unable to predict if a different pandemic
could have similar or different impacts on our business, financial condition, or share price. Future developments in these and other
areas present material uncertainty and risk with respect to our clinical trials, business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 46; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Capital Resources and Impairments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
have a limited operating history and a history of operating losses and expect to incur significant additional operating losses.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
planned principal operations are the development and commercialization of new cell therapy products focused on treatment of blood cancers,
certain non-malignant disorders and organ transplantations. We are currently conducting research and development activities in order
to facilitate the continued transition of the patented technology we license from the laboratory to clinical trials. We have a limited
operating history. Therefore, there is limited historical financial information upon which to base an evaluation of our performance.
Our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by companies
in their early stages of operations. We have generated net losses since we began operations, including net losses of $5,472,435
and $4,560,165 for the years ended December 31, 2021 and 2020, respectively. We expect to incur substantial additional net expenses
over the next several years as our research, development, and commercial activities increase. The amount of future losses and when, if
ever, we will achieve profitability are uncertain. Our ability to generate revenue and achieve profitability will depend on, among other
things, successful completion of the preclinical and clinical development of our product candidates; obtaining necessary regulatory approvals
from the U.S. Food and Drug Administration (the “FDA”) and international regulatory agencies; successful manufacturing, sales,
and marketing arrangements; and raising sufficient funds to finance our activities. If we are unsuccessful at some or all of these undertakings,
our business, prospects, and results of operations may be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
will need to secure additional financing.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that we will incur operating losses for the foreseeable future. Our historical cash burn rate was approximately $350,000 per
month. As of December 31, 2021, we had cash in the amount of $93,095. Based on our current resources, we will not be able to continue
to operate without additional immediate funding. If we are not successful in securing additional financing, we may be required to delay
significantly, reduce the scope of or eliminate one or more of our research or development programs, downsize our general and administrative
infrastructure, or seek alternative measures to avoid insolvency, including arrangements with collaborative partners or others that may
require us to relinquish rights to certain of our technologies, product candidates or products. Our future capital requirements will
depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, timing, progress, costs, and results of discovery, preclinical development, and clinical trials for our current or future
    product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of clinical trials required for regulatory approval of our current or future product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing, and outcome of regulatory review of any of our current or future product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of manufacturing clinical and commercial supplies of our current or future product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of future commercialization activities, including manufacturing, marketing, sales, and distribution, for any of
    our product candidates for which we receive marketing approval;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights,
    and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual
    property rights;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain existing, and establish new, strategic collaborations, licensing, or other arrangements and the financial terms
    of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    to attract, hire, and retain skilled personnel;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of operating as a public company;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party
    and government payers;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing
    any potential interruptions or delays resulting from factors related to the COVID-19 pandemic;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of competing technological and market developments; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we acquire or invest in businesses, products, and technologies.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to raise additional funds will depend on financial, economic, political and market conditions and other factors, over which we
may have no or limited control. Market volatility resulting from the COVID-19 pandemic or other factors could also adversely impact our
ability to access capital as and when needed. Additional funds may not be available when we need them, on terms that are acceptable to
us, or at all. If adequate funds are not available to us on a timely basis, we could be required to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay,
    limit, reduce, or terminate preclinical studies, clinical trials, or other research and development activities, or eliminate one
    or more of our development programs altogether; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay,
    limit, reduce, or terminate our efforts to access manufacturing capacity, establish sales and marketing capabilities or other activities
    that may be necessary to commercialize our product candidates, or reduce our flexibility in developing or maintaining our sales and
    marketing strategy.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>


<!-- Field: Page; Sequence: 47; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">There
is substantial doubt about our ability to continue as a going concern.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we had a working capital deficit and accumulated deficit of $9,826,135 and $31,178,428, respectively.
During the year ended December 31, 2021, we incurred a net loss of $5,472,435. We have historically incurred operating losses
and may continue to incur operating losses for the foreseeable future. We believe that these conditions raise substantial doubt about
our ability to continue as a going concern within one year from the date these financial statements are issued. This may hinder
our future ability to obtain financing or may force us to obtain financing on less favorable terms than would otherwise be available.
We have not generated revenues to-date. Our primary source of operating funds since inception has been equity and debt financings. Our
plans include continued efforts to raise additional capital through debt and equity financings. There is no assurance that these funds
will be sufficient to enable us to fully complete our development activities or attain profitable operations. If we are unable to obtain
such additional financing on a timely basis or, notwithstanding any request we may make, if our debt holders do not agree to convert
their notes into equity or extend the maturity dates of their notes, we may have to curtail our development, marketing and promotional
activities, which would have a material adverse effect on our business, financial condition and results of operations, and ultimately
we could be forced to discontinue our operations and liquidate. There can be no assurance that we will be able to continue as a going
concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
are an early-stage company with an unproven business strategy and may never achieve commercialization of our candidate products or profitability.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are at an early stage of development and commercialization of our technologies and product candidates. We have not yet begun to market
any products and, accordingly, have not begun to generate revenues from the commercialization of our products. Our products will require
significant additional clinical testing and investment prior to commercialization. A commitment of substantial resources by ourselves
and, potentially, our partners to conduct time-consuming research and clinical trials will be required if we are to complete the development
of our product candidates. There can be no assurance that any of our product candidates will meet applicable regulatory standards, obtain
required regulatory approvals, be capable of being produced in commercial quantities at reasonable costs or be successfully marketed.
Most of our product candidates are not expected to be commercially available for several years, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
are in default of payment obligations under certain promissory notes.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As of December 31, 2021 and through
the date of this filing, notes payable with principal amounts totaling $1,554,912 and $1,329,912, respectively, were past due. Although
only one holder of a note with the principal amount of $250,000 has elected to pursue remedies against us, no assurance can be given
that the other holders will not do so in the future. The institution of collection actions could have a material adverse effect on our
business and could force us to seek relief through insolvency or other proceedings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">There
may be additional issuances of shares of preferred stock in the future.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles of Incorporation permit us to issue up to 10,000,000 shares of preferred stock and our board of directors has authorized 1,335,000
shares of Series A Convertible Preferred and 500,000 shares of Series C Convertible Preferred Stock, for issuance. Our board of directors
could authorize the issuance of additional series of preferred stock in the future and such preferred stock could grant holders preferred
rights on parity with the Series A Preferred and Series C Preferred as to dividend payments and liquidation preference. The issuances
of other series of preferred stock could have the effect of reducing the amounts available to the holders Series A Preferred and Series
C Preferred in the event of our liquidation, winding-up or dissolution. It may also reduce cash dividend payments on the Series A Preferred
if we do not have sufficient funds to pay dividends on all Series A Preferred outstanding and outstanding parity preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
articles of incorporation allow for our board to create a new series of preferred stock without further approval by our stockholders,
which could adversely affect the rights of the holders of our Common Stock.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has the authority to fix and determine the relative rights and preferences of preferred stock. Our Board of Directors
have the authority to issue up to 10,000,000 shares of our preferred stock terms of which may be determined by the Board without further
stockholder approval. As a result, our Board of Directors could authorize the issuance of a series of preferred stock that would grant
to holders the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed
to the holders of Common Stock and the right to the redemption of the shares, together with a premium, prior to the redemption of our
Common Stock. In addition, our Board of Directors could authorize the issuance of a series of preferred stock that has greater voting
power than our Common Stock or that is convertible into our Common Stock, which could decrease the relative voting power of our Common
Stock or result in dilution to our existing stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 48; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">There
is not an active liquid trading market for the Company’s Common Stock.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is required to report under the Exchange Act and its Common Stock is eligible for quotation on the OTC Markets. However, there
is no regular active trading market in the Company’s Common Stock, and we cannot give an assurance that an active trading market
will develop. If an active market for the Company’s Common Stock develops, there is a significant risk that the Company’s
stock price may fluctuate dramatically in the future in response to any of the following factors, some of which are beyond our control:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
    in our quarterly operating results;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 87%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    that our revenue or income are below analysts’ expectations;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic slowdowns;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 86%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of large blocks of the Company’s Common Stock; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 87%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
Common Stock is subject to the “penny stock” rules of the Securities and Exchange Commission, which may make it more difficult
for stockholders to sell our Common Stock.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has adopted Rule 15g-9 which establishes the definition of a “penny stock,” for the purposes relevant to us, as any equity
security that has a market price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock,
unless exempt, the rules require that a broker or dealer approve a person’s account for transactions in penny stocks, and the broker
or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock
to be purchased.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to approve a person’s account for transactions in penny stocks, the broker or dealer must obtain financial information and
investment experience objectives of the person, and make a reasonable determination that the transactions in penny stocks are suitable
for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of
transactions in penny stocks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to
the penny stock market, which, in highlight form sets forth the basis on which the broker or dealer made the suitability determination,
and that the broker or dealer received a signed, written agreement from the investor prior to the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more
difficult for investors to dispose of the Company’s Common Stock if and when such shares are eligible for sale and may cause a
decline in the market value of its stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions
payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies
available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent
price information for the penny stock held in the account and information on the limited market in penny stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
may not be able to attract the attention of brokerage firms because we became a public company by means of a reverse acquisition.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we became public through a “reverse acquisition,” securities analysts of brokerage firms may not provide coverage of us since
there is little incentive to brokerage firms to recommend the purchase of our Common Stock. No assurance can be given that brokerage
firms will want to conduct any secondary offerings on behalf of the Company in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Voting
power of our shareholders is highly concentrated by insiders.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
officers, directors and affiliates currently own approximately 20% of our outstanding common stock. Such concentrated control of the
Company may adversely affect the value of our ordinary shares. If you acquire our ordinary shares, you may have no effective voice in
our management. Sales by our insiders or affiliates, along with any other market transactions, could affect the value of our ordinary
shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
do not intend to pay dividends to holders of Common Stock for the foreseeable future.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45.1pt; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have paid no dividends on our Common Stock to date and it is not anticipated that any dividends will be paid to holders of our Common
Stock in the foreseeable future. While our future dividend policy will be based on the operating results and capital needs of the business,
it is currently anticipated that any earnings will be retained to finance our future expansion and for the implementation of our business
plan. As an investor, you should take note of the fact that a lack of a dividend can further affect the market value of our stock and
could significantly affect the value of any investment in our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 49; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Other
General Factors</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Applicable
regulatory requirements, including those contained in and issued under the Sarbanes-Oxley Act of 2002, may make it difficult for the
Company to retain or attract qualified officers and directors, which could adversely affect the management of its business and its ability
to obtain or retain listing of its Common Stock.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be unable to attract and retain those qualified officers, directors and members of board committees required to provide for
effective management because of the rules and regulations that govern publicly held companies, including, but not limited to, certifications
by principal executive officers. The enactment of the Sarbanes-Oxley Act has resulted in the issuance of a series of related rules and
regulations and the strengthening of existing rules and regulations by the SEC, as well as the adoption of new and more stringent rules
by the stock exchanges. The perceived increased personal risk associated with these changes may deter qualified individuals from accepting
roles as directors and executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
some of these changes heighten the requirements for board or committee membership, particularly with respect to an individual’s
independence from the corporation and level of experience in finance and accounting matters. The Company may have difficulty attracting
and retaining directors with the requisite qualifications. If the Company is unable to attract and retain qualified officers and directors,
the management of its business and its ability to obtain or retain listing of our shares of Common Stock on any stock exchange (assuming
the Company elects to seek and are successful in obtaining such listing) could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">If
we fail to maintain effective internal controls over financial reporting, the price of our common stock may be adversely affected.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, our management identified weaknesses in our internal controls and although our management believes such weaknesses have been
remediated, our internal control over financial reporting may still or could in the future have weaknesses and conditions that could
require correction or remediation, the disclosure of which may have an adverse impact on the price of our common stock. We are required
to establish and maintain appropriate internal controls over financial reporting. Failure to establish those controls, or any failure
of those controls once established, could adversely affect our public disclosures regarding our business, prospects, financial condition
or results of operations. In addition, management’s assessment of internal controls over financial reporting may identify weaknesses
and conditions that need to be addressed in our internal controls over financial reporting or other matters that may raise concerns for
investors. Any actual or perceived weaknesses and conditions that need to be addressed in our internal control over financial reporting
or disclosure of management’s assessment of our internal controls over financial reporting may have an adverse impact on the price
of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
are required to comply with certain provisions of Section 404 of the Sarbanes-Oxley Act of 2002 and if we fail to comply in a timely
manner, our business could be harmed and our stock price could decline.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rules
adopted by the SEC pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 require an annual assessment of internal controls over financial
reporting, and for certain issuers an attestation of this assessment by the issuer’s independent registered public accounting firm.
The standards that must be met for management to assess the internal controls over financial reporting as effective are evolving and
complex, and require significant documentation, testing, and possible remediation to meet the detailed standards. We expect to incur
significant expenses and to devote resources to Section 404 compliance on an ongoing basis. It is difficult for us to predict how long
it will take or how costly it will be to complete the assessment of the effectiveness of our internal control over financial reporting
for each year and to remediate any deficiencies in our internal control over financial reporting. As a result, we may not be able to
complete the assessment and remediation process on a timely basis. In addition, although attestation requirements by our independent
registered public accounting firm are not presently applicable to us, we could become subject to these requirements in the future and
we may encounter problems or delays in completing the implementation of any resulting changes to internal controls over financial reporting.
In the event that our principal executive and financial officer determines that our internal control over financial reporting is not
effective as defined under Section 404, we cannot predict how regulators will react or how the market prices of our shares will be affected;
however, we believe that there is a risk that investor confidence and share value may be negatively affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">As
an issuer of “penny stock,” the protection provided by the federal securities laws relating to forward looking statements
does not apply to us.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
federal securities laws provide a safe harbor for forward-looking statements made by a public company that files reports under the federal
securities laws, this safe harbor is not available to issuers of penny stocks. As a result, we will not have the benefit of this safe
harbor protection in the event of any legal action based upon a claim that the material provided by us contained a material misstatement
of fact or was misleading in any material respect because of our failure to include any statements necessary to make the statements not
misleading. Such an action could hurt our financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
issuance of Common Stock upon exercise of warrants or options may depress the price of our Common Stock.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we had 34,360,546 shares of Common Stock issued and outstanding and outstanding warrants to purchase 11,108,079
shares of Common Stock. The issuance of shares of Common Stock upon exercise of outstanding warrants or options could result in substantial
dilution to our stockholders, which may have a negative effect on the price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 50; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
stock price may be volatile or may decline regardless of our operating performance, resulting in substantial losses for investors.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock may be highly volatile and may fluctuate substantially as a result of a variety of factors, some of
which are related in complex ways. The market price of our common stock may fluctuate significantly in response to numerous factors,
many of which are beyond our control, including the factors listed below and other factors describe in this “Risk Factors”
section:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commencement, enrollment, or results of current and future preclinical studies and clinical trials and trials we may conduct, or
    changes in the development status of our product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect
    to the applicable regulatory authority’s review of such filings, including, without limitation, the issuance by the FDA of
    a “refusal to file” letter or a request for additional information;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    results or delays in clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    decision to initiate a preclinical study or clinical trial, not to initiate a preclinical study or clinical trial or to terminate
    an existing preclinical study or clinical trial;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    actions taken by regulatory agencies with respect to our preclinical studies or clinical trials, manufacturing supply chain or sales
    and marketing activities, including failure to receive regulatory approval of our product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in laws or regulations, including, but not limited to, preclinical study or clinical trial requirements for approvals;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    adverse changes to our relationship with manufacturers or suppliers;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing,
    supply or distribution shortages;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to commercialize our product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the structure of healthcare payment systems;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    or departures of key scientific or management personnel;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    serious safety concerns related to the use of our product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection
    for our technologies;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
    in our results of operations;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    cash position;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication
    of research reports about us or our industry, or <i>in vivo</i> and <i>ex vivo</i> cell engineering products in particular, or positive
    or negative recommendations or withdrawal of research coverage by securities analysts;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    made by us or our competitors of new product and service offerings, acquisitions, strategic relationships, joint ventures, or capital
    commitments;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to establish collaborations, if needed;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to effectively manage our growth;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    size and growth of our initial target markets;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the market valuations of similar companies;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">press
    reports, whether or not true, about our business;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    or perceived potential sales of our common stock by us or our stockholders in the future;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overall
    fluctuations in the equity markets;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ineffectiveness
    of our internal controls;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting practices or principles;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    or developments in the global regulatory environment;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation
    involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    political and economic conditions; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which are beyond our control.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 51; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock market in general and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations
that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors
may negatively affect the market price of our common stock, regardless of our actual operating performance. If the market price of our
common stock after this offering does not exceed the initial public offering price, you may not realize any return on, and may lose some
or all of, your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each
of which may cause our stock price to fluctuate or decline.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous
factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing
    and variations in the level of expense related to the current or future development of our programs;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing
    and status of enrollment for our clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impacts
    from the COVID-19 pandemic on us or third parties with which we engage;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of clinical trials, or the addition or termination of clinical trials or funding support by us or potential future partners;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under potential
    future arrangements or the termination or modification of any such potential future arrangements;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation proceeding
    in which we may become involved;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    and departures of key personnel;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strategic
    decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes
    in business strategy;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    any product candidate we may develop receive regulatory approval, the timing and terms of such approval and market acceptance and
    demand for such product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and cost to establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain
    marketing approval and intend to commercialize on our own or jointly with current or future collaborators;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    developments affecting current or future product candidates or those of our competitors;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of expense or gain associated with the change in value of the success payments and contingent consideration; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in general market and economic conditions.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could
decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to
fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not
be relied upon as an indication of our future performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">If
we take advantage of specified reduced disclosure requirements applicable to a “smaller reporting company”, the information
that we provide to stockholders may be different than they might receive from other public companies.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a company with less than $100 million in revenue during our last fiscal year and a public float of less than $250 million, we qualify
as a “smaller reporting company”. As a smaller reporting company, we may take advantage of specified reduced disclosure and
other requirements that are otherwise applicable generally to public companies. These provisions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 88%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
                                            two years of audited financial statements in addition to any required unaudited interim financial
                                            </span><span style="font-family: Times New Roman, Times, Serif">statements with correspondingly
                                            reduced “Management’s Discussion and Analysis of Financial Condition and Results
                                            of Operations” disclosure;</span></p></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 52; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduced
    disclosure about our executive compensation arrangements;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from the auditor attestation requirement in the assessment of our internal control over financial reporting.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of our status as a “smaller reporting company,” the information that we provide stockholders may be different than
you might get from other public companies in which you hold stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">We
could be subject to securities class action litigation.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, securities class action litigation has often been instituted against companies following periods of volatility in the market
price of a company’s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management’s
attention and resources, which would harm our business, operating results, or financial condition. Additionally, the dramatic increase
in the cost of directors’ and officers’ liability insurance may cause us to opt for lower overall policy limits or to forgo
insurance that we may otherwise rely on to cover significant defense costs, settlements, and damages awarded to plaintiffs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Tax Cuts and Jobs Act of 2017, as modified by the Coronavirus Aid, Relief, and Economic Stability Act, or CARES Act, our federal
net operating losses, or NOLs, generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the
deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain
if and to what extent various states will conform to the Tax Cuts and Jobs Act of 2017, or the CARES Act. In addition. under Sections
382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change,” generally
defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period,
the corporation’s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes
(such as research and development tax credits) to offset its post-change income or taxes may be limited. Shifts in our stock ownership
(some of which are outside our control). As a result, our ability to use our pre-change NOLs and tax credits to offset post-change taxable
income, if any, could be subject to limitations. Similar provisions of state tax law may also apply. In addition, at the state level,
there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state
taxes owed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>ITEM
2. PROPERTIES.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters is located at 57 West 57<sup>th</sup> Street, New York, NY 10019 under an annual lease. The telephone number
at such address is (646) 416-7896. We believe that our facilities are adequate and suitable for our current operations. To the extent
that other office space is required, we believe that such space is readily available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>ITEM
3. LEGAL PROCEEDINGS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as described below, we are not involved in any pending legal proceeding or litigations and, to the best of our knowledge, no governmental
authority is contemplating any proceeding to which we are a party or to which any of our properties is subject, which would reasonably
be likely to have a material adverse effect on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
January 2019, the holder of a promissory note in the principal amount of $250,000 due on March 16, 2016 instituted a collection action
in the Supreme Court of the State of New York, County of New York. On June 12, 2019, the plaintiff served a motion for summary judgment
through the Secretary of State which was heard on July 12, 2019 and granted. The Company contends that it was not given sufficient notice
under the applicable statute and did not have an opportunity to oppose the motion. Judgment was entered in October 2019 in the amount
of $267,680. The Company brought a motion to vacate based on the jurisdictional defect of the motion in not providing the required amount
of time, but that motion was denied in February 2021 without properly addressing the jurisdictional issues raised by the Company. The
Company has appealed the denial and then filed a motion to Renew and Reargue the motion to vacate based on the Court’s failure
to address critical issues. That motion was also denied on April 15, 2021 without addressing the Company’s arguments. The Company
has appealed the second denial as well and is pursuing both appeals in a consolidated manner so as to resolve all issues together. While
the Company’s motions were pending, the plaintiff has commenced steps to collect judgment. During 2021, $103,088 was released to
an officer of the court and has been accounted for as partial note repayment. In addition, a third party deposited the full amount of
the unpaid judgment with the court on behalf of the Company in 2021, which created an automatic stay of enforcement of this matter and
which will be used to resolve the underlying note in the event of an adverse outcome on appeal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>ITEM
4. MINE SAFETY DISCLOSURES.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>


<!-- Field: Page; Sequence: 53; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>ITEM
5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Market
for Common Equity and Related Stockholder Matters</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently quoted under the symbol “CLCS” on the OTCQB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 11, 2022, there were 182 holders of record of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Dividends</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our common stock. We currently intend to retain future earnings, if any, to finance
the expansion of our business. As a result, we do not anticipate paying any cash dividends in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Warrants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we had outstanding warrants to purchase an aggregate of 11,108,079 shares of common stock with a weighted
average exercise price of $1.02 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Securities
Authorized for Issuance Under Equity Compensation Plans</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Our Board of Directors adopted the 2019
Equity Incentive Plan (the “Plan”) in August 2019. <span style="background-color: white">A total of 7,900,000 shares of common
stock were initially reserved for issuance under the Plan and the number of reserved shares increases on the first day of each year in
an amount equal to the lesser of 3% of the number of shares of common stock outstanding on the last day of the preceding year or the
amount determined by our Board of Directors. As of December 31, 2021, a total of 9,688,454 shares of common stock were reserved for issuance
under the Plan. The Plan permits the Board of Directors to issue stock options, stock appreciation rights, restricted stock, restricted
stock units, performance and other awards to employees, consultants and directors of the Company. As of the date of filing, the Company’s
shareholders have not approved the Plan. </span>The number of stock options outstanding under the Plan, the weighted average exercise
price of the outstanding options, and the number of securities remaining available for issuance as of December 31, 2021 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY
COMPENSATION PLAN TABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Plan
    category</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of securities to be issued upon exercise of outstanding options, warrants and rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-average
                                            exercise price of outstanding options, warrants and rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of securities remaining available for future issuance under equity compensation plans (excluding
                                            securities reflected in column (a))</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Equity
    compensation plans approved by security holders</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Equity
    compensation plans not approved by security holders</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,182,004</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.80</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,506,450&nbsp;</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,182,004</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.80</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,506,450&nbsp;</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>


<!-- Field: Page; Sequence: 54; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
November 17, 2021 through March 21, 2022 convertible notes in the aggregate principal amount of $1,550,698 automatically converted into
206,759 shares of our Series C Convertible Preferred Stock on the maturity dates of the convertible notes. We relied upon the exemption
provided by Section 3(a)(9) of the Securities Act in connection with these transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
November 17, 2021 through March 21, 2022 we issued an aggregate of 90,511 shares of our common stock to holders of convertible notes
in lieu of cash interest upon the maturity of the notes. We relied upon the exception provided by Section 4(2) of the Securities Act
in connection with these transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2021 we issued a convertible note in the principal amount of $40,000 and a five-year warrant to purchase 32,000 shares of common
stock at an exercise price of $1.25 per share to a consultant in exchange for advisory services. The note is convertible into shares
of Series C Preferred Stock at a conversion price of $7.50 per share. We relied upon the exception provided by Section 4(2) of the Securities
Act in connection with this transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
December 7, 2021 and April 4, 2022, we issued convertible notes in the aggregate principal amount of $315,000 to eight accredited investors.
The notes mature six months from the date of issuance and accrue interest at a rate of eight percent (8%) per annum. The notes are convertible
into shares of our Series C Preferred Stock at a conversion price of $7.50 per share at the holder’s option. In connection with
the issuance of the notes, we issued five year warrants to purchase an aggregate of 252,000 shares of common stock at an exercise price
of $1.25 per share. We relied upon the exemption provided by Section 4(2) of the Securities Act in connection with these transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, we issued a convertible promissory note in the principal amount of up to $6,000,000. The note bears interest at a rate of
10% per annum and will mature twelve months from the date of issuance. The holder has agreed to loan an aggregate of $2,500,000 to us
under the note and advanced $1,000,000 under the note in March 2022. The holder has the right, at his option, to convert the note into
shares of the Company’s Series B Convertible Preferred Stock at a conversion price of $7.50 per share at any time after the creation
and sale of the Series B Convertible Preferred Stock. Interest accruing under the note will be payable upon the maturity of the note
and may be paid at the Company’s option in either cash or shares of the Company’s common stock (valued at $0.75 for purposes
of calculating the number of shares). For each $500,000 advanced under the note, the holder will be issued a warrant to purchase 400,000
shares of the Company’s Common Stock at an exercise price of $1.25 per share. The Company relied upon the exemption provided by
Section 4(2) of the Securities Act in connection with this transaction.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuer
Purchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>ITEM
6. [RESERVED]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>ITEM
7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
Management Discussion and Analysis (“MD&amp;A”) contains “forward-looking statements,” which represent our projections,
estimates, expectations or beliefs concerning among other things, financial items that relate to management’s future plans or objectives
or to our future economic and financial performance. In some cases, you can identify these statements by terminology such as “may,”
“should,” “plans,” “believe,” “will,” “anticipate,” “estimate,”
“expect,” “project” or “intend,” including their opposites or similar phrases or expressions.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should be aware that these statements are projections or estimates as to future events and are subject to a number of factors that may
tend to influence the accuracy of the statements. These forward-looking statements should not be regarded as a representation by the
Company or any other person that the events or plans of the Company will be achieved. You should not unduly rely on these forward-looking
statements, which speak only as of the date of this MD&amp;A. Except as may be required under applicable securities laws, we undertake
no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this MD&amp;A or
to reflect the occurrence of unanticipated events. You should, however, review the factors and risks we describe under “Risk Factors”
in this Annual Report on Form 10-K. Actual results may differ materially from any forward-looking statement.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Overview</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a cell therapy company focused on immunotherapy. Since our inception, we have been involved with the development of proprietary immune
system management technology licensed from Yeda, the commercial arm of the Weizmann Institute. We have recently shifted the focus of
our research and development efforts to MD Anderson.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 55; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
technology addresses one of the most fundamental challenges within human immunology: how to tune the immune response such that it tolerates
selected desirable foreign cells, but continues to attack all other (undesirable) targets. In simpler terms, a number of potentially
life-saving treatments have limited effectiveness today because the patient’s immune system rejects them. For example, while HSCT
- hematopoietic stem cell transplantation (e.g. bone marrow transplantation) has become a preferred therapeutic approach for treating
blood cell cancer, most patients do not have a matched family donor. Although matched unrelated donors and cord blood can each provide
an option for such patients, haploidentical stem cell transplants (sourced from partially mismatched family members) are rapidly gaining
favor as a treatment of choice. This is still a risky and difficult procedure primarily because of potential conflicts between host and
donor immune systems and also due to viral infections that often follow even successful HSCT while the compromised new immune system
works to reconstitute itself by using the transplanted stem cells. Today, rejection is partially overcome using aggressive immune suppression
treatments that leave the patient exposed to many dangers by compromising their immune system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unique advantage of Cell Source technology lies in the ability to induce sustained tolerance of transplanted cells (or organs) by the
recipient’s immune system in a setting that requires only mild immune suppression, while avoiding the most common post-transplant
complications. The scientific term for inducing such tolerance in a transplantation setting is chimerism, where the recipient’s
immune system tolerates the co-existence of the (genetically different) donor type and host (recipient) type cells. Attaining sustained
chimerism is an important prerequisite to achieving the intrinsic GvL (graft versus leukemia) effect of HSCT and supporting the
reconstitution of normal hematopoiesis (generation of blood cells, including those that protect healthy patients from cancer) in blood
cancer patients. Preclinical data and initial clinical data show that Cell Source’s Veto Cell technology (currently in a clinical
trial in the US) can provide superior results in allogeneic (donor-derived) HSCT by allowing for haploidentical stem cell transplants
under a mild conditioning regimen, while avoiding the most common post-transplant complications. Combining this with CAR (Chimeric Antigen
Receptor) T cell therapy as a unified VETO CAR-T treatment, we will be able to treat patients in relapse as well as those in remission
and use the cancer killing power of CAR-T to protect the patient while their immune system fully reconstitutes, thus providing an end-to-end
solution for blood cancer treatment by potentially delivering a fundamentally safer and more effective allogeneic HSCT: prevention of
relapse; avoidance GvHD; prevention of viral infections; and enhanced persistence of GvL effect. This means that the majority of patients
will be able to find a donor, and will have access to a potentially safer procedure with higher long term survival rates than what either
donor-derived HSCT or autologous CAR-T each on their own currently provide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability to induce permanent chimerism (and thus sustained tolerance) in patients – which allows the transplantation to overcome
rejection without having to compromise the rest of the immune system - may open the door to effective treatment of a number of severe
medical conditions, in addition to blood cancers, which are characterized by this need. These include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    broader set of cancers, including solid tumors, that can potentially be treated effectively using genetically modified cells such
    as CAR-T cell therapy, but also face efficacy and economic constraints due to limited persistence based on immune system issues (i.e.,
    the need to be able to safely and efficiently deliver allogeneic CAR-T therapy). Inducing sustained tolerance to CAR-T cells may
    bring reduced and cost and increased efficacy by allowing for off-the-shelf (vs. patient-derived) treatments with more persistent
    cancer killing capability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organ
    failure and transplantation. A variety of conditions can be treated by the transplantation of vital organs. However, transplantation
    is limited both by the insufficient supply of available donor organs and the need for lifelong, daily anti-reject treatments post-transplant.
    Haploidentical organ transplants, with sustained chimerism, have the potential to make life saving transplants accessible to the
    majority of patients, with the prospect of improved life quality and expectancy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-malignant
    hematological conditions (such as type one diabetes and sickle cell anemia) which could, in many cases, also be more effectively
    treated by stem cell transplantation if the procedure could be made safer and more accessible by inducing sustained tolerance in
    the stem cell transplant recipient.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Human
Capital Resources</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than our Chief Executive Officer, we currently do not have any full-time employees, but retain the services of independent contractors/consultants
on a contract-employment basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Recent
Developments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preclinical
Results and Clinical Results</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
two years of intensive collaboration with Professor Zelig Eshhar, the inventor of CAR-T cell therapy, preclinical data confirmed that
Veto Cells can markedly extend persistence of genetically modified T cells from the same donor and that genetically modified Veto Cells
can effectively inhibit tumors expressing an antigen recognized by the transgenic T cell receptor. Furthermore, human Veto Cells transfected
with CAR exhibit anti-tumor activity in-vitro without losing their veto activity. These preclinical results have formed the basis of
our current development of a clinical protocol for allogeneic VETO CAR-T HSCT combined therapy for blood cancer treatment. Cell Source
plans to submit this protocol for approval by the end of 2022. The Phase 1/2 clinical trial at the University of Texas MD Anderson Cancer
Center, using Cell Source’s Anti-viral Veto Cells, has successfully completed the first treatment cohort, with 3 patients each
receiving a haploidentical HSCT under reduced intensity conditioning with Veto Cells. This first in human dose optimization trial has
thus far shown that the initial dose is in fact the optimal dose, as all three patients had successful stem cell engraftment after 42
days, in the absence of GvHD. Cell Source is now continuing the trial as it proceeds with the next cohorts of patients, using the same
dose level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 56; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>COVID-19</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
novel coronavirus (“COVID-19”) pandemic continues to impact global economic conditions. The Company is closely monitoring
the outbreak of COVID-19 and its impact on the Company’s operations, financial position, cash flows and its industry in general.
The Company considered the impact of COVID-19 on its business and operational assumptions and estimates, and determined there were no
material adverse impacts on the Company’s results of operations and financial position as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
the economic uncertainty caused by the COVID-19 pandemic has made and may continue to make it difficult for the Company to forecast operating
results, including the timing and ability of the Company to initiate and/or complete current and/or future preclinical studies and/or
clinical trials, disrupt the Company’s regulatory activities, and/or have other adverse effects on the Company’s clinical
development. The duration and extent of the impact from the COVID-19 pandemic depend on future developments that cannot be accurately
predicted at this time, and if the Company is not able to respond to and manage the impact of such events effectively, the Company’s
business may be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that precautionary measures, whether adopted by the Company or imposed by others, will be effective, and such measures
could negatively affect the Company’s financial condition, cash flows, and results of operations. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Consolidated
Results of Operations</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Year
Ended December 31, 2021 Compared with the Year Ended December 31, 2020</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expense was $1,323,408
and $998,554 for the years ended December 31, 2021 and 2020, respectively, an increase of $324,854, or 33%. The increase was primarily
attributable to clinical trial milestones reached during the second and third quarters of 2021 related to the enrollment of patients,
which resulted in additional expense recognized related to our agreement with MD Anderson as well as an increase in the budget for sponsored
research there. This was partially offset by less expense recognized related to the research agreement with Yeda during the 2021 period
as compared to the 2020 period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expense was $2,695,164
and $2,639,482 for the years ended December 31, 2021 and 2020, respectively, an increase of $55,682, or 2%. General and administrative
expenses are primarily comprised of compensation, legal, and other professional fees.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Interest expense for the years ended December
31, 2021 and 2020 was $629,201 and $636,156, respectively, a decrease of $6,955, or 1%. The decrease was a result of the change in fair
value of the Company common stock, offset by the increased amount of interest-bearing convertible notes payable outstanding during the
2021 period as compared to the 2020 period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amortization
of Debt Discount</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of debt discount was $731,502 and $301,250 for the years ended December 31, 2021 and 2020, respectively, an increase of $430,252, or
143%. The increase is primarily associated with the increased amount and fair value of warrants issued in connection with convertible
notes payable during the 2021 period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Derivative Liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in fair value of derivative liabilities for the year ended December 31, 2020 was a gain of $16,977 due to the reduction in fair
value of warrants and conversion options as a result of drawing closer to their expiration dates. There was no such gain or loss in the
2021 period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Gain
on Forgiveness of Accrued Interest</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, we recognized a gain on forgiveness of accrued interest of $49,983 in connection with the repayment
of certain notes payable. There was no such gain or loss in the 2020 period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 57; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Gain
on Exchange of Accrued Interest for Common Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, we recognized a $132,502 gain on exchange of accrued interest for common stock, which represents the
excess carrying value of the accrued interest as compared to the issuance date fair value of the common stock. There was no such gain
or loss in the 2021 period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loss
on Extinguishment of Notes Payable</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021 and 2020, we recognized $143,143 and $134,202, respectively, of loss on extinguishment of notes payable
in connection with the extension, repayment, and conversion of notes payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
measure our liquidity in a number of ways, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 56%"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">93,095</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">241,619</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Working
    capital deficiency</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9,826,135</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,950,882</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2021, we had
not generated any revenues, had a net loss of $5,472,435 and had used cash in operations of $3,378,682. As of December 31, 2021, we had
a working capital deficiency of $9,826,135 and an accumulated deficit of $31,178,428. As of December 31, 2021 and through the date of
this filing, notes payable with principal amounts totaling $1,554,912 and $1,329,912, respectively, were past due and are classified
as current liabilities on the consolidated balance sheet as of December 31, 2021.We will continue to incur net operating losses to fund
operations. These conditions raise substantial doubt about our ability to continue as a going concern for at least one year from the
date these financial statements are issued. Subsequent to December 31, 2021, we received proceeds of $1,245,000 through the issuance
of convertible notes payable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently funding our operations on a month-to-month basis. Our ability to continue our operations is dependent on the execution
of management’s plans, which include the raising of capital through the debt and/or equity markets, until such time that funds
provided by operations are sufficient to fund working capital requirements. We may need to incur additional liabilities with certain
related parties to sustain our existence. If we were not to continue as a going concern, we would likely not be able to realize our assets
at values comparable to the carrying value or the fair value estimates reflected in the balances set out in the preparation of our financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurances that we will be successful in generating additional cash from equity or debt financings or other sources to be used
for operations. Should we not be successful in obtaining the necessary financing to fund our operations, we would need to curtail certain
or all operational activities and/or contemplate the sale of our assets, if necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021 and 2020, our sources and uses of cash were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Used in Operating Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
experienced negative cash flows from operating activities for the years ended December 31, 2021 and 2020 in the amounts of $3,378,682
and $2,774,631, respectively. The net cash used in operating activities for the year ended December 31, 2021 was primarily due to cash
used to fund a net loss of $5,472,435, adjusted for net non-cash expenses in the aggregate amount of $1,392,513, partially offset
<span style="background-color: white">by </span>$<span style="background-color: white">701,240</span><span style="background-color: white">
of net cash provided by changes in the levels of operating assets and liabilities. The net cash used in operating activities for the
year ended December 31, 2020 was primarily due to cash used to fund a net loss of $4,560,165, adjusted for net non-cash expenses in the
aggregate amount of $1,362,196, </span>partially offset <span style="background-color: white">by $423,338 of net cash provided by changes
in the levels of operating assets and liabilities.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Provided by Financing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities for the years ended December 31, 2021 and 2020 was $3,226,658 and $2,991,842, respectively. The
net cash provided by financing activities during the year ended December 31, 2021 was attributable to $3,907,820 of proceeds from the
issuance of convertible notes payable, offset by the repayments of notes payable in the amount of $203,088, $60,500 of repayments of
advances payable, $125,000 of repayments of convertible notes payable and $292,574 of repayment of financing liability. The net cash
provided by financing activities during the year ended December 31, 2020 was attributable to $728,347 of proceeds from the issuance of
Series A preferred stock, $2,547,500 of proceeds from the issuance of convertible notes payable, $100,000 of proceeds from the issuance
of notes payable, $114,000 of proceeds from advances payable, $1,995 of proceeds from a warrant exercise, offset by the repayments of
notes payable in the amount of $200,000, $154,000 of repayments of advances payable and $146,000 of repayments of convertible notes payable.
	</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 58; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Off-Balance
Sheet Arrangements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any off-balance sheet arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Critical
Accounting Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements and related disclosures in conformity with U.S. GAAP. These accounting principles require us to make
estimates and judgments that can affect the reported amounts of assets and liabilities as of the date of the financial statements as
well as the reported amounts of revenue and expense during the periods presented. We believe that the estimates and judgments upon which
it relies are reasonably based upon information available to us at the time that it makes these estimates and judgments. To the extent
that there are material differences between these estimates and actual results, our financial results will be affected. The accounting
policies that reflect our more significant estimates and judgments and which we believe are the most critical to aid in fully understanding
and evaluating our reported financial results are described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is not intended to be a comprehensive list of all of our accounting policies or estimates. Our accounting policies are more
fully described in Note 3 – Summary of Significant Accounting Policies, in our financial statements included elsewhere in this
annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Convertible
Instruments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative
financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC”). The accounting treatment of derivative financial instruments requires that the
Company record embedded conversion options and any related freestanding instruments at their fair values as of the inception date of
the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash
income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments
at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of
the date of the event that caused the reclassification. Embedded conversion options and any related freestanding instruments are recorded
as a discount to the host instrument and are amortized as interest expense over the term of the related debt instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the instrument is determined to not be a derivative liability, the Company then evaluates for the existence of a beneficial conversion
feature by comparing the commitment date fair value to the effective conversion price of the instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Black-Scholes option pricing model was used to estimate the fair value of the Company’s warrants and embedded conversion options.
The Black-Scholes option pricing model includes subjective input assumptions that can materially affect the fair value estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair
Value of Financial Instruments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the fair value of financial assets and liabilities based on ASC 820 “Fair Value Measurements and Disclosures”
(“ASC 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair
value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize
the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 — quoted prices in active markets for identical assets or liabilities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 59; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company’s financial instruments, such as cash, other current assets, accounts payable, accrued expenses
and other current liabilities approximate fair values due to the short-term nature of these instruments. The carrying amounts of Company’s
credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates,
are comparable to rates of returns for instruments of similar credit risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stock-Based
Compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The
fair value of the award is measured on the grant date and is then recognized over the period the services are required to be provided
in exchange for the award, usually the vesting period. Awards granted to directors are treated on the same basis as awards granted to
employees. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because the Company’s common stock historically
was not actively traded on a public market, the fair value of the Company’s restricted equity instruments is estimated by management
based on observations of the sales prices of both restricted and freely tradable common stock, or instruments convertible into common
stock based on the option pricing model discussed below. The Company obtained a third-party valuation of its common stock as of December
31, 2021 and 2020, which was considered in management’s estimation of fair value during the years ended December 31, 2021 and 2020.
The third-party valuation was performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’
Accounting and Valuation Guide, <i>Valuation of Privately-Held-Company Equity Securities Issued as Compensation.</i> The estimates used
by management are considered highly complex and subjective. The Company anticipates that once its shares become more actively traded,
the use of such estimates will no longer be necessary to determine the fair value of its common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
independent appraisals utilized the option pricing method, or OPM, as the most reliable method with the following steps being applied:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishment
    of total enterprise or equity value;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analysis
    of equity rights for each class of security;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selection
    of appropriate model for valuation purposes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination
    of key valuation inputs; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computation
    of the fair value of the subject security.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the OPM, it was determined the Company’s common stock had a fair value of $0.34 and $0.47 per share as of December 31, 2021 and
2020, respectively, which included a discount for lack of marketability of 30%. Furthermore, the independent appraisal determined the
Company’s expected volatility was 90% by evaluating historical and implied volatilities of guideline companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_013"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements are presented following the signature page to this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_014"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_015"></span>ITEM
9A. CONTROLS AND PROCEDURES.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed
under the Exchange Act, such as this Annual Report, is recorded, processed, summarized and reported within the time periods specified
in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated
and communicated to our management, including the Principal Executive and Financial Officer, as appropriate to allow timely decisions
regarding required disclosure. Internal controls are procedures which are designed with the objective of providing reasonable assurance
that (1) our transactions are properly authorized, recorded and reported; and (2) our assets are safeguarded against unauthorized or
improper use, to permit the preparation of our consolidated financial statements in conformity with United States generally accepted
accounting principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 60; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the preparation of this Annual Report, management, with the participation of our Principal Executive and Financial Officer,
has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule
13a-15(e) and 15d-15(e)). Based upon that evaluation, our Principal Executive and Financial Officer concluded that, as of December 31,
2021, our disclosure controls and procedures were effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Internal
Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Management’s
Annual Report on Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f)
under the Exchange Act. Internal control over financial reporting is a process designed by, or under the supervision of, our Principal
Executive and Financial Officer, and effected by the Board of Directors, management and other personnel, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
U.S. GAAP including those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately
and fairly reflect our transactions and the disposition of our assets, (ii) provide reasonable assurance that transactions are recorded
as necessary to permit preparation of financial statements in accordance with U.S. GAAP and that receipts and expenditures are being
made only in accordance with authorizations of our management and Board of Directors, and (iii) provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision and with the participation of our management, including our principal executive and financial officer, we conducted an
evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2021, based on the Internal Control-Integrated
Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) (2013 Framework). Based on this
evaluation under the 2013 Framework, our principal executive and financial officer concluded that our internal control over financial
reporting was effective as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in Internal Controls</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act)
during the quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitations
of the Effectiveness of Control</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of
the control system are met. Because of the inherent limitations of any control system, no evaluation of controls can provide absolute
assurance that all control issues, if any, within a company have been detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Attestation
Report of Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report does not contain an attestation report of our independent registered public accounting firm regarding internal control
over financial reporting since the rules for smaller reporting companies provide for this exemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_016"></span>ITEM
9B. OTHER INFORMATION.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_017"></span>ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 61; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_018"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_019"></span>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
are the names and certain information regarding the Company’s executive officers and directors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Age</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Title(s)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 36%"><span style="font-family: Times New Roman, Times, Serif">Dennis
    Brown</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif">72</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 50%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Director
    (Chairman)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Itamar
    Shimrat</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">62</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Chief
    Executive Officer, Chief Financial Officer and Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">David
    Zolty</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">71</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Ben
    Friedman</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">62</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Darlene
    Soave</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">78</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">George
    Verstraete</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">68</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Director</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
Dennis M. Brown, PhD, </b>was elected Director of the Company on June 30, 2014 and as Chairman of the Board on May 18, 2015. Dr. Brown
became the Chair of our Audit Committee in September 2015. Dr. Brown is a founder and Chief Scientific Officer of Kintara Therapeutics,
Inc. (Nasdaq: KTRA). Dr. Brown has more than thirty years of drug discovery and development experience. Since 2000 to the present, Dr.
Brown has served as Chairman of Mountain View Pharmaceutical’s Board of Directors and is the President of Valent. Dr. Brown has
focused over the past 5 years on the development of Kintara (formerly under the name DelMar Pharmaceuticals), (serving as its Chief Scientific
Officer since January 25, 2013 and Director since February 11, 2013. His extensive technical expertise, successful track record as an
inventor, executive and director in the field of medical technology position him as an authoritative voice on the scientific, intellectual
property, finance and commercialization and well as general management issues for Cell Source both now and in the future. In 1999 he
founded ChemGenex Therapeutics, which merged with a publicly traded Australian company in 2004 to become ChemGenex Pharmaceuticals (ASX:
CXS/NASDAQ: CXSP), of which he served as President and a Director until 2009. He was previously a co-founder of Matrix Pharmaceutical,
Inc., where he served as Vice President (VP) of Scientific Affairs from 1985-1995 and as VP, Discovery Research, from 1995-1999. He also
previously served as an Assistant Professor of Radiology at Harvard University Medical School and as a Research Associate in Radiology
at Stanford University Medical School. He received his B.A. in Biology and Chemistry (1971), M.S. in Cell Biology (1975) and Ph.D. in
Radiation and Cancer Biology (1979), all from New York University. Dr. Brown is an inventor of about 34 issued U.S. patents and applications,
many with foreign counterparts. Dr. Brown’s scientific knowledge and experience qualifies him to serve on our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Itamar
Shimrat</b>, CEO, CFO and Director, is a Canadian businessman and a founding member of Cell Source Israel. Since Cell Source Israel’s
inception, Mr. Shimrat served as a Director, Chief Financial Officer and, in October 2013, he was appointed Chief Executive Officer.
From March 2009 through September 2011, Mr. Shimrat served as Chief Financial Officer and Director of Rainbow Energy Ltd. From September
2011 through October 2013, Mr. Shimrat served as Chief Financial Officer and Director of Cell Source Ltd. From August 2012 to present,
Mr. Shimrat served as Director of Step Up - Olim Madrega Inc. From October 2013 to March 2022, Mr. Shimrat served as Chief Executive
Officer and Director of Cell Source Ltd. Previously, Mr. Shimrat served as an Executive Vice President at First International Bank of
Israel from March 2005 until April, 2008. Prior to 2008, he served as a senior manager at McKinsey &amp; Company’s Tel Aviv office
after having being elected Partner at Mitchell Madison Group and consulting for Bain &amp; Co. Mr. Shimrat led major profit improvement
programs for leading corporations ranging from American Express and Barclays to El Al Airlines. He has been a Director of two private
companies: Rainbow Energy Ltd., a company in the renewable energy industry, and Step Up - Olim Madrega Ltd., a company in the wheelchair
industry, and also was on the Allocations Committee of Matan, a leading Israeli philanthropic organization. He holds an MBA with Distinction
from the Ivey Business School of the University of Western Ontario in Canada. Itamar brings to Cell Source significant knowledge and
experience in the area of corporate finance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>David
Zolty</b> has been a Director of Cell Source Israel since November 2011 and of our Board of Directors since June 30, 2014, and is a Canadian
businessman who has owned and managed various Canadian enterprises since 1968. From more than five years prior through the present, Mr.
Zolty served as Director of Management and Administration for Hightower Investments. In the mid 1970’s David was one of the founders
of TNT Appliances, a coin laundry and appliance sales and service company, primarily serving the Canadian burgeoning multi-family apartment
industry. The company grew to be the second largest coin laundry in Canada and was sold in and about 2002. While owning and managing
TNT, David was also involved in many real estate acquisitions both through TNT and the Zolty family real estate portfolio. Upon David’s
father Morris Zolty’s retirement, David took a larger role in the Zolty family business where David currently holds a 12% ownership
interest and has served in various roles therein for more than 5 years. David has received an honors BA and has done his post graduate
work at the University of Toronto in the field of Religious Studies. He is also involved in a number of local charities and is a long
standing board member of Camp Agudah Toronto, a children’s summer camp which have facilities at Port Carling, Ontario. His extensive
business experience and community involvement are an asset to Cell Source.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 62; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ben
Friedman</b>, BBA, BGS, LLB, has been a Director of Cell Source Israel since November 2011 and of our Board of Directors since June 30,
2014, and is a Canadian business executive with over 25 years’ experience in real estate and commerce. From more than five years
prior through the present, Mr. Friedman served as Director and Vice President of Ranee Management. Since 1985, he has served as Owner
and CEO of Saucham Holdings Ltd., a private real estate holding and development company active throughout Canada. He is, and has been
for more than five years, a managing partner and Director of The Zolty Group, a private company specializing in the development and ownership
of high rise multi-unit residential buildings in Canada and the United States. He continues to act as Director of numerous private business
related enterprises in the high tech, medical, and laser technology fields, and is a Director of an array of non-profit educational and
vocational institutions. Mr. Friedman’s experience as both an executive, along with his degrees in both business and law, position
him well to help guide Cell Source through its development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company’s directors are elected at the annual meeting of shareholders to hold office until the annual meeting of shareholders for
the ensuing year or until their successors have been duly elected and qualified. Officers are elected annually by the Board of Directors
and serve at the discretion of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Darlene
Soave </b>was appointed to the Company’s Board of Directors effective March 25, 2021. Ms. Soave, a native of Detroit, was a Co-
founder and Director of Soave Enterprises, a diversified management and investment company. For over 40 years, she played key roles in
its business successes, which were primarily achieved through investing in well-run companies, providing them with the tools and resources
necessary to further enhance their businesses, and gauging real-world results through the use of proprietary performance metrics. From
the start, a defining characteristic of Soave Enterprises was its nurturing a highly entrepreneurial culture. The company rapidly grew
from humble beginnings into one of the industry’s largest and most respected environmental services and waste management groups.
Over the following decades, Soave Enterprises went on to flourish in a broad array of industries and endeavors. These include: Coastal
Florida luxury condominiums; Chicago-area Budweiser distributorships; Metal recycling operations in the Midwest; Mercedes-Benz retail
operations in Kansas City; and a Washington, D.C.-area master-planned residential community. Today, its diversified portfolio generates
annual revenues exceeding $1.8 billion. Through the DG Group Inc., Ms. Soave’s current holdings encompass a vertically integrated
portfolio of over 500 income-producing residential properties in addition to various other commercial assets. DG Group identifies, grows,
and sustains its portfolio businesses by leveraging the combined strengths of their management teams and financial resources. DG Group’s
holdings also include an array of companies that are committed to health-enhancing and potentially life-saving technologies. A hallmark
of DG Group is its singular approach to combining state-of-the-art technology with quality, hands-on leadership. It was Ms. Soave’s
lifelong advocacy and personal embodiment of ‘anti-aging’ that captured her initial interest and ultimately led to her investment
and involvement in Cell Source. Ms. Soave has served on the Board of Directors of Soave Enterprises, The Detroit Historical Society,
The Detroit Symphony Orchestra, Barrett House (for abused women and children), Friends of Fleck, and the Restoration Board of the Detroit
Opera House. Ms. Soave’s extensive business experience qualifies her to serve on our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>George
Verstraete</b> was appointed to the Company’s Board of Directors in March 2022. Mr. Verstraete is an entrepreneur who has owned
and/or managed various enterprises since 1980. An expert in real estate development and property management, Mr. Verstraete currently
serves as President of DGR Management. He also serves as a Director of Southern Desert Operations LLC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Board
Leadership Structure and Role in Risk Oversight</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the small size and early stage of the Company, we have not adopted a formal policy on whether the Chairman and Chief Executive Officer
positions should be separate or combined. Dr. Brown serves as the Chairman whereas Mr. Shimrat serves as the Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors (“Board”) is primarily responsible for overseeing our risk management processes on behalf of the Company.
The Board receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate regarding
our Company’s assessment of risks. In addition, the Board focuses on the most significant risks facing our Company and our Company’s
general risk management strategy, and also ensures that risks undertaken by our Company are consistent with the Board’s appetite
for risk. While the Board oversees our company’s risk management, management is responsible for day-to-day risk management processes.
We believe this division of responsibilities is the most effective approach for addressing the risks facing our company and that our
board leadership structure supports this approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Involvement
in Certain Legal Proceedings</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors and executive officers have not been involved in any of the following events during the past ten years:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer
    either at the time of the bankruptcy or within two years prior to that time;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor
    offenses);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
    permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking
    activities or to be associated with any person practicing in banking or securities activities;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 63; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    found by a court of competent jurisdiction in a civil action, the SEC or the Commodity Futures Trading Commission to have violated
    a Federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    subject of, or a party to, any Federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed,
    suspended or vacated, relating to an alleged violation of any Federal or state securities or commodities law or regulation, any law
    or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or
    fraud in connection with any business entity; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization,
    any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members
    or persons associated with a member.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Code
of Ethics</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not adopted a Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer,
principal accounting officer or controller, or persons performing similar functions because of the small number of persons involved in
the management of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Board
Meetings and Attendance</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company’s Board of Directors held one meeting and acted by written consent on 11
occasions. All of our Directors were present at the meetings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Nominating
Committee</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not adopted any procedures by which security holders may recommend nominees to our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Audit
Committee</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee of the Board of Directors operates under a charter that has been approved by the Board of Directors. The Audit Committee
of the Board of Directors is responsible for overseeing our accounting and financial reporting processes and the audits of our financial
statements. Until April 2019, the members of the Audit Committee were Messrs. Brown (Chair) and Yoram Drucker. Mr. Drucker resigned his
position as a member of the Company’s Board of Directors in April 2019 and has since been replaced by Ben Friedman.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors determined that Mr. Drucker was an “audit committee financial expert,” as that is defined in Item 407(d)(5)
of Regulation S-K. Mr. Drucker was an “independent director” based on the definition of independence in Listing Rule 5605(a)(2)
of The Nasdaq Stock Market. The Board of Directors has determined that Mr. Friedman is an “independent director” and an “audit
committee financial expert” based upon said definitions. The Audit Committee held four meetings during the fiscal year ended
December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Delinquent
Section 16(a) Reports</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Exchange Act requires our directors and executive officers and persons who own more than 10% of the issued and outstanding
shares of our common stock to file reports of initial ownership of common stock and other equity securities and subsequent changes in
that ownership with the SEC. Officers, directors and greater than ten percent stockholders are required by SEC regulation to furnish
us with copies of all Section 16(a) forms they file. To our knowledge, during the fiscal year ended December 31, 2021, all Section 16(a)
filing requirements applicable to our officers, directors and greater than 10% beneficial owners were complied with, except that Forms
4 filed by each of David Zolty, Dennis Brown and Ben Friedman to report the issuance of shares of common stock as payment of in-kind
dividends on the shares of Series A Preferred Stock that they own were filed two days late.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_020"></span>ITEM
11. EXECUTIVE COMPENSATION.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth all compensation earned in respect of the Company’s principal executive officer (“PEO”)
for 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Name
    and Principal Position</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Salary</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Bonus</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stock
    <br>
    Awards</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Option<br>
    Awards(1)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">All
    Other Compensation</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 20%"><span style="font-family: Times New Roman, Times, Serif">Itamar
    Shimrat</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">203,652</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;-</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">219,100</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;-</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">422,752</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">181,742</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">181,742</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amounts reported in this column represents the grant-date fair value of option awards granted during the year ended December 31,
    2021, calculated in accordance with FASB ASC Topic 718. The assumptions used in calculating these amounts are discussed in Note 10
    of the Notes to Consolidated Financial Statements included in this Annual Report.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 64; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Director
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information concerning the compensation of our non-employee directors for the fiscal year ended December
31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Change
    in</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Present
    Value</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">and</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fees</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Nonqualified</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Earned
    or</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Deferred</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Paid
    In</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Stock</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Option</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Compensation</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">All
    Other</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Year</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Salary</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Awards</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Awards
    </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Earnings</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Compensation</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dennis
Brown<sup></sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 6%"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right; width: 8%"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right; width: 8%"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right; width: 8%">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right; width: 8%"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right; width: 8%"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right; width: 8%">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Zolty<sup></sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ben
Friedman<sup></sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Outstanding
Equity Awards at Fiscal Year End</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table presents the outstanding equity awards held as of December 31, 2021 by our sole executive officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OUTSTANDING
EQUITY AWARDS AT FISCAL YEAR-END</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td colspan="18" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Option
    Awards</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock
    Awards</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Name</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Number
    of Securities Underlying Unexercised Options (#) Exercisable</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Number
    of Securities Underlying Unexercised Options (#) Unexercisable</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity
    Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Option
    Exercise Price ($)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Option
    Expiration Date</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Number
    of Shares or Units of Stock That Have Not Vested (#)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Market
    Value of Shares or Units of Stock That Have Not Vested ($)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity
    Incentive Plan Awards: Number of Unexercised Shares, Units or Other Rights That Have Not Vested (#)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity
    Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 19%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Itamar
    Shimrat</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,350,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">—</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">—</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1.00
                                            </span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3/7/2026</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">—</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">—</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">—</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">—</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    exercise price of this option is equal to the Fair Market Value of the Shares on the date of grant (as defined in the Company’s
    2019 Equity Incentive Plan).</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Risk
Management</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not believe risks arising from its compensation policies and practices for its employees are reasonably likely to have a
material adverse effect on the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Equity
Grant Committee</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the Board of Directors created an Equity Grant Committee and authorized it to make equity awards to employees, consultants
and other service providers. Mr. Brown and Mr. Shimrat are the current members of the Equity Grant Committee. The Equity Grant Committee
acted by written consent on eight occasions during the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Compensation
Committee Interlocks and Insider Participation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
the Board of Directors does not have a standing compensation committee, or a committee performing similar functions, except for the Equity
Grant Committee. During the fiscal year ended 2021, the entire Board of Directors deliberated with respect to executive compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>


<!-- Field: Page; Sequence: 65; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_021"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables sets forth certain information, as of the date set forth below, with respect to the beneficial ownership of the outstanding
Common Stock, Series A Preferred Stock and Series C Preferred Stock by (i) any holder of more than five (5%) percent of the applicable
class; (ii) each of the Company’s executive officers and directors; and (iii) the Company’s directors and executive officers
as a group. Except as otherwise indicated, each of the stockholders listed below has sole voting and investment power over the shares
beneficially owned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Shares Beneficially
Owned(1)<br>
As of April 11, 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    and Address of Beneficial Owner(2):</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent(3)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    A Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent(4)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent(5)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent
    of Total Voting Power</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itamar Shimrat,
    Chief Executive Officer, Chief Financial Officer and Director</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,925,004</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.39</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.58</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Zolty, Director</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,536,405</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.41</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,888</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.91</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ben Friedman, Director
    (8)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,245,932</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.91</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,553</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.24</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dennis Brown, Director
    (Executive Chairman)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">634,622
                                            </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.81</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,667</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Darlene Soave, Director</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,511,755</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.71</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.93</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George Verstraete, Director</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All directors and executive
    officers as a group (6 persons)</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13,418,180</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>32.31</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>194.442</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.49</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>-</b>&nbsp;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<b>&nbsp;</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.29</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yair Reisner 1515 Holcombe
    Boulevard Houston, Texas 77030</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,782,004</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.91</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.73</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YEDA Research &amp; Development
    Co., Ltd. P.O. Box 905 Rehovot, 76100, Israel</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,155,348</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.02</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hua Tuo Online (Hong Kong)
    Limited Suite 5207, 52/F Central Plaza 18 Harbour Road Wanchai, Hong Kong</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,821,562</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.01</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.93</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.48</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acuity Investments LLC
    124 South Gay Street Knoxville, Tennessee 37902</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,720,309</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.87</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130,402</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.72</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IGEA Ventures 1057 Commerce
    Avenue Union, New Jersey 07083</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,552,634</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.42</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108,667</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.96</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ingram Tynes 820 Shades
    Creek Parkway, Suite 2300 Birgmingham, Alabama 35209</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">799,054</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.07</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,330</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.74</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.767</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.52</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Tenenbaum 100 Newbury
    Road, Suite 210 Thousand Oaks, California 91320</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">442,100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,667</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.865</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Susan McCracken 4459 Decatur
    Drive Ferndale, Washington 98248</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">549,695</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.02</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,333</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.04</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Digimine, LLC 156 West
    Saddle River Road Saddle River, New Jersey 07458</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,307,249</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,296</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.65</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.47</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<!-- Field: Page; Sequence: 66; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.5in">(1)</td><td style="text-align: justify">Beneficial ownership is determined in accordance with the rules of
                                 the SEC and generally includes voting or investment power with respect to securities. Shares of common
                                 stock subject to options or warrants currently exercisable or convertible, or exercisable or convertible
                                 within 60 days of April 11, 2022 are deemed outstanding for computing the percentage of the person holding
                                 such option or warrant but are not deemed outstanding for computing the percentage of any other person.</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Except as otherwise
                                            indicated, the address of each beneficial owner is c/o Cell Source, Inc., 57 West 57<sup>th
                                            </sup>Street, Suite 400, New York, New York 10019.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Based on 34,397,078
                                            shares of common stock issued and outstanding as of April 11, 2022.</span></td></tr>
<tr style="vertical-align: top">
<td>(4)</td><td style="text-align: justify">Based on 1,342,195 shares of Series A Preferred Stock issued and outstanding as of April
            11, 2022.</td></tr>
<tr style="vertical-align: top">
<td>(5)</td><td style="text-align: justify">Based on 455,443 shares of Series C Preferred Stock issued and outstanding as of April
            11, 2022</td></tr>
<tr style="vertical-align: top">
<td>(6)</td><td style="text-align: justify">Includes 1,350,000 shares of common stock issuable upon the exercise of options to purchase
            common stock at an exercise price of $1.00 per share.</td></tr>
<tr style="vertical-align: top">
<td>(7)</td><td style="text-align: justify">Includes 300,000 shares of common stock issuable upon the exercise of options to purchase
            common stock at an exercise price of $0.75 per share and 108,880 shares of common stock issuable upon conversion of 10,888
            shares of Series A Preferred Stock.</td></tr>
<tr style="vertical-align: top">
<td>(8)</td><td style="text-align: justify">Mr. Friedman’s beneficial ownership includes shares beneficially owned by his wife,
            Phyllis Friedman.</td></tr>
<tr style="vertical-align: top">
<td>(9)</td><td style="text-align: justify">Includes 435,530 shares of common stock issuable upon conversion of 43,553 shares of Series
            A Preferred Stock and 300,000 shares of common stock issuable upon the exercise of options to purchase common stock at an
            exercise price of $0.75 per share.</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">(10)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Includes 450,000 shares
                                            of common stock issuable upon the exercise of options to purchase common stock at an exercise
                                            price of $0.75 per share and 66,670 shares of common stock issuable upon conversion of 6,667
                                            shares of Series A Preferred Stock.</span></td></tr>
<tr style="vertical-align: top">
<td>(11)</td><td style="text-align: justify">Includes 1,333,340 shares of common stock issuable upon conversion of 133,334 shares
             of Series A Preferred Stock and 2,800,000 shares of common stock issuable upon the exercise of warrants having an exercise
             price of $0.75 per share.</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">(12)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Includes 3,782,004
                                            shares of common stock issuable upon the exercise of options to purchase common stock at
                                            an exercise price of $0.75 per share.</span></td></tr>
<tr style="vertical-align: top">
<td>(13)</td><td style="text-align: justify">Includes 1,333,340 shares of common stock issuable upon conversion of 133,334 shares
             of Series A Preferred Stock.</td></tr>
<tr style="vertical-align: top">
<td>(14)</td><td style="text-align: justify">Includes 30,934 shares owned by Acuity Capital, LLC, an affiliate of the shareholder,
             and 1,304,020 shares of common stock issuable upon the conversion of 130,402 shares of Series A Preferred Stock, including
             99,408 shares of Series A Preferred Stock owned by Acuity Capital, LLC.</td></tr>
<tr style="vertical-align: top">
<td>(15)</td><td style="text-align: justify">Includes 1,086,670 shares of common stock issuable upon the conversion of 108,667 shares
             of Series A Preferred Stock.</td></tr>
<tr style="vertical-align: top">
<td>(16)</td><td style="text-align: justify">Includes 233,300 shares of common stock issuable upon conversion of 23,330 shares of
             Series A Preferred Stock, 400,000 shares of common stock upon the conversion of 40,000 shares of Series C Preferred Stock
             and 80,000 shares of common stock issuable upon the exercise of warrants having an exercise price of $1.25 per share.</td></tr>
<tr style="vertical-align: top">
<td>(17)</td><td style="text-align: justify">Includes 266,670 shares of common stock issuable upon conversion of 26,667 shares of
             Series C Preferred Stock and 160,000 shares of common stock issuable upon the exercise of warrants having an exercise price
             of $1.25 per share.</td></tr>
<tr style="vertical-align: top">
<td>(18)</td><td style="text-align: justify">Includes 333,330 shares of common stock issuable upon conversion of 33,333 shares of
             Series C Preferred Stock and 200,000 shares of common stock issuable upon the exercise of warrants having an exercise price
             of $1.25 per share.</td></tr>
                                                                                                          <tr style="vertical-align: top">
<td>(19)</td><td style="text-align: justify">Includes 712,960 shares of common stock issuable upon conversion of 71,296 shares of
             Series C Preferred Stock and 517,778 shares of common stock issuable upon the exercise of warrants having an exercise price
             of $1.25 per share.</td></tr>
                                                                                                          </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>


<!-- Field: Page; Sequence: 67; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_022"></span>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Certain
Relationships and Related Transactions</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains an exclusive worldwide license
to certain intellectual property of Yeda, the commercial arm of the Weizmann Institute, which currently owns 3,155,348 shares of Company
common stock. Dr. Reisner, who heads the Reisner Laboratory at MD Anderson, owns options to purchase 3,782,004 shares of Company common
stock. See the section entitled “Intellectual Property” in this Annual Report on Form 10-K.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, the Yeda License Agreement was amended
to reduce the Company’s funding obligation for the period from October 2017 through September 2018 to $500,000 and $100,000 for
the period from October 2018 through June 2019. In addition, the License Agreement was amended to provide that the Company would fund
an additional $100,000 of research during 2018 and the Company’s obligation to fund the original research was reduced by $50,000.
The Company funded the additional $100,000 of additional research in April 2018 and $50,000 was credited against the amount that would
have otherwise been funded by the Company for the period from July 2018 through September 2018. After giving effect to these amendments
and this credit, the Company was required to fund $100,000 for the three-month period ended June 30, 2018, $50,000 for the three month
period ended December 2018, and is required to fund $25,000 for the three month period ending March 2019 and $25,000 for the three month
period ending June 2019. In connection with Amendments No. 5, 6 and 7 to the License Agreement, the latest of which was dated November
15, 2020, the research conducted (“Further Research”) under the Agreement was extended to cover the period from July 1, 2019
to March 31, 2020 and the associated research budget for this period was a total of $235,000. In addition, these amendments and an amendment effective December 2, 2021
amended the milestones and related completion dates. If the Company fails to achieve any of the milestones by the dates set forth in the
agreement, Yeda is entitled to terminate the license upon written notice to the Company. To date, the Company has been deemed to have
met all of the milestones and the next milestone in the agreement is January 1, 2025. Either Yeda or the Company may terminate the agreement
and the license after the commitment of a material breach by the other party and in certain other instances as detailed in the agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2021 and 2020, the Company recorded expenses in operations of approximately $50,000 and $164,000,
respectively, related to its Agreement with Yeda.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
May 2017, the Company received a loan of $180,000 from an entity owned by Ben Friedman and a loan of $45,000 from an entity owned by
David Zolty. Each of Mr. Friedman and Mr. Zolty is a director of the Company. The loans, which are non-interest bearing and became due
on May 18, 2018, remained outstanding as of December 31, 2021. As of December 31, 2021, the Company had accrued an obligation to issue
warrants to purchase 49,500 and 198,000 shares, respectively, at an exercise price of $0.75 per share to the entity owned by Mr. Friedman
and Mr. Zolty as a result of the Company’s failure to repay these notes by the maturity date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2018, the Company received a non-interest-bearing short-term advance in the amount of $100,000 from David Zolty. <span style="background-color: white">Because
the short-term advance was not repaid by the Company on or before January 15, 2019, the Company was required under the terms of the advance
to (i) issue to Mr. Zolty warrants to purchase 100,000 shares of common stock on such date and (ii) </span>to further issue warrants
to purchase 25,000 shares of common stock for each month that the advance remains outstanding after such date. As of December 31, 2021,
the entire amount of the advance was outstanding. As of December 31, 2021, the Company was required to issue warrants to purchase an
aggregate of 975,000 shares <span style="background-color: white">at an exercise price of $0.75 per share </span>to Mr. Zolty in connection
with this advance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has agreed to issue warrants to purchase 134,000 shares of common stock at an exercise price of $0.75 per share to Mr. Zolty
in consideration of Mr. Zolty making a $134,000 payment to Yeda on the Company’s behalf in 2016. As of December 31, 2021, the Company
had not issued the warrants to Mr. Zolty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Darlene
Soave was appointed to our Board of Directors effective</span> March <span style="background-color: white">25, 2021. On October 28, 2019,
as amended most recently on December 31, 2021, the Company issued a convertible note payable to Ms. Soave that has a principal amount
of $6,000,000. </span>The convertible note, as amended, bears interest at 10% per annum and matures on October 28, 2022. Ms. Soave has
the right, at her option, to convert the note into shares of the Company’s Series B Convertible Preferred Stock at a price of $7.50
per share at any time after the designation and sale of the Series B Convertible Preferred Stock. Interest accruing under the note will
be payable upon the maturity of the note and may be paid at the Company’s option in either cash or shares of the Company’s
common stock (calculated based upon $0.75 per share for purposes of calculating the number of shares of common stock to be issued). For
each $500,000 advanced under the note, Ms. Soave will be issued a five-year warrant to purchase 400,000 shares of the Company’s
common stock at an exercise price of $1.25 per share. <span style="background-color: white">During the years ended December 31, 2021
and 2021, the Company received advances of $1,500,000 and $1,500,000, respectively. </span>As of December 31, 2021, $3,500,000 of principal
under the convertible note was outstanding and the Company had issued warrants to purchase 2,800,000 shares of common stock at an exercise
price of $1.25 per share to Ms. Soave.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">George Verstraete was appointed to our Board of
Directors on March 10, 2022. On March 10, 2022, the Company issued <span style="background-color: white">a convertible note payable to
Mr. </span>Verstraete <span style="background-color: white">that has a principal amount of $6,000,000</span>. The note bears interest
at a rate of 10% per annum and matures on March 10, 2023. Mr. Verstraete has the right, at his option, to convert the note into shares
of the Company’s Series B Convertible Preferred Stock at a conversion price of $7.50 per share at any time after the designation
and sale of the Series B Convertible Preferred Stock. Interest accruing under the note will be payable upon the maturity of the note
and may be paid at the Company’s option in either cash or shares of the Company’s common stock (calculated based upon $0.75
per share for purposes of calculating the number of shares of common stock to be issued). For each $500,000 advanced under the note,
Mr. Verstraete will be issued a five-year warrant to purchase 400,000 shares of the Company’s common stock at an exercise price
of $1.25 per share. Mr. Verstraete advanced $1,000,000 to the Company under the note in March 2022, such that such amount is currently
outstanding as of the date of filing.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 68; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Director
Independence</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our directors are independent, as that term is defined under the Nasdaq Marketplace Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_023"></span>ITEM
14. PRINCIPAL ACCOUNTING FEES AND SERVICES.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of fees for professional services rendered by our independent registered public accounting firm for the years
ended December 31, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Audit Fees</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">131,070</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">141,625</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Tax fees</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">18,540</p></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">149,610</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,625</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
fees represent fees for professional services performed for the audit of our annual financial statements and the review of our quarterly
financial statements, as well as services that are normally provided in connection with statutory and regulatory filings or engagements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">Tax fees were for tax compliance
services for the years ended December 31, 2020 and 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee is responsible for the appointment, compensation and oversight of the work of the independent registered public accountants
and approves in advance any services to be performed by the independent registered public accountants, whether audit-related or not.
The Audit Committee reviews each proposed engagement to determine whether the provision of services is compatible with maintaining the
independence of the independent registered public accountants. The fees shown above were pre-approved either by our Board or our Audit
Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 69; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_024"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_025"></span>ITEM
15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Index to Financial Statements immediately following the signature page of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
Statement Schedules</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial statement schedules are omitted because they are not applicable or the required information is shown in the financial statements
or notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibits are included as part of this Annual Report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
                                                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
    (1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414040712/v382279_ex2-1.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Exchange Agreement, dated June 30, 2014, by and between Cell Source, Ltd., and Ticket to See, Inc.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
    (1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414040712/v382279_ex3-1.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Association of Cell Source Limited, dated August 14, 2011, as amended on November 11, 2013</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
    (2)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552713000223/ex3-1.txt" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Incorporation of Ticket to See, Inc., dated June 6, 2012</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
    (3)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552714000387/ex3-1.txt" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Articles of Incorporation of Ticket to See, Inc., dated June 23, 2014</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
    (4)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552714000350/ex3-1.txt" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Articles of Incorporation of Ticket to See, Inc., dated May 20, 2014</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
    (2)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552713000223/ex3-2.txt" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws of Cell Source, Inc., dated June 6, 2012</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5
    (18)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552714000350/ex3-1.txt" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation with respect to Series A Preferred Stock dated November 14, 2016</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/ex4-1.htm" tabindex="18">Description of Common Stock</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1
    (1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414040712/v382279_ex10-1.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Subscription Agreement</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2
    (1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414040712/v382279_ex10-2.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Registration Rights Agreement</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4
    (1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552714000391/ex10-1.txt" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Consultant Warrant(8)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5
    (1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414040712/v382279_ex10-4.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Researcher Company Warrant</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6
    (1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414040712/v382279_ex10-5.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Company Warrant</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8
    (1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414040712/v382279_ex10-7.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and License Agreement by and between Yeda Research and Development Company Limited and Cell Source Limited, dated October 3, 2011</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9
    (1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414040712/v382279_ex10-8.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Research and License Agreement</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10
    (1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414040712/v382279_ex10-7.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation and Exclusive Option Agreement by and between Yeda Research and Development Company Limited and Cell Source Limited, dated Oct. 3, 2011 (included in Exhibit 10.7)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11
    (1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414040712/v382279_ex10-10.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment dated April 1, 2014 to Evaluation and Exclusive Option Agreement by and between Yeda Research and Development Company Limited and Cell Source Limited</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12
    (1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414040712/v382279_ex10-11.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment dated June 22, 2014 to Evaluation and Exclusive Option Agreement by and between Yeda Research and Development Company Limited and Cell Source Limited</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13
    (1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414040712/v382279_ex10-12.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement by and between Cell Source Limited and Professor Yair Reisner</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14
    (6)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414047983/v384131_ex10-13.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Amendment No. 1 to Registration Rights Agreement</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15
    (7)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414057412/v389695_ex10-14.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bridge Funding Agreement</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16
    (5)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414051396/v387117_ex10-11.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Amendment dated June 22, 2014 to Evaluation and Exclusive Option Agreement by and between Yeda Research and Development Company Limited and Cell Source Limited</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17
    (8)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552714000391/ex10-1.txt" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Consulting Agreement pursuant to which the Company issued warrants to purchase an aggregate of 2,000,000 shares of the Company’s common stock</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18
    (9)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420414071793/v395554_ex10-1.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Promissory Note issued to the Company’s Chief Executive Officer</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19(10)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420415020440/v406249_ex10-1.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of March 2015 Promissory Note</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20(10)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420415020440/v406249_ex10-2.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of March 2015 Warrant</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21(11)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420415035198/v412327_ex4-1.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Note Amendment Letter Agreement</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22(11)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420415035198/v412327_ex10-1.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of May 2015 Note</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23(11)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420415035198/v412327_ex10-2.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of May 2015 Warrant</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24(12)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420415036460/v412837_ex10-1.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Advisory/Consulting Agreement</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25(13)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552715000365/ex10-1.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zolty Promissory Note</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26(13)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552715000365/ex10-2.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zolty Warrant</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27(13)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552715000365/ex10-3.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of July 2015 Convertible Promissory Note</span></a></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 70; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28(13)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552715000365/ex10-4.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of July 2015 Warrant</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29(15)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552716000733/ex10-29.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Bridge Note Subscription Agreement</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30(15)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552716000733/ex10-30.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Convertible Note</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31(15)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552716000733/ex10-31.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of March 2016 Note</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32(15)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552716000733/ex10-32.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of March 2016 Warrant</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33(18)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552718000154/10-33.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of July 2016 Warrants</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34(18)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552718000154/ex10-34.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment to Research and License Agreement dated as of November 28, 2016 between the Company and Yeda Research and Development Company Limited</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35(18)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552718000154/ex10-35.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Amendment to Research and License Agreement dated as of March 29, 2018 between the Company and Yeda Research and Development Company Limited</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36(18)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552718000154/ex10-36.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourth Amendment to Research and License Agreement dated as of March 30, 2018 between the Company and Yeda Research and Development Company Limited</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.36(a)*</td>
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/ex10-36a.htm" tabindex="18">Fifth Amendment to Research and License Agreement dated as of June 30, 2019 between the Company and Yeda Research and Development Company Limited</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37(16)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552716000772/ex10-1.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Note due July 27, 2016</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38(17)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552716000871/ex10-1.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory Note dated May 10, 2016</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39(19)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552719000114/ex10-40.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsored Research Agreement dated November 28, 2018 between The University of Texas M.D. Anderson Cancer Center and Cell Source Limited**</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39(a)(20)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552719000089/ex10-39a.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Veto Cell Production and Clinical Trial Program Agreement dated as of April 4, 2019 between Cell Source Limited and the University of Texas M.D. Cancer Center**</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39(b)*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/ex10-39b.htm" tabindex="18">Amendment No. 2 to Sponsored Research Agreement dated October 18, 2021 between the University of Texas MD Anderson Cancer Center and Cell Source Ltd. (28)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40(19)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552719000114/ex10-39.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement for Veto Cell Production and Clinical Trial Program dated February 19, 2019 between The University of Texas M.D. Anderson Cancer Center and Cell Source Limited**</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41(21)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552719000139/ex10-40.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019 Equity Incentive Plan</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42(21)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552719000139/ex10-41.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Option Agreement dated as of August 11, 2019 before Cell Source, Inc. and Yair Reisner</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43(21)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552719000139/ex10-41.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Option Agreement dated as of August 11, 2019 between Cell Source, Inc. and Yair Reisner</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44(21)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552719000139/ex10-43.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Promissory Note dated July 2, 2019</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45(21)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552719000139/ex10-44.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Promissory Note dated May 20, 2019</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.46(21)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000116552719000139/ex10-55.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory Note dated July 29, 2019</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.47(22)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033420000672/clcs_ex1047.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Note effective October 28, 2019</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.48(22)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033420000672/clcs_ex1048.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sixth Amendment to Research and License Agreement effective December 31, 2019 between Yeda Research and Development Company Limited and Cell Source Limited**</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.49(23)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033420001244/clcs_ex1049.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Promissory Note dated January 10, 2020</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.50(23)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033420001244/clcs_ex1050.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant dated February 13, 2020</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.51(24)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033420002131/clcs_ex1051.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement between Cell Source, Inc. and Purchaser of 10% OID Convertible Promissory Note.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.53(24)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033420002131/clcs_ex1052.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of 10% OID Convertible Promissory Note.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.54(24)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033420002131/clcs_ex1053.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant issued to purchaser of 10% OID Convertible Promissory Note.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.54(25)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033420002809/clcs_ex1054.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant issued to Members of Scientific Advisory Board.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.55(25)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033420002809/clcs_ex1055.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant issued to Service Providers.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.56(25)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033420002809/clcs_ex1056.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Director Stock Option Agreement.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.57(25)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033420002809/clcs_ex1057.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Consultant Stock Option Agreement.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.58(25)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033420002809/clcs_ex1058.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of 8% Convertible Promissory Note.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.59(25)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033420002809/clcs_ex1059.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant issued to Purchasers of 8% Convertible Promissory Note</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.60(26)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033421000923/clcs_ex1060.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Note Exchange Agreement between Cell Source, Inc. and holder of 10% OID Convertible Promissory Note.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.62(26)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033421000923/clcs_ex1061.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amended and Restated 10.0% Convertible Note.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.63(26)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000164033421000923/clcs_ex1063.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seventh Amendment to Research and License Agreement dated November 15, 2020 between Yeda Research and Development Company Limited and Cell Source Limited&nbsp;</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.63(a)*</td>
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/ex10-63a.htm" tabindex="18">Eighth Amendment to Research and License Agreement dated as of December 2, 2021 between the Company and Yeda Research and Development Company Limited</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.64(27)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000149315221019491/ex10-64.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Amended and Restated Convertible Note issued to Darlene Soave.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.68*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/ex10-68.htm" tabindex="18">10% Convertible Note issued to George Verstraete</a>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21(14)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000114420415015954/v401669_ex21.htm" style="-sec-extract: exhibit" tabindex="18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Subsidiaries</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/ex31-1.htm" tabindex="18">Certification
    of principal executive and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1569340/000149315222010133/ex32-1.htm" tabindex="18">Certification
    of principal executive and principal financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 71; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 1, 2014.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on June
    6, 2012.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on June 26, 2014.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on June 6, 2014.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-Q filed with the Securities and Exchange Commission on August 19, 2014.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on August
    8, 2014.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Registration Statement Form S-1/A filed with the Securities and Exchange Commission on September
    23, 2014.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on June 30, 2014.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on December 2, 2014.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on April 1, 2015.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on June 3, 2015.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on June 10, 2015.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 8-K filed with the Securities and Exchange Commission on July 28, 2015.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-K filed with the Securities and Exchange Commission on March 13, 2015.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-K filed with the Securities and Exchange Commission on April 14, 2016.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-Q filed with the Securities and Exchange Commission on May 13, 2016.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-Q filed with the Securities and Exchange Commission on August 15, 2016.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-K filed with the Securities and Exchange Commission on July 25, 2018.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-K/A filed with the Securities and Exchange Commission on June 19, 2019.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-Q filed with the Securities and Exchange Commission on May 20, 2019.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-Q filed with the Securities and Exchange Commission on August 14, 2019.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-K filed with the Securities and Exchange Commission on March 30, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-Q filed with the Securities and Exchange Commission on May 15, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-Q filed with the Securities and Exchange Commission on August 14, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-Q filed with the Securities and Exchange Commission on November 13, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-K filed with the Securities and Exchange Commission on April 15, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-Q filed by the Company with the Securities and Exchange Commission on August 12, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Company’s Form 10-Q filed with the Securities and Exchange Commission on November 15, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
    </span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    Herewith</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    information has been excluded from this exhibit because (i) it is not material and (ii) would be competitively harmful if publicly
    disclosed.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_026"></span>ITEM
16. FORM 10-K SUMMARY.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 72; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_027"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CELL
    SOURCE, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    April 15, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Itamar Shimrat</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itamar
    Shimrat</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive, Financial and Accounting Officer)</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SIGNATURE</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>TITLE</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>DATE</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>By:
    </i></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Dennis Brown</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    15, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dennis
    Brown</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>By:</i></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Itamar Shimrat</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, Chief Financial Officer and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    15, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itamar
    Shimrat</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
                                            Executive, Financial and Accounting Officer)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>By:</i></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ben Friedman</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    15, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ben
    Friedman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>By:</i></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    David Zolty</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    15, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Zolty</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>By:</i></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Darlene Soave</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    15, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Darlene
    Soave</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    George Verstraete</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    15, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Verstraete</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<!-- Field: Page; Sequence: 73; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CELL
SOURCE, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_10" tabindex="18">Report
    of Independent Registered Public Accounting Firm</a> (PCAOB ID: <span id="xdx_90A_edei--AuditorFirmId_c20210101__20211231_zb6hQu3atgv3"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorFirmId" inside-table="true" id="fact-identifier-32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">688</ix:nonnumeric></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_11" tabindex="18">Consolidated
    Balance Sheets as of December 31, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_12" tabindex="18">Consolidated
    Statements of Operations for the Years Ended December 31, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_13" tabindex="18">Consolidated
    Statements of Changes in Stockholders’ Deficiency for the Years Ended December 31, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_14" tabindex="18">Consolidated
    Statements of Cash Flows for the Years Ended December 31, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_16" tabindex="18">Notes
    to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 74; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_10"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders and Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
Source, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Cell Source, Inc. and Subsidiary (the “Company”) as of
December 31, 2021 and 2020, the related consolidated statements of operations, changes in stockholders’ deficiency and cash
flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the
“financial statements”). In our opinion, the financial statements present fairly, in all material respects, the
financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of
the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United
States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Explanatory
Paragraph – Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more
fully described in Note 2, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise
additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company’s
ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The consolidated
financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated
or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Valuation
of Common Stock Price</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 3 to the consolidated financial statements, the Company obtained a third-party valuation of its common stock
price, which was used to estimate the fair value of equity instruments issued for stock based compensation as of and for the year
ended  December 31, 2021. The estimates used by management are considered highly complex and subjective. The independent
valuation performed utilized the option pricing method, or OPM, as the most reliable method with the following steps being
applied:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishment
                                            of total enterprise or equity value;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analysis
                                            of equity rights for each class of security;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selection
                                            of appropriate model for valuation purposes;</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination
                                            of key valuation inputs; and</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computation
                                            of the fair value of the subject security.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the OPM, it was determined the Company’s common stock fair value was $0.34 per share as of December 31, 2021, which included
a discount for lack of marketability of 30%. Furthermore, the independent valuation determined the Company’s expected
volatility was 90% by evaluating historical and implied volatilities of guideline companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
identified the valuation of the Company’s common stock price as a critical audit matter. The Company’s common stock price
is highly subjective and requires a higher degree of auditor judgment as the Company’s common stock price was determined by using
highly subjective estimates made by management. Further, specialized valuation skills were needed to assess the Company’s process
and value the common stock price using the option pricing model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary procedures we performed to address this critical audit matter included the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            identified and considered the relevance, reliability and sufficiency of the sources of data
                                            used by the Company in developing the assumptions used to determine the common stock price.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            obtained an understanding of the factors considered and assumptions made by management and
                                            the Company’s valuation specialist in developing the estimate of the common stock price,
                                            the sources of data relevant to these factors and assumptions and the procedures used to
                                            obtain the data and the methods used to calculate the estimate.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            evaluated the reasonableness of the valuation methods and assumptions used by management
                                            and the Company’s valuation specialist to estimate the common stock price and reperformed
                                            the calculation of the estimate of the common stock price with the assistance of our valuation
                                            specialists.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marcum <span style="font-variant: small-caps">llp</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90F_edei--AuditorName_c20210101__20211231_zO3YItIUXJn9"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorName" inside-table="false" id="fact-identifier-33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Marcum</ix:nonnumeric></span> </span><span style="font-variant: small-caps">llp</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-variant: small-caps"></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company’s auditor since 2014.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--AuditorLocation_c20210101__20211231_zW1aUolb2HS4"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorLocation" inside-table="false" id="fact-identifier-34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">New
York, NY</ix:nonnumeric></span></span><br>
April 15, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_11"></span>CELL
SOURCE, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_111_zu1PiuukutN4" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td id="xdx_49F_20211231_z4TO7OJvPKui" style="font-family: Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td id="xdx_499_20201231_zTG5KxoGeyUg" style="font-family: Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AssetsAbstract_iB_zCJc5CbHnVFb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrentAbstract_i01B_zuX45b348jx6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current
    Assets:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzeL3_zTamR293CcHa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 68%"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-35" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">93,095</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">241,619</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidExpenseCurrent_i02I_maCzeL3_zkfMUPh3I4w4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:PrepaidExpenseCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">203,750</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:PrepaidExpenseCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">177,569</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OtherAssetsCurrent_i02I_maCzeL3_zmduftFTwixk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other
    current assets</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:OtherAssetsCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,922</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:OtherAssetsCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-40" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,651</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AssetsCurrent_i02TI_mtCzeL3_maCz3E9_zsDI3UBpXWG2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    Current Assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AssetsCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">313,767</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AssetsCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">448,839</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_405_eus-gaap--RestrictedCashNoncurrent_i01I_maCz3E9_zohnjhrzFZod" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Restricted
    cash</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0063"><span><ix:nonfraction name="us-gaap:RestrictedCashNoncurrent" contextref="AsOf2021-12-31" id="fact-identifier-43" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0063" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:RestrictedCashNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,500</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_i01TI_mtCz3E9_ztFZKW4SCqd6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Assets</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">313,767</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">452,339</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Liabilities
    and Stockholders’ Deficiency</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesCurrentAbstract_i01B_zCglyQp7Q63e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current
    Liabilities:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableCurrent_i02I_maCziEE_maLz0mn_zv9cBIr02FKc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts
    payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccountsPayableCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">223,041</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccountsPayableCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">193,095</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCziEE_maLz0mn_zYtclt1rSRs8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-49" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,097,021</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,159,950</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_404_ecustom--AccruedExpensesRelatedPartiesCurrent_i02I_maCziEE_maLz0mn_zLFjRV0IdGI1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses - related parties</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedExpensesRelatedPartiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">72,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedExpensesRelatedPartiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-52" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">198,701</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPayableCurrent_i02I_maCziEE_maLz0mn_zYOGolpaVOP3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    interest</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:InterestPayableCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">532,960</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:InterestPayableCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">515,910</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40D_ecustom--AccruedInterestRelatedPartiesCurrent_i02I_maCziEE_maLz0mn_zuj5i6JtitTi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    interest - related parties</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedInterestRelatedPartiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-55" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">649,265</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedInterestRelatedPartiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">481,334</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_406_eus-gaap--DeferredCompensationLiabilityCurrent_i02I_maCziEE_maLz0mn_zmBjs9m1hZ5h" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:DeferredCompensationLiabilityCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-57" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">766,102</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:DeferredCompensationLiabilityCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">724,185</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NotesPayableCurrent_i02I_maCziEE_maLz0mn_z1YGsHrfS72a" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Notes
    payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-59" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">759,912</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,013,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_i02I_maCziEE_maLz0mn_zqdJpDlBfnE3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Notes
    payable - related parties</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_405_ecustom--ConvertibleNotesPayableCurrentNet_i02I_pp0p0_maLz0mn_znWJa2t0Yrvh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible
    notes payable, net of debt discount of $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zheZoYZkbn1" title="Debt discount"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextref="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-63" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71,124</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">and $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pp0p0_c20201231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zII1jgeNQWAk" title="Debt discount"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextref="AsOf2020-12-31_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82,403</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif">as of December 31, 2021 and 2020, respectively</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:ConvertibleNotesPayableCurrentNet" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-65" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,834,446</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:ConvertibleNotesPayableCurrentNet" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,493,153</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ConvertibleDebtCurrent_i02I_maCziEE_maLz0mn_zH0iRfljw0t" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible
    notes payable - related parties, net of debt discount of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableRelatedPartiesMember_zT6k4SFZ67e6" title="Debt discount"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableRelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span> and $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pp0p0_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableRelatedPartiesMember_z9tdvQVCiScl" title="Debt discount"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextref="AsOf2020-12-31_custom_ConvertibleNotesPayableRelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,317</ix:nonfraction></span></span> as of December 31, 2021 and 2020, respectively</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleDebtCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-69" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,725,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleDebtCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,149,683</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_400_ecustom--AdvancesPayableCurrent_i02I_maCziEE_maLz0mn_zY0aJ5fiF1r1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Advances
    payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AdvancesPayableCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-71" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">135,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AdvancesPayableCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-72" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">195,500</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40E_ecustom--AdvancesPayableRelatedPartyCurrent_i02I_maCziEE_maLz0mn_z8dnJGityKRd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Advances
    payable - related party</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AdvancesPayableRelatedPartyCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AdvancesPayableRelatedPartyCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-74" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_maLz0mn_zckeQVkCvOog" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financing
    liability</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,926</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0120"><span><ix:nonfraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextref="AsOf2020-12-31" id="fact-identifier-76" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0120" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DividendsPayableCurrent_i02I_maCziEE_maLz0mn_ztS9e0eQbQUa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    dividend payable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:DividendsPayableCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">67,229</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:DividendsPayableCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-78" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,210</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesCurrent_i01TI_mtLz0mn_maLASEzWUB_zDX6iFitE2Se" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:LiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-79" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,139,902</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:LiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-80" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,399,721</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CommitmentsAndContingencies_i01I_maCzj8v_maLASEzWUB_zsm4DAj7nk83" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commitments
    and contingencies (Note 11)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0129"><span><ix:nonfraction name="us-gaap:CommitmentsAndContingencies" contextref="AsOf2020-12-31" id="fact-identifier-81" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0129" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">&nbsp;</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stockholders’
    Deficiency:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_407_eus-gaap--PreferredStockValue_i02I_zsLLJWrmhwCj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Convertible
    Preferred Stock, $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20201231_zWdqON5yTOK8" title="Preferred stock par or stated value, per share"><span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231_z0vB78oSH6af" title="Preferred stock par or stated value, per share"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-82" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-83" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></ix:nonfraction></span></span></span></span>
    <span style="font-family: Times New Roman, Times, Serif">par value, <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20201231_zl9z8tSbT6G5" title="Preferred stock, shares authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211231_z752vIIzrYb" title="Preferred stock, shares authorized"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-84" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000,000</ix:nonfraction></span></ix:nonfraction></span></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">shares authorized;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zUyzwujtwo8b" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series
    A Convertible Preferred Stock, <span id="xdx_904_ecustom--ConvertiblePreferredStockSharesDesignated_iI_pid_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zpmgjkCpflzh" title="Preferred stock, shares designated"><span id="xdx_901_ecustom--ConvertiblePreferredStockSharesDesignated_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zUeWHIcBMSk" title="Preferred stock, shares designated"><span><ix:nonfraction name="CLCS:ConvertiblePreferredStockSharesDesignated" contextref="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-86" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><span><ix:nonfraction name="CLCS:ConvertiblePreferredStockSharesDesignated" contextref="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-87" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,335,000</ix:nonfraction></span></ix:nonfraction></span></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">shares designated, <span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zmsDgNtVriqd" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zWrp4Eon6Yn2" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pid_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zVjjKqP4gFc9" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zJ8iWTbyl2Pa" title="Preferred stock, shares outstanding"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-88" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,342,195</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></span></span></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">shares issued and outstanding as of December 31, 2021 and
    2020, respectively; liquidation preference of $<span id="xdx_900_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zLpza2B3izp6" title="Preferred stock liquidation preference value"><span><ix:nonfraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextref="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-92" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,066,463</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">and $<span id="xdx_905_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zsEwn5RzuiWh" title="Preferred stock liquidation preference value"><span><ix:nonfraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextref="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,091,672</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">as of December 31, 2021 and 2020, respectively</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,342</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-95" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,342</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_409_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zXK5TDMAk0r4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series
    C Convertible Preferred Stock, <span id="xdx_90F_ecustom--ConvertiblePreferredStockSharesDesignated_iI_pid_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zyQNA7O4CJUa" title="Preferred stock, shares designated"><span id="xdx_90D_ecustom--ConvertiblePreferredStockSharesDesignated_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zhNWkdxhDgU1" title="Preferred stock, shares designated"><span><ix:nonfraction name="CLCS:ConvertiblePreferredStockSharesDesignated" contextref="AsOf2020-12-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><span><ix:nonfraction name="CLCS:ConvertiblePreferredStockSharesDesignated" contextref="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">500,000</ix:nonfraction></span></ix:nonfraction></span></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">shares designated, <span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zBIOg9MxsQWf" title="Preferred stock, shares outstanding"><span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zmx1nYNVfV3l" title="Preferred stock, shares issued"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-98" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-99" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">272,021</ix:nonfraction></span></ix:nonfraction></span></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">and <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zevGGLFfq9ah"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pid_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zI6FgrvtXbFg" title="Preferred stock, shares issued"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2020-12-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-100" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2020-12-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-101" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></ix:nonfraction></span></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">shares issued and outstanding as of December 31, 2021 and
    2020, respectively; liquidation preference of $<span id="xdx_90E_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zAjYWFmStOJk" title="Preferred stock liquidation preference value"><span><ix:nonfraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextref="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,107,388</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">and $<span id="xdx_90A_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zbCpQLdBjH4c" title="Preferred stock liquidation preference value"><span><ix:nonfraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextref="AsOf2020-12-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-103" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">as of December 31, 2021 and 2020, respectively</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-104" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">272</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0165"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2020-12-31_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-105" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0165" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_406_eus-gaap--PreferredStockValue_i01I_maSEzlRc_zcf4vJGABS4h" style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Preferred stock, value</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--CommonStockValue_i02I_pp0p0_maSEzlRc_zFBhyOQMBdO" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock, $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20201231_zFxfltSi1d23"><span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211231_z5ia1P0IwEQd" title="Common stock par or stated value, per share"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-106" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-107" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></ix:nonfraction></span></span></span></span> <span style="font-family: Times New Roman, Times, Serif">par
    value, <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20201231_zpz9Nt4rvDAi"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20211231_zKCY6ekY3hOi" title="Common stock, shares authorized"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-108" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-109" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span></span> <span style="font-family: Times New Roman, Times, Serif">shares
    authorized; <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_pid_c20211231_zRmx6Hh6Gkbj" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231_z5qO6AI6UF64" title="Common stock, shares outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-110" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-111" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,360,546</ix:nonfraction></span></ix:nonfraction></span></span></span></span> <span style="font-family: Times New Roman, Times, Serif">and
    <span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20201231_zEgDI9oyeA31" title="Common stock, shares outstanding"><span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pid_c20201231_zGV3AZYeMy54" title="Common stock, shares issued"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-113" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,538,411</ix:nonfraction></span></ix:nonfraction></span></span></span></span> <span style="font-family: Times New Roman, Times, Serif">shares
    issued and outstanding as of December 31, 2021 and 2020, respectively</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,361</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-115" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,538</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AdditionalPaidInCapital_i02I_maCz97r_maSEzlRc_zfNaoupZ8ID2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional
    paid-in capital</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapital" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,316,318</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapital" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-117" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,724,731</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_400_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCz97r_maSEzlRc_zhURhEtmE3x4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-118" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,178,428</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-119" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,705,993</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzlRc_maLASEzWUB_zToirlBDgiCg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Stockholders’ Deficiency</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-120" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,826,135</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-121" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,947,382</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzWUB_zt5ZDH6F4log" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Liabilities and Stockholders’ Deficiency</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-122" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">313,767</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-123" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">452,339</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_12"></span>CELL
SOURCE, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_113_zGC6Wo6LMe4h" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td id="xdx_495_20210101__20211231_zWFru5I8gXYb" style="font-family: Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td id="xdx_49A_20200101__20201231_zHZ76eY2Ib3l" style="font-family: Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Years Ended</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpensesAbstract_iB_zBou3Ek1GSw3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    Expenses:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzw4J_zvS4UaoqpDnj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,273,352</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-125" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">834,943</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_404_ecustom--ResearchAndDevelopmentRelatedParty_i01_maCzw4J_zqXNIvvWzyKc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development - related party</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:ResearchAndDevelopmentRelatedParty" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-126" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50,056</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:ResearchAndDevelopmentRelatedParty" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-127" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">163,611</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzw4J_zWV0QDZVnrCf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-128" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,695,164</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-129" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,639,482</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpenses_i01T_mtCzw4J_msCz7wH_z5QXmRzWWfCd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Operating Expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-130" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,018,572</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-131" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,638,036</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iT_mtCz7wH_maCz7or_zqAplsRAXat8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    From Operations</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-132" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,018,572</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-133" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,638,036</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_ziyfFrmxLSng" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    (Expense) Income:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpenseOther_i01N_di_msNIEzQFw_z6vcVm7mX6Si" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest
    expense</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:InterestExpenseOther" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-134" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">380,230</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<span><ix:nonfraction name="us-gaap:InterestExpenseOther" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">397,727</ix:nonfraction></span></p></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_ecustom--InterestExpenseRelatedParties_i01N_di_msNIEzQFw_zxflAKtE8vUi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest
    expense - related parties</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="CLCS:InterestExpenseRelatedParties" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-136" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">248,971</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="CLCS:InterestExpenseRelatedParties" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-137" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">238,429</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--AmortizationOfDebtDiscountPremium_i01N_di_msNIEzQFw_z6LXNj2GQUn1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization
    of debt discount</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-138" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">408,619</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-139" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">140,771</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_ecustom--AmortizationOfDebtDiscountRelatedParty_i01N_di_msNIEzQFw_zK9BNY78Gm0k" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Amortization of debt discount - related
    party</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(<span><ix:nonfraction name="CLCS:AmortizationOfDebtDiscountRelatedParty" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-140" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">322,883</ix:nonfraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(<span><ix:nonfraction name="CLCS:AmortizationOfDebtDiscountRelatedParty" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-141" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">160,479</ix:nonfraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_maNIEzQFw_zRAFidKSm3Ul" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change
    in fair value of derivative liabilities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0247"><span><ix:nonfraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextref="From2021-01-01to2021-12-31" id="fact-identifier-142" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0247" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-143" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,977</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_400_ecustom--GainOnForgivenessOfAccruedInterest_i01_maNIEzQFw_zvQ88lESUd8h" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain
    on forgiveness of accrued interest</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:GainOnForgivenessOfAccruedInterest" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-144" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">49,983</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0251"><span><ix:nonfraction name="CLCS:GainOnForgivenessOfAccruedInterest" contextref="From2020-01-012020-12-31" id="fact-identifier-145" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0251" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_409_ecustom--GainOnExchangeOfAccruedInterestForCommonStock_i01_maNIEzQFw_zemQEUfgwI4e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain
    on exchange of accrued interest for common stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0253"><span><ix:nonfraction name="CLCS:GainOnExchangeOfAccruedInterestForCommonStock" contextref="From2021-01-01to2021-12-31" id="fact-identifier-146" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0253" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:GainOnExchangeOfAccruedInterestForCommonStock" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-147" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">132,502</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_401_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maNIEzQFw_zUpds87Zr6Nl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    on extinguishment of notes payable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-148" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">143,143</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-149" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">134,202</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpense_i01T_maCz7or_mtNIEzQFw_zxyhspatxrt3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Other Expense</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:NonoperatingIncomeExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-150" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,453,863</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:NonoperatingIncomeExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-151" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">922,129</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_iT_mtCz7or_maNILATzc8f_zdC58m8RmSj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    Loss</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-152" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,472,435</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-153" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,560,165</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_pp0p0_di_msNILATzc8f_zFG84r0eypKf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Dividend
    attributable to Series A and Series C preferred stockholders</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-154" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">973,205</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-155" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">877,736</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzc8f_zR1PdHSh0Ht6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    Loss Applicable to Common Stockholders</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-156" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,445,640</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-157" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,437,901</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareBasicAndDiluted_pid_zU0jIHbbvOLl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    Loss Per Common Share - Basic and Diluted</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-158" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.19</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-159" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.19</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_iB_zNcNDoAA5w61" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Common Shares Outstanding -</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i01_z6db2oa1YgNh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 30pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Basic
    and Diluted</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-160" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,116,729</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-161" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,098,905</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_13"></span>CELL
SOURCE, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIENCY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_114_zKW6gyP8eSqh" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Deficiency" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesAConvertiblePreferredStockMember_zNxCD0IGszqi" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesCConvertiblePreferredStockMember_ztJ3o3PJnwV9" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zQmIvbTC0pj7" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zkmJvqLBRJib" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zTrKLWr4XvVh" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_4BC_zqgCxYt8lQP9" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Convertible
    Preferred</span></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Convertible
    Preferred</span></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Additional</b></span></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Total</span></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stock
    - Series A</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stock
    - Series C</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Common
    Stock</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Paid-In</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Accumulated</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stockholders’</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Capital</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Deficit</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Deficiency</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_432_c20200101__20201231_eus-gaap--StockholdersEquity_iS_ziGo3wySywak" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 28%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Balance,
    January 1, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zzkXd937GFA4" title="Balance, shares" style="font-family: Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2019-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-162" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,245,083</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-163" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,245</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNxHEtZcVgR1" title="Balance, shares" style="font-family: Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0289"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2019-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-164" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0289" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0281"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-165" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0281" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwbjENQtRoTb" title="Balance, shares" style="font-family: Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-166" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,076,762</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-167" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,077</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-168" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,375,565</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-169" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,145,828</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-170" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,741,941</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zHbrLZzKBn1h" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of Series A Convertible Preferred Stock for cash</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200101__20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zCR8HsVSn57e" title="Issuance of Series A Convertible Preferred Stock for cash, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-171" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">97,112</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-172" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">97</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0294"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-173" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0294" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0295"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-174" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0295" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-175" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">728,250</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0297"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-176" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0297" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-177" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">728,347</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalAbstract_iB_zq82u0K0vCsb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Series
    A Convertible Preferred Stock dividends:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_zDqBKh3xxgHb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Accrual
    of earned dividends</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0309"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-178" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0309" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0310"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-179" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0310" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0311"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-180" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0311" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-181" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">877,736</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0313"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-182" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0313" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-183" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">877,736</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DividendsPreferredStockPaidinkind_zKZ5M8WgtrRj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Payment
    of dividends in kind</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0316"><span><ix:nonfraction name="us-gaap:DividendsPreferredStockPaidinkind" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-184" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0316" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0317"><span><ix:nonfraction name="us-gaap:DividendsPreferredStockPaidinkind" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-185" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0317" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_98D_ecustom--DividendsPreferredStockPaidinkindShares_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmSdvHTgvYMi" title="Payment of dividends in kind, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:DividendsPreferredStockPaidinkindShares" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-186" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,152,568</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:DividendsPreferredStockPaidinkind" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-187" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,152</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:DividendsPreferredStockPaidinkind" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-188" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">863,219</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0320"><span><ix:nonfraction name="us-gaap:DividendsPreferredStockPaidinkind" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-189" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0320" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:DividendsPreferredStockPaidinkind" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-190" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">864,371</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zqnvZCP3PcSe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of warrants in connection with issuance of notes payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0325"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-191" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0325" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0326"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-192" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0326" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0327"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-193" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0327" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-194" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">259,208</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0329"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-195" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0329" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-196" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">259,208</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zShqqB4ffQkf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of common stock in connection with extension of notes payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0332"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-197" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0332" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0333"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-198" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0333" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJbv2NWOUbxb" title="Issuance of common stock in connection with extension of notes payable, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-199" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">752,500</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-200" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">752</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-201" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">187,373</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0336"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-202" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0336" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-203" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">188,125</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_402_ecustom--IssuanceOfWarrantsInConnectionWithIssuanceOfAdvancePayable_zKz7F82XGpk7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of warrants in connection with issuance of advance payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0341"><span><ix:nonfraction name="CLCS:IssuanceOfWarrantsInConnectionWithIssuanceOfAdvancePayable" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-204" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0341" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0342"><span><ix:nonfraction name="CLCS:IssuanceOfWarrantsInConnectionWithIssuanceOfAdvancePayable" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-205" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0342" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0343"><span><ix:nonfraction name="CLCS:IssuanceOfWarrantsInConnectionWithIssuanceOfAdvancePayable" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-206" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0343" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:IssuanceOfWarrantsInConnectionWithIssuanceOfAdvancePayable" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-207" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">24,386</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0345"><span><ix:nonfraction name="CLCS:IssuanceOfWarrantsInConnectionWithIssuanceOfAdvancePayable" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-208" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0345" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:IssuanceOfWarrantsInConnectionWithIssuanceOfAdvancePayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-209" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">24,386</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_407_ecustom--IssuanceOfCommonStockInExchangeOfAccruedInterest_zoSJcgj5wRQa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of common stock in exchange of accrued interest</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0348"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockInExchangeOfAccruedInterest" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-210" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0348" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0349"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockInExchangeOfAccruedInterest" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-211" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0349" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_987_ecustom--IssuanceOfCommonStockInExchangeOfAccruedInterestShares_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy3RMZl71TKb" title="Issuance of common stock in exchange of accrued interest, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockInExchangeOfAccruedInterestShares" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-212" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">265,534</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockInExchangeOfAccruedInterest" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-213" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">266</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockInExchangeOfAccruedInterest" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-214" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">66,383</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0352"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockInExchangeOfAccruedInterest" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-215" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0352" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockInExchangeOfAccruedInterest" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-216" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">66,649</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_40F_ecustom--ReclassificationOfDerivativeLiabilitiesToEquity_zw6fTyEUoqO2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Reclassification
    of derivative liabilities to equity</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0357"><span><ix:nonfraction name="CLCS:ReclassificationOfDerivativeLiabilitiesToEquity" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-217" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0357" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0358"><span><ix:nonfraction name="CLCS:ReclassificationOfDerivativeLiabilitiesToEquity" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-218" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0358" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0359"><span><ix:nonfraction name="CLCS:ReclassificationOfDerivativeLiabilitiesToEquity" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-219" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0359" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:ReclassificationOfDerivativeLiabilitiesToEquity" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-220" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">345,830</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0361"><span><ix:nonfraction name="CLCS:ReclassificationOfDerivativeLiabilitiesToEquity" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-221" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0361" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:ReclassificationOfDerivativeLiabilitiesToEquity" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-222" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">345,830</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_40C_ecustom--IssuanceOfCommonStockInConnectionWithWarrantExercise_zkK3ThqFr21l" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of common stock in connection with warrant exercise</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0364"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockInConnectionWithWarrantExercise" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-223" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0364" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0365"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockInConnectionWithWarrantExercise" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-224" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0365" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_981_ecustom--IssuanceOfCommonStockSharesInConnectionWithWarrantExercise_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zumbUvuwkxd1" title="Issuance of common stock in connection with warrant exercise, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockSharesInConnectionWithWarrantExercise" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-225" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,995,376</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockInConnectionWithWarrantExercise" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-226" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,995</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0367"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockInConnectionWithWarrantExercise" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-227" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0367" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0368"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockInConnectionWithWarrantExercise" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-228" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0368" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockInConnectionWithWarrantExercise" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-229" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,995</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_409_eus-gaap--CompensationRelatedCostsAbstract_iB_zcO6jYAwa8Z4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stock-based
    compensation:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zwVoiVor1hNi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Common
    stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0380"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-230" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0380" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0381"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-231" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0381" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zg0foseKf4yd" title="Common stock, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-232" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,295,671</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-233" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,296</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-234" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">322,622</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0384"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-235" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0384" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-236" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">323,918</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zdhh1fjZSC59" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Options</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0389"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-237" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0389" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0390"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-238" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0390" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0391"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-239" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0391" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-240" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">115,800</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0393"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-241" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0393" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-242" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">115,800</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition_zzGMzOJOlHIe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0396"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-243" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0396" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0397"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-244" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0397" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0398"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-245" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0398" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-246" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">313,831</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0400"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-247" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0400" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-248" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">313,831</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ProfitLoss_zFj1bMLNkiP7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Net
    loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0405"><span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-249" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0405" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0406"><span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-250" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0406" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-251" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,560,165</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-252" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,560,165</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_430_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zWRywjzJvCX6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Balance,
    December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zZdMsg3B43o8" title="Balance, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-253" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,342,195</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-254" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,342</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zXtWNQaazyFf" title="Balance, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0419"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-255" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0419" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0411"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-256" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0411" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGKfD3ksfKs6" title="Balance, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-257" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,538,411</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-258" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,538</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-259" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,724,731</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-260" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,705,993</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-261" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,947,382</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_438_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zvea7Qdfyav7" style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="display: none; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Beginning
    balance, value</span></td><td style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zTUO0qwOMw6b" title="Beginning balance, shares" style="display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-262" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,342,195</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-263" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,342</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zFTWibb23566" title="Beginning balance, shares" style="display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0432"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-264" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0432" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0424"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-265" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0424" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTMgIIwt7p3g" title="Beginning balance, shares" style="display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-266" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,538,411</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-267" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,538</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-268" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,724,731</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-269" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,705,993</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-270" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,947,382</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_409_ecustom--ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock_zV4Zz66Vab5a" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Conversion
    of convertible notes payable and accrued interest into Series C Convertible Preferred Stock and common stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0436"><span><ix:nonfraction name="CLCS:ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-271" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0436" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_98B_ecustom--ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertibleSharesPreferredStockAndCommonStock_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zR4QGfyKyALh" title="Conversion of convertible notes payable and notes payable and accrued interest into Series C Convertible Preferred Stock and common stock, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertibleSharesPreferredStockAndCommonStock" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-272" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">272,592</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-273" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">273</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_983_ecustom--ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertibleSharesPreferredStockAndCommonStock_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjTpjO7idetf" title="Conversion of convertible notes payable and notes payable and accrued interest into Series C Convertible Preferred Stock and common stock, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertibleSharesPreferredStockAndCommonStock" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">134,891</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-275" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">135</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-276" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,145,233</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0440"><span><ix:nonfraction name="CLCS:ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-277" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0440" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-278" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,145,641</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringConvertiblePreferredStockAndWarrantsIssuedInConnectionWithLossOnExtinguishmentOfNotesPayable_zvlOIk396k5e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Series
    C Convertible Preferred Stock and warrants issued in connection with loss on extinguishment of notes payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0447"><span><ix:nonfraction name="CLCS:StockIssuedDuringConvertiblePreferredStockAndWarrantsIssuedInConnectionWithLossOnExtinguishmentOfNotesPayable" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-279" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0447" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_988_ecustom--StockIssuedDuringConvertiblePreferredStockAndWarrantsIssuedInConnectionWithSharesLossOnExtinguishmentOfNotesPayable_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zmfVg1NMzGv" title="Series C Convertible Preferred Stock and warrants issued in connection with loss on extinguishment of notes payable, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:StockIssuedDuringConvertiblePreferredStockAndWarrantsIssuedInConnectionWithSharesLossOnExtinguishmentOfNotesPayable" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">14,429</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:StockIssuedDuringConvertiblePreferredStockAndWarrantsIssuedInConnectionWithLossOnExtinguishmentOfNotesPayable" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-281" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">14</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0449"><span><ix:nonfraction name="CLCS:StockIssuedDuringConvertiblePreferredStockAndWarrantsIssuedInConnectionWithLossOnExtinguishmentOfNotesPayable" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-282" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0449" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:StockIssuedDuringConvertiblePreferredStockAndWarrantsIssuedInConnectionWithLossOnExtinguishmentOfNotesPayable" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-283" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">143,411</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0451"><span><ix:nonfraction name="CLCS:StockIssuedDuringConvertiblePreferredStockAndWarrantsIssuedInConnectionWithLossOnExtinguishmentOfNotesPayable" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-284" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0451" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:StockIssuedDuringConvertiblePreferredStockAndWarrantsIssuedInConnectionWithLossOnExtinguishmentOfNotesPayable" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-285" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">143,425</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalAbstract_iB_zXbXiL3EAUXe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Series
    A and C Convertible Preferred Stock dividends:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_zlamiBnzRXW1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Accrual
    of earned dividends</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0463"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-286" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0463" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0464"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-287" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0464" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0465"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-288" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0465" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-289" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">973,205</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0467"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-290" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0467" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-291" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">973,205</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--DividendsPreferredStockPaidinkind_zq9PYUZMKuT3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Payment
    of dividends in kind</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0470"><span><ix:nonfraction name="us-gaap:DividendsPreferredStockPaidinkind" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-292" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0470" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0471"><span><ix:nonfraction name="us-gaap:DividendsPreferredStockPaidinkind" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-293" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0471" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_988_ecustom--DividendsPreferredStockPaidinkindShares_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn50hN8wESrj" title="Payment of dividends in kind, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:DividendsPreferredStockPaidinkindShares" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-294" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,241,669</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:DividendsPreferredStockPaidinkind" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-295" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,242</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:DividendsPreferredStockPaidinkind" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-296" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">929,944</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0474"><span><ix:nonfraction name="us-gaap:DividendsPreferredStockPaidinkind" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-297" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0474" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:DividendsPreferredStockPaidinkind" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-298" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">931,186</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueOther_zSPZPPzv9Kv1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of common stock pursuant to cashless warrant exercise</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zr7Q4SKtkJe2" title="Issuance of common stock pursuant to cashless warrant exercise, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-299" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,071</ix:nonfraction></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-300" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-301" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125</ix:nonfraction></span>)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zck6wmqDZcij" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of warrants in connection with issuance of convertible notes payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0488"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-302" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0488" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0489"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-303" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0489" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0490"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-304" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0490" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-305" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">480,195</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0492"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-306" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0492" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-307" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">480,195</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zJyuclFSOR93" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of warrants in connection with exchange of convertible notes payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0495"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-308" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0495" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0496"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-309" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0496" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0497"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-310" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0497" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-311" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">139,728</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0499"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-312" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0499" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-313" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">139,728</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_403_ecustom--WarrantsIssuedInSatisfactionOfAccruedInterest_zsGGhKZEfZti" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Warrants
    issued in satisfaction of accrued interest</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0502"><span><ix:nonfraction name="CLCS:WarrantsIssuedInSatisfactionOfAccruedInterest" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-314" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0502" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0503"><span><ix:nonfraction name="CLCS:WarrantsIssuedInSatisfactionOfAccruedInterest" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-315" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0503" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0504"><span><ix:nonfraction name="CLCS:WarrantsIssuedInSatisfactionOfAccruedInterest" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-316" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0504" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:WarrantsIssuedInSatisfactionOfAccruedInterest" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-317" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">247,566</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0506"><span><ix:nonfraction name="CLCS:WarrantsIssuedInSatisfactionOfAccruedInterest" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-318" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0506" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:WarrantsIssuedInSatisfactionOfAccruedInterest" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">247,566</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_403_ecustom--ConversionOfSeriesCConvertiblePreferredStockIntoCommonStock_zB57tFylU8K8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Conversion
    of Series C Convertible Preferred Stock into common stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0509"><span><ix:nonfraction name="CLCS:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStock" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-320" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0509" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_989_ecustom--ConversionOfSharesSeriesCConvertiblePreferredStockIntoCommonStock_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zTzGfEJGOWti" title="Conversion of Series C Convertible Preferred Stock into common stock, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="CLCS:ConversionOfSharesSeriesCConvertiblePreferredStockIntoCommonStock" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="Shares" inside-table="true" id="fact-identifier-321" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">15,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="CLCS:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStock" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-322" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">15</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_983_ecustom--ConversionOfSharesSeriesCConvertiblePreferredStockIntoCommonStock_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFSNN8QLnbaa" title="Conversion of Series C Convertible Preferred Stock into common stock, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:ConversionOfSharesSeriesCConvertiblePreferredStockIntoCommonStock" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-323" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">150,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStock" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-324" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">150</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="CLCS:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStock" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-325" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">135</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0513"><span><ix:nonfraction name="CLCS:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStock" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-326" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0513" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0514"><span><ix:nonfraction name="CLCS:ConversionOfSeriesCConvertiblePreferredStockIntoCommonStock" contextref="From2021-01-01to2021-12-31" id="fact-identifier-327" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0514" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_403_ecustom--WarrantsModificationExpense_zUQEpynQVNK8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Warrants
    modification expense</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0520"><span><ix:nonfraction name="CLCS:WarrantsModificationExpense" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-328" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0520" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0521"><span><ix:nonfraction name="CLCS:WarrantsModificationExpense" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-329" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0521" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0522"><span><ix:nonfraction name="CLCS:WarrantsModificationExpense" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-330" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0522" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:WarrantsModificationExpense" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-331" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">29,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0524"><span><ix:nonfraction name="CLCS:WarrantsModificationExpense" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-332" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0524" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:WarrantsModificationExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-333" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">29,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_406_ecustom--CommonStockValueIssuedInSatisfactionOfAccruedCompensation_zvllX6SJMril" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Common
    stock issued in satisfaction of accrued compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0527"><span><ix:nonfraction name="CLCS:CommonStockValueIssuedInSatisfactionOfAccruedCompensation" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-334" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0527" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0528"><span><ix:nonfraction name="CLCS:CommonStockValueIssuedInSatisfactionOfAccruedCompensation" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-335" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0528" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_980_ecustom--CommonStockSharesIssuedInSatisfactionOfAccruedCompensation_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDRQaxKKYBM5" title="Common stock issued in satisfaction of accrued compensation, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:CommonStockSharesIssuedInSatisfactionOfAccruedCompensation" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-336" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">15,099</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:CommonStockValueIssuedInSatisfactionOfAccruedCompensation" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-337" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">16</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:CommonStockValueIssuedInSatisfactionOfAccruedCompensation" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-338" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7,081</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0531"><span><ix:nonfraction name="CLCS:CommonStockValueIssuedInSatisfactionOfAccruedCompensation" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-339" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0531" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="CLCS:CommonStockValueIssuedInSatisfactionOfAccruedCompensation" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-340" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7,097</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_403_eus-gaap--CompensationRelatedCostsAbstract_iB_zAr5BG1r1jPd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stock-based
    compensation:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_i01_ziOl7pnuaM3e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Common
    stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0543"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-341" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0543" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0544"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-342" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0544" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmSduJHFq5Rg" title="Common stock, shares" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-343" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">155,405</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-344" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">155</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-345" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">72,885</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0547"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-346" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0547" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-347" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">73,040</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_i01_zxfpjxK2DCq6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Options</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0552"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-348" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0552" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0553"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-349" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0553" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0554"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-350" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0554" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-351" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">206,400</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0556"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-352" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0556" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-353" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">206,400</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition_i01_zFTBTxq0BiTj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0559"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-354" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0559" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0560"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-355" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0560" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0561"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-356" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0561" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-357" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">163,609</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0563"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-358" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0563" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-359" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">163,609</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ProfitLoss_zvF2JxiDhMH2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Net
    loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0566"><span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="fact-identifier-360" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0566" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0567"><span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" id="fact-identifier-361" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0567" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0568"><span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-362" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0568" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0569"><span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-363" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0569" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-364" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,472,435</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-365" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,472,435</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td></tr>
  <tr id="xdx_430_c20210101__20211231_eus-gaap--StockholdersEquity_iE_ztewlfc5au55" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Balance,
    December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zbMc0egmajX2" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-366" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,342,195</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-367" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,342</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zejDVn0E4D9k" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-368" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">272,021</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-369" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">272</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZFP7W1GGsig" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-370" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,360,546</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-371" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,361</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-372" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,316,318</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-373" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,178,428</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-374" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,826,135</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_431_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zLAN7xEgxDpd" style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Ending
    balance, value</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zrAxhBaFHfxf" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-375" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,342,195</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-376" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,342</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zeaCV2DkWL17" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">272,021</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-378" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">272</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCZ1OQGKwBKb" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-379" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,360,546</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-380" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,361</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-381" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,316,318</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-382" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,178,428</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; font-family: Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-383" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,826,135</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">)</span></td></tr>
</tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_14"></span>CELL
SOURCE, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_112_z6vQfEhQXol5" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td id="xdx_496_20210101__20211231_zH07v7eCJ628" style="font-family: Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td id="xdx_494_20200101__20201231_zvehpCIJRf5l" style="font-family: Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    Years Ended</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zwykYTaOz5t7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    Flows From Operating Activities:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_maCzyMx_z70GbRFIWZq1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-384" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,472,435</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-385" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,560,165</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zXuyVDSNegH4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments
    to reconcile net loss to net cash used in operating activities:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_msCzyMx_zG0bRcjgNX0i" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change
    in fair value of derivative liabilities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0608"><span><ix:nonfraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextref="From2021-01-01to2021-12-31" id="fact-identifier-386" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0608" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-387" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,977</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_maCzyMx_zsALZNwLZMS9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization
    of debt discount</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-388" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">731,502</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-389" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">301,250</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40C_ecustom--GainOnForgivenessOfAccruedInterest_i02N_di_msCzyMx_zR02lWP38NJi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain
    on forgiveness of accrued interest</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="CLCS:GainOnForgivenessOfAccruedInterest" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-390" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">49,983</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0615"><span><ix:nonfraction name="CLCS:GainOnForgivenessOfAccruedInterest" contextref="From2020-01-012020-12-31" id="fact-identifier-391" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0615" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msCzyMx_zvUUFlvAGwuf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss
    on extinguishment of notes payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-392" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">143,143</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-393" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">134,202</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40D_ecustom--GainOnExchangeOfAccruedInterestForCommonStock_i02N_di_msCzyMx_zqbsobJrPtua" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gain
    on exchange of accrued interest for common stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0620"><span><ix:nonfraction name="CLCS:GainOnExchangeOfAccruedInterestForCommonStock" contextref="From2021-01-01to2021-12-31" id="fact-identifier-394" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0620" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="CLCS:GainOnExchangeOfAccruedInterestForCommonStock" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-395" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">132,502</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40D_ecustom--WarrantModificationExpense_i02_maCzyMx_zeTx2lfQD1fb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant
    modification expense</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:WarrantModificationExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-396" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">29,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0624"><span><ix:nonfraction name="CLCS:WarrantModificationExpense" contextref="From2020-01-012020-12-31" id="fact-identifier-397" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0624" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_406_eus-gaap--OtherNoncashExpense_i02_maCzyMx_zkrklOnCt8t1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-cash
    interest expense - warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:OtherNoncashExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-398" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">119,450</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:OtherNoncashExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-399" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">284,555</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensationAbstract_i02B_zdmVYE7xzRya" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based
    compensation:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockOptionPlanExpense_i03_maCzyMx_z3Bn8mde4FC4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:StockOptionPlanExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-400" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">206,400</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:StockOptionPlanExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-401" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">115,800</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_409_ecustom--WarrantsBasedCompensation_i03_maCzyMx_zrPEmUVjyYl5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:WarrantsBasedCompensation" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-402" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">160,045</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:WarrantsBasedCompensation" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-403" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">319,358</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_406_ecustom--CommonStockBasedCompensation_i03_maCzyMx_z9GZov6hvi85" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 30pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common
    stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:CommonStockBasedCompensation" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-404" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">52,956</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:CommonStockBasedCompensation" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-405" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">356,510</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zJF3VH5ZOBYi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes
    in operating assets and liabilities:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInPrepaidExpense_i03N_di_msCzyMx_zoJch0tOknIe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-406" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">294,319</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-407" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">120,373</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOtherCurrentAssets_i03N_di_msCzyMx_zp8Az0mUjmn9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    current assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-408" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,729</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-409" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maCzyMx_zqpDkhk9EjN7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts
    payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-410" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,946</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-411" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57,680</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_maCzyMx_zurvmBzV9Cc9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-412" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">62,929</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-413" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,091</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_405_ecustom--IncreaseDecreaseInAccruedLiabilitiesRelatedParties_i03_maCzyMx_zC2f4W1H93D8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses - related parties</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="CLCS:IncreaseDecreaseInAccruedLiabilitiesRelatedParties" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-414" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">126,701</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:IncreaseDecreaseInAccruedLiabilitiesRelatedParties" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-415" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,367</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInInterestPayableNet_i03_maCzyMx_zKhWHZAD5xj9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    interest</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-416" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">270,964</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-417" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">155,024</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40B_ecustom--IncreasedecreaseinaccruedInterestRelatedParties_i03_maCzyMx_zb1JYMm9o6L7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    interest - related parties</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:IncreasedecreaseinaccruedInterestRelatedParties" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-418" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">210,250</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:IncreasedecreaseinaccruedInterestRelatedParties" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-419" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">159,067</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDeferredCompensation_i03_maCzyMx_zcIjysj6mHQb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    compensation</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInDeferredCompensation" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-420" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">72,662</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInDeferredCompensation" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-421" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">93,454</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzyMx_maCCERCzllK_zAN41NEkD98h" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net
    Cash Used In Operating Activities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-422" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,378,682</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-423" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,774,631</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zo0d1CEe16vd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    Flows From Financing Activities:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_i01_maCzxxF_zpXiOPWQbU11" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from issuance of Series A Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0674"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextref="From2021-01-01to2021-12-31" id="fact-identifier-424" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0674" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-425" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">728,347</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromConvertibleDebt_i01_maCzxxF_zwEXXZxgaEBh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from issuance of convertible notes payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-426" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,407,820</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-427" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,047,500</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromRelatedPartyDebt_i01_maCzxxF_zfIDTzoDJiC4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Proceeds from issuance of convertible
    notes payable - related party</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-428" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,500,000</ix:nonfraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-429" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,500,000</ix:nonfraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromNotesPayable_i01_maCzxxF_zqeO7h4SsOtc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from issuance of notes payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0683"><span><ix:nonfraction name="us-gaap:ProceedsFromNotesPayable" contextref="From2021-01-01to2021-12-31" id="fact-identifier-430" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0683" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ProceedsFromNotesPayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-431" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromWarrantExercises_i01_maCzxxF_zj8L5wvpEfFg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from warrant exercise</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0686"><span><ix:nonfraction name="us-gaap:ProceedsFromWarrantExercises" contextref="From2021-01-01to2021-12-31" id="fact-identifier-432" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0686" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ProceedsFromWarrantExercises" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-433" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,995</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_402_eus-gaap--RepaymentsOfNotesPayable_i01N_di_msCzxxF_zfdNjOHOuuR9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Repayment
    of notes payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:RepaymentsOfNotesPayable" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-434" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">203,088</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:RepaymentsOfNotesPayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-435" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--RepaymentsOfConvertibleDebt_i01N_di_msCzxxF_z8n0wytRLiy5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Repayment
    of convertible notes payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:RepaymentsOfConvertibleDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-436" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:RepaymentsOfConvertibleDebt" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-437" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">146,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--FinanceLeasePrincipalPayments_i01N_di_msCzxxF_zfCYDEP61xqd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Repayment
    of financing liability</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:FinanceLeasePrincipalPayments" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-438" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">292,574</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0696"><span><ix:nonfraction name="us-gaap:FinanceLeasePrincipalPayments" contextref="From2020-01-012020-12-31" id="fact-identifier-439" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0696" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromOtherDebt_i01_maCzxxF_ztWtYyk0NIfd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from advances payable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0698"><span><ix:nonfraction name="us-gaap:ProceedsFromOtherDebt" contextref="From2021-01-01to2021-12-31" id="fact-identifier-440" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0698" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ProceedsFromOtherDebt" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-441" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">114,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--RepaymentsOfOtherDebt_i01N_di_msCzxxF_zsOZkPAtqBo8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Repayment
    of advances payable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:RepaymentsOfOtherDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-442" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60,500</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:RepaymentsOfOtherDebt" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-443" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">154,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzxxF_maCCERCzllK_z6bwrdbcQZX7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net
    Cash Provided By Financing Activities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-444" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,226,658</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-445" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,991,842</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzllK_z54JPDz5Csgj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 30pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    (Decrease) Increase In Cash and Restricted Cash</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-446" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">152,024</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-447" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">217,211</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zz2ha8dyo4x1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and Restricted Cash - Beginning of Year</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-448" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">245,119</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextref="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-449" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,908</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zMSYshkZXKWc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and Restricted Cash - End of Year</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-450" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">93,095</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-451" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">245,119</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--RestrictedCashAndCashEquivalentsAbstract_iB_zTEs7jmSd0z3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    and restricted cash consisted of the following:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_403_eus-gaap--Cash_i01E_zwF1KCcU6Pm8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Cash</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:Cash" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-452" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">93,095</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:Cash" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-453" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">241,619</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--RestrictedCash_i01E_zXNIQLtT5fd3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Restricted
    cash</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0722"><span><ix:nonfraction name="us-gaap:RestrictedCash" contextref="AsOf2021-12-31" id="fact-identifier-454" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0722" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:RestrictedCash" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-455" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,500</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_409_eus-gaap--RestrictedCashAndCashEquivalents_i01E_zdLxLtKKDVU1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and restricted cash</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:RestrictedCashAndCashEquivalents" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-456" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">93,095</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:RestrictedCashAndCashEquivalents" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-457" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">245,119</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_15"></span>CELL
SOURCE, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    Year Ended</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_407_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z0tjD1QwKDH5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Supplemental
    Disclosures of Cash Flow Information:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    paid for:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--InterestPaidNet_i01_zmImyYZbNnC6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; width: 68%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Interest</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0731"><span><ix:nonfraction name="us-gaap:InterestPaidNet" contextref="From2021-01-01to2021-12-31" id="fact-identifier-458" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0731" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:InterestPaidNet" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-459" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">70,379</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxesPaidNet_i01_zT24nqqBHKz4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income
    taxes</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:IncomeTaxesPaidNet" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-460" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,768</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0735"><span><ix:nonfraction name="us-gaap:IncomeTaxesPaidNet" contextref="From2020-01-012020-12-31" id="fact-identifier-461" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0735" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_408_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zExBHRJWFs5k" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-cash
    investing and financing activities:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_404_ecustom--AccrualOfEarnedPreferredStockDividends_i01_zwOace7l0Al9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrual
    of earned preferred stock dividends</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="CLCS:AccrualOfEarnedPreferredStockDividends" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-462" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">973,205</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="CLCS:AccrualOfEarnedPreferredStockDividends" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-463" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">877,736</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--StockIssued1_i01_zt7Z0DrSsADa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common
    stock issued in connection with payment of Series A Convertible Preferred Stock dividends in-kind</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:StockIssued1" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-464" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">931,186</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:StockIssued1" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-465" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">864,371</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_402_ecustom--ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCPreferredStockAndCommonStock_i01_zt5XA7Yeyv38" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Conversion
    of convertible notes payable and accrued interest into Series C Preferred Stock and common stock</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCPreferredStockAndCommonStock" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-466" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,145,641</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0747"><span><ix:nonfraction name="CLCS:ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCPreferredStockAndCommonStock" contextref="From2020-01-012020-12-31" id="fact-identifier-467" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0747" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40D_ecustom--SeriesCConvertiblePreferredStockIssuedInConnectionWithLossOnExtinguishmentOfNotesPayable_i01_zHmuicIYcFZk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series
    C Convertible Preferred Stock issued in connection with loss on extinguishment of notes payable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:SeriesCConvertiblePreferredStockIssuedInConnectionWithLossOnExtinguishmentOfNotesPayable" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-468" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">143,425</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0750"><span><ix:nonfraction name="CLCS:SeriesCConvertiblePreferredStockIssuedInConnectionWithLossOnExtinguishmentOfNotesPayable" contextref="From2020-01-012020-12-31" id="fact-identifier-469" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0750" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_406_ecustom--ReclassificationOfDerivativeLiabilitiesEquity_i01_zEeJ4lNNjvqk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Reclassification
    of derivative liabilities to equity</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0752"><span><ix:nonfraction name="CLCS:ReclassificationOfDerivativeLiabilitiesEquity" contextref="From2021-01-01to2021-12-31" id="fact-identifier-470" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0752" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:ReclassificationOfDerivativeLiabilitiesEquity" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-471" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">345,830</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_407_ecustom--ConversionOfConvertiblePreferredStockIntoCommonStock_i01_zeAh9W1toci4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Conversion
    of Series C Convertible Preferred Stock into common stock</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:ConversionOfConvertiblePreferredStockIntoCommonStock" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-472" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">150</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0756"><span><ix:nonfraction name="CLCS:ConversionOfConvertiblePreferredStockIntoCommonStock" contextref="From2020-01-012020-12-31" id="fact-identifier-473" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0756" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_405_ecustom--IssuanceOfCommonStockPursuantToCashlessWarrantExercise_i01_zDMp51aIPJue" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of common stock pursuant to cashless warrant exercise</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockPursuantToCashlessWarrantExercise" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-474" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">125</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0759"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockPursuantToCashlessWarrantExercise" contextref="From2020-01-012020-12-31" id="fact-identifier-475" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0759" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_409_ecustom--CommonStockIssuedInSatisfactionOfAccruedCompensation_i01_zqV9e6MeIrxb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Common
    stock issued in satisfaction of accrued compensation</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:CommonStockIssuedInSatisfactionOfAccruedCompensation" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-476" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7,097</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0762"><span><ix:nonfraction name="CLCS:CommonStockIssuedInSatisfactionOfAccruedCompensation" contextref="From2020-01-012020-12-31" id="fact-identifier-477" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0762" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40D_ecustom--FinancingOfDirectorsAndOfficersInsurance_i01_pp0p0" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Financing
    of Directors and Officer’s insurance</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:FinancingOfDirectorsAndOfficersInsurance" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-478" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">320,500</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0765"><span><ix:nonfraction name="CLCS:FinancingOfDirectorsAndOfficersInsurance" contextref="From2020-01-012020-12-31" id="fact-identifier-479" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0765" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_409_ecustom--AccruedInterestConvertedIntoNotesPayable_i01_zL1TIf8QXPqf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    interest converted into notes payable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedInterestConvertedIntoNotesPayable" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-480" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">41,950</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0768"><span><ix:nonfraction name="CLCS:AccruedInterestConvertedIntoNotesPayable" contextref="From2020-01-012020-12-31" id="fact-identifier-481" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0768" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40B_ecustom--IssuanceOfWarrantsInConnectionWithIssuanceOfNotesPayable_i01_z2yAhwQDgLQl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of warrants in connection with the issuance of notes payable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:IssuanceOfWarrantsInConnectionWithIssuanceOfNotesPayable" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-482" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">480,195</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0771"><span><ix:nonfraction name="CLCS:IssuanceOfWarrantsInConnectionWithIssuanceOfNotesPayable" contextref="From2020-01-012020-12-31" id="fact-identifier-483" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0771" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40B_ecustom--IssuanceOfWarrantsInSatisfactionOfAccruedInterest_i01_z2tyq1ZLJsg1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of warrants in satisfaction of accrued interest</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:IssuanceOfWarrantsInSatisfactionOfAccruedInterest" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-484" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">247,566</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:IssuanceOfWarrantsInSatisfactionOfAccruedInterest" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-485" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">66,649</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40B_ecustom--IssuanceOfPlacementAgentWarrants_i01_zpmS6L3FpOd5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of placement agent warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0776"><span><ix:nonfraction name="CLCS:IssuanceOfPlacementAgentWarrants" contextref="From2021-01-01to2021-12-31" id="fact-identifier-486" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0776" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:IssuanceOfPlacementAgentWarrants" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-487" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10,907</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40C_ecustom--IssuanceOfCommonStockAsDebtDiscountInConnection_i01_z5KkBKnyHOW8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of common stock as debt discount in in connection with extension of notes payable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0779"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockAsDebtDiscountInConnection" contextref="From2021-01-01to2021-12-31" id="fact-identifier-488" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0779" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStockAsDebtDiscountInConnection" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-489" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">188,125</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40E_ecustom--OriginalIssueDiscountInConnectionWithConvertibleNotePayable_i01_zZjBQ2YEb7Rj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Original
    issue discount in connection with convertible note payable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0782"><span><ix:nonfraction name="CLCS:OriginalIssueDiscountInConnectionWithConvertibleNotePayable" contextref="From2021-01-01to2021-12-31" id="fact-identifier-490" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0782" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:OriginalIssueDiscountInConnectionWithConvertibleNotePayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-491" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">58,556</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_402_ecustom--RepaymentOfConvertibleNotePayableAndAccruedInterestByThirdParty_i01_zMd5W6ka9qi8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Repayment
    of convertible note payable and accrued interest by third party</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0785"><span><ix:nonfraction name="CLCS:RepaymentOfConvertibleNotePayableAndAccruedInterestByThirdParty" contextref="From2021-01-01to2021-12-31" id="fact-identifier-492" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0785" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:RepaymentOfConvertibleNotePayableAndAccruedInterestByThirdParty" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-493" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100,896</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40D_ecustom--WarrantsAndConversionOptionsIssuedInConnectionWithIssuanceAndExtensionOfNotesPayable_i01_za2vT3AGiPg4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants
    and conversion options issued in connection with issuance and extension of notes payable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0788"><span><ix:nonfraction name="CLCS:WarrantsAndConversionOptionsIssuedInConnectionWithIssuanceAndExtensionOfNotesPayable" contextref="From2021-01-01to2021-12-31" id="fact-identifier-494" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0788" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:WarrantsAndConversionOptionsIssuedInConnectionWithIssuanceAndExtensionOfNotesPayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-495" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">259,208</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40C_ecustom--AccrualOfWarrantsPayableInConnectionWithIssuanceOfConvertibleNotesPayable_i01_z5Ua66NunFEa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrual
    of warrants payable in connection with issuance of convertible notes payable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0791"><span><ix:nonfraction name="CLCS:AccrualOfWarrantsPayableInConnectionWithIssuanceOfConvertibleNotesPayable" contextref="From2021-01-01to2021-12-31" id="fact-identifier-496" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0791" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccrualOfWarrantsPayableInConnectionWithIssuanceOfConvertibleNotesPayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-497" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">82,006</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40A_ecustom--WarrantsIssuedInConnectionWithIssuanceOfAdvancePayable_i01_zTA3gK9Gbcdi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants
    issued in connection with issuance of advance payable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0794"><span><ix:nonfraction name="CLCS:WarrantsIssuedInConnectionWithIssuanceOfAdvancePayable" contextref="From2021-01-01to2021-12-31" id="fact-identifier-498" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0794" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:WarrantsIssuedInConnectionWithIssuanceOfAdvancePayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-499" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">24,386</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_16"></span>CELL
SOURCE, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-500" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zqLcDjlGtvB7" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
1 – <span id="xdx_825_zeaqPx8XI3L7">Business Organization, Nature of Operations and Risks and Uncertainties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization
and Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
Source, Inc. (“Cell Source”, “CSI” or the “Company”) is a Nevada corporation formed on June 6, 2012
that is the parent company of Cell Source Limited (“CSL”), a wholly owned subsidiary which was founded in Israel in 2011
in order to commercialize a suite of inventions relating to certain cancer treatments. The Company is a biotechnology company focused
on developing cell therapy treatments based on the management of immune tolerance. The Company’s lead prospective product is its
patented Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking
of immune responses. CSL’s Veto Cell immune system management technology is based on technologies patented, owned, and licensed
to CSL by Yeda Research and Development Company Limited, an Israeli corporation (“Yeda”) (see Note 11, <i>Commitments and
Contingencies</i>). The Company’s target indications include: lymphoma, leukemia and multiple myeloma through the facilitation
of safer and more accessible stem cell (e.g. bone marrow) transplantation acceptance, treatment of end stage kidney disease and other
non-malignant organ diseases through improved organ transplantation (broadened donor pool, reduced dependence on post-transplant anti-rejection
therapy), and ultimately treating a variety of cancers and non-malignant diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
and Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The novel coronavirus (“COVID-19”)
pandemic continues to impact global economic conditions. The Company is closely monitoring the outbreak of COVID-19 and its impact
on the Company’s operations, financial position, cash flows and its industry in general. The Company considered the impact of COVID-19
on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s
results of operations and financial position as of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Similarly, the economic uncertainty caused by
the COVID-19 pandemic has made and may continue to make it difficult for the Company to forecast operating results, including the timing
and ability of the Company to initiate and/or complete current and/or future preclinical studies and/or clinical trials, disrupt the
Company’s regulatory activities, and/or have other adverse effects on the Company’s clinical development. The duration and
extent of the impact from the COVID-19 pandemic depend on future developments that cannot be accurately predicted at this time, and if
the Company is not able to respond to and manage the impact of such events effectively, the Company’s business may be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">There can be no assurance that precautionary
measures, whether adopted by the Company or imposed by others, will be effective, and such measures could negatively affect the Company’s
financial condition, cash flows, and results of operations. The financial statements do not include any adjustments that might result
from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-501" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_802_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zwMnbGMOUTcg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
2 – <span id="xdx_82A_zmbEG9aEJxi4">Going Concern and Management’s Plans</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021 and 2020, the Company had not generated any revenues, had recurring net losses of approximately $<span id="xdx_900_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20210101__20211231_zxPqqJoA75ak"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" sign="-" unitref="USD" inside-table="false" id="fact-identifier-502" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,472,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_904_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20200101__20201231_zoaZ9Weba52d"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" sign="-" unitref="USD" inside-table="false" id="fact-identifier-503" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,560,000</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, and used cash in operations of approximately $<span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3d_di_c20210101__20211231_zOIyWVwq2CO6"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" sign="-" unitref="USD" inside-table="false" id="fact-identifier-504" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,379,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_900_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3d_di_c20200101__20201231_z4qbSTkuFexd"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" sign="-" unitref="USD" inside-table="false" id="fact-identifier-505" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,775,000</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. As of December 31, 2021, the Company had a working capital deficiency of approximately $<span id="xdx_900_ecustom--WorkingCapitalSurplusDeficiency_iI_pp0p0_c20211231_zMJvcLZSGFc3" title="Working capital deficiency"><span><ix:nonfraction name="CLCS:WorkingCapitalSurplusDeficiency" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-506" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">9,826,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and an accumulated deficit of approximately $<span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3d_di_c20211231_zTKNnnxco4Q8"><span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" sign="-" unitref="USD" inside-table="false" id="fact-identifier-507" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,178,000</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
As of December 31, 2021 and through the date of this filing, notes payable with principal amounts totaling $<span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20210101__20211231_zvjxCpNV2ru6" title="Principal amounts"><span><ix:nonfraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-508" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,554,912</ix:nonfraction></span></span> and $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20200101__20201231_zNdw4vQPXe6g"><span><ix:nonfraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-509" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,329,912</ix:nonfraction></span></span>,
respectively, were past due and are classified as current liabilities on the consolidated balance sheet as of December 31, 2021. The
Company will continue to incur net operating losses to fund operations. These conditions raise substantial doubt about the Company’s
ability to continue as a going concern for at least one year from the date these financial statements are issued. Subsequent to December
31, 2021 and as more fully described in Note 13, <i>Subsequent Events</i>, the Company received aggregate proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromConvertibleDebt_c20220101__20220415__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFAbwRIFhmP9" title="Proceeds from issuance of convertible debt"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2022-01-012022-04-15_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-510" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,245,000</ix:nonfraction></span></span> from
the issuance of convertible notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is currently funding its operations on a month-to-month basis. While there can be no assurance that it will be successful, the
Company is in active negotiations to raise additional capital. The Company’s primary sources of operating funds since inception
have been equity and debt financings. Management’s plans include continued efforts to raise additional capital through debt and
equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development
activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding
any request the Company may make, if the Company’s debt holders do not agree to convert their notes into equity or extend the maturity
dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material
adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced
to discontinue its operations and liquidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the
United States of America (“U.S. GAAP”), which contemplate continuation of the Company as a going concern and the realization
of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented
in the financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements
do not include any adjustment that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-511" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zhL5JRyR8kz6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
3 – <span id="xdx_82D_zDBXdNuK38g1">Summary of Significant Accounting Policies</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-512" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zx3EhtrOXAM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_865_zUk45jdJCQdb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Principles
of Consolidation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company’s financial statements are consolidated and include the accounts of CSI and CSL. All significant intercompany transactions
have been eliminated in the consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:UseOfEstimates" inside-table="false" id="fact-identifier-513" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_846_eus-gaap--UseOfEstimates_zXbSfKfNzrDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_861_zhhkkwRTIVpb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use
of Estimates</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that
affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. Management
bases its estimates and judgements on historical experience and on various other assumptions that it believes are reasonable under the
circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported
for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations
for equity securities, and stock-based compensation. Certain of the Company’s estimates could be affected by external conditions,
including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have
an effect on the Company’s estimates and could cause actual results to differ from those estimates. Estimates and assumptions are
periodically reviewed and the effects of any material revisions are reflected in the consolidated financial statements in the period
that they are determined to be necessary. See the <i>Stock-Based Compensation</i> section of this footnote for additional discussion
of the use of estimates in estimating the fair value of the Company’s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-514" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zTy37zWe7ge7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86D_zBGj7OpVXlo1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cash
and Cash Equivalents</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly-liquid instruments with an original maturity of three months or less when purchased to be cash equivalents.
As of December 31, 2021 and 2020, the Company did <span id="xdx_908_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20211231_zoWF52WMggSl" title="Cash equivalents"><span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20201231_zA0URKPagt15" title="Cash equivalents"><span><ix:nonfraction name="us-gaap:CashEquivalentsAtCarryingValue" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-515" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CashEquivalentsAtCarryingValue" contextref="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-516" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></span></span>t have any cash equivalents. The Company maintains cash in bank accounts, which,
at times, may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. The Company has not experienced any losses
in such accounts, periodically evaluates the creditworthiness of the financial institutions and has determined the credit exposure to
be negligible. The Company’s foreign bank accounts are not subject to FDIC insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="CLCS:ConvertibleInstrumentsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-517" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_84A_ecustom--ConvertibleInstrumentsPolicyTextBlock_zYGUMTohrph6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86B_ztaZsf2PHE9f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Convertible
Instruments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative
financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC”). The accounting treatment of derivative financial instruments requires that the
Company record embedded conversion options and any related freestanding instruments at their fair values as of the inception date of
the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash
income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments
at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of
the date of the event that caused the reclassification. Embedded conversion options and any related freestanding instruments are recorded
as a discount to the host instrument and are amortized as interest expense over the term of the related debt instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Black-Scholes option pricing model was used to estimate the fair value of the Company’s warrants and embedded conversion options.
The Black-Scholes option pricing model includes subjective input assumptions that can materially affect the fair value estimates. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="CLCS:PreferredStockPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-518" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_847_ecustom--PreferredStockPolicyTextBlock_zHuZROZcpU65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_866_ziBVR82PAOxa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Preferred
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement
of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at
fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within
the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control)
are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" inside-table="false" id="fact-identifier-519" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_znMKdCjoygzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_867_ztJTiON8om4l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair
Value of Financial Instruments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the fair value of financial assets and liabilities based on ASC 820 “Fair Value Measurements and Disclosures”
(“ASC 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair
value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize
the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 — quoted prices in active markets for identical assets or liabilities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company’s financial instruments, such as cash, other current assets, accounts payable, accrued expenses
and other current liabilities approximate fair values due to the short-term nature of these instruments. The carrying amounts of Company’s
credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates,
are comparable to rates of returns for instruments of similar credit risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-520" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zNT3wWDYChD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86A_zhEkdI8PcHHd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Income
Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CSI
is the parent of CSL, a wholly owned Israeli subsidiary. The Company is subject to federal and New York state and city income taxes in
the United States and federal income taxes in the State of Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded
in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference
between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”)
at enacted tax rates in effect for the years in which such temporary differences are expected to reverse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position
taken or expected to be taken in a tax return.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company’s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and
administrative expenses in the consolidated statements of operations. Tax related interest and penalties of $<span id="xdx_907_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_c20210101__20211231_zCWIyzY9V5S" title="Income tax interest and penalties"><span><ix:nonfraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-521" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,768</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_c20200101__20201231_za6d8HPea2te" title="Income tax interest and penalties"><span><ix:nonfraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-522" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were charged to the consolidated statements
of operations during the years ended December 31, 2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" inside-table="false" id="fact-identifier-523" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_zxI8FjqFfWqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86E_zQtlgSG6fJka" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and Development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are recognized to operations as they are incurred and consist of fees paid to consultants, clinical trials and
related clinical manufacturing costs, license and milestone fees. The Company records prepaid expenses on its consolidated balance sheets
for the payment of research and development expenses in advance of services being provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" inside-table="false" id="fact-identifier-524" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zjMbcAlXlUPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86C_zfGUNdxFWovl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stock-Based
Compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The
fair value of the award is measured on the grant date and is then recognized over the period the services are required to be provided
in exchange for the award, usually the vesting period. Awards granted to directors are treated on the same basis as awards granted to
employees. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the Company’s common stock historically was not actively traded on a public market, the fair value of the Company’s restricted
equity instruments is estimated by management based on observations of the sales prices of both restricted and freely tradable common
stock, or instruments convertible into common stock based on the option pricing model discussed below. The Company obtained a
third-party valuation of its common stock as of December 31, 2021 and 2020, which was considered in management’s estimation of
fair value during the years ended December 31, 2021 and 2020. The third-party valuation was performed in accordance with the guidance
outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, <i>Valuation of Privately-Held-Company
Equity Securities Issued as Compensation.</i> The estimates used by management are considered highly complex and subjective. The Company
anticipates that once its shares become more actively traded, the use of such estimates will no longer be necessary to determine the
fair value of its common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
independent appraisals utilized the option pricing method, or OPM, as the most reliable method with the following steps being applied:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishment
    of total enterprise or equity value;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analysis
    of equity rights for each class of security;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selection
    of appropriate model for valuation purposes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination
    of key valuation inputs; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computation
    of the fair value of the subject security.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the OPM, it was determined the Company’s common stock had a fair value of $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--PlanNameAxis__custom--OptionPricingMethodMember_zUZ7wg7r5rbe" title="Common stock fair value per share"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextref="From2021-01-012021-12-31_custom_OptionPricingMethodMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-525" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.34</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20200101__20201231__us-gaap--PlanNameAxis__custom--OptionPricingMethodMember_zEWFApdLh1ya" title="Common stock fair value per share"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextref="From2020-01-012020-12-31_custom_OptionPricingMethodMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-526" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.47</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share as of December 31, 2021 and 2020, respectively,
which included a discount for lack of marketability of <span id="xdx_901_ecustom--OptionsPricingMethodDiscountRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--OptionPricingMethodMember_zuEo5C1dIOi7" title="Options pricing method discount rate"><span><ix:nonfraction name="CLCS:OptionsPricingMethodDiscountRate" contextref="From2021-01-012021-12-31_custom_OptionPricingMethodMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-527" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.
Furthermore, the independent appraisal determined the Company’s expected volatility was <span id="xdx_907_ecustom--ExpectedVolatilityRate_pid_dp_c20210101__20211231__us-gaap--PlanNameAxis__custom--OptionPricingMethodMember_zf6FP9o5hX6a" title="Expected volatility rate"><span><ix:nonfraction name="CLCS:ExpectedVolatilityRate" contextref="From2021-01-012021-12-31_custom_OptionPricingMethodMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-528" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">90</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
by evaluating historical and implied volatilities of guideline companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-529" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84C_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zjmPdCyRz1N7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_869_zQHIzgj9DCoi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Foreign
Currency Translation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company’s functional and reporting currency is the United States Dollar. The functional currency of the Company’s operating
subsidiary is their local currency (The New Israeli Shekel). Assets and liabilities are translated based on the exchange rates at the
balance sheet date, while revenue and expense accounts are translated at the actual exchange rates in the effect of the date of the transaction
during the year. Equity accounts are translated at historical exchange rates. The resulting translation gain and loss adjustments are
accumulated as a component of other comprehensive income. Foreign currency gains and losses resulting from transactions denominated in
foreign currencies, including intercompany transactions, are included in results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded approximately $<span id="xdx_90F_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c20210101__20211231_zuSZAc6lhMJ8" title="Foreign currency translation loss"><span><ix:nonfraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-530" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">99,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_905_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c20200101__20201231_zO3q4r9xFm88" title="Restructuring reserve translation adjustment"><span><ix:nonfraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-531" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of transaction losses for the years ended December
31, 2021 and 2020, respectively. Such amounts have been classified within general and administrative expenses in the accompanying consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-532" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_z0AzmpBS3nSl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86C_zoac6UU7aNSe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net
Loss Per Common Share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes basic net loss per share by dividing net loss by the weighted average number of common shares outstanding for the period
and excludes the effects of any potentially dilutive securities. Diluted earnings per share includes the dilution that would occur upon
the exercise or conversion of all dilutive securities into common stock using the “treasury stock” and/or “if converted”
methods, as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-533" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_893_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z29izmLNXFfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock equivalents associated with the following securities are excluded from the calculation of weighted average dilutive common
shares because their inclusion would have been anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B1_zkXiWbWN9CNj" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">Schedule
of Weighted Average Dilutive Common Shares Anti-dilutive</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zuV5abbvq6N3" title="Weighted average dilutive common shares,Options" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-012021-12-31_custom_StockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-534" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,182,004</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zOcBptUdR7S6" title="Weighted average dilutive common shares,Options" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31_custom_StockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-535" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,332,004</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQng8QnuMLEg" title="Weighted average dilutive common shares, warrants" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-536" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,108,079</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zVIHCz15aGa9" title="Weighted average dilutive common shares, warrants" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-537" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,580,676</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span id="xdx_F4C_zLXzfMn1Dcd9" style="font-family: Times New Roman, Times, Serif">Convertible
    notes [1] [2]</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_fWzFdIFsyXQ_____zMbuyGTdBVUj" title="Weighted average dilutive common shares, convertible notes" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-012021-12-31_custom_ConvertibleNotesMember" id="fact-identifier-538" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" data-original-id="Fact000867" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,169,929</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_fWzFdIFsyXQ_____zR4F1QMU5fTc" title="Weighted average dilutive common shares, convertible notes" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31_custom_ConvertibleNotesMember" id="fact-identifier-539" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" data-original-id="Fact000869" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,606,219</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Convertible
    preferred stock</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zC9wr1Q5PhU1" title="Weighted average dilutive common shares, convertible preferred stock" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-012021-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-540" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,142,160</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_z0PbE9sHhnZg" title="Weighted average dilutive common shares, convertible preferred stock" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-541" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,421,950</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_z6VdCQ0ZGmMe" title="Total" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-542" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,602,172</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_z9Iz3sbWty9j" title="Total" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-543" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,940,849</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F08_zpWxCYfgkunk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[1]</span></td><td style="text-align: justify"><span id="xdx_F18_zaAjKLDSF0Kd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000878" xml:lang="en-US">Convertible
                                            notes are assumed to be converted at the rate of $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231_ziDLO9BdXO1h" title="Debt instrument convertible conversion price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdlaWdodGVkIEF2ZXJhZ2UgRGlsdXRpdmUgQ29tbW9uIFNoYXJlcyBBbnRpLWRpbHV0aXZlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-544" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span></span>
                                            per
                                            common share, which is the conversion price as of December 31, 2021. However, as further
                                            described in Note 8, <i>Notes Payable</i>, such conversion rates are subject to adjustment
                                            under certain circumstances, which may result in the issuance of common shares greater than
                                            the amount indicated.</ix:footnote></span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F05_zaSTCDStn5Dc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[2]</span></td><td style="text-align: justify"><span id="xdx_F1B_zpdoda8Vpsh3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000881" xml:lang="en-US">Excludes
                                            shares of common stock underlying convertible notes that are expected to become convertible
                                            into shares of Series B Convertible Preferred Stock since such stock had not been designated
                                            by the Company as of December 31, 2021.</ix:footnote></span></td>
</tr></tbody></table>

</ix:nonnumeric></span><p id="xdx_8A3_zXruiWdIhZjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-545" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zehDYboliqub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="xdx_863_zSEYb7ZtQWxa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Comprehensive
Income (Loss)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reports comprehensive income (loss) and its components in its consolidated financial statements. Comprehensive income (loss)
consists of net loss and foreign currency translation adjustments affecting stockholders’ deficiency that, under U.S. GAAP, are
excluded from net loss. The differences between net loss as reported and comprehensive income (loss) have historically been immaterial.
As of December 31, 2021, the exchange rate between the U.S. Dollar and the New Israeli Shekel was <span id="xdx_90C_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20211231__srt--ConsolidatedEntitiesAxis__custom--IsraeliShekelMember__srt--RangeAxis__srt--MinimumMember_zDSkZpITPAA8" title="Foreign currency exchange rate translation"><span><ix:nonfraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextref="AsOf2021-12-31_custom_IsraeliShekelMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="false" id="fact-identifier-546" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_905_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20211231__srt--ConsolidatedEntitiesAxis__custom--IsraeliShekelMember__srt--RangeAxis__srt--MaximumMember_zialuoUv3AK" title="Foreign currency exchange rate translation"><span><ix:nonfraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextref="AsOf2021-12-31_custom_IsraeliShekelMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="false" id="fact-identifier-547" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.21</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and the weighted average exchange rate for the
year then ended was <span id="xdx_908_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20211231__srt--ConsolidatedEntitiesAxis__custom--IsraeliShekelMember__srt--RestatementAxis__custom--WeightedAveragesMember__srt--RangeAxis__srt--MinimumMember_ztpbYdV2n8d8" title="Foreign currency exchange rate translation"><span><ix:nonfraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextref="AsOf2021-12-31_custom_IsraeliShekelMember_custom_WeightedAveragesMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="false" id="fact-identifier-548" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_90C_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20211231__srt--ConsolidatedEntitiesAxis__custom--IsraeliShekelMember__srt--RestatementAxis__custom--WeightedAveragesMember__srt--RangeAxis__srt--MaximumMember_zBTW30q8hGm2" title="Foreign currency exchange rate translation"><span><ix:nonfraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextref="AsOf2021-12-31_custom_IsraeliShekelMember_custom_WeightedAveragesMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="false" id="fact-identifier-549" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.09</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
As of December 31, 2020, the exchange rate between the U.S. Dollar and the New Israeli Shekel was <span id="xdx_902_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20201231__srt--ConsolidatedEntitiesAxis__custom--IsraeliShekelMember__srt--RangeAxis__srt--MinimumMember_zPEhFan6hry1" title="Foreign currency exchange rate translation"><span><ix:nonfraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextref="AsOf2020-12-31_custom_IsraeliShekelMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="false" id="fact-identifier-550" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_905_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20201231__srt--ConsolidatedEntitiesAxis__custom--IsraeliShekelMember__srt--RangeAxis__srt--MaximumMember_zgWNBfXQdvx3" title="Foreign currency exchange rate translation"><span><ix:nonfraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextref="AsOf2020-12-31_custom_IsraeliShekelMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="false" id="fact-identifier-551" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.10</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and the weighted average exchange rate for the
year then ended was <span id="xdx_90E_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20201231__srt--ConsolidatedEntitiesAxis__custom--IsraeliShekelMember__srt--RestatementAxis__custom--WeightedAveragesMember__srt--RangeAxis__srt--MinimumMember_z9bUGbSgW8uh" title="Foreign currency exchange rate translation"><span><ix:nonfraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextref="AsOf2020-12-31_custom_IsraeliShekelMember_custom_WeightedAveragesMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="false" id="fact-identifier-552" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_90D_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_pid_c20201231__srt--ConsolidatedEntitiesAxis__custom--IsraeliShekelMember__srt--RestatementAxis__custom--WeightedAveragesMember__srt--RangeAxis__srt--MaximumMember_zZqhEzRb4iCk" title="Foreign currency exchange rate translation"><span><ix:nonfraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextref="AsOf2020-12-31_custom_IsraeliShekelMember_custom_WeightedAveragesMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="false" id="fact-identifier-553" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.90</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" inside-table="false" id="fact-identifier-554" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z7J3nEcdNNn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_863_zDeTeuaxCkOg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Reclassifications</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior period amounts have been reclassified
to conform to the fiscal 2021 presentation, including cash accounts that have been reclassified from cash to restricted cash and amounts
related to a convertible notes payable have been reclassified to disclose that they relate to a note that is payable to a related party.
These reclassifications have no impact on the previously reported net loss.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-555" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_846_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_z0rWhQVWl95b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_865_zXZ7wSgSzSHj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Subsequent
Events</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates events that have occurred after the balance sheet date but through the date these financial statements are issued.
Based upon that evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required
adjustment or disclosure in the consolidated financial statements except as disclosed in Note 13, <i>Subsequent Events</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-556" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zMgCRkndlKja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86D_zH9vLJKERMKf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Recent
Accounting Standards</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure
Requirements for Fair Value Measurement (“ASU 2018-13”). The amendments in ASU 2018-13 modify the disclosure requirements
on fair value measurements based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments
on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3
fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent
interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to
all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. Early
adoption is permitted, including adoption in an interim period. The adoption of ASU 2018-13 on January 1, 2021 did not have a material
impact on its financial position, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2019, the FASB issued ASU 2019-11, “Codification Improvements to Topic 326, Financial Instruments — Credit
Losses” (“ASU 2019-11”). ASU 2019-11 is an accounting pronouncement that amends ASU 2016-13, “Financial Instruments — Credit
Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.” The amendments update guidance on reporting credit
losses for financial assets. These amendments affect loans, debt securities, trade receivables, net investments in leases, off balance
sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual
right to receive cash. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2021, including
interim periods within those fiscal years. All entities may adopt the amendments through a cumulative-effect adjustment to retained earnings
as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). The
adoption of ASU 2019-11 on January 1, 2022 did not have a material impact on its financial position, results of operations, and cash
flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” which
is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general
principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for
fiscal years beginning after December 15, 2021. The adoption of ASU 2019-12 on January 1, 2022 did not have a material impact on its
financial position, results of operations, and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”
which simplifies the accounting for convertible instruments by eliminating certain accounting models when the conversion features are
not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums
accounted for as paid-in-capital. Under this ASU, certain debt instruments with embedded conversion features will be accounted for as
a single liability measured at its amortized cost. Additionally, this ASU eliminates the treasury stock method to calculate diluted earnings
per share for convertible instruments. The new guidance is effective for annual periods beginning after December 15, 2023, including
interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2020-06 effective January 1, 2022 which
eliminated the need to assess whether a beneficial conversion feature needed to be recognized upon either (a) the future issuance of
new convertible notes; or (b) the resolution of any contingent beneficial conversion features.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the Financial Accounting Standards Board (the “FASB”) issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications
and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts
in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options. This new standard provides clarification and reduces diversity in an issuer’s accounting for modifications
or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification
or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal
years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new
standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in
an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The adoption
of ASU 2021-04 on January 1, 2022 did not have a material impact on its financial position, results of operations, and cash flows.</span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-557" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_807_eus-gaap--FairValueDisclosuresTextBlock_ze941g3EVL95" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
4 – <span id="xdx_824_zM9KRSci6sWk">Fair Value</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-558" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_896_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zlQkWUt6Q5pb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the changes in fair value, including net transfers in and/or out, of all of the Company’s
instruments recorded at fair value, which were all Level 3 liabilities measured at fair value on a recurring basis using unobservable
inputs during the years ended December 31, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B8_zyLolxoI1jNh" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Changes in Fair Value of Liabilities Measured at Fair Value on a Recurring Basis</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accrued</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accrued</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Derivative</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Interest</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Compensation</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Liability</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 44%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance
    - January 1, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--FairValueInputsMeasuredOnRecurringBasisBeginningBalance_iS_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedInterestMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zo8nL4svvnkb" title="Beginning balance" style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:FairValueInputsMeasuredOnRecurringBasisBeginningBalance" contextref="AsOf2019-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-559" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">173,275</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--FairValueInputsMeasuredOnRecurringBasisBeginningBalance_iS_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zmGl2g2rTCOe" title="Balance, beginning" style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:FairValueInputsMeasuredOnRecurringBasisBeginningBalance" contextref="AsOf2019-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-560" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">57,952</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--FairValueInputsMeasuredOnRecurringBasisBeginningBalance_iS_c20200101__20201231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zrSRGk7eLild" title="Beginning balance" style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:FairValueInputsMeasuredOnRecurringBasisBeginningBalance" contextref="AsOf2019-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-561" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">351,900</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--FairValueInputsMeasuredOnRecurringBasisBeginningBalance_iS_c20200101__20201231_zbTus4SoUU0l" title="Beginning balance" style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:FairValueInputsMeasuredOnRecurringBasisBeginningBalance" contextref="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-562" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">583,127</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    compensation - common stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_986_ecustom--AccruedCompensationCommonStock_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedInterestMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZIrU0NfpUId" title="Accrued compensation common stock" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0919"><span><ix:nonfraction name="CLCS:AccruedCompensationCommonStock" contextref="From2020-01-012020-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-563" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0919" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_981_ecustom--AccruedCompensationCommonStock_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z4oCcAEQswGd" title="Accrued compensation- common stock" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedCompensationCommonStock" contextref="From2020-01-012020-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-564" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10,021</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_989_ecustom--AccruedCompensationCommonStock_c20200101__20201231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zmzzkUhYGLOd" title="Accrued compensation- common stock" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0923"><span><ix:nonfraction name="CLCS:AccruedCompensationCommonStock" contextref="From2020-01-012020-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-565" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0923" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98C_ecustom--AccruedCompensationCommonStock_c20200101__20201231_zufdGKLxNj6a" title="Accrued compensation-common stock" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedCompensationCommonStock" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-566" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10,021</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    interest - common stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_984_ecustom--AccruedInterestCommonStock_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedInterestMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0zSDQqX1jc3" title="Accrued interest- common stock" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedInterestCommonStock" contextref="From2020-01-012020-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-567" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">56,875</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98D_ecustom--AccruedInterestCommonStock_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYGhGvEE7BE7" title="Accrued interest- common stock" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0929"><span><ix:nonfraction name="CLCS:AccruedInterestCommonStock" contextref="From2020-01-012020-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-568" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0929" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_983_ecustom--AccruedInterestCommonStock_c20200101__20201231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zvHFNaIrwDZ1" title="Accrued interest- common stock" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0931"><span><ix:nonfraction name="CLCS:AccruedInterestCommonStock" contextref="From2020-01-012020-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-569" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0931" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_987_ecustom--AccruedInterestCommonStock_c20200101__20201231_zGNLI7dvri1c" title="Accrued interest- common stock" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedInterestCommonStock" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-570" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">56,875</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    interest - warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98B_ecustom--AccruedInterestWarrantsOne_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedInterestMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFmt14Rlu9Uf" title="Accrued interest- warrants" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedInterestWarrantsOne" contextref="From2020-01-012020-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-571" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">117,806</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_980_ecustom--AccruedInterestWarrantsTwo_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zh8H6ESZmUBi" title="Accrued interest- warrants" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0937"><span><ix:nonfraction name="CLCS:AccruedInterestWarrantsTwo" contextref="From2020-01-012020-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-572" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0937" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_987_ecustom--AccruedInterestWarrantsThree_c20200101__20201231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZxQ4nr75Mf1" title="Accrued interest - warrants" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0939"><span><ix:nonfraction name="CLCS:AccruedInterestWarrantsThree" contextref="From2020-01-012020-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-573" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0939" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98C_ecustom--AccruedInterestWarrantsOne_c20200101__20201231_z0cLf4ytJ2B" title="Accrued interest - warrants" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedInterestWarrantsOne" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-574" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">117,806</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    interest - warrants - related party</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_989_ecustom--AccruedInterestWarrantRelatedParty_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedInterestMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zJ6sLulqQWdg" title="Accrued interest- warrants- related party" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedInterestWarrantRelatedParty" contextref="From2020-01-012020-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-575" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">47,563</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98D_ecustom--AccruedInterestWarrantRelatedParty_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zaij2f0qNNi1" title="Accrued interest- warrants- related party" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0945"><span><ix:nonfraction name="CLCS:AccruedInterestWarrantRelatedParty" contextref="From2020-01-012020-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-576" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0945" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_988_ecustom--AccruedInterestWarrantRelatedParty_c20200101__20201231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zG4yXLRG36Xi" title="Accrued interest- warrants- related party" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0947"><span><ix:nonfraction name="CLCS:AccruedInterestWarrantRelatedParty" contextref="From2020-01-012020-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-577" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0947" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98D_ecustom--AccruedInterestWarrantRelatedParty_c20200101__20201231_zDGMjU4NpNMc" title="Accrued interest- warrants- related party" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedInterestWarrantRelatedParty" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-578" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">47,563</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change
    in fair value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_980_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedInterestMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z3b1l5uBpSac" title="Change in fair value" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextref="From2020-01-012020-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-579" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">201,192</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98E_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zjvyzTNDUCw6" title="Change in fair value" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextref="From2020-01-012020-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-580" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,275</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_985_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20200101__20201231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzjSatyZMf5h" title="Change in fair value" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextref="From2020-01-012020-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-581" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,977</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_980_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20200101__20201231_zQnHaSHtQtOh" title="Change in fair value" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-582" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">223,490</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_988_ecustom--IssuanceOfWarrants_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedInterestMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zehiXLE2PsE4" title="Issuance of warrants" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0959"><span><ix:nonfraction name="CLCS:IssuanceOfWarrants" contextref="From2020-01-012020-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-583" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0959" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_988_ecustom--IssuanceOfWarrants_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zls7XKfZkFoc" title="Issuance of warrrants" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="CLCS:IssuanceOfWarrants" contextref="From2020-01-012020-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-584" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10,877</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_988_ecustom--IssuanceOfWarrants_c20200101__20201231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zsAPQkJoXele" title="Issuance of warrants" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:IssuanceOfWarrants" contextref="From2020-01-012020-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-585" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10,907</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98F_ecustom--IssuanceOfWarrants_c20200101__20201231_zwmnPM0dyoUd" title="Issuance of warrants" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:IssuanceOfWarrants" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-586" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of common stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98B_ecustom--IssuanceOfCommonStock_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedInterestMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQtaVLbQBo26" title="Issuance of common stock" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="CLCS:IssuanceOfCommonStock" contextref="From2020-01-012020-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-587" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">56,875</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_981_ecustom--IssuanceOfCommonStock_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zczqLBSsKfhl" title="Issuance of common stock" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="CLCS:IssuanceOfCommonStock" contextref="From2020-01-012020-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-588" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">11,418</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_980_ecustom--IssuanceOfCommonStock_c20200101__20201231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkGoRttoW4B7" title="Issuance of common stock" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0971"><span><ix:nonfraction name="CLCS:IssuanceOfCommonStock" contextref="From2020-01-012020-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-589" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0971" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_986_ecustom--IssuanceOfCommonStock_c20200101__20201231_zxpwisIUDQN1" title="Issuance of common stock" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="CLCS:IssuanceOfCommonStock" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-590" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">68,293</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Reclassification
    of derivative liabilities to equity</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_982_ecustom--ReclassificationOfDerivativeLiabilitiesToEquityOne_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedInterestMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zsVKzqYn42Yk" title="Reclassification of derivative liabilities to equity" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0975"><span><ix:nonfraction name="CLCS:ReclassificationOfDerivativeLiabilitiesToEquityOne" contextref="From2020-01-012020-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-591" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0975" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98E_ecustom--ReclassificationOfDerivativeLiabilities_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z7oztoy2ZpRb" title="Reclassification of derivative liabilities to equity" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0977"><span><ix:nonfraction name="CLCS:ReclassificationOfDerivativeLiabilities" contextref="From2020-01-012020-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-592" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0977" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_985_ecustom--ReclassificationOfDerivativeLiabilitiesToEquities_c20200101__20201231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zqXfSGlRQFU1" title="Reclassification of derivative liabilities to equity" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="CLCS:ReclassificationOfDerivativeLiabilitiesToEquities" contextref="From2020-01-012020-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-593" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">345,830</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98B_ecustom--ReclassificationOfDerivativeLiabilitiesToEquityTen_c20200101__20201231_zI0DetfcsHre" title="Reclassification of derivative liabilities to equity" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="CLCS:ReclassificationOfDerivativeLiabilitiesToEquityTen" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-594" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">345,830</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance
    - December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_980_ecustom--FairValueInputsMeasuredOnRecurringBasisBeginningBalance_iS_c20210101__20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedInterestMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z3B2J4mxKFC3" title="Beginning balance" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:FairValueInputsMeasuredOnRecurringBasisBeginningBalance" contextref="AsOf2020-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-595" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">539,836</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_987_ecustom--FairValueInputsMeasuredOnRecurringBasisBeginningBalance_iS_c20210101__20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zgOoaa9SjQNl" title="Beginning balance" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:FairValueInputsMeasuredOnRecurringBasisBeginningBalance" contextref="AsOf2020-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-596" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">84,953</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98F_ecustom--FairValueInputsMeasuredOnRecurringBasisBeginningBalance_iS_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zR1T8e4NMfo9" title="Beginning balance" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0987"><span><ix:nonfraction name="CLCS:FairValueInputsMeasuredOnRecurringBasisBeginningBalance" contextref="AsOf2020-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-597" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0987" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98C_ecustom--FairValueInputsMeasuredOnRecurringBasisBeginningBalance_iS_c20210101__20211231_zydNoDPPKnEd" title="Beginning balance" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:FairValueInputsMeasuredOnRecurringBasisBeginningBalance" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-598" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">624,789</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change
    in fair value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_983_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20210101__20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedInterestMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zM5lkcg4NX5c" title="Change in fair value" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextref="From2021-01-012021-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-599" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">54,783</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_981_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20210101__20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zG3EDBJABMp4" title="Change in fair value" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextref="From2021-01-012021-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-600" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,647</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98D_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_c20210101__20211231_z6q6FPXv2k37" title="Change in fair value" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-601" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78,430</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrual
    of warrant obligation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_985_ecustom--AccruedInterestWarrantOne_c20210101__20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedInterestMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zic5Gmx2hbpk" title="Accrual of warrant obligation" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedInterestWarrantOne" contextref="From2021-01-012021-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-602" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">164,857</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98B_ecustom--AccruedInterestWarrantOne_c20210101__20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z4dUVgES9yW6" title="Accrual of warrant obligation" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0999"><span><ix:nonfraction name="CLCS:AccruedInterestWarrantOne" contextref="From2021-01-012021-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-603" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0999" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_982_ecustom--AccruedInterestWarrantOne_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znmJ7lB9mrw9" title="Accrual of warrant obligation" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1001"><span><ix:nonfraction name="CLCS:AccruedInterestWarrantOne" contextref="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-604" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1001" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_980_ecustom--AccruedInterestWarrantOne_c20210101__20211231_zMtxPjfIuw8d" title="Accrual of warrant obligation" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedInterestWarrantOne" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-605" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">164,857</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_981_ecustom--IssuanceOfWarrants_c20210101__20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedInterestMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUV827e5mxxf" title="Issuance of warrants" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="CLCS:IssuanceOfWarrants" contextref="From2021-01-012021-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-606" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">247,566</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_985_ecustom--IssuanceOfWarrants_c20210101__20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6hx3PwVYTig" title="Issuance of warrants" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1007"><span><ix:nonfraction name="CLCS:IssuanceOfWarrants" contextref="From2021-01-012021-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-607" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1007" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_988_ecustom--IssuanceOfWarrants_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6LkJ1XsZ5Bd" title="Issuance of warrants" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1009"><span><ix:nonfraction name="CLCS:IssuanceOfWarrants" contextref="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-608" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1009" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_981_ecustom--IssuanceOfWarrants_c20210101__20211231_zfqIF5xDgXH8" title="Issuance of warrants" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="CLCS:IssuanceOfWarrants" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-609" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">247,566</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    - December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_ecustom--FairValueInputsMeasuredOnRecurringBasisEndingBalance_iE_c20210101__20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedInterestMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z4FBOKaHvs08" title="Ending balance" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:FairValueInputsMeasuredOnRecurringBasisEndingBalance" contextref="AsOf2021-12-31_custom_AccruedInterestMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-610" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">402,344</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--FairValueInputsMeasuredOnRecurringBasisEndingBalance_iE_c20210101__20211231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--AccruedCompensationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIlGDmhlnNp9" title="Ending balance" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:FairValueInputsMeasuredOnRecurringBasisEndingBalance" contextref="AsOf2021-12-31_custom_AccruedCompensationMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-611" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">61,306</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--FairValueInputsMeasuredOnRecurringBasisEndingBalance_iE_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zjvA9nJugMF6" title="Ending balance" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1017"><span><ix:nonfraction name="CLCS:FairValueInputsMeasuredOnRecurringBasisEndingBalance" contextref="AsOf2021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-612" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1017" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_ecustom--FairValueInputsMeasuredOnRecurringBasisEndingBalance_iE_c20210101__20211231_zRzVbMKgreo4" title="Ending balance" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:FairValueInputsMeasuredOnRecurringBasisEndingBalance" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-613" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">463,650</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A7_zJH2kGJczUV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 6, <i>Accrued Compensation </i>for additional details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar
techniques and at least one significant model assumption or input is unobservable. The Company’s Level 3 liabilities shown in the
above table consist of warrants with “down-round protection”, as the Company is unable to determine if it will have sufficient
authorized common stock to settle such arrangements, warrants deemed to be derivative liabilities according to the Company’s sequencing
policy in accordance with ASC 815-40-35-12, the embedded conversion options within its convertible notes payable and an accrued obligation
to issue warrants and common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-614" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_894_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zMntcVOAxWq4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model utilized in the valuation of Level 3 liabilities, the Company used the following approximate
assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<span id="xdx_8BF_zHOMhqxRm3h9" style="display: none">Schedule
of Assumptions Used for Valuation of Level 3 Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zh2jPAPeOq1g" title="Derivative liability, measurement input" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextref="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-615" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.87</ix:nonfraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%-<span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zDWKd8Lq5tm6" title="Derivative liability, measurement input"><span><ix:nonfraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextref="AsOf2021-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-616" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.26</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zBQDtpiv7K0g" title="Derivative liability, measurement input"><span><ix:nonfraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextref="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-617" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.28</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
                                            - <span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zLgw6JfwJ4Fa" title="Derivative liability, measurement input"><span><ix:nonfraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextref="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-618" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.37</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    term (years)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_ecustom--DerivativeLiabilityMeasurementInputExpectedTerm_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_z4Y2KEiq0hdg" title="Derivative liability, expected term (years)" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember" format="ixt-sec:duryear" name="CLCS:DerivativeLiabilityMeasurementInputExpectedTerm" inside-table="true" id="fact-identifier-619" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4.00</ix:nonnumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span id="xdx_903_ecustom--DerivativeLiabilityMeasurementInputExpectedTerm_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zvOlFxpAIDhb" title="Derivative liability, expected term (years)"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember" format="ixt-sec:duryear" name="CLCS:DerivativeLiabilityMeasurementInputExpectedTerm" inside-table="true" id="fact-identifier-620" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.00</ix:nonnumeric></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--DerivativeLiabilityMeasurementInputExpectedTerm_dtY_c20200101__20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zUOTPlDCCWY6" title="Derivative liability, expected term (years)"><span><ix:nonnumeric contextref="From2020-01-012020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember" format="ixt-sec:duryear" name="CLCS:DerivativeLiabilityMeasurementInputExpectedTerm" inside-table="true" id="fact-identifier-621" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4.00</ix:nonnumeric></span></span>
                                            </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <span id="xdx_900_ecustom--DerivativeLiabilityMeasurementInputExpectedTerm_dtY_c20200101__20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zJoaXJSN6cu6" title="Derivative liability, expected term (years)"><span><ix:nonnumeric contextref="From2020-01-012020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember" format="ixt-sec:duryear" name="CLCS:DerivativeLiabilityMeasurementInputExpectedTerm" inside-table="true" id="fact-identifier-622" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.00</ix:nonnumeric></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    volatility</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z6wXDaiwXHei" title="Derivative liability, measurement input"><span><ix:nonfraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextref="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-623" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zJdBw7RpP3Cg" title="Derivative liability, measurement input"><span><ix:nonfraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextref="AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-624" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%-<span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zPCE26xTRRke" title="Derivative liability, measurement input"><span><ix:nonfraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextref="AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-625" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">110</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    dividends</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zzLbid84lLI9" title="Derivative liability, measurement input"><span><ix:nonfraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextref="AsOf2021-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-626" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.00</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zWKTmMncTbil" title="Derivative liability, measurement input"><span><ix:nonfraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextref="AsOf2020-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-627" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.00</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8AF_zScaZWVWoBlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected term used is the contractual life of the instrument being valued. Since the Company’s stock has not been publicly traded
for a sufficiently long period of time or with significant volume, the Company is utilizing an expected volatility based on a review
of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned
public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon
bonds with a remaining term consistent with the expected term of the instrument being valued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the Company had an obligation to issue <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231_z41SfSlB8Sy7" title="Common stock shares issued for sevice, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-628" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">154,495</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock to service providers that
had a fair value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20211231_zhfuSOdZIdVe" title="Common stock shares issued for sevice, value"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-629" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,528</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which was a component of accrued compensation on the consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 8, <i>Notes Payable</i> and Note 11, <i>Commitments and Contingencies</i> for additional details associated with the issuance of
warrants which were deemed to be derivative liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-630" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_802_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zybez6qsRZ99" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
5 – <span id="xdx_824_zfee9Mf15Ucd">Accrued Expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-631" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_89C_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zyyzvPmdn3yg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8BE_zRR6fIldnM89" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Accrued Expenses</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tbody><tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" id="xdx_49B_20211231_zHsGxPlolnPj" style="display: none; font-family: Times New Roman, Times, Serif; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" id="xdx_49E_20201231_zHkzkiXyW15b" style="display: none; font-family: Times New Roman, Times, Serif; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_404_ecustom--AccruedResearchAndDevelopment_iI_maALCzKwp_z16wQKKkx972" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    research and development</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedResearchAndDevelopment" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-632" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">596,773</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedResearchAndDevelopment" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-633" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">709,574</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_406_ecustom--AccruedThirdPartyPayments_iI_maALCzKwp_z2Z341PACzub" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    third-party payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedThirdPartyPayments" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-634" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,816</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedThirdPartyPayments" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-635" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">116,326</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_406_ecustom--AccruedLegalFees_iI_maALCzKwp_zHaM9NNLak21" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    legal fees</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedLegalFees" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-636" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">118,687</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedLegalFees" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-637" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">113,996</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzKwp_zAxI8GYl5iVi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    other professional fees</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedProfessionalFeesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-638" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">336,517</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedProfessionalFeesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-639" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">201,805</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALCzKwp_zr2XorL8aXq3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    director compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-640" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,750</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-641" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,750</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzKwp_zi3QRGajy62j" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other
    accrued expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-642" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,478</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-643" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,499</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzKwp_zpCYi8vCHQWb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    accrued expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-644" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,097,021</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-645" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,159,950</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8AA_zSADQihP4Sj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 10, <i>Stockholders’ Deficiency – Stock Warrants</i> for details associated with the extinguishment of accrued compensation
to the Company’s Scientific Advisory Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="CLCS:AccruedCompensationTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-646" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_807_ecustom--AccruedCompensationTextBlock_zyZojjegQxig" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
6 – <span id="xdx_82F_zOhIhWKZTrxi">Accrued Compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="CLCS:AccruedCompensationTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-647" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_891_ecustom--AccruedCompensationTableTextBlock_zs38JIwe4MQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
compensation consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B0_zg7DFgvPJAig" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none">Schedule
of Accrued Compensation</b></span><b style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tbody><tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="display: none; font-family: Times New Roman, Times, Serif; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" id="xdx_492_20211231_z3qIGdGea7al" style="display: none; font-family: Times New Roman, Times, Serif; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" id="xdx_490_20201231_zKLqOJPmMWNg" style="display: none; font-family: Times New Roman, Times, Serif; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AccruedIncomeTaxesCurrent_iI_maDCLCzxjs_zfw135uYCYS4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Withholding
    </span><span style="font-family: Times New Roman, Times, Serif">tax</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedIncomeTaxesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-648" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">124,718</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedIncomeTaxesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-649" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">122,457</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_407_ecustom--AccruedSocialSecurityCurrent_iI_maDCLCzxjs_znTGSvVGM6Ea" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Social
    security</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedSocialSecurityCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-650" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">40,616</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedSocialSecurityCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-651" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">39,211</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maDCLCzxjs_zxz01PwCu8k" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based
    compensation - common stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-652" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,528</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-653" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">72,613</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40A_ecustom--StockbasedCompensationWarrants_iI_maDCLCzxjs_zmZ4YnglAebc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based
    compensation - warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:StockbasedCompensationWarrants" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-654" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8,777</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:StockbasedCompensationWarrants" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-655" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">12,341</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AccruedInsuranceCurrent_iI_maDCLCzxjs_z5YoURswpKcl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pension
    insurance</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedInsuranceCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-656" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">241,733</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedInsuranceCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-657" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">206,067</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedSalariesCurrent_iI_maDCLCzxjs_z1NAcAfzYZnl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    payroll</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedSalariesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-658" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">88,753</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedSalariesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-659" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">84,745</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AccruedVacationCurrent_iI_maDCLCzxjs_zDeky1tb9zX4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Vacation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedVacationCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-660" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,898</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:AccruedVacationCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-661" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57,111</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_40A_ecustom--AccruedSeveranceCurrent_iI_maDCLCzxjs_z5sSMeFEbCO2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Severance</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedSeveranceCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-662" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">143,079</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:AccruedSeveranceCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-663" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">129,640</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr id="xdx_406_eus-gaap--DeferredCompensationLiabilityCurrent_iTI_mtDCLCzxjs_zAEy2ygTrTIl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    accrued compensation</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:DeferredCompensationLiabilityCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-664" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">766,102</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:DeferredCompensationLiabilityCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-665" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">724,185</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8AD_zLREcsMhDCF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-666" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_807_eus-gaap--OtherLiabilitiesDisclosureTextBlock_zsCh9K5HxwU6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
7 – <span id="xdx_82E_zCpLkM1RnMle">Advances Payable</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances
payable and advances payable – related party represent cash received from lenders. See Note 12, <i>Related Party Transactions</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 6, 2020, in connection with an advance in the amount of $<span id="xdx_90B_ecustom--ProceedsFromAdvancesPayable_c20200505__20200506_zp4Rwft8lZV4" title="Advance amount"><span><ix:nonfraction name="CLCS:ProceedsFromAdvancesPayable" contextref="From2020-05-052020-05-06" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-667" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100,000</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
the Company issued a <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtYxL_c20200505__20200506_zgjyjLBwJsrk" title="Warrants vesting period::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1113"><span><ix:nonnumeric contextref="From2020-05-052020-05-06" id="fact-identifier-668" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="xdx2ixbrl1113" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">five</ix:nonnumeric></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
immediately vested warrant to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20200506_zka0T6tYIw94" title="Warrant issued to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-05-06" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-669" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20200506_z4MXzkReyaWc" title="Share price"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2020-05-06" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-670" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The warrant had an issuance date relative
fair value of $<span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_c20200505__20200506_zgXodZ4kfFp7" title="Fair value of warrants"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2020-05-052020-05-06" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-671" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,386</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which was recorded as interest expense on the consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021 and 2020, the Company received cash advances of $<span id="xdx_90C_ecustom--ProceedsFromAdvancesPayable_c20210101__20211231_z7TYdvYO3f9d" title="Proceeds from advances payable"><span><ix:nonfraction name="CLCS:ProceedsFromAdvancesPayable" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-672" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_907_ecustom--ProceedsFromAdvancesPayable_c20200101__20201231_zNCTVm8od2j8" title="Proceeds from advances payable"><span><ix:nonfraction name="CLCS:ProceedsFromAdvancesPayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-673" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">114,000</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, and repaid cash advances of $<span id="xdx_90A_ecustom--RepaymentOfAdvancesPayable_c20210101__20211231_zNuxJW9wszHe" title="Repayment of cash in advance"><span><ix:nonfraction name="CLCS:RepaymentOfAdvancesPayable" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-674" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">60,500</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_ecustom--RepaymentOfAdvancesPayable_c20200101__20201231_zRDVi7lBdrVj" title="Repayment of cash in advance"><span><ix:nonfraction name="CLCS:RepaymentOfAdvancesPayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-675" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">154,000</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-676" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zxnRwGzTWEh5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
8 – <span id="xdx_82B_zvFsoWsiLPsl">Notes Payable</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a variety of outstanding debt instruments consisting of: a) notes payable, b) notes payable to related parties, c) convertible
notes payable, and d) convertible notes payable to related parties. The notes within each of those groups are described in the sections
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and through the date of this filing, notes payable with principal amounts totaling $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zYkbzgf17w75" title="Debt instrument, principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2021-12-31_custom_NotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-677" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,554,912</ix:nonfraction></span></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zYAEBJad8pKh" title="Debt instrument, principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-12-31_custom_NotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-678" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,329,912</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively, were past due and are classified as
current liabilities on the consolidated balance sheet as of December 31, 2021. Such notes continue to accrue interest and all relevant
penalties have been accrued as of December 31, 2021. Of such past due notes payable, a holder of a note with principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__srt--TitleOfIndividualAxis__custom--NoteholderMember_zW4K9hluXOue" title="Debt instrument, principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2021-12-31_custom_NoteholderMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-679" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">250,000</ix:nonfraction></span></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued a notice of default. See Note 11, <i>Commitments
and Contingencies – Litigation </i>for additional details. The Company is in negotiations with all holders of notes payable to
extend the maturity dates of such notes or to convert the principal and accrued interest into equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021 and 2020, the Company recorded interest expense of $<span id="xdx_906_eus-gaap--InterestExpenseDebt_c20210101__20211231_z1xQ51rvsgXd" title="Interest expense"><span><ix:nonfraction name="us-gaap:InterestExpenseDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-680" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">629,201</ix:nonfraction></span></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
$<span id="xdx_900_eus-gaap--InterestExpenseDebt_c20200101__20201231_zKUGsenEkwad" title="Interest expense"><span><ix:nonfraction name="us-gaap:InterestExpenseDebt" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-681" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">636,156</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, and amortization of debt discount of $<span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_zfTVgdU5NGR2" title="Amortization of debt discount"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2021-01-012021-12-31_custom_NotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-682" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">731,502</ix:nonfraction></span></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_zfkxnus4YDC5" title="Amortization of debt discount"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2020-01-012020-12-31_custom_NotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-683" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">301,250</ix:nonfraction></span></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively. As of December 31, 2021 and 2020,
the Company had $<span id="xdx_900_ecustom--AccruedInterestAndPenalties_iI_c20211231_z3SCAoS4IUhd" title="Accrued interest and penalities"><span><ix:nonfraction name="CLCS:AccruedInterestAndPenalties" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-684" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,182,225</ix:nonfraction></span></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_906_ecustom--AccruedInterestAndPenalties_iI_c20201231_zv8QynjxnOM1" title="Accrued interest and penalities"><span><ix:nonfraction name="CLCS:AccruedInterestAndPenalties" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-685" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">997,244</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, of accrued interest (including interest in the form of warrants (see Note 4)) and penalties related to notes payable, which
is included with accrued interest and accrued interest – related parties on the consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShortTermDebtTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-686" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_899_eus-gaap--ScheduleOfShortTermDebtTextBlock_zc7hgXM9Yx6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)
Notes payable consist of the following:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8BD_z6dXdRlz7RZ3" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Notes Payable</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; width: 4%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">i)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; width: 62%"><span style="font-family: Times New Roman, Times, Serif">Notes
    issued on March 26, 2015</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--NotesPayableCurrent_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--NotesIssuedOnMarch26TwoThousandFifteenMember_zxnzOTWAPObk" title="Total" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2021-12-31_custom_NotesIssuedOnMarch26TwoThousandFifteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-687" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">296,912</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--NotesPayableCurrent_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NotesIssuedOnMarch26TwoThousandFifteenMember_zXNmjzwgv4Tc" title="Total" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2020-12-31_custom_NotesIssuedOnMarch26TwoThousandFifteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-688" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Note
    issued on May 15, 2015<br></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_985_eus-gaap--NotesPayableCurrent_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--NoteIssuedOnMay15TwoThousandFifteenMember_zs9jDSbDU06f" title="Total" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2021-12-31_custom_NoteIssuedOnMay15TwoThousandFifteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-689" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">250,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_987_eus-gaap--NotesPayableCurrent_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NoteIssuedOnMay15TwoThousandFifteenMember_zB9NG1MxrGeb" title="Total" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2020-12-31_custom_NoteIssuedOnMay15TwoThousandFifteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-690" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">250,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Note
    issued on May 10, 2016</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98A_eus-gaap--NotesPayableCurrent_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--NoteIssuedOnMay10TwoThousandSixteenMember_z0WITKXMdob8" title="Total" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2021-12-31_custom_NoteIssuedOnMay10TwoThousandSixteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-691" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98D_eus-gaap--NotesPayableCurrent_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NoteIssuedOnMay10TwoThousandSixteenMember_z9PNgFa9bJ41" title="Total" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2020-12-31_custom_NoteIssuedOnMay10TwoThousandSixteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-692" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">iv)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Notes
    issued on various dates from July 20, 2016 to October 13, 2016</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_985_eus-gaap--NotesPayableCurrent_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--NotesIssuedOnVariousDatesFromJuly20TwoThousandSixteenToOctober13TwoThousandSixteenMember_zzZ4UR8zJe86" title="Total" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2021-12-31_custom_NotesIssuedOnVariousDatesFromJuly20TwoThousandSixteenToOctober13TwoThousandSixteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-693" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_989_eus-gaap--NotesPayableCurrent_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NotesIssuedOnVariousDatesFromJuly20TwoThousandSixteenToOctober13TwoThousandSixteenMember_zcsvhif7GELf" title="Total" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2020-12-31_custom_NotesIssuedOnVariousDatesFromJuly20TwoThousandSixteenToOctober13TwoThousandSixteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-694" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Note
    issued on February 26, 2018</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_986_eus-gaap--NotesPayableCurrent_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--NoteIssuedOnFebruaryTwentySixTwoThousandEightteenMember_zYL0vqHLgpC2" title="Total" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2021-12-31_custom_NoteIssuedOnFebruaryTwentySixTwoThousandEightteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-695" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_987_eus-gaap--NotesPayableCurrent_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NoteIssuedOnFebruaryTwentySixTwoThousandEightteenMember_zW58m9QYKbEi" title="Total" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2020-12-31_custom_NoteIssuedOnFebruaryTwentySixTwoThousandEightteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-696" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">vii)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Note
    issued on July 29, 2019</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_985_eus-gaap--NotesPayableCurrent_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--NoteIssuedOnJulyTwentyNineTwoThousandNinteenMember_zbdUrRkTPwS1" title="Total" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1171"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2021-12-31_custom_NoteIssuedOnJulyTwentyNineTwoThousandNinteenMember" id="fact-identifier-697" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1171" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98D_eus-gaap--NotesPayableCurrent_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NoteIssuedOnJulyTwentyNineTwoThousandNinteenMember_z4c9c4KV30Xk" title="Total" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2020-12-31_custom_NoteIssuedOnJulyTwentyNineTwoThousandNinteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-698" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--NotesPayableCurrent_iI_c20211231_zjg6fozoTc4j" title="Total" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-699" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">759,912</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--NotesPayableCurrent_iI_c20201231_zYAcA77wpD8f" title="Total" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-700" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,013,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A0_zuPVboBotKs" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
regarding certain of these notes are as follows (which numbering corresponds to the above table):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">i)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 15, 2020, the maturity date a promissory note in the principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20200415__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zCXy5A0tX103" title="Debt instrument, principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-04-15_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-701" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">250,000</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
    originally due in 2015, was extended to <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_c20200414__20200415__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z7LBLaR64Zbl" title="Debt maturity date"><span><ix:nonnumeric contextref="From2020-04-142020-04-15_custom_PromissoryNoteMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="true" id="fact-identifier-702" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">April 15, 2021</ix:nonnumeric></span></span>. In connection with this extension, the Company issued an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200414__20200415__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zHzEOKuAAHWb" title="Common stock shares issued during period, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-04-142020-04-15_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-703" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">375,000</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock to the holder with
    a fair value of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200414__20200415__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zMC75r1LAtqd" title="Common stock shares issued during period, value"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-04-142020-04-15_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-704" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">93,750</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
    The Company determined the extension was a note extinguishment and recorded a loss on extinguishment of notes payable of $<span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zSmcPigDfOQ3" title="Gain loss on extinguishment of debt"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2020-01-012020-12-31_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-705" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">93,750</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the consolidated statements of operations
    during the year ended December 31, 2020. During year ended December 31, 2021, the Company paid $<span id="xdx_90F_eus-gaap--RepaymentsOfNotesPayable_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zPjdqGUC0ft4" title="Repayments of notes payable"><span><ix:nonfraction name="us-gaap:RepaymentsOfNotesPayable" contextref="From2021-01-012021-12-31_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-706" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">203,088</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to noteholders as a partial repayment
    of principal such that the notes had $<span id="xdx_908_eus-gaap--NotesPayable_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_ztmGQseQkUQd" title="Notes payable"><span><ix:nonfraction name="us-gaap:NotesPayable" contextref="AsOf2021-12-31_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-707" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">296,912</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding as of December 31, 2021
    after the partial repayment. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 11- Commitments
    and Contingencies - Litigation for information regarding the partial repayment of these notes during 2021 in connection with a legal
    matter related to certain of these notes. As of the date of  filing, this note was past due.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 15, 2020, the maturity date a promissory note in the principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20200415__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_z4oytxPkED18"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-04-15_custom_PromissoryNoteOneMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-708" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
    originally due in 2016, was extended to <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_c20200414__20200415__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zHLERw6Zp4l4"><span><ix:nonnumeric contextref="From2020-04-142020-04-15_custom_PromissoryNoteOneMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="true" id="fact-identifier-709" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">April
    15, 2021</ix:nonnumeric></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. In connection with this extension,
    the Company issued an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200414__20200415__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zySnuXuMA8T"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-04-142020-04-15_custom_PromissoryNoteOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-710" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock to the holder with
    a fair value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200414__20200415__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zqGOpJTarKKf"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-04-142020-04-15_custom_PromissoryNoteOneMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-711" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,500</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
    The Company determined the extension was a note extinguishment and recorded a loss on extinguishment of notes payable of $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zgMbUSQngbEc"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2020-01-012020-12-31_custom_PromissoryNoteOneMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-712" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,500</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the consolidated statements of operations
    during the year ended December 31, 2020. On July 29, 2020, the Company fully repaid the principal of a promissory note in the amount
    of $<span id="xdx_907_eus-gaap--RepaymentsOfNotesPayable_c20200728__20200729__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zyzKAMHWs617"><span><ix:nonfraction name="us-gaap:RepaymentsOfNotesPayable" contextref="From2020-07-282020-07-29_custom_PromissoryNoteOneMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-713" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
    As of the date of filing, this note was past due.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    November 9, 2021, the Company entered into an agreement with a noteholder to exchange a note payable in the principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20211109__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zBFuptUSW4e3" title="Debt instrument, principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2021-11-09_custom_NotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-714" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211107__20211109__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_z5FMh7qexDN3" title="Common stock shares issued during period, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-11-072021-11-09_custom_NotesPayableMember_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-715" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,429</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series C Convertible Preferred
    Stock and immediately vested five-year warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211109__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zVEpGXPijN99" title="Warrants issued to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2021-11-09_custom_NotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-716" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,290</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company’s common stock
    at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211109__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zENprOpZ3ST5" title="Warrant exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-11-09_custom_NotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-717" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The exchange was accounted for
    as a debt extinguishment and, as such, the Company recorded a loss on extinguishment of $<span id="xdx_906_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_znD87K2MHu8" title="Gain loss on extinguishment of debt"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2021-01-012021-12-31_custom_NotesPayableMember_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-718" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">93,425</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on its consolidated statement of operations
    during the year ended December 31, 2021.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2020, the Company issued a note payable in the principal amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20200603__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zOJfaGo3XATi" title="Debt instrument, principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-06-03_custom_NotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-719" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The note does not accrue interest and matures on December 3, 2020. The note was repaid in full by the Company on June 18, 2020. In connection
with the note issuance, the Company issued a five-year immediately vested warrant to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20200603__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zjGa4gzXVfWb" title="Warrants issued to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-06-03_custom_NotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-720" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200603__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zxktkia6epj2" title="Warrant exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-06-03_custom_NotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-721" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The warrant had an issuance date relative
fair value of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20200603__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zM64lbSeOWSh" title="Debt unamortized discount"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2020-06-03_custom_NotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-722" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,466</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which was recorded as a debt discount and was to be amortized over the term of the note, however, was recognized during the year ended
December 31, 2020 as a result of the repayment of the note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="CLCS:NotesPayableDueToRelatedPartiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-723" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_893_ecustom--NotesPayableDueToRelatedPartiesTableTextBlock_zM8dZcKV1jg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b)
Notes payable due to related parties consist of the following:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none">&nbsp;<span id="xdx_8B3_zVzhCgt2TxLh" style="display: none">Schedule
of Notes Payable Due to Related Parties</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; width: 4%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 62%"><span style="font-family: Times New Roman, Times, Serif">Note
    issued on November 26, 2014</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--NoteIssuedOnNovemberTwentySixTwoThousandFourteenMember_zCPr3sKmimd" title="Notes payable due to related parties" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextref="AsOf2021-12-31_custom_NoteIssuedOnNovemberTwentySixTwoThousandFourteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-724" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NoteIssuedOnNovemberTwentySixTwoThousandFourteenMember_zpMDMpNgRLih" title="Notes payable due to related parties" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextref="AsOf2020-12-31_custom_NoteIssuedOnNovemberTwentySixTwoThousandFourteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-725" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Note
    issued on July 20, 2015</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98D_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--NotesIssuedOnJuly202015TwoThousandFifteenMember_zIOkr3Q5AJad" title="Notes payable due to related parties" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextref="AsOf2021-12-31_custom_NotesIssuedOnJuly202015TwoThousandFifteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-726" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_988_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NotesIssuedOnJuly202015TwoThousandFifteenMember_zYB3zctUUSbc" title="Notes payable due to related parties" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextref="AsOf2020-12-31_custom_NotesIssuedOnJuly202015TwoThousandFifteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-727" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231_zfiUzsJmNFJi" title="Notes payable due to related parties" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-728" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20201231_zEQfyd8t1Ql1" title="Notes payable due to related parties" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-729" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A3_z97k43hc6WQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-730" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_89C_eus-gaap--ConvertibleDebtTableTextBlock_zpWRTApXOlZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c)
Convertible notes payable consist of the following:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_zJu5UyoGMg95" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none">Schedule
of Convertible Notes Payable</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left; width: 4%"><span style="display: none; font-family: Times New Roman, Times, Serif">i)</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; width: 2%"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="display: none; font-family: Times New Roman, Times, Serif; width: 62%; text-align: left"></td><td style="display: none; font-family: Times New Roman, Times, Serif; width: 2%"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="display: none; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember_zc276wAMR74j" title="Convertible notes payable" style="display: none; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2021-12-31_custom_ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-731" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,000</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="display: none; font-family: Times New Roman, Times, Serif; width: 2%"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="display: none; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ConvertibleNotesPayable_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember_zRr95h8AfQUl" title="Convertible notes payable" style="display: none; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2020-12-31_custom_ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-732" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">137,753</ix:nonfraction></span></span></td><td style="display: none; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">i)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible
    notes issued on July 24, 2015, net of debt discount of $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember_zhCSnuCjHa07" title="Debt instrument, unamortized discount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2021-12-31_custom_ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-733" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">and $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember_zdnQqrm1DcH6" title="Debt instrument, unamortized discount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2020-12-31_custom_ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-734" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,247</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">as of December 31, 2021 and 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember_z6BG9w8r5Q69" title="Convertible notes payable" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2021-12-31_custom_ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-735" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ConvertibleNotesPayable_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember_z13vRRecVGAl" title="Convertible notes payable" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2020-12-31_custom_ConvertibleNotesIssuedOnJuly24TwoThousandFifteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-736" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">137,753</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible
    notes issued on October 7, 2015</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_987_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnOctober7TwoThousandFifteenMember_zlz2jJnMrEI9" title="Convertible notes payable" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2021-12-31_custom_ConvertibleNotesIssuedOnOctober7TwoThousandFifteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-737" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">265,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_981_eus-gaap--ConvertibleNotesPayable_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnOctober7TwoThousandFifteenMember_zL4a1ADsv1ma" title="Convertible notes payable" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2020-12-31_custom_ConvertibleNotesIssuedOnOctober7TwoThousandFifteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-738" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">265,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible
    notes issued on May 18, 2017</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98A_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnMay18TwoThousandSeventeenMember_zmeWtlWviitl" title="Convertible notes payable" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2021-12-31_custom_ConvertibleNotesIssuedOnMay18TwoThousandSeventeenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-739" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">135,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_984_eus-gaap--ConvertibleNotesPayable_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnMay18TwoThousandSeventeenMember_zqv4YiQp0IA3" title="Convertible notes payable" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2020-12-31_custom_ConvertibleNotesIssuedOnMay18TwoThousandSeventeenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-740" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">135,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">iv)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible
    notes issued on July 29, 2020, net of debt discount of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblenoteissuedonJulyTwentyNineTwentyTwentyMember_zLNrk6i4hxid" title="Debt instrument, unamortized discount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2021-12-31_custom_ConvertibleNoteIssuedOnJulyTwentyNineTwentyTwentyMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-741" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">and $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblenoteissuedonJulyTwentyNineTwentyTwentyMember_zYz6Up2Cfm5f" title="Debt instrument, unamortized discount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2020-12-31_custom_ConvertibleNoteIssuedOnJulyTwentyNineTwentyTwentyMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-742" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,318</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">as of December 31, 2021 and 2020, respectively</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_985_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblenoteissuedonJulyTwentyNineTwentyTwentyMember_zrvt0RANjX6j" title="Convertible notes payable" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1257"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2021-12-31_custom_ConvertibleNoteIssuedOnJulyTwentyNineTwentyTwentyMember" id="fact-identifier-743" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1257" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_982_eus-gaap--ConvertibleNotesPayable_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblenoteissuedonJulyTwentyNineTwentyTwentyMember_z35v8ALWjSTf" title="Convertible notes payable" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2020-12-31_custom_ConvertibleNoteIssuedOnJulyTwentyNineTwentyTwentyMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-744" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">543,238</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">v)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible
    notes issued between October 11 and October 15, 2020, net of debt discount of $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedBetweenOctoberElevenandOctoberFifteenTwentyTwentyMember_z3m0bQvz9sK3" title="Debt instrument, unamortized discount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2021-12-31_custom_ConvertibleNotesIssuedBetweenOctoberElevenandOctoberFifteenTwentyTwentyMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-745" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">and $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedBetweenOctoberElevenandOctoberFifteenTwentyTwentyMember_zFH0NR0Wy1sk" title="Debt instrument, unamortized discount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2020-12-31_custom_ConvertibleNotesIssuedBetweenOctoberElevenandOctoberFifteenTwentyTwentyMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-746" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,402</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">as of December 31, 2021 and 2020, respectively</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedBetweenOctoberElevenandOctoberFifteenTwentyTwentyMember_z9VF7yrdOar3" title="Convertible notes payable" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1265"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2021-12-31_custom_ConvertibleNotesIssuedBetweenOctoberElevenandOctoberFifteenTwentyTwentyMember" id="fact-identifier-747" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1265" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_983_eus-gaap--ConvertibleNotesPayable_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedBetweenOctoberElevenandOctoberFifteenTwentyTwentyMember_zHzjh3d8CLa4" title="Convertible notes payable" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2020-12-31_custom_ConvertibleNotesIssuedBetweenOctoberElevenandOctoberFifteenTwentyTwentyMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-748" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">135,598</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">vi)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible
    notes issued between December 11 and December 15, 2020, net of debt discount of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedBetweenDecemberElevenandDecemberFifteenTwentyTwentyMember_z7x7UBvO2rP5" title="Debt instrument, unamortized discount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2021-12-31_custom_ConvertibleNotesIssuedBetweenDecemberElevenandDecemberFifteenTwentyTwentyMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-749" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">and $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedBetweenDecemberElevenandDecemberFifteenTwentyTwentyMember_zru4iADiGMg9" title="Debt instrument, unamortized discount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2020-12-31_custom_ConvertibleNotesIssuedBetweenDecemberElevenandDecemberFifteenTwentyTwentyMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-750" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">48,435</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">as of December 31, 2021 and 2020, respectively</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_984_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedBetweenDecemberElevenandDecemberFifteenTwentyTwentyMember_z2fq2xIxEIW9" title="Convertible notes payable" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1273"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2021-12-31_custom_ConvertibleNotesIssuedBetweenDecemberElevenandDecemberFifteenTwentyTwentyMember" id="fact-identifier-751" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1273" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98E_eus-gaap--ConvertibleNotesPayable_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedBetweenDecemberElevenandDecemberFifteenTwentyTwentyMember_z29OtJyGLXP2" title="Convertible notes payable" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2020-12-31_custom_ConvertibleNotesIssuedBetweenDecemberElevenandDecemberFifteenTwentyTwentyMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-752" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">276,565</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">vii)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Convertible
    notes issued between July 8 and December 15, 2021, net of debt discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedBetweenJulyEightandDecemberFifteenTwentyTwentyOneMember_zRlxy1EEpxW5"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2021-12-31_custom_ConvertibleNotesIssuedBetweenJulyEightandDecemberFifteenTwentyTwentyOneMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-753" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71,124</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">as of December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_981_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedBetweenJulyEightandDecemberFifteenTwentyTwentyOneMember_z4vpHDtWSVga" title="Convertible notes payable" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2021-12-31_custom_ConvertibleNotesIssuedBetweenJulyEightandDecemberFifteenTwentyTwentyOneMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-754" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,414,446</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98B_eus-gaap--ConvertibleNotesPayable_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedBetweenJulyEightandDecemberFifteenTwentyTwentyOneMember_zP4CC0JBsdM5" title="Convertible notes payable" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1280"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2020-12-31_custom_ConvertibleNotesIssuedBetweenJulyEightandDecemberFifteenTwentyTwentyOneMember" id="fact-identifier-755" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ConvertibleNotesPayable_iI_c20211231_zKtjwAbAiCei" title="Convertible notes payable" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-756" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,834,446</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ConvertibleNotesPayable_iI_c20201231_z51XWWVRejof" title="Convertible notes payable" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-757" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,493,153</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A1_z0PCoBxveKKb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
regarding certain of these notes are as follows (which numbering corresponds to the above table):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    various dates from February 20, 2020 through February 24, 2020, the maturity dates of three convertible notes in the aggregate principal
    amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20200224__us-gaap--DebtInstrumentAxis__custom--ThreeConvertibleNotesMember_zrjlY9I7DN99" title="Debt instrument, principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-02-24_custom_ThreeConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-758" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">145,000</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were extended to <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20200220__20200224__us-gaap--DebtInstrumentAxis__custom--ThreeConvertibleNotesMember_zMseIxC63UO9" title="Debt maturity date"><span><ix:nonnumeric contextref="From2020-02-202020-02-24_custom_ThreeConvertibleNotesMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="true" id="fact-identifier-759" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">February 15, 2021</ix:nonnumeric></span></span>. The notes
    had previous maturity dates ranging from January 2017 to February 2018. In connection with these extensions, the parties agreed that
    (i) the Company would issue an aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200220__20200224__us-gaap--DebtInstrumentAxis__custom--ThreeConvertibleNotesMember_zB1b9UHOqc9i" title="Common stock shares issued during period, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-02-202020-02-24_custom_ThreeConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-760" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">227,500</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock to the holders with
    a fair value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200220__20200224__us-gaap--DebtInstrumentAxis__custom--ThreeConvertibleNotesMember_z0WbDZP2hU9l" title="Common stock shares issued during period, value"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-02-202020-02-24_custom_ThreeConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-761" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56,875</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and (ii) a conversion price floor of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20200224__us-gaap--DebtInstrumentAxis__custom--ThreeConvertibleNotesMember_z5p3Nees8cTl" title="Debt conversion price"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2020-02-24_custom_ThreeConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-762" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share would be established. The Company
    determined the transaction was a note modification and the fair value of the common stock was setup as a debt discount and will be
    amortized over the amended term of the notes. On March 31, 2020, the Company issued the shares of common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    March 11, 2021, the Company entered into convertible note purchase agreements with two noteholders whereby the Company agreed to
    repurchase an aggregate of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20210311__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementsMember_zQGbeUTPmaV1" title="Debt instrument, principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2021-03-11_custom_ConvertibleNotePurchaseAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-763" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,000</ix:nonfraction></span></span></span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of convertible notes payable for the same amount in cash,
    at which time the notes were cancelled. In connection with the repayment, the parties agreed that the Company was no longer required
    to pay accrued interest associated with the notes payable in the amount of $<span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210311__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementsMember_zxgE9SbDpyk6" title="Accrued interest"><span><ix:nonfraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextref="AsOf2021-03-11_custom_ConvertibleNotePurchaseAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-764" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">49,983</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
    As a result, the Company recognized a gain on forgiveness of accrued interest of $<span id="xdx_904_ecustom--GainOnForgivenessOfAccruedInterest_c20210308__20210311__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementsMember_zebJFIyAwrob" title="Gain on forgiveness of accrued interest"><span><ix:nonfraction name="CLCS:GainOnForgivenessOfAccruedInterest" contextref="From2021-03-082021-03-11_custom_ConvertibleNotePurchaseAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-765" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">49,983</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on its consolidated statement of operations
    during the year ended December 31, 2021.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    July 29, 2020, the Company issued a convertible note payable in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_c20200729__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" title="Debt instrument, principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-07-29_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-766" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">555,556</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for net proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_c20200728__20200729__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" title="Proceeds from convertible debt"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2020-07-282020-07-29_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-767" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">497,500</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gross proceeds of $<span id="xdx_907_ecustom--GrossProceedsFromConvertibleDebt_c20200728__20200729__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" title="Gross proceeds from convertible debt"><span><ix:nonfraction name="CLCS:GrossProceedsFromConvertibleDebt" contextref="From2020-07-282020-07-29_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-768" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">500,000</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">less $<span id="xdx_902_eus-gaap--DeferredFinanceCostsNet_c20200729__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" title="Debt issuance cost"><span><ix:nonfraction name="us-gaap:DeferredFinanceCostsNet" contextref="AsOf2020-07-29_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-769" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,500</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of issuance costs) which matures on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20200728__20200729__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember" title="Debt maturity date"><span><ix:nonnumeric contextref="From2020-07-282020-07-29_us-gaap_ConvertibleNotesPayableMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="true" id="fact-identifier-770" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">January
    29, 2021</ix:nonnumeric></span></span>. The
    note accrues interest at <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_c20200729__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd" title="Debt instrument interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2020-07-29_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-771" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13</ix:nonfraction></span>%</span> per annum and is <span id="xdx_901_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20200728__20200729__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember" title="Debt conversion, description"><span><ix:nonnumeric contextref="From2020-07-282020-07-29_us-gaap_ConvertibleNotesPayableMember" name="us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature" inside-table="true" id="fact-identifier-772" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">convertible into common stock at the lower of (i) a conversion price of $0.75 per share
    (the “Fixed Conversion Price”) or (ii) in the event of a default, as defined in the note, a conversion price of 65% of
    the lowest volume weighted average price for the ten consecutive trading days ending on the trading day that is immediately prior
    to the applicable conversion date (the “Default Conversion Price”).</ix:nonnumeric></span></span> The Default Conversion Price shall not apply before
    March 29, 2021</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. So long as the convertible
    note is outstanding, upon any issuance by the Company of any equity at an effective price lower than the conversion price (the “Base
    Conversion Price”), then the conversion price shall be reduced to equal such Base Conversion Price. The Company determined
    the embedded conversion option in connection with the Default Conversion Price should not be bifurcated and accounted for as a derivative
    liability. The original issuance discount of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_c20200729__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" title="Debt unamortized discount"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2020-07-29_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-773" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">55,556</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and debt issuance costs of $<span id="xdx_90D_eus-gaap--DeferredFinanceCostsNet_iI_pp0p0_c20200729__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_ziCIKS9zFS43" title="Debt issuance cost"><span><ix:nonfraction name="us-gaap:DeferredFinanceCostsNet" contextref="AsOf2020-07-29_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-774" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,500</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were each recorded as a debt discount and
    will be amortized over the term of the note. In connection to the issuance of the convertible note payable, the Company issued a
    <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20200729__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z5aVd4meZTJi" title="Warrant term::XDX::5"><span style="-sec-ix-hidden: xdx2ixbrl1320"><span><ix:nonnumeric contextref="AsOf2020-07-29_us-gaap_ConvertibleNotesPayableMember" format="ixt-sec:duryear" id="fact-identifier-775" name="us-gaap:WarrantsAndRightsOutstandingTerm" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1320" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">five</ix:nonnumeric></span></span></span>-year immediately vested warrant to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20200729__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd" title="Warrants issued to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-07-29_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-776" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">146,199</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price
    of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200729__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd" title="Warrant exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-07-29_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-777" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.95</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, which may be exercised on a cashless
    basis. The warrant had an issuance date relative fair value of $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20200728__20200729__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" title="Warrants fair value"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2020-07-282020-07-29_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-778" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,098</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
    which was recorded as a debt discount and will amortized over the term of the note.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 28, 2021, the Company issued a convertible note payable in the amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_c20210128__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2021-01-28_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-779" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">647,222</ix:nonfraction></span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which
matures on <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_c20210127__20210128__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember"><span><ix:nonnumeric contextref="From2021-01-272021-01-28_us-gaap_ConvertibleNotesPayableMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="false" id="fact-identifier-780" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">July
28, 2021</ix:nonnumeric></span></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in exchange for another note in the
principal amount of $<span id="xdx_904_eus-gaap--ConvertibleNotesPayable_c20210128__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2021-01-28_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-781" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">555,556</ix:nonfraction></span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
accrued interest at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_c20210128__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2021-01-28_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-782" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13</ix:nonfraction></span>% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
annum and had accrued interest of $<span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_c20210128__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0"><span><ix:nonfraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextref="AsOf2021-01-28_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-783" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,948</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The new note accrues interest at <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20210128__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableNewNoteMember_z8NiXcN3tcml"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2021-01-28_custom_ConvertibleNotesPayableNewNoteMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-784" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
per annum and such interest is payable at maturity, at the Company’s option, in cash or as payment-in-kind in common stock at
a rate of $<span id="xdx_909_eus-gaap--SharePrice_iI_c20210128__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zbBEDegFReSg"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-01-28_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-785" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. The note is convertible at the holder’s option into Series C Convertible Preferred Stock at a price of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210128__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_ztQ0UdLVdNKf"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2021-01-28_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-786" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share and automatically converts into Series C Convertible Preferred Stock on the maturity date. In connection with the issuance of
the convertible note, the Company issued a <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20210128__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zZHVJB1t2XPg" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1335"><span><ix:nonnumeric contextref="AsOf2021-01-28_us-gaap_ConvertibleNotesPayableMember" id="fact-identifier-787" name="us-gaap:WarrantsAndRightsOutstandingTerm" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="xdx2ixbrl1335" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">five</ix:nonnumeric></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
immediately vested warrant to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20210128__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2021-01-28_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-788" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">517,778</ix:nonfraction></span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of common stock at an exercise price $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210128__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-01-28_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-789" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. The warrants had an issuance date fair value of $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20210127__20210128__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2021-01-272021-01-28_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-790" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">106,183</ix:nonfraction></span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
was recognized immediately. The Company determined the transaction was an extinguishment and, as a result, recognized a loss on
extinguishment of notes payable of $<span id="xdx_905_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zJFQmaKS8nvc"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2021-01-012021-12-31_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-791" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">49,718</ix:nonfraction></span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
the consolidated statement of operations during the year ended December 31, 2021. This convertible note payable was converted into
Series C Convertible Preferred Stock during the year ended December 31, 2021. See elsewhere in this note for additional
details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    October 15, 2020, the Company issued a convertible note payable in the principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_c20201015__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" title="Debt instrument, principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-10-15_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-792" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the note accrues interest at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_c20201015__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd" title="Debt instrument interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2020-10-15_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-793" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span>%</span>
    per annum and matures six months from issuance. Interest is payable at maturity at the option of the holder or may be paid at the
    option of the Company is cash or shares of the Company’s common stock at $<span id="xdx_905_eus-gaap--SharePrice_c20201015__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd" title="Share price"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2020-10-15_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-794" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. This note will automatically convert
    on the maturity date into shares of Series B Convertible Preferred Stock at a conversion price of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20201015__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd" title="Debt conversion price"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2020-10-15_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-795" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Company issued a <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20201015__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_znpWv3m7gFgc" title="Warrant term::XDX::5"><span style="-sec-ix-hidden: xdx2ixbrl1349"><span><ix:nonnumeric contextref="AsOf2020-10-15_us-gaap_ConvertibleNotesPayableMember" format="ixt-sec:duryear" id="fact-identifier-796" name="us-gaap:WarrantsAndRightsOutstandingTerm" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1349" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">five</ix:nonnumeric></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
    immediately vested warrant for the purchase of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201015__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd" title="Warrants issued to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-10-15_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-797" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">80,000</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price
    of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201015__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd" title="Warrant exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-10-15_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-798" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The warrant had an issuance date
    relative fair value of $<span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_c20201015__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" title="Debt unamortized discount"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2020-10-15_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-799" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,382</ix:nonfraction></span></span></span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which was recorded as a debt discount and will amortized
    over the term of the note.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    October 20, 2020, the Company issued a convertible note payable in the principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_c20201020__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" title="Debt instrument, principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-10-20_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-800" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the note accrues interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_c20201020__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd" title="Debt instrument interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2020-10-20_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-801" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span>%</span>
    per annum and matures six months from issuance. Interest is payable at maturity at the option of the holder or may be paid at the
    option of the Company is cash or shares of the Company’s common stock at $<span id="xdx_901_eus-gaap--SharePrice_c20201020__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd" title="Share price"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2020-10-20_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-802" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. This note will automatically convert
    on the maturity date into shares of Series B Convertible Preferred Stock at a conversion price of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20201020__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd" title="Debt conversion price"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2020-10-20_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-803" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Company issued a <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20201020__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zIe1FtlalBGg" title="Warrant term::XDX::5"><span style="-sec-ix-hidden: xdx2ixbrl1365"><span><ix:nonnumeric contextref="AsOf2020-10-20_us-gaap_ConvertibleNotesPayableMember" format="ixt-sec:duryear" id="fact-identifier-804" name="us-gaap:WarrantsAndRightsOutstandingTerm" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1365" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">five</ix:nonnumeric></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
    immediately vested warrant for the purchase of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201020__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd" title="Warrants issued to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-10-20_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-805" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,000</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price
    of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201020__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd" title="Warrant exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-10-20_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-806" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The warrant had an issuance date
    relative fair value of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_c20201020__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0" title="Debt unamortized discount"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2020-10-20_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-807" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,194</ix:nonfraction></span></span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which
    was recorded as a debt discount and will amortized over the term of the note.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 27, 2021, the Company amended the following terms of two convertible notes in the aggregate principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_c20210427__us-gaap--DebtInstrumentAxis__custom--TwoConvertibleNotesMember_pp0p0" title="Debt instrument, principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2021-04-27_custom_TwoConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-808" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">:
    (i) the maturity dates were extended to <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20210425__20210427__us-gaap--DebtInstrumentAxis__custom--TwoConvertibleNotesMember" title="Debt maturity date"><span><ix:nonnumeric contextref="From2021-04-252021-04-27_custom_TwoConvertibleNotesMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="true" id="fact-identifier-809" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">October
    15, 2021</ix:nonnumeric></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, (ii) the interest rate was amended
    from <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_c20210427__us-gaap--DebtInstrumentAxis__custom--TwoConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_z7oaz4XOZFo1" title="Debt instrument interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2021-04-27_custom_TwoConvertibleNotesMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-810" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span>%</span>
    per annum to <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_c20210427__us-gaap--DebtInstrumentAxis__custom--TwoConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_z52ADOveqSxa" title="Debt instrument interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2021-04-27_custom_TwoConvertibleNotesMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-811" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span>%</span>
    per annum and (iii) the shares into which the notes may be converted was amended from Series B Preferred Stock to Series C Preferred
    Stock. The Company determined the amendment represented a debt modification.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2021, the notes were converted into Series C Convertible Preferred Stock. See below for details.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    December 11, 2020, the Company issued a convertible note payable in the principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20201211__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-12-11_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-812" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the note accrues interest at <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_c20201211__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2020-12-11_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-813" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span>%
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per annum and matures six months from issuance.
    Interest is payable at maturity at the option of the holder or may be paid at the option of the Company is cash or shares of the
    Company’s common stock at $<span id="xdx_903_eus-gaap--SharePrice_c20201211__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2020-12-11_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-814" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. This note will automatically convert
    on the maturity date into shares of Series C Convertible Preferred Stock at a conversion price of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20201211__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2020-12-11_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-815" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Company issued a <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20201211__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zGMgVmAorpnk" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1384"><span><ix:nonnumeric contextref="AsOf2020-12-11_us-gaap_ConvertibleNotesPayableMember" id="fact-identifier-816" name="us-gaap:WarrantsAndRightsOutstandingTerm" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1384" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">five</ix:nonnumeric></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
    immediately vested warrant for the purchase of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201211__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-12-11_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-817" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,000</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price
    of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201211__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-12-11_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-818" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The warrant had an issuance date
    relative fair value of $<span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_c20201210__20201211__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2020-12-102020-12-11_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-819" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,197</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which was recorded as a debt discount and
    will be amortized over the term of the note.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    December 15, 2020, the Company issued a convertible note payable in the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_c20201215__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-12-15_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-820" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,000</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the note accrues interest at <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_c20201215__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2020-12-15_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-821" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span>%
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per annum and matures six months from issuance.
    Interest is payable at maturity at the option of the holder or may be paid at the option of the Company is cash or shares of the
    Company’s common stock at $<span id="xdx_907_eus-gaap--SharePrice_c20201215__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2020-12-15_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-822" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. This note will automatically convert
    on the maturity date into shares of Series C Convertible Preferred Stock at a conversion price of $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20201215__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2020-12-15_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-823" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Company issued a <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20201215__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zZF80L90xtu3" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1392"><span><ix:nonnumeric contextref="AsOf2020-12-15_us-gaap_ConvertibleNotesPayableMember" id="fact-identifier-824" name="us-gaap:WarrantsAndRightsOutstandingTerm" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1392" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">five</ix:nonnumeric></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
    immediately vested warrant for the purchase of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201215__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-12-15_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-825" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,000</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price
    of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201215__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pdd"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-12-15_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-826" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The warrant had an issuance date
    relative fair value of $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20201210__20201215__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_pp0p0"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2020-12-102020-12-15_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-827" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,009</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which was recorded as a debt discount and
    will be amortized over the term of the note.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    December 15, 2020, the Company issued a convertible note payable in the principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_c20201215__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pp0p0"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-12-15_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-828" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">250,000</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the note accrues interest at <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_c20201215__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pdd"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2020-12-15_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-829" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span>%
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per annum and matures six months from issuance.
    Interest is payable at maturity at the option of the holder or may be paid at the option of the Company is cash or shares of the
    Company’s common stock at $<span id="xdx_906_eus-gaap--SharePrice_c20201215__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pdd"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2020-12-15_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-830" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. This note will automatically convert
    on the maturity date into shares of Series C Convertible Preferred Stock at a conversion price of $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20201215__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pdd"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2020-12-15_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-831" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Company issued a <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20201215__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_zrpV1GFctGrg" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1400"><span><ix:nonnumeric contextref="AsOf2020-12-15_custom_ConvertibleNotesPayableOneMember" id="fact-identifier-832" name="us-gaap:WarrantsAndRightsOutstandingTerm" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1400" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">five</ix:nonnumeric></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
    immediately vested warrant for the purchase of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201215__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pdd"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-12-15_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-833" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price
    of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201215__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pdd"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-12-15_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-834" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The warrant had an issuance date
    relative fair value of $<span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_c20201210__20201215__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pp0p0"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2020-12-102020-12-15_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-835" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,985</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which was recorded as a debt discount and
    will be amortized over the term of the note.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2021, the notes were converted into Series C Convertible Preferred Stock. See below for details.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2021, the Company issued convertible notes payable in the aggregate principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pp0p0"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-836" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,407,820</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which have maturity dates ranging from
    <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateRangeStart1_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_zf5MttC851M7"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_ConvertibleNotesPayableOneMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDateRangeStart1" inside-table="true" id="fact-identifier-837" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">July
    7, 2021</ix:nonnumeric></span></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateRangeEnd1_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_zrOGbSYZDz9e"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_ConvertibleNotesPayableOneMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDateRangeEnd1" inside-table="true" id="fact-identifier-838" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">June
    15, 2022</ix:nonnumeric></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The notes accrue interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pdd"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-839" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span>%
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per annum and are convertible at any time
    at the option of the holder into the Company’s Series C Convertible Preferred Stock at a conversion price of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pdd"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-840" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The notes automatically convert
    into Series C Convertible Preferred Stock on the maturity date. In connection with the issuances, the Company issued <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_zucAdJ9rKud5" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1409"><span><ix:nonnumeric contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableOneMember" id="fact-identifier-841" name="us-gaap:WarrantsAndRightsOutstandingTerm" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1409" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">five</ix:nonnumeric></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year
    immediately vested warrants to purchase an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pdd"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-842" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,926,358</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise
    price $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pdd"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-843" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The warrants had an issuance date
    relative fair value of $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pp0p0"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2021-01-012021-12-31_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-844" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">397,485</ix:nonfraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which will be amortized over the term of
    the notes. Of the notes that were issued during the year (a) notes with principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_z1wv1N8iSDZ3" title="Principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextref="From2021-01-012021-12-31_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-845" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">922,250</ix:nonfraction></span></span> were converted
    during the year ended December 31, 2021 (see elsewhere in this Note for details) and (b) notes with principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20220101__20220415__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3hCBgZDaiZ7"><span><ix:nonfraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextref="From2022-01-012022-04-15_custom_ConvertibleNotesPayableOneMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-846" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,375,698</ix:nonfraction></span></span>
    were converted subsequent to December 31, 2021 (see Note 13 for details).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2021, the certain of these notes were converted into Series C Convertible Preferred Stock. See below
    for details.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2020, a third party repaid the convertible note in full on behalf of the Company, which payment included a prepayment penalty
for an aggregate total payment of $<span id="xdx_90D_eus-gaap--RepaymentsOfConvertibleDebt_pp0p0_c20191215__20200103__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zB87YFSuTdE4" title="Repayments of convertible debt"><span><ix:nonfraction name="us-gaap:RepaymentsOfConvertibleDebt" contextref="From2019-12-152020-01-03_custom_ConvertibleNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-847" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,896</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal and interest of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200103__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zbSVUcUXrom5" title="Debt instrument, principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-01-03_custom_ConvertibleNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-848" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">68,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_904_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20200103__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zMNHQRegP7J9" title="Accrued interest"><span><ix:nonfraction name="us-gaap:InterestPayableCurrent" contextref="AsOf2020-01-03_custom_ConvertibleNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-849" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,896</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively), which was fully repaid by the Company to the third party as of December 31, 2020. The Company determined the transaction
was a note extinguishment and recorded a loss on extinguishment of notes payable of $<span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20191215__20200103__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zWV5CGmNYMv6" title="Gain loss on extinguishment of debt"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2019-12-152020-01-03_custom_ConvertibleNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-850" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,441</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2020, the Company issued a convertible note payable in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_c20200101__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pp0p0" title="Debt instrument, principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-01-01_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-851" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78,000</ix:nonfraction></span></span>. The note accrues interest at <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_c20200101__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pdd" title="Debt instrument interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2020-01-01_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-852" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>%</span> per annum and matures on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20200101__20200110__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember" title="Debt maturity date"><span><ix:nonnumeric contextref="From2020-01-012020-01-10_custom_ConvertibleNotesPayableOneMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="false" id="fact-identifier-853" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">January 10, 2021</ix:nonnumeric></span></span>. <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateTerms_c20200101__20200110__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember" title="Interest rate, description"><span><ix:nonnumeric contextref="From2020-01-012020-01-10_custom_ConvertibleNotesPayableOneMember" name="us-gaap:DebtInstrumentInterestRateTerms" inside-table="false" id="fact-identifier-854" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Any amount of principal or interest which is not paid at maturity shall accrue interest at 22% per annum. The note also includes certain prepayment penalties that provide for payments ranging from 115% to 140% of the then-outstanding principal and interest.</ix:nonnumeric></span></span> <span id="xdx_901_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20200101__20200110__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember" title="Debt conversion, description"><span><ix:nonnumeric contextref="From2020-01-012020-01-10_custom_ConvertibleNotesPayableOneMember" name="us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature" inside-table="false" id="fact-identifier-855" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The note is convertible at the option of the holder into common stock at 61% of the lowest trading price during the ten (10) consecutive trading days prior to the conversion date at any time during the period which is 180 days following the issuance
date of the convertible note and ending on the later of (i) January 10, 2021 or (ii), in the event of default, the date of the payment
of the default amount.</ix:nonnumeric></span></span> The convertible note contained an original issuance discount of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_c20200101__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pp0p0" title="Debt unamortized discount"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2020-01-01_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-856" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,000</ix:nonfraction></span></span> which was recorded as a debt discount and
will be amortized over the term of the note. On July 6, 2020, the Company repaid the convertible note in full, which payment included
a prepayment penalty, for an aggregate total payment of $<span id="xdx_908_eus-gaap--RepaymentsOfNotesPayable_c20200701__20200706__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pp0p0" title="Repayments of notes payable"><span><ix:nonfraction name="us-gaap:RepaymentsOfNotesPayable" contextref="From2020-07-012020-07-06_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-857" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">115,483</ix:nonfraction></span></span> (principal and interest of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_c20200706__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pp0p0" title="Debt instrument, principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-07-06_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-858" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78,000</ix:nonfraction></span></span> and $<span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_c20200706__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_pp0p0" title="Accrued interest"><span><ix:nonfraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextref="AsOf2020-07-06_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-859" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,483</ix:nonfraction></span></span>, respectively). In connection
with the repayment, the Company recorded a loss on extinguishment of notes payable of $<span id="xdx_905_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_zVsY8wfkD5Y7" title="Gain loss on extinguishment of debt"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2021-01-012021-12-31_custom_ConvertibleNotesPayableOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-860" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,511</ix:nonfraction></span></span> in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, convertible notes payable in the aggregate principal amount $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_pp0p0"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-861" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,044,473</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were converted into <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_pdd"><span><ix:nonfraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextref="From2021-01-012021-12-31_custom_ConvertibleNotesPayableTwoMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-862" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">272,592</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series C Convertible Preferred Stock
at an effective conversion price of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_pdd"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableTwoMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-863" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Company elected to convert accrued
interest on the same convertible notes payable in the aggregate amount of $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_pp0p0"><span><ix:nonfraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-864" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">101,168</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">into <span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember__us-gaap--FinancialInstrumentAxis__custom--AccruedInterestMember_zKVwIjPCjQH1"><span><ix:nonfraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextref="From2021-01-012021-12-31_custom_ConvertibleNotesPayableTwoMember_custom_AccruedInterestMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-865" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">134,891</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an effective conversion
price of $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember__us-gaap--FinancialInstrumentAxis__custom--AccruedInterestMember_zqc4vA5Nkvpb"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableTwoMember_custom_AccruedInterestMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-866" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per common share. The Company analyzed the notes
for a beneficial conversion feature and determined that there was none because the notes have an effective conversion price of $<span id="xdx_90A_eus-gaap--SharePrice_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_pdd"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableTwoMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-867" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share of underlying common stock, which exceeds
the $<span id="xdx_903_eus-gaap--SharePrice_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember__srt--RangeAxis__srt--MaximumMember_zNEJ44ESJ2vl"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableTwoMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-868" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.47</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share commitment date fair value of the common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="CLCS:ConvertibleNotesPayableDueToRelatedPartiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-869" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_897_ecustom--ConvertibleNotesPayableDueToRelatedPartiesTableTextBlock_zukbX163pqD7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d)
Convertible notes payable due to related parties consist of the following:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none">&nbsp;<span id="xdx_8BE_z4XP7t76t1pj" style="display: none">Schedule
of Convertible Notes Payable Due to Related Parties</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 68%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">i) <span style="font-family: Times New Roman, Times, Serif">Convertible
    notes issued on May 18, 2017</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td title="Convertible notes payable due to related parties" id="xdx_981_eus-gaap--ConvertibleDebtNoncurrent_iI_pp0p0_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnMayEighteenTwoThousandSeventeenMember_zGocn8NzkW4d" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleDebtNoncurrent" contextref="AsOf2021-12-31_custom_ConvertibleNotesIssuedOnMayEighteenTwoThousandSeventeenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-870" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">225,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td title="Convertible notes payable due to related parties" id="xdx_981_eus-gaap--ConvertibleDebtNoncurrent_iI_pp0p0_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnMayEighteenTwoThousandSeventeenMember_zSDWj6AxfbE3" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ConvertibleDebtNoncurrent" contextref="AsOf2020-12-31_custom_ConvertibleNotesIssuedOnMayEighteenTwoThousandSeventeenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-871" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">225,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">ii) Convertible note issued on
    October 28, 2019, net of debt discount of $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnOctoberTwentyEightTwoThousandNineteenMember_zYWlX39B65D9" title="Debt discount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgRHVlIHRvIFJlbGF0ZWQgUGFydGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextref="AsOf2021-12-31_custom_ConvertibleNotesIssuedOnOctoberTwentyEightTwoThousandNineteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-872" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span> and $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnOctoberTwentyEightTwoThousandNineteenMember_zTRDYzwpWEr8" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIFBheWFibGUgRHVlIHRvIFJlbGF0ZWQgUGFydGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextref="AsOf2020-12-31_custom_ConvertibleNotesIssuedOnOctoberTwentyEightTwoThousandNineteenMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-873" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,317</ix:nonfraction></span></span> as of December 31, 2021 and 2020, respectively</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--ConvertibleDebtNoncurrent_iI_pp0p0_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnOctoberTwentyEightTwoThousandNineteenMember_z1iGeoBK8aqd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleDebtNoncurrent" contextref="AsOf2021-12-31_custom_ConvertibleNotesIssuedOnOctoberTwentyEightTwoThousandNineteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-874" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,500,000</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--ConvertibleDebtNoncurrent_iI_pp0p0_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesIssuedOnOctoberTwentyEightTwoThousandNineteenMember_zYlOQ7OdphJ7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleDebtNoncurrent" contextref="AsOf2020-12-31_custom_ConvertibleNotesIssuedOnOctoberTwentyEightTwoThousandNineteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-875" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,924,683</ix:nonfraction></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">Convertible
    notes</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ConvertibleDebtNoncurrent_iI_pp0p0_c20211231_z0rysQ8RZzG6" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleDebtNoncurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-876" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,725,000</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ConvertibleDebtNoncurrent_iI_pp0p0_c20201231_z33ekam0RFl2" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleDebtNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-877" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,149,683</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  </tbody></table>


</ix:nonnumeric></span><p id="xdx_8A6_zdMQKkx0BYjl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tbody><tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, the Company had accrued an obligation
to issue warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_zdKedwbsVO1j"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-878" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">247,500</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_901_eus-gaap--SharePrice_iI_c20211231_z4AI8G8T7JCe"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-879" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share as a result of the Company’s failure to repay these notes on the May 18, 2018 maturity date. As a result, the Company had
accrued an aggregate of $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210101__20211231_zRNVnqxrQpuk"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-880" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,106</ix:nonfraction></span></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">associated with the fair value of these obligations as of December
31, 2021, which amount is included in accrued interest – related parties on the consolidated balance sheets.</span></td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify">&nbsp;</td>
  <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify">ii)</td>
  <td style="text-align: justify">On March 2, 2020, the Company received further proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_c20200301__20200302__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zwJIoTA20Jr9"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2020-03-012020-03-02_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-881" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span></span> through a previously issued
  convertible note dated October 28, 2019 in the then-principal amount of up to $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20200302__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zcrjeW5LWn7l"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-03-02_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-882" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,500,000</ix:nonfraction></span></span>, such that the Company had received aggregate
  proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromConvertibleDebt_c20200301__20200302__us-gaap--DebtInstrumentAxis__custom--SoaveNoteMember_z4vrOKflPgCk"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2020-03-012020-03-02_custom_SoaveNoteMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-883" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,000,000</ix:nonfraction></span></span> under the convertible note (the “Soave Note”).</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify">&nbsp;</td>
  <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
  <td style="text-align: justify">&nbsp;</td>
  <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On
                                  June 18, 2020, the Company received further proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_c20200615__20200618__us-gaap--DebtInstrumentAxis__custom--SoaveNoteMember_zUW6Nv3HLpD6"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2020-06-152020-06-18_custom_SoaveNoteMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-884" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span></span> under the Soave Note, such that the
                                  Company had now received aggregate proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_c20200615__20200618__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zorAHrUwA9P4"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2020-06-152020-06-18_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-885" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,500,000</ix:nonfraction></span></span> under the convertible note. In connection
                                  with the receipt of these proceeds, the Company issued a five-year immediately vested warrant for the
                                  purchase of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20200618__us-gaap--DebtInstrumentAxis__custom--SoaveNoteMember_zFVrdhCYzQr3"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-06-18_custom_SoaveNoteMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-886" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,200,000</ix:nonfraction></span></span> shares of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200618__us-gaap--DebtInstrumentAxis__custom--SoaveNoteMember_zgiGPytsEV98"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-06-18_custom_SoaveNoteMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-887" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span></span> per share. The warrant had
                                  an issuance date relative fair value of $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20200618__us-gaap--DebtInstrumentAxis__custom--SoaveNoteMember_zKGhqj0S7m8c"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2020-06-18_custom_SoaveNoteMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-888" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">153,790</ix:nonfraction></span></span>, which was recorded as a debt discount and will amortized
                                  over the term of the note. The Soave Note had an original maturity date of <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_c20200615__20200618__us-gaap--DebtInstrumentAxis__custom--SoaveNoteMember_zFGIHIhqa9p1"><span><ix:nonnumeric contextref="From2020-06-152020-06-18_custom_SoaveNoteMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="true" id="fact-identifier-889" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">October 31, 2020</ix:nonnumeric></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">On December 3, 2020,
the Company and Ms. Soave entered into an agreement whereby the maturity date of the note was extended to <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_c20201201__20201203__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember"><span><ix:nonnumeric contextref="From2020-12-012020-12-03_custom_MsSoaveMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="true" id="fact-identifier-890" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">October 31, 2021</ix:nonnumeric></span></span>, the Company
received additional proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromConvertibleDebt_c20201201__20201203__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember_pp0p0"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2020-12-012020-12-03_custom_MsSoaveMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-891" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span></span>, the principal amount was increased to $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_c20201203__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember_pp0p0"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-12-03_custom_MsSoaveMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-892" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,000,000</ix:nonfraction></span></span> and the interest rate was increased from <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_c20201203__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember__srt--RangeAxis__srt--MinimumMember_pdd"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2020-12-03_custom_MsSoaveMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-893" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span></span>%
to <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_c20201203__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember__srt--RangeAxis__srt--MaximumMember_pdd"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2020-12-03_custom_MsSoaveMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-894" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span></span>% (effective on the date of receipt of funds). Lastly, in connection with the amendment, the Company accrued an obligation to issue
a five-year immediately vested warrant for the purchase of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201203__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember_zAaoEjZXzRBe"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-12-03_custom_MsSoaveMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-895" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">400,000</ix:nonfraction></span></span> shares of common stock at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201203__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember_pdd"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-12-03_custom_MsSoaveMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-896" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span></span> per share with
a relative fair value of $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_c20201203__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember_pp0p0"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2020-12-03_custom_MsSoaveMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-897" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82,006</ix:nonfraction></span></span> which was recorded as a debt discount and will be amortized over the term of the note. The obligation
to issue these warrants was included within accrued interest on the consolidated balance sheets as of December 31, 2020. The warrants
were issued in 2021 and had <span style="background-color: white">an issuance date fair value of $<span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_c20201201__20201203__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember_pp0p0"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2020-12-012020-12-03_custom_MsSoaveMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-898" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82,350</ix:nonfraction></span></span>.&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="background-color: white">Ms.
Soave was appointed to the Company’s Board of Directors effective</span> March <span style="background-color: white">25, 2021,
such that she became a related party as of such date and, accordingly, the note was payable to a related party. Effective March </span>2,
<span style="background-color: white">August 5, and December 31,</span> 2021, the Company amended <span style="background-color: white">the
Soave Note.</span> In connection with <span style="background-color: white">the amendments</span>, during the <span style="background-color: white">year
</span>ended <span style="background-color: white">December</span> 31, 2021, the Company (i) received further proceeds of $<span style="background-color: white"><span id="xdx_90C_eus-gaap--ProceedsFromConvertibleDebt_c20210101__20211231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zY4bmYmaBOgh" title="Proceeds from convertible debt"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2021-01-012021-12-31_custom_BoardOfDirectorsMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-899" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,500,000</ix:nonfraction></span></span>,</span>
<span style="background-color: white">such that as of December 31, 2021, an aggregate of $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember_pp0p0"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2021-12-31_custom_MsSoaveMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-900" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,500,000</ix:nonfraction></span></span>&nbsp;of proceeds were outstanding
under the note,</span> (ii) increased the principal amount to $<span style="background-color: white"><span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember_pp0p0"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2021-12-31_custom_MsSoaveMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-901" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,000,000</ix:nonfraction></span></span>, </span>(iii) issued five-year
immediately vested warrants for the purchase of <span style="background-color: white"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember_pdd"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2021-12-31_custom_MsSoaveMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-902" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,200,000</ix:nonfraction></span></span></span> shares of common stock at an exercise
price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember_pdd"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-12-31_custom_MsSoaveMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-903" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span></span> per share that had an issuance date fair value of $<span style="background-color: white"><span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember_pp0p0"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2021-01-012021-12-31_custom_MsSoaveMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-904" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">247,567</ix:nonfraction></span></span> </span>which will be
amortized over the term of the note<span style="background-color: white">, (iv) extended</span> the maturity date to <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_MsSoaveMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="true" id="fact-identifier-905" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">October 28, 2022</ix:nonnumeric></span></span>
<span style="background-color: white">(v)</span> and <span style="background-color: white">provided Ms. Soave </span>the <span style="background-color: white">ability
to</span> elect to convert the <span style="background-color: white">Soave Note</span> into shares of Series B Convertible Preferred
Stock at a conversion price of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsSoaveMember_pdd"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2021-12-31_custom_MsSoaveMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-906" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span></span> per share at any time after the creation of the Series B Convertible Preferred Stock and before
the maturity date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">As of the date of issuance
of the <span style="background-color: white">Soave Note,</span> December 31, 2021 <span style="background-color: white">and </span>through
the date of filing, the Series B Convertible Preferred Stock had not been designated by the Board nor had the Company sold shares of
its Series B Convertible Preferred Stock. As a result, as the definition of a firm commitment had not been met since the note was not
convertible as of its date of issuance or as of December 31, 2021, the Company did not analyze the <span style="background-color: white">Soave
Note’s</span> embedded conversion option to determine if it qualifies as a derivative financial instrument or beneficial conversion
feature.</p>
</td></tr>
</tbody></table>

<!-- Field: Split-Segment; Name: 002 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<ix:exclude><!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-907" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zo0bD4xfSW5l" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
9 – <span id="xdx_82C_zv4sonJlX6Q5">Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-908" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_896_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zVWYZaVH1iZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loss before income taxes consists of the following US and Israeli components:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<span id="xdx_8B4_zDcl6K4C7TP1" style="display: none">Schedule of Income Before Income Taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tbody><tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_zTrxKE1NN82b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&nbsp;</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" id="xdx_497_20200101__20201231_z8RzrNga7oCj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&nbsp;</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td><td>&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOzrfr_zBSCXECNU9J3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">United States</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-909" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,957,487</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-910" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,074,379</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOzrfr_znAemvPv9jd9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Israel</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-911" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">514,947</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-912" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">485,786</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzrfr_zVxGfYHthQRh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Loss before income taxes</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-913" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,472,434</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-914" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,560,165</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8AC_zI8FswhNUAc7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-915" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zsww68gtk2J7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provision for income taxes consists of the following expenses (benefits):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<span id="xdx_8BB_zMQUFNTivjIh" style="display: none">Schedule
of Component of Income Tax Expenses (Benefit)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tbody><tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" id="xdx_490_20210101__20211231_zQUCSpOgLAga" style="font-weight: bold; text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" id="xdx_492_20200101__20201231_zlm5nOEgMAj9" style="text-align: justify">&nbsp;</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td><td>&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zfgtLs5K8We8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax benefit:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pp0p0_maDITEBzT5j_zX2Ae6LlHska" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: justify">Federal</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-916" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">994,748</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-917" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">883,028</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_i01_pp0p0_maDITEBzT5j_zZO7ftUsHMwe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Foreign</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-918" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">118,438</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-919" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">111,731</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pp0p0_maDITEBzT5j_zHNNaVixwWW7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">US State and local</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-920" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">658,716</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-921" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">546,636</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_mtDITEBzT5j_maITEBzpyM_zKkkrTQ7pOFa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Deferred</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-922" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,771,902</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-923" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,541,395</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxExpenseBenefitValuationAllowance_iN_pp0p0_di_msITEBzpyM_z0DM09wcWPdl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="CLCS:IncomeTaxExpenseBenefitValuationAllowance" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-924" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,771,902</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="CLCS:IncomeTaxExpenseBenefitValuationAllowance" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-925" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,541,395</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBzpyM_zlOikRHG3MJj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Provision for income taxes</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1529"><span><ix:nonfraction name="us-gaap:IncomeTaxExpenseBenefit" contextref="From2021-01-01to2021-12-31" id="fact-identifier-926" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1529" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1530"><span><ix:nonfraction name="us-gaap:IncomeTaxExpenseBenefit" contextref="From2020-01-012020-12-31" id="fact-identifier-927" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1530" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A6_zCdgLbGjqrOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-928" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z0v3FRP9E842" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provision for income taxes differs from the United States federal statutory rate as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<span id="xdx_8B0_zVs1tfTFfySk" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tbody><tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" id="xdx_494_20210101__20211231_zVBVWDSFNHhf" style="font-weight: bold; text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" id="xdx_49E_20200101__20201231_zVjObYRbM8p8" style="text-align: justify">&nbsp;</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td><td>&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_zqYVg9zaRMo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Tax expense at the federal statutory rate</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 16%; text-align: right">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-929" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 16%; text-align: right">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-930" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zY1q4uZ2agm5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State and local taxes, net of federal benefit</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-931" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.8</ix:nonfraction></span></td><td style="text-align: left">)%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-932" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.6</ix:nonfraction></span></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_z2sylfdF6sTc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Statutory rate differential - domestic versus foreign</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-933" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span></td><td style="text-align: left">)%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-934" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductions_pid_dp_uPure_zoYADLQVjhob" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Permanent differences</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-935" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0</ix:nonfraction></span></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-936" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.9</ix:nonfraction></span></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_zkZ0IGnoUV16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Research and development tax credits</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-937" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0</ix:nonfraction></span></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-938" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0</ix:nonfraction></span></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_uPure_zMMvVhvMN1vf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Prior period true-up and other</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-939" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.6</ix:nonfraction></span></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-940" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.9</ix:nonfraction></span></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zPPnIDrxUDSh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-941" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32.4</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-942" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33.8</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zDRG2OSabQNc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-943" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-944" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A6_zTFpsH1wNdsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-945" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_891_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zo19GH5PPuXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<span id="xdx_8BA_zkx1w1aEb0m7" style="display: none">Schedule of Deferred Tax Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tbody><tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" id="xdx_494_20211231_zMrOMxo7fgR5" style="font-weight: bold; text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" id="xdx_496_20201231_zZKPZjl5Kr08" style="text-align: justify">&nbsp;</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: justify">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td><td>&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGzkt4_zKRYOb1jr4Y" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Net operating loss carryforwards</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-946" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,950,435</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-947" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,196,269</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGzkt4_zE8RTKKSluIc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Stock-based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-948" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">539,058</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-949" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">424,524</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_maDTAGzkt4_zIZRqxNoJWs" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred foreign research and development expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-950" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,753</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-951" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">54,214</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGzkt4_z3sFpUXm22Be" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Research and development tax credits</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1569"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextref="AsOf2021-12-31" id="fact-identifier-952" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1569" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">&nbsp;</ix:nonfraction></span></span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-953" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">69,337</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGzkt4_maDTANzMHM_z9KBUk4xtvR7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Deferred tax assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGross" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-954" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,516,246</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGross" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-955" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,744,344</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzMHM_z0OmZ51Ul3te" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-956" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,516,246</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-957" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,744,344</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzMHM_zQfrVF7MiPd9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1578"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsNet" contextref="AsOf2021-12-31" id="fact-identifier-958" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1578" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1579"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsNet" contextref="AsOf2020-12-31" id="fact-identifier-959" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1579" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8AB_zckcbq0zknoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and 2020, the Company had approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231_zvKyf6EIrXz4" title="Operating loss carryforwards"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-960" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,500,000</ix:nonfraction></span></span> and $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20201231_z9nVApv7MFOb" title="Operating loss carryforwards"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-961" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,400,000</ix:nonfraction></span></span> of domestic federal, state and local net operating
loss carryforwards (“NOLs”), respectively, that may be available to offset future taxable income in that jurisdiction. Approximately
$<span id="xdx_903_ecustom--OperatingLossCarryforwardsSubjectToExpiration_iI_pp0p0_c20211231_z7S8g5pJ9MYk" title="Operating loss carryforwards subject to expiration"><span><ix:nonfraction name="CLCS:OperatingLossCarryforwardsSubjectToExpiration" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-962" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,000,000</ix:nonfraction></span></span> of those NOLs from both periods will expire during the years ranging from 2034 to 2037. The balances of approximately $<span id="xdx_903_ecustom--OperatingLossCarryforwardsNotSubjectToExpiration_iI_pp0p0_c20211231_zWI7wlS8njXk" title="Operating loss carryforwards not subject to expiration"><span><ix:nonfraction name="CLCS:OperatingLossCarryforwardsNotSubjectToExpiration" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-963" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">12,500,000</ix:nonfraction></span></span>
and $<span id="xdx_90E_ecustom--OperatingLossCarryforwardsNotSubjectToExpiration_iI_pp0p0_c20201231_zhksHge4h1Dj" title="Operating loss carryforwards not subject to expiration"><span><ix:nonfraction name="CLCS:OperatingLossCarryforwardsNotSubjectToExpiration" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-964" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7,400,000</ix:nonfraction></span></span> for the years ended December 31, 2021 and 2020, respectively, have no expiration dates for federal and local purposes,
but expire in 2038 to 2041 for state purposes. The utilization of NOLs to offset future taxable income may be subject to annual limitations
under Internal Revenue Code Section 382 and similar state and local statutes as a result of ownership changes that could occur in the
future. As of December 31, 2021 and 2020, the Company had approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zwMgVFo8smye" title="Operating loss carryforwards"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2021-12-31_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-965" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,500,000</ix:nonfraction></span></span> and $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20201231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zTSZXy79Bes8" title="Operating loss carryforwards"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2020-12-31_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-966" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,900,000</ix:nonfraction></span></span> of Israeli NOLs, respectively, that
may be available to offset future taxable income in that jurisdiction. Those NOLs have no expiration dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has assessed the likelihood that deferred tax assets will be realized in accordance with the provisions of ASC 740 <i>Income
Taxes</i> (“ASC 740”). ASC 740 requires that such a review considers all available positive and negative evidence, including
the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. ASC 740 requires that
a valuation allowance be established when it is “more likely than not” that all, or a portion of, deferred tax assets will
not be realized. After the performance of such reviews as of December 31, 2021 and 2020, management believes that uncertainty exists
with respect to future realization of its deferred tax assets and has, therefore, established a full valuation allowance as of those
dates. Thus, the Company increased the valuation allowance by $<span id="xdx_906_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pp0p0_c20210101__20211231_zIvuxpTCpPl9" title="Change in valuation allowance"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-967" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,771,902</ix:nonfraction></span></span> and $<span id="xdx_905_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pp0p0_c20200101__20201231_z8crvtlDH5B9" title="Change in valuation allowance"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-968" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,541,395</ix:nonfraction></span></span> during the years ended December 31, 2021 and
2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated and concluded that there were <span id="xdx_905_eus-gaap--LiabilityForUncertainTaxPositionsCurrent_iI_do_c20211231_zYlbv6hnWdLi" title="Uncertain tax positions"><span id="xdx_901_eus-gaap--LiabilityForUncertainTaxPositionsCurrent_iI_do_c20201231_zkI5ZzpIL0G4" title="Uncertain tax positions"><span><ix:nonfraction name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-969" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextref="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-970" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></span></span> material uncertain tax positions requiring recognition in the Company’s consolidated
financial statements as of December 31, 2021 and 2020. The Company does <span id="xdx_905_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20211231_zUWxDkauS2hl" title="Unrecognized tax benefits"><span id="xdx_90E_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20201231_z9jOIqbm74D" title="Unrecognized tax benefits"><span><ix:nonfraction name="us-gaap:UnrecognizedTaxBenefits" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-971" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:UnrecognizedTaxBenefits" contextref="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-972" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></span></span>t expect any significant changes in its unrecognized tax benefits
within twelve months of the reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company’s domestic federal tax returns remain subject to audit, beginning with the 2016 tax returns. The Company intends to file
its Israeli tax returns for the years ended December 31, 2014 through 2021. No tax audits were commenced or were in process during the
years ended December 31, 2021 and 2020.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-973" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zl9q0iCe8GJ8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
10 – <span id="xdx_821_zpYzKDhv5eoa">Stockholders’ Deficiency</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Authorized
Capital</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the Company was authorized to issue <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zJlsGBoEgDV8" title="Common stock, shares authorized"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-974" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, par value of $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zhoWo4dvcF8b" title="Common stock, par value"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-975" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, and <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zZgISVZaU9Gc" title="Preferred stock, shares authorized"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-976" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of preferred stock, par value of $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zDTOg5buqVbk" title="Preferred stock, par value"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-977" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The holders of the Company’s
common stock are entitled to one vote per share. The preferred stock was designated as <span id="xdx_900_ecustom--ConvertiblePreferredStockSharesDesignated_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_pdd" title="Preferred stock, shares designated"><span><ix:nonfraction name="CLCS:ConvertiblePreferredStockSharesDesignated" contextref="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-978" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,335,000</ix:nonfraction></span></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series A Convertible Preferred Stock
and <span id="xdx_902_ecustom--ConvertiblePreferredStockSharesDesignated_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_pdd" title="Preferred stock, shares designated"><span><ix:nonfraction name="CLCS:ConvertiblePreferredStockSharesDesignated" contextref="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-979" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">500,000</ix:nonfraction></span></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series C Convertible Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Common
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company issued an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--ConsultingServicesMember_zREoajK6kO8h" title="Stock issued during period for services, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextref="From2020-01-012020-12-31_custom_ConsultingServicesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-980" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,295,671</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock with an issuance date
fair value of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--ConsultingServicesMember_zFJRWwcUr3pg" title="Stock issued during period for services, value"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2020-01-012020-12-31_custom_ConsultingServicesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-981" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">323,918</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to service providers in connection with consulting
services provided. In connection with the issuances, the Company expects to recognize the fair value of the common stock over the service
period, such that it recognized stock-based compensation expense of $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--ConsultingServicesMember_zrhJNRw1w311" title="Share based compensation expense"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-01-012020-12-31_custom_ConsultingServicesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-982" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">323,918</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">during the year ended December 31, 2020, which
amount was included within general and administrative expenses on the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company issued an aggregate of <span id="xdx_901_ecustom--StockIssuedDuringPeriodForAccruedInterestShares_pp0d_c20200101__20201231_zkh396L0HzTf" title="Stock issued during period for accrued interest, shares"><span><ix:nonfraction name="CLCS:StockIssuedDuringPeriodForAccruedInterestShares" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-983" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">265,534</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock with a fair value of $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodForAccruedInterestValue_iI_pp0p0_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWb6qK6uTXX" title="Stock issued during period for accrued interest, value"><span><ix:nonfraction name="CLCS:StockIssuedDuringPeriodForAccruedInterestValue" contextref="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-984" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">66,649</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in exchange for accrued interest in the aggregate
amount of $<span id="xdx_906_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20201231_zEzq8Kkc1CHc" title="Accrued interest"><span><ix:nonfraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-985" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">199,151</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company recognized the difference of $<span id="xdx_902_ecustom--GainOnExchangeOfAccruedInterestForCommonStock_pp0p0_c20200101__20201231_zVh29ZX9DUo9" title="Gain on exchange of accrued interest for common stock"><span><ix:nonfraction name="CLCS:GainOnExchangeOfAccruedInterestForCommonStock" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-986" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">132,502</ix:nonfraction></span></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a gain on forgiveness of accrued interest
for common stock on the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2020, Yeda exercised a warrant to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201026__us-gaap--RelatedPartyTransactionAxis__custom--YedaMember_zNqm9iYh9God" title="Warrants to purchase common stock, shares"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-10-26_custom_YedaMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-987" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,995,376</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201102__us-gaap--RelatedPartyTransactionAxis__custom--YedaMember_zoWNZkFcjUda" title="Warrant exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-11-02_custom_YedaMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-988" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share for proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20201025__20201102__us-gaap--RelatedPartyTransactionAxis__custom--YedaMember_zNKLaC4EGxtl" title="Proceeds from warrant exercised"><span><ix:nonfraction name="us-gaap:ProceedsFromWarrantExercises" contextref="From2020-10-252020-11-02_custom_YedaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-989" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,995</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which resulted in the issuance of <span id="xdx_90F_ecustom--StockIssuedDuringPeriodForWarrantExerciseShares_c20201025__20201102__us-gaap--RelatedPartyTransactionAxis__custom--YedaMember_znREzTcTbxm8" title="Stock issued during period for warrant exercise, shares"><span><ix:nonfraction name="CLCS:StockIssuedDuringPeriodForWarrantExerciseShares" contextref="From2020-10-252020-11-02_custom_YedaMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-990" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,995,376</ix:nonfraction></span></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantMember_zR3D8oU4cOn1" title="Stock issued during period for share based compensation, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextref="From2021-01-012021-12-31_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-991" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,099</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock to a consultant in satisfaction
of accrued compensation with an issuance date fair value of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantMember_zAWjICh9OZ1i" title="Stock issued during period for share based compensation, value"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextref="From2021-01-012021-12-31_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-992" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,097</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantMember_zIBFsd6dEi61" title="Stock issued during period, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-01-012021-12-31_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-993" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">155,405</ix:nonfraction></span></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock to consultants which had
an issuance date fair value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantMember_z0sHkBi7RYAg" title="Stock issued during period, value"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-994" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">73,040</ix:nonfraction></span></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which was recognized immediately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__srt--TitleOfIndividualAxis__custom--NoteholderMember_zwOZZ96muNOg" title="Stock issued during period, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-01-012021-12-31_custom_NoteholderMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-995" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,071</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock pursuant to a cashless
warrant exercise by a noteholder of warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231__srt--TitleOfIndividualAxis__custom--NoteholderMember_zKMw1kdkbnOc" title="Warrants to purchase common stock, shares"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2021-12-31_custom_NoteholderMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-996" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">221,275</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__srt--TitleOfIndividualAxis__custom--NoteholderMember_zq6OGoN4Ciek" title="Warrant exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-12-31_custom_NoteholderMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-997" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued <span id="xdx_904_ecustom--ConversionOfAccruedInterestInCommonStockShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5O7BpiEtLX3" title="Conversion of accrued interest in common stock, shares"><span><ix:nonfraction name="CLCS:ConversionOfAccruedInterestInCommonStockShares" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-998" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">134,891</ix:nonfraction></span></span> shares of common stock in connection with the conversion of accrued interest.
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 8, <i>Notes Payable and Convertible
Notes Payable </i>for additional details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 10, <i>Stockholders’ Deficiency – Series A Convertible Preferred Stock</i> for details associated with the issuance
of common stock in satisfaction of preferred stock dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 10, <i>Stockholder’s Deficiency – Series C Convertible Preferred Stock</i> for details associated with the issuance
of common stock upon conversion of preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
A Convertible Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 29, 2020, the Board of Directors extended the expiration date of the Private Placement Memorandum (“PPM”) to March
31, 2020 and has authorized two sixty-day extensions beyond that date at management’s discretion, under which the Company continues
to raise up to $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0d_c20200129__20200331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--PlanNameAxis__custom--PrivatePlacementMemorandumMember_zKivfGXmDehi" title="Convertible preferred stock, value"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextref="From2020-01-292020-03-31_custom_SeriesAConvertiblePreferredStockMember_custom_PrivatePlacementMemorandumMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-999" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">via the sale of up to <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200129__20200331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--PlanNameAxis__custom--PrivatePlacementMemorandumMember_ztGNctiR1w99" title="Convertible preferred stock, shares"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2020-01-292020-03-31_custom_SeriesAConvertiblePreferredStockMember_custom_PrivatePlacementMemorandumMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1000" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,333,333</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series A Convertible Preferred Stock
at $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20200331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--PlanNameAxis__custom--PrivatePlacementMemorandumMember_zDI4txYxCNgj" title="Convertible preferred stock, par value"><span><ix:nonfraction name="us-gaap:SharesIssuedPricePerShare" contextref="AsOf2020-03-31_custom_SeriesAConvertiblePreferredStockMember_custom_PrivatePlacementMemorandumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1001" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. On March 25, 2020, the Board of Directors
extended the expiration date of the PPM to May 30, 2020. On May 27, 2020, the Board of Directors extended the expiration date of the
PPM to July 29, 2020. On July 27, 2020, the Company’s PPM was now fully subscribed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company received aggregate proceeds of $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20200101__20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zt3R16hqNeq9" title="Sale of stock transaction amount"><span><ix:nonfraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextref="From2020-01-012020-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1002" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">728,347</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the sale of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pp0d_c20200101__20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zuhTtEUvp0id" title="Sale of conversion shares"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2020-01-012020-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-1003" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">97,112</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series A Convertible Preferred Stock
at $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zl3dnQPQrPod" title="Sale of stock price per share"><span><ix:nonfraction name="us-gaap:SaleOfStockPricePerShare" contextref="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1004" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 1, 2020, there was an accrued dividend payable of $<span id="xdx_90A_ecustom--AccruedDividendPayable_iI_c20200101_zPIu5COJbrna" title="Accrued dividend payable"><span><ix:nonfraction name="CLCS:AccruedDividendPayable" contextref="AsOf2020-01-01" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1005" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25,210</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
During the year ended December 31, 2020, the Company accrued additional preferred dividends of $<span id="xdx_904_eus-gaap--DividendsPreferredStock_c20200101__20201231_zApdBkpUkFmk" title="Additional accrued dividend payable"><span><ix:nonfraction name="us-gaap:DividendsPreferredStock" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1006" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">877,736</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and issued <span id="xdx_907_ecustom--CommonStockAccruedDividendIssued_iI_c20201231_zLWLJxprSu88" title="Accrued dividend issued"><span><ix:nonfraction name="CLCS:CommonStockAccruedDividendIssued" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1007" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,152,568</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at $<span id="xdx_903_ecustom--AdditionalAccruedDividendParValue_iI_c20201231_zZoVBaHq2sw5" title="Additional accrued dividend par value"><span><ix:nonfraction name="CLCS:AdditionalAccruedDividendParValue" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1008" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share pursuant to the terms of the Series
A Convertible Preferred Stock Certificate of Designation with a value of $<span id="xdx_90E_ecustom--AccruedDividendDesignation_pp0p0_c20200101__20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zKHyAGdVPj15" title="Accrued dividend designation, value"><span><ix:nonfraction name="CLCS:AccruedDividendDesignation" contextref="From2020-01-012020-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1009" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">864,371</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
such that there was an accrued dividend payable as of December 31, 2020 of $<span id="xdx_90B_ecustom--AccruedDividendPayable_iI_c20201231_ztHhbBtY6zne" title="Accrued dividend payable"><span><ix:nonfraction name="CLCS:AccruedDividendPayable" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1010" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25,210</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
During the year ended December 31, 2021, the Company accrued additional preferred dividends of $<span id="xdx_901_eus-gaap--DividendsPreferredStock_c20210101__20211231_zPJcRm60lR77" title="Additional accrued dividend payable"><span><ix:nonfraction name="us-gaap:DividendsPreferredStock" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1011" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">905,975</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and issued <span id="xdx_905_ecustom--CommonStockAccruedDividendIssued_iI_c20211231_zQ2jOxhA8359" title="Accrued dividend issued"><span><ix:nonfraction name="CLCS:CommonStockAccruedDividendIssued" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1012" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,241,669</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at $<span id="xdx_90E_ecustom--AdditionalAccruedDividendParValue_iI_c20211231_zVT5iVFP4ypd" title="Additional accrued dividend par value"><span><ix:nonfraction name="CLCS:AdditionalAccruedDividendParValue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1013" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share pursuant to the terms of the Series
A Convertible Preferred Stock Certificate of Designation with a value of $<span id="xdx_902_ecustom--AccruedDividendDesignation_pp0p0_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zC8LxqPk94Z3" title="Accrued dividend designation, value"><span><ix:nonfraction name="CLCS:AccruedDividendDesignation" contextref="From2021-01-012021-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1014" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">931,186</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
such that there was no accrued dividend payable as of December 31, 2021 related to the Series A Convertible Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
C Convertible Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 26, 2021, the Company’s Board of Directors approved the designation of <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20210726__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zIFQLF7KQdri" title="Preferred stock designation, shares"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-07-26_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1015" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20210726_zbARZi8nuEI6" title="Preferred stock, authorized shares"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-07-26" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1016" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorized shares of preferred stock as Series
C Convertible Preferred Stock, par value $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210726__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zUzWusH9uV32" title="Preferred stock, par value"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-07-26_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1017" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. On July 26, 2021, the Company filed
the Certificate of Designation with the State of Nevada related to the Series C Preferred Stock. The Series C Preferred stock has a stated
value of $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210726__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z7ToUFCwbufb" title="Preferred stock, par value"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-07-26_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1018" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion.
</i>Each share of Series C Preferred Stock is convertible into shares of common stock (subject to adjustment as provided in the related
certificate of designation of preferences, rights and limitations) at the option of the holder at any time. The number of shares of common
stock which are issuable upon conversion of the Series C Preferred Stock shall be equal to the number of shares of Series C Preferred
Stock to be converted, multiplied by the stated value of $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210726__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z7gV0E1twIoa" title="Preferred stock, par value"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-07-26_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1019" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, divided by the conversion price in
effect at the time of conversion, initially at $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210726__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_z77ppusm8na6"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2021-07-26_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1020" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Mandatory
Conversion. </i>On the earlier of (i) July 27, 2025 or (ii) any of the Company’s treatment candidates receiving approval from the
U.S. or European agencies, all of the outstanding shares of Series C Preferred Stock will automatically convert to common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation
Preference.</i> In the event of the liquidation, dissolution or winding-up of the Company, the Series C Preferred Stock will rank senior
to common stock and any other class of capital stock which does not expressly rank senior to or pari passu with the Series C Preferred
Stock and will rank pari passu with the Series A and Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting
Rights.</i> <span id="xdx_904_eus-gaap--PreferredStockVotingRights_c20210724__20210726__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zbXAFtUl5iF2" title="Preferred stock voting rights, description"><span><ix:nonnumeric contextref="From2021-07-242021-07-26_custom_SeriesCConvertiblePreferredStockMember" name="us-gaap:PreferredStockVotingRights" inside-table="false" id="fact-identifier-1021" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The
holders of Series C Preferred Stock have the right to vote on any matter submitted to a vote of holders of common stock, voting together
with the common stock as one class, on an as-converted basis</ix:nonnumeric></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends.
</i><span id="xdx_903_eus-gaap--PreferredStockDividendPaymentTerms_c20210724__20210726__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zuzXJPMPekh9" title="Preferred Stock, Dividend Payment Terms"><span><ix:nonnumeric contextref="From2021-07-242021-07-26_custom_SeriesCConvertiblePreferredStockMember" name="us-gaap:PreferredStockDividendPaymentTerms" inside-table="false" id="fact-identifier-1022" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Holders
of shares of Series C Preferred Stock will be entitled to receive cumulative dividends at an annual rate of <span id="xdx_90A_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20210724__20210726__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zrBx9AP1GzKd" title="Preferred stock devidend, percentage" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction name="us-gaap:PreferredStockDividendRatePercentage" contextref="From2021-07-242021-07-26_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-1023" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span></span></ix:nonnumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the stated value. Dividends are payable semi-annually on June 30 and December 31, commencing on December 31, 2022, either by (i) issuance
of shares of common stock at the rate of $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210726_zYcfDcooqgQh" title="Issuance of shares of common stock rate, per share"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-07-26" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1024" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span></span> per share of common stock or (ii) in cash, at the Company’s option.</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zUg2OTLJbavi" title="Number of shares converted"><span><ix:nonfraction name="us-gaap:ConversionOfStockSharesConverted1" contextref="From2021-01-012021-12-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1025" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series C Preferred Stock were converted
into <span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zt5QAVRkpLa2" title="Shares issued upon conversion"><span><ix:nonfraction name="us-gaap:ConversionOfStockSharesIssued1" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1026" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at the shareholder’s
election. The Company analyzed the Series C Preferred Stock for a beneficial conversion feature and determined that there was none because
the Series C Preferred Stock has an effective conversion price of $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_z8sigXkeH0B2"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1027" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share of underlying common stock, which exceeds
the $<span id="xdx_906_ecustom--CommitmentDateFairValueOfCommonStock_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvFwr8G8PGlg" title="Commitment date fair value of common stock"><span><ix:nonfraction name="CLCS:CommitmentDateFairValueOfCommonStock" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1028" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.47</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share commitment date fair value of the common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company accrued additional preferred dividends of $<span id="xdx_903_eus-gaap--DividendsPayableCurrent_iI_c20211231_zRRjvYgCmFph" title="Additonal preferred dividends payable"><span><ix:nonfraction name="us-gaap:DividendsPayableCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1029" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">67,229</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">related to the Series C Convertible Preferred
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued <span id="xdx_90F_eus-gaap--ConversionOfStockSharesIssued1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zS9DpHSTQQwg" title="Preferred stock shares issued"><span><ix:nonfraction name="us-gaap:ConversionOfStockSharesIssued1" contextref="From2021-01-012021-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1030" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">272,592</ix:nonfraction></span></span> shares of Series C Convertible Preferred Stock in connection</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
with conversions of notes payable into Series C Convertible Preferred Stock. See Note 8,&nbsp;<i>Notes Payable – Convertible
Notes Payable&nbsp;</i>for additional details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equity
Incentive Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 13, 2019, the Company’s Board of Directors approved the adoption of the Company’s 2019 Equity Incentive Plan (the
“Plan”). A total of <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pp0d_c20190813_zoyTc48cZ6Di" title="Common stock are reserved for issuance under the Plan"><span><ix:nonfraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextref="AsOf2019-08-13" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-1031" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,900,000</ix:nonfraction></span></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock are reserved for issuance under the
Plan, which permits the Board of Directors to issue stock options, stock appreciation rights, restricted stock, restricted stock units,
performance and other awards to employees, consultants and directors of the Company. As of the date of filing, the Company’s shareholders
have not approved the Plan. As of December 31, 2021, a total of <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pp0d_c20211231_zbFvaleebNj2" title="Common stock are reserved for issuance under the Plan"><span><ix:nonfraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-1032" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,506,450</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares were available for future issuance
under the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stock-Based
Compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company recognized stock-based compensation expense of $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20211231_z7yqLF7wljyh"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1033" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">419,401</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(consisting of expense related to common stock,
options and warrants of $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwSuwccqASG8"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1034" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,956</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(of which, $<span id="xdx_908_ecustom--ShareBasedCompensationIncludedInStockholdersDeficiency_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMXp47KvvHvl"><span><ix:nonfraction name="CLCS:ShareBasedCompensationIncludedInStockholdersDeficiency" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1035" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">73,040</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">has been included within stockholder’s
deficiency and $(<span id="xdx_900_ecustom--AccruedCompensation_iI_pp0p0_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmCUQUJQnAhe"><span><ix:nonfraction name="CLCS:AccruedCompensation" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1036" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20,084</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
has been included within accrued compensation), $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztQnibddvif5"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1037" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">206,400</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYj5ELMrIxHk"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember24399703" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1038" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">160,045</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(of which, $<span id="xdx_90D_ecustom--ShareBasedCompensationIncludedInStockholdersDeficiency_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztyBIeDNP7vj"><span><ix:nonfraction name="CLCS:ShareBasedCompensationIncludedInStockholdersDeficiency" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember24399703" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1039" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">163,609</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">has been included within stockholder’s
deficiency and $(<span id="xdx_908_ecustom--AccruedCompensation_iI_pp0p0_c20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zHBWDg7aPRc8"><span><ix:nonfraction name="CLCS:AccruedCompensation" contextref="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1040" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,564</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
has been included within accrued compensation), respectively). During the year ended December 31, 2020, the Company recognized stock-based
compensation expense of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20201231_zLyPKaoINbg6"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1041" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">791,668</ix:nonfraction></span></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(consisting of expense related to common stock, options and
warrants of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKdgx4dWj3H5"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1042" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">356,510</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
$<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLVWChQNzcS6"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-01-012020-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1043" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">115,800</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEAIkRaGCG9a"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-01-012020-12-31_us-gaap_WarrantMember24399828" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1044" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">319,358</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively). See Note 6, <i>Accrued Compensation</i> for additional details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z5FtiWkf5Cgk"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1045" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">419,401</ix:nonfraction></span></span> of stock-based compensation expense was included within general and administrative
expenses and $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zhUWpfNQN7bl"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1046" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span> was included within research and development on the consolidated statement of operations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
During the year ended December
31, 2020, $<span id="xdx_906_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zz6O68PrrnZk"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1047" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">791,668</ix:nonfraction></span></span> of stock-based compensation expense was included within general and administrative expenses and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zRkrahZIB2bk"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1048" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span> was included within
research and development on the consolidated statement of operations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, there was $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20211231_zhyXqY3yK5i3" title="Unrecognized stock based compensation expense"><span><ix:nonfraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1049" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,372</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of unrecognized stock-based compensation
expense to be recognized over a weighted average period of <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20211231_zHdoIsH3Uc2" title="Unrecognized stock based compensation expense, years"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" inside-table="false" id="fact-identifier-1050" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.13</ix:nonnumeric></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stock
Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 13, 2020, the Company issued five-year placement agent warrants to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0d_c20200213__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z91fOlAsrVeb" title="Warrant to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-02-13_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-1051" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">66,653</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200213__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMTC83eGRnH9" title="Exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-02-13_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1052" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share in satisfaction of accrued liabilities
of $<span id="xdx_90E_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20200213__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zvSOKSJk9Ntg"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2020-02-13_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1053" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,907</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that were earned in connection with the sale
of Series A Convertible Preferred Stock during the year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 20, 2020, the Company issued a five-year warrant to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200520__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zt7B00o1CWm8" title="Warrant to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-05-20_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1054" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200520__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUXoJCecVvVi" title="Exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-05-20_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1055" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to a service provider in connection
with consulting services to be provided. The warrant had an issuance date fair value of $<span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20200518__20200520__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zujp1W07vAuf" title="Fair value of warrant"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2020-05-182020-05-20_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1056" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,129</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
In connection with the issuance, the Company expects to recognize the fair value of the warrants over the service period, such that it
recognized stock-based compensation expense of $<span id="xdx_906_eus-gaap--ShareBasedCompensation_pp0p0_c20200518__20200520__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zktbS3hBgXzb" title="Stock-based compensation expense"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-05-182020-05-20_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1057" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,322</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">during the year ended December 31, 2020, which
amount was included within general and administrative expenses on the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 19, 2020, the Company issued five-year immediately vested warrants to purchase an aggregate of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0d_c20200819__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTHPLKvilTy" title="Warrant to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-08-19_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-1058" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,598,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200819__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfmEh7wKO2U6" title="Exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-08-19_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1059" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to members of the Company’s Scientific
Advisory Board. The warrants had an aggregate issuance date fair value of $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20200817__20200819__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdarrOgThOlb" title="Value of shares reserved for future issuance"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2020-08-172020-08-19_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1060" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">257,700</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which was recognized immediately within general
and administrative expenses on the consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 20, 2020, the Company issued a five-year warrant to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200820__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMiJQRhI93R5" title="Warrant to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-08-20_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1061" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200820__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVNY3hcXCiEj" title="Exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-08-20_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1062" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to a service provider in connection
with consulting services to be provided. The warrant vests in equal monthly installments during the sixteen-month period commencing one
month after the date of the issuance. The warrant had an issuance date fair value of $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20200817__20200820__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1OsnMbrF52g" title="Fair value of warrant"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2020-08-172020-08-20_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1063" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,200</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which will be recognized over the service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 15, 2020, the Company issued a five-year warrant to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201015__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z07oOyLKgCz5" title="Warrant to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-10-15_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1064" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201015__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLItYu0XQ991" title="Exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-10-15_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1065" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to a service provider in connection
with consulting services to be provided. The warrant vests in equal monthly installments during the sixteen-month period commencing one
month after the date of the issuance. The warrant had an issuance date fair value of $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20201013__20201015__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztByOu1JlXob" title="Fair value of warrant"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2020-10-132020-10-15_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1066" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57,300</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which will be recognized over the service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 19, 2020, the Company issued a five-year warrant to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0d_c20201119__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAxbuWgVKAL1" title="Warrant to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-11-19_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-1067" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201119__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zldjs6kdHI7e" title="Exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-11-19_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1068" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to a service provider in connection
with consulting services to be provided. <span id="xdx_901_ecustom--DescriptionOfWarrants_c20201101__20201119__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOgrPNdX2aT" title="Description of warrants"><span><ix:nonnumeric contextref="From2020-11-012020-11-19_us-gaap_WarrantMember" name="CLCS:DescriptionOfWarrants" inside-table="false" id="fact-identifier-1069" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100,000
warrants vest on December 1, 2020 and the remaining 100,000 warrants vest in equal monthly installments during the twelve-month period
commencing on January 1, 2021</ix:nonnumeric></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The warrant had
an issuance date fair value of $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20201117__20201119__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyM42nVFKxvk" title="Fair value of warrant"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2020-11-172020-11-19_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1070" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57,400</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which will be recognized over the service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company issued a five-year warrant to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201231__us-gaap--AwardDateAxis__custom--DecemberOneTwoThousandTwentyMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zt47oybNWs0k" title="Warrant to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-12-31_custom_DecemberOneTwoThousandTwentyMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1071" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__us-gaap--AwardDateAxis__custom--DecemberOneTwoThousandTwentyMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmR7Z2Uma3Q6" title="Exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-12-31_custom_DecemberOneTwoThousandTwentyMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1072" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to a service provider in connection
with consulting services to be provided. The warrant vests in equal monthly installments during the sixteen-month period commencing one
month after the date of the issuance. The warrant had an issuance date fair value of $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20201201__20201231__us-gaap--AwardDateAxis__custom--DecemberOneTwoThousandTwentyMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztwUfJ0BHFAl" title="Fair value of warrant"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2020-12-012020-12-31_custom_DecemberOneTwoThousandTwentyMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1073" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">43,000</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which will be recognized over the service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 5, 2021, the Company issued a five-year immediately vested warrant to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210105__us-gaap--AwardDateAxis__custom--JanuaryFiveTwoThousandTwentyOneMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAtcP96hM33c" title="Warrant to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2021-01-05_custom_JanuaryFiveTwoThousandTwentyOneMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1074" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210105__us-gaap--AwardDateAxis__custom--JanuaryFiveTwoThousandTwentyOneMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3DmteeWWW95" title="Exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-01-05_custom_JanuaryFiveTwoThousandTwentyOneMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1075" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.95</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to a note holder in satisfaction of
certain noteholder rights. The warrant had an issuance date fair value of $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210103__20210105__us-gaap--AwardDateAxis__custom--JanuaryFiveTwoThousandTwentyOneMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjwIuRyJJf9j" title="Fair value of warrant"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2021-01-032021-01-05_custom_JanuaryFiveTwoThousandTwentyOneMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1076" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,545</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which was recognized immediately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued a five-year immediately vested warrant to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231__us-gaap--AwardDateAxis__custom--DecemberThirtyFirstTwoThousandTwentyOneMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrqFfc2oMfUb" title="Warrant to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2021-12-31_custom_DecemberThirtyFirstTwoThousandTwentyOneMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1077" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--AwardDateAxis__custom--DecemberThirtyFirstTwoThousandTwentyOneMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7RGeAzXlbZh" title="Exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-12-31_custom_DecemberThirtyFirstTwoThousandTwentyOneMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1078" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to a consultant for services provided
to the Company. The warrant had an issuance date fair value of $<span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210101__20211231__us-gaap--AwardDateAxis__custom--DecemberThirtyFirstTwoThousandTwentyOneMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zm4Gul1Hu3o7" title="Fair value of warrant"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2021-01-012021-12-31_custom_DecemberThirtyFirstTwoThousandTwentyOneMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1079" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,200</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which was recognized immediately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2021, the Company extended the expiration date of a warrant to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210831__us-gaap--AwardDateAxis__custom--AugustTwoThousandTwentyOneMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMIhX0n3LLnb" title="Warrant to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2021-08-31_custom_AugustTwoThousandTwentyOneMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1080" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210831__us-gaap--AwardDateAxis__custom--AugustTwoThousandTwentyOneMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkBYOHYNZdW" title="Exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-08-31_custom_AugustTwoThousandTwentyOneMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1081" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share from August 4, 2021 to August 4, 2025
and extended the expiration date of a warrant to purchase <span id="xdx_90C_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExtended_iI_c20210831__us-gaap--AwardDateAxis__custom--AugustTwoThousandTwentyOneMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdwiT0wJlbLk" title="Warrant to purchase common stock"><span><ix:nonfraction name="CLCS:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExtended" contextref="AsOf2021-08-31_custom_AugustTwoThousandTwentyOneMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1082" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">37,500</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210831__us-gaap--AwardDateAxis__custom--AugustTwoThousandTwentyOneMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjjkh00Ryct8" title="Exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-08-31_custom_AugustTwoThousandTwentyOneMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1083" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share from August 26, 2021 to August 26,
2025. The Company determined the transactions represented award modifications and recognized incremental expense of $<span id="xdx_904_ecustom--WarrantModificationExpense_c20210101__20211231__us-gaap--AwardDateAxis__custom--AugustTwoThousandTwentyOneMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9sCHXjdIuw2" title="Warrant modification expense."><span><ix:nonfraction name="CLCS:WarrantModificationExpense" contextref="From2021-01-012021-12-31_custom_AugustTwoThousandTwentyOneMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1084" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">29,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">within interest expense on the consolidated statement
of operations during the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2021, the Company
issued warrants to purchase an aggregate of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211231_zmlWBp6BQFyl" title="Warrant to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1085" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,792,426</ix:nonfraction></span></span> shares of common stock in connection with notes payable. See Note 8, <i>Notes Payable
</i>for additional details.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 4, <i>Fair Value</i> for details associated with warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-1086" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z7uBAKdhJ4ak" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the warrant activity during the year ended December 31, 2021 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<span id="xdx_8BA_zKaAuClcupk2" style="display: none">Schedule
of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Life</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">In
    Years</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif">Outstanding,
    January 1, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231_zvmXbECfOuq7" title="Number of Warrants, Outstanding, Beginning" style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1087" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,580,676</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20210101__20211231_zAePBUSKRW9h" title="Weighted Average Exercise Price, Outstanding, Beginning" style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1088" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.90</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231_z4qWI64uElA8" title="Number of Warrants, Issued" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1089" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,038,426</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zl3QGtMs0Ibg" title="Weighted Average Exercise Price, Isuued" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1090" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.24</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif">Warrant down round adjustment</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantDownRoundAdjustment_c20210101__20211231_zyPvcwdyDVuc" title="Number of Warrants, Warrant Down Round Adjustment" style="font-family: Times New Roman, Times, Serif; text-align: right"><span><ix:nonfraction name="CLCS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantDownRoundAdjustment" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1091" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,409</ix:nonfraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsWarrantDownRoundAdjustmentWeightedAverageExercisePrice_c20210101__20211231_zd64BdjAPNxd" title="Weighted Average Exercise Price, Warrant Down Round Adjustment" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1826"><span><ix:nonfraction name="CLCS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsWarrantDownRoundAdjustmentWeightedAverageExercisePrice" contextref="From2021-01-01to2021-12-31" id="fact-identifier-1092" unitref="USDPShares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1826" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&nbsp;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231_zL6AJRgNlE1a" title="Number of Warrants, Exercised" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1093" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">221,275</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_c20210101__20211231_zLvj1jFVAVVc" title="Weighted Average Exercise Price, Exercised" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1094" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.91</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Expired/Canceled</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20210101__20211231_zyKjl5lx34Gj" title="Number of Warrants, Expired/Cacelled" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1095" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">296,157</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredCacelledWeightedAverageExercisePrice_c20210101__20211231_z4i50ZFn8pBg" title="Weighted Average Exercise Price, Expired/Cacelled" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredCacelledWeightedAverageExercisePrice" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1096" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.75</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding,
    December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231_zTNlA70FEOa4" title="Number of Warrants, Outstanding, Ending" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1097" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,108,079</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20210101__20211231_zyGzUQBpuvg8" title="Weighted Average Exercise Price, Outstanding, Ending" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1098" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.02</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_zbIKtzeum4qb" title="Weighted Average Remaining Life (In Years), Outstanding" style="font-family: Times New Roman, Times, Serif"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="CLCS:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" inside-table="true" id="fact-identifier-1099" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4.3</ix:nonnumeric></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20210101__20211231_zFSCgBRdK62g" title="Intrinsic Value, Outstanding, Ending" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1842"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextref="AsOf2021-12-31" id="fact-identifier-1100" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1842" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercisable,
    December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20211231_zYgyTvTkNrBj" title="Number of Warrants, Exercisable" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1101" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">11,089,172</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20211231_zKNbjxl3oDZk" title="Weighted Average Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="CLCS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.02</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_zJ49YgqLAGC3" title="Weighted Average Remaining Life (In Years), Exercisable" style="font-family: Times New Roman, Times, Serif"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="CLCS:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm" inside-table="true" id="fact-identifier-1103" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4.3</ix:nonnumeric></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20210101__20211231_zFVVfF3ed7Id" title="Intrinsic Value, Exercisable, Ending" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1850"><span><ix:nonfraction name="CLCS:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" contextref="AsOf2021-12-31" id="fact-identifier-1104" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1850" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A0_zH45qi53JURc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_WarrantMember24401546" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-1105" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0OfURMjlGol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding outstanding and exercisable warrants at December 31, 2021 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8BE_zmx3hJ8o4Zai" style="display: none">Schedule
of Outstanding and Exercisable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Exercisable</td><td style="font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zOSLD820m6ml" title="Outstanding, Exercise Price" style="width: 22%; text-align: right"><span><ix:nonfraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextref="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1106" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zA9evNmPJB95" title="Outstanding, Outstanding Number Of Shares" style="width: 22%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextref="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1107" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,014,653</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 22%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBJQL22hauTk" title="Exercisable, Weighted Average Remaining Life (In Years)"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_WarrantMember_custom_ExercisePriceOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-1108" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.5</ix:nonnumeric></span></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_ze05uGeZBZH2" title="Exercisable, Outstanding Number Of Shares" style="width: 20%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextref="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1109" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,995,746</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zf1L85BYVkob" title="Outstanding, Exercise Price" style="text-align: right"><span><ix:nonfraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextref="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1110" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.95</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zg9ohfRxyeJg" title="Outstanding, Outstanding Number Of Shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextref="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1111" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zoEJ98mTV7k" title="Exercisable, Weighted Average Remaining Life (In Years)"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_WarrantMember_custom_ExercisePriceTwoMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-1112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.0</ix:nonnumeric></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z4bvzBfmE6Df" title="Exercisable, Outstanding Number Of Shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextref="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1113" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zqBVhDtPTvz3" title="Outstanding, Exercise Price" style="text-align: right"><span><ix:nonfraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextref="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zQY0hsnsHUx3" title="Outstanding, Outstanding Number Of Shares" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextref="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1115" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,968,426</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zU7DyKmb7xqc" title="Exercisable, Weighted Average Remaining Life (In Years)"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_WarrantMember_custom_ExercisePriceThreeMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-1116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.9</ix:nonnumeric></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zPXrbXmZaFyg" title="Exercisable, Outstanding Number Of Shares" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextref="AsOf2021-12-31_us-gaap_WarrantMember_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1117" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,968,426</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zC8G9TmP35Ia" title="Outstanding, Outstanding Number Of Shares" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextref="AsOf2021-12-31_us-gaap_WarrantMember24401984" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1118" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,108,079</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9nEEpu5Pr6a" title="Exercisable, Weighted Average Remaining Life (In Years)"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_WarrantMember24401546" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-1119" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.3</ix:nonnumeric></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOoFWS6ZmKl6" title="Exercisable, Outstanding Number Of Shares" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextref="AsOf2021-12-31_us-gaap_WarrantMember24401984" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1120" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,089,172</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table>


</ix:nonnumeric></span><p id="xdx_8AE_z9oPik2eAQkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stock
Options</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 19, 2020, the Company granted five-year immediately vested stock options to purchase an aggregate of <span id="xdx_90B_ecustom--StockOptionsToPurchaseCommonStock_iI_pp0d_c20200819_zhUoQtKv3jkl" title="Stock options to purchase common stock"><span><ix:nonfraction name="CLCS:StockOptionsToPurchaseCommonStock" contextref="AsOf2020-08-19" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-1121" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,050,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20200819_z8v5nhB5Xef4" title="Exercise price"><span><ix:nonfraction name="us-gaap:SharesIssuedPricePerShare" contextref="AsOf2020-08-19" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1122" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share to directors of the Company under the 2019 Equity Incentive Plan. The stock options had a grant date value of $<span id="xdx_902_ecustom--FairValueOfOption_iI_pp0p0_c20200819_z2mVHxHCF7vg" title="Fair value of option"><span><ix:nonfraction name="CLCS:FairValueOfOption" contextref="AsOf2020-08-19" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1123" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">103,600</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which was recognized immediately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 7, 2020, the Company granted five-year stock options to purchase <span id="xdx_900_ecustom--StockOptionsToPurchaseCommonStock_iI_pp0d_c20201007_zNMP7DLJoZ3l"><span><ix:nonfraction name="CLCS:StockOptionsToPurchaseCommonStock" contextref="AsOf2020-10-07" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-1124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">500,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at an exercise price of
$<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20201007_zZv5fL6elJI"><span><ix:nonfraction name="us-gaap:SharesIssuedPricePerShare" contextref="AsOf2020-10-07" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1125" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.00</ix:nonfraction></span></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share to a director of CSL. The shares vest ratably over two years from the date of grant. The stock options had a grant date fair value
of $<span id="xdx_903_ecustom--FairValueOfOption_iI_pp0p0_c20201007_zwhvqDaYXYF4"><span><ix:nonfraction name="CLCS:FairValueOfOption" contextref="AsOf2020-10-07" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1126" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">97,600</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. During the year ended December 31, 2021, the option was forfeited prior to vesting
and, accordingly, the Company recognized a forfeiture credit during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2021, the Company granted <span id="xdx_901_ecustom--StockOptionsToPurchaseCommonStock_iI_pp0d_c20210308_zbMlteseQfC3" title="Stock options to granted common stock"><span><ix:nonfraction name="CLCS:StockOptionsToPurchaseCommonStock" contextref="AsOf2021-03-08" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-1127" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,350,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">five-year immediately vested options under the
Company’s Equity Incentive Plan to the Chief Executive Offer of the Company (of which, <span id="xdx_900_ecustom--StockOptionsToPurchaseCommonStock_iI_pp0d_c20210308__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zt3H3TmD26N5" title="Vested stock option granted, shares"><span><ix:nonfraction name="CLCS:StockOptionsToPurchaseCommonStock" contextref="AsOf2021-03-08_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-1128" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">750,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were granted for service as Chief Executive Officer
and <span id="xdx_90D_ecustom--StockOptionsToPurchaseCommonStock_iI_pp0d_c20210308__srt--TitleOfIndividualAxis__srt--DirectorMember_zPEzoreDMqT5" title="Vested stock option granted, shares"><span><ix:nonfraction name="CLCS:StockOptionsToPurchaseCommonStock" contextref="AsOf2021-03-08_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-1129" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">600,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were granted for service as a director) with
an exercise price $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pp0d_c20210308_zoKmdShPiKF9" title="Exercise price"><span><ix:nonfraction name="us-gaap:SharesIssuedPricePerShare" contextref="AsOf2021-03-08" format="ixt:numdotdecimal" decimals="0" unitref="USDPShares" inside-table="false" id="fact-identifier-1130" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.00</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The options had a grant date fair
value of $<span id="xdx_90F_ecustom--FairValueOfOption_iI_pp0p0_c20211231_znvj0QYTlLY5" title="Fair value of option"><span><ix:nonfraction name="CLCS:FairValueOfOption" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1131" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">218,600</ix:nonfraction></span></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which
was recognized during the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-1132" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zMIWXVMIbYAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B4_zmSE0UVajJU" style="display: none">Schedule
of Stock Options Assumption Used</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td style="text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="text-align: center; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td style="text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td style="text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; font-weight: bold">&nbsp;</td><td style="text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td><td style="text-align: center">&nbsp;</td><td style="text-align: center">&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td><td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 20%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfTcymZK7cKi" title="Risk-free interest rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-1133" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.26</ix:nonfraction></span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 20%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIIn9XsdmHP3" title="Risk-free interest rate" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2020-01-012020-12-31_srt_MinimumMember_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-1134" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.15</ix:nonfraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIxYBVrYEV7j" title="Risk-free interest rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2020-01-012020-12-31_srt_MaximumMember_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-1135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.21</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbZV63fTkhI" title="Expected term (years)"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-1136" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.50</ix:nonnumeric></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdSphAhAI0Ug" title="Expected term (years)" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonnumeric contextref="From2020-01-012020-12-31_srt_MinimumMember_us-gaap_StockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-1137" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.50</ix:nonnumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOglNEaPUsY4" title="Expected term (years)"><span><ix:nonnumeric contextref="From2020-01-012020-12-31_srt_MaximumMember_us-gaap_StockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-1138" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.18</ix:nonnumeric></span></span></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZR5tlp9Wk6h" title="Expected volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-1139" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90</ix:nonfraction></span></span></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKS2xatdMPq9" title="Expected volatility" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2020-01-012020-12-31_srt_MinimumMember_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-1140" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90</ix:nonfraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0s7gb95OJee" title="Expected volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2020-01-012020-12-31_srt_MaximumMember_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-1141" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">110</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znckNVnqYi38" title="Expected dividends"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-1142" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.00</ix:nonfraction></span></span></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zr4mVaStJ7r3" title="Expected dividends"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextref="From2020-01-012020-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-1143" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.00</ix:nonfraction></span></span></td><td style="text-align: left">%</td></tr>
  </tbody></table>


</ix:nonnumeric></span><p id="xdx_8AA_znf6hFrpUnW4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected term used is the contractual life of the instrument being valued. Since the Company’s stock has not been publicly traded
for a sufficiently long period of time or with significant volume, the Company is utilizing an expected volatility based on a review
of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned
public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon
bonds with a remaining term consistent with the expected term of the instrument being valued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average estimated grant date fair value of the stock options granted for the year ended December 31, 2021 and 2020 was approximately
$<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231_z9NBOt4kKSf6" title="Weighted average estimated grant date fair value"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1144" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.16</ix:nonfraction></span></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231_zxqXHFmhh79h" title="Weighted average estimated grant date fair value"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1145" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.13</ix:nonfraction></span></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-1146" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zKJlcK4Qim25" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the option activity during the year ended December 31, 2021 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<span id="xdx_8BC_zvGqThNkVfn2" style="display: none">Summary
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Life</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">In
    Years</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif">Outstanding,
    January 1, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zz0je1URBNLb" title="Number of Options, Outstanding, Beginning" style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1147" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,332,004</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zVOopxV2pVZ2" title="Weighted Average Exercise Price, Outstanding, Beginning" style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1148" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.77</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_zKLpWZ4ySW1i" title="Number of Options, Granted" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1149" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,350,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zE6skQomWfzk" title="Weighted Average Exercise Price, Granted" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1150" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.00</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210101__20211231_zGb5vEGT7pe6" title="Number of Options, Exercised" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1941"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2021-01-01to2021-12-31" id="fact-identifier-1151" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1941" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zrdWlL4EQ09k" title="Weighted Average Exercise Price, Exercised" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1943"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextref="From2021-01-01to2021-12-31" id="fact-identifier-1152" unitref="USDPShares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1943" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Expired/forfeited</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20210101__20211231_z5o30DhO5sP1" title="Number of Options, Expired/forfeited" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1153" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zdbb6kwaxebc" title="Weighted Average Exercise Price, Expired/forfeited" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1154" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.00</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding,
    December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20211231_zi2m7EdJg4vk" title="Number of Options, Outstanding, Ending" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1155" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,182,004</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zlG3NzshyT9" title="Weighted Average Exercise Price, Outstanding, Ending" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1156" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.80</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zcn6XS2glsm6" title="Weighted Average Remaining Life (In Years), Outstanding" style="font-family: Times New Roman, Times, Serif"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-1157" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.2</ix:nonnumeric></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231_zel68evxHfI5" title="Intrinsic Value, Outstanding, Ending" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1955"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextref="AsOf2021-12-31" id="fact-identifier-1158" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1955" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercisable,
    December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20210101__20211231_zqZwfAwDWMvl" title="Number of Options, Exercisable, Ending" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1159" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,182,004</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zc1JIF1cS1j7" title="Weighted Average Exercise Price, Exercisable, Beginning" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1160" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.80</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_z2Kh2b2X8oJ3" title="Weighted Average Remaining Life (In Years), Exercisable" style="font-family: Times New Roman, Times, Serif"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" inside-table="true" id="fact-identifier-1161" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.2</ix:nonnumeric></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20210101__20211231_zSoZDzwHuNc9" title="Intrinsic Value, Exercisable, Ending" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1963"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextref="AsOf2021-12-31" id="fact-identifier-1162" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1963" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A2_zf9ocD6zXTLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_StockOptionsMember24401578" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-1163" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zPEsUYhwZtkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding outstanding and exercisable options at December 31, 2021 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B4_zeHNHVxbikX3" style="display: none">Schedule
of Outstanding and Exercisable</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tbody><tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options
    Outstanding</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options
    Exercisable</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining
    Life</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Option</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">In
    Years</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zTC7c1QFl2gf" title="Outstanding, Exercise Price" style="font-family: Times New Roman, Times, Serif; width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextref="AsOf2021-12-31_custom_StockOptionsMember_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1164" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z9L8ADyvNKKj" title="Outstanding, Outstanding Number Of Shares" style="font-family: Times New Roman, Times, Serif; width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextref="AsOf2021-12-31_custom_StockOptionsMember_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1165" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,832,004</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 22%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6SulHk2iBV2" title="Exercisable, Weighted Average Remaining Life (In Years)" style="font-family: Times New Roman, Times, Serif"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_StockOptionsMember_custom_ExercisePriceOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-1166" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.7</ix:nonnumeric></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zgvxPLztsN9i" title="Exercisable, Outstanding Number Of Shares" style="font-family: Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextref="AsOf2021-12-31_custom_StockOptionsMember_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1167" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,832,004</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ziXZ6NL5xvSf" title="Outstanding, Exercise Price" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextref="AsOf2021-12-31_custom_StockOptionsMember_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-1168" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.00</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z01VJEPOgDu6" title="Outstanding, Outstanding Number Of Shares" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextref="AsOf2021-12-31_custom_StockOptionsMember_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1169" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,350,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zVgRS4bDMXyd" title="Exercisable, Weighted Average Remaining Life (In Years)" style="font-family: Times New Roman, Times, Serif"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_StockOptionsMember_custom_ExercisePriceTwoMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-1170" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.2</ix:nonnumeric></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ze36lXFzMsIj" title="Exercisable, Outstanding Number Of Shares" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextref="AsOf2021-12-31_custom_StockOptionsMember_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1171" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,350,000</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zauh0jDhL88f" title="Outstanding, Outstanding Number Of Shares" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextref="AsOf2021-12-31_custom_StockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1172" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,182,004</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zHzd0n9LJPTg" title="Exercisable, Weighted Average Remaining Life (In Years)" style="font-family: Times New Roman, Times, Serif"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_StockOptionsMember24401578" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-1173" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.2</ix:nonnumeric></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zPtdT4arwCHj" title="Exercisable, Outstanding Number Of Shares" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextref="AsOf2021-12-31_custom_StockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-1174" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,182,004</ix:nonfraction></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></td></tr>
  </tbody></table>
<!-- Field: Split-Segment; Name: 003 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

</ix:nonnumeric></span></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-1175" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zCeXOJQCuBnb" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
11 – <span id="xdx_824_zJv071B28KGk">Commitments and Contingencies</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Yeda
Research and License Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2011, the Company entered into a Research and License Agreement (the “Agreement”) with Yeda Research and Development
Company Limited (“Yeda”) for Veto Cell technology and an exclusive option to negotiate an additional license for organ regeneration
technology. Yeda is the technology transfer and commercial arm of the Weizmann Institute, for research conducted at the Weizmann Institute
for an invention comprising methods of bone marrow transplantation and cell therapy utilizing Veto Cells. As Yeda is a founder and a
significant shareholder of the Company, it is a related party. If the Company fails to achieve any of the milestones by the dates set
forth in the Agreement, Yeda is entitled to terminate the license upon written notice to the Company. In December, 2021, the Company
and Yeda amended the agreement to extend the next milestone to January 1, 2025. To date, the Company has been deemed to have met all
of the milestones. Either Yeda or the Company may terminate the agreement and the license after the commitment of a material breach by
the other party and in certain other instances as detailed in the agreement. Through December 31, 2021, the Company has made all required
payments under the terms of the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company paid Yeda a total of $<span id="xdx_90D_ecustom--BudgetReserchExpense_iI_c20211231__us-gaap--RelatedPartyTransactionAxis__custom--YedaMember_zYOKG97BTFmd"><span><ix:nonfraction name="CLCS:BudgetReserchExpense" contextref="AsOf2021-12-31_custom_YedaMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1176" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">243,500</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90D_ecustom--BudgetReserchExpense_iI_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--YedaMember_zUHdtk8rJs31"><span><ix:nonfraction name="CLCS:BudgetReserchExpense" contextref="AsOf2020-12-31_custom_YedaMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1177" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">165,282</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">during the years ended December 31, 2021 and
2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021 and 2020, the Company recorded research and development expenses of approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--YedaResearchAndLicenseAgreementMember_z9l86bvOwOw4" title="Research and development expenses"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2021-01-012021-12-31_custom_YedaResearchAndLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1178" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--YedaResearchAndLicenseAgreementMember_zonr8Udj2uK9" title="Research and development expenses"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2020-01-012020-12-31_custom_YedaResearchAndLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1179" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">164,000</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, related to the Agreement. As of December 31, 2021 and 2020, the Company had $<span id="xdx_903_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20211231__us-gaap--TypeOfArrangementAxis__custom--YedaResearchAndLicenseAgreementMember_zrckRACvkRhf" title="Accrued research and development expenses"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2021-12-31_custom_YedaResearchAndLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1180" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_900_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20201231__us-gaap--TypeOfArrangementAxis__custom--YedaResearchAndLicenseAgreementMember_zKN4sMU0Ai58" title="Accrued research and development expenses"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2020-12-31_custom_YedaResearchAndLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1181" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">136,919</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, of accrued research and development expenses pursuant to the Agreement with Yeda, which are included within accrued
expenses on the consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">MD
Anderson Sponsored Research Agreements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 28, 2018, the Company entered into a Sponsored Research Agreement with The University of Texas M.D. Anderson Cancer Center (“MD
Anderson”) for a research study in the area of stem cells. The Sponsored Research Agreement shall be for three years and can be
extended by mutual written agreement. The Company committed to engage MD Anderson to perform research services in the amount of approximately
$<span id="xdx_906_ecustom--AmountPayableForResearchServices_iI_pp0p0_c20181128__us-gaap--PlanNameAxis__custom--SponsoredResearchAgreementMember__us-gaap--AwardDateAxis__custom--FromJanuaryOneTwoThousandNineteenToDecemberThirtyOneTwoThousandTwentyOneMember_zAe6JhLULG18"><span><ix:nonfraction name="CLCS:AmountPayableForResearchServices" contextref="AsOf2018-11-28_custom_SponsoredResearchAgreementMember_custom_FromJanuaryOneTwoThousandNineteenToDecemberThirtyOneTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1182" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,500,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from January 1, 2019 to December 31, 2021 (approximately
$<span id="xdx_904_ecustom--BudgetReserchExpense_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementMember__srt--RangeAxis__srt--MinimumMember_zRlq0ohnZYy8"><span><ix:nonfraction name="CLCS:BudgetReserchExpense" contextref="AsOf2021-12-31_custom_SponsoredResearchAgreementMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1183" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">500,000</ix:nonfraction></span>
</span></span><span id="xdx_902_ecustom--DescriptionOfAmountPayableForResearch_c20210101__20211231__us-gaap--PlanNameAxis__custom--SponsoredResearchAgreementMember__us-gaap--AwardDateAxis__custom--FromJanuaryOneTwoThousandNineteenToDecemberThirtyOneTwoThousandTwentyOneMember_zisOexOMrdSk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_SponsoredResearchAgreementMember_custom_FromJanuaryOneTwoThousandNineteenToDecemberThirtyOneTwoThousandTwentyOneMember" name="CLCS:DescriptionOfAmountPayableForResearch" inside-table="false" id="fact-identifier-1184" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">each
year for three years). The Sponsored Research Agreement was amended on December 2, 2020 in order to increase the research budget for
the year ending December 31, 2021 from approximately $</ix:nonnumeric></span></span><span id="xdx_904_ecustom--BudgetReserchExpense_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementMember__srt--RangeAxis__srt--MinimumMember_zynIT1DdI92" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><ix:nonfraction name="CLCS:BudgetReserchExpense" contextref="AsOf2021-12-31_custom_SponsoredResearchAgreementMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1185" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">500,000</ix:nonfraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to $<span id="xdx_904_ecustom--BudgetReserchExpense_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementMember__srt--RangeAxis__srt--MaximumMember_zw7yYpQBU9l4"><span><ix:nonfraction name="CLCS:BudgetReserchExpense" contextref="AsOf2021-12-31_custom_SponsoredResearchAgreementMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1186" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">800,000</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
In October 2021, the Sponsored Research Agreement was amended to extend the agreement by one year to November 27, 2022
and define the budget during such one-year period to be approximately $<span id="xdx_908_ecustom--BudgetReserchExpense_iI_c20211231__us-gaap--PlanNameAxis__custom--SponsoredResearchAgreementMember_zjzkFG7C80Tk"><span><ix:nonfraction name="CLCS:BudgetReserchExpense" contextref="AsOf2021-12-31_custom_SponsoredResearchAgreementMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1187" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,300,000</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sponsored Research Agreement may be terminated: (a) immediately by the written agreement of both parties; (b) by the Company at the end
of each twelve month period following the commencement of the study, with sixty days’ notice to MD Anderson; (c) by MD Anderson
for health, safety or regulatory reasons or if the Company breaches this Agreement and fails to cure such breach within fifteen business
days of notice of such breach by MD Anderson; or (d) immediately by either party if at any time the Principal Investigator becomes unable
to conduct the study, and the parties cannot agree upon a mutually acceptable successor to the Principal Investigator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 19, 2019, the Company entered into an agreement, which was amended on April 4, 2019 and August 13, 2019, with MD Anderson for the latter to perform cell production and conduct Phase 1/2 human
clinical trials. In connection with that agreement, the Company committed to fund such work in the amount of approximately $<span id="xdx_90D_ecustom--AmountPayableUnderAgreement_iI_pp0p0_c20211231__srt--TitleOfIndividualAxis__custom--MDAndersonMember_zCtCGYMz82Ie" title="Amount payable under agreement"><span><ix:nonfraction name="CLCS:AmountPayableUnderAgreement" contextref="AsOf2021-12-31_custom_MDAndersonMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1188" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,038,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">over a two-year period beginning that same date,
with payments becoming due as certain specified milestones are met by MD Anderson.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--MDAndersonSponsoredResearchAgreementsMember_zNfrEGUo3qod" title="Research and development expense"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2021-01-012021-12-31_custom_MDAndersonSponsoredResearchAgreementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1189" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,126,685</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--MDAndersonSponsoredResearchAgreementsMember_znb8bnqJ7TMg" title="Research and development expense"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2020-01-012020-12-31_custom_MDAndersonSponsoredResearchAgreementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1190" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">724,943</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of research and development expenses during the
years ended December 31, 2021 and 2020, respectively, associated with services provided by MD Anderson, under the two agreements dated
November 2018 and February 2019. As of December 31, 2021, the Company had $<span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20211231__us-gaap--TypeOfArrangementAxis__custom--MDAndersonSponsoredResearchAgreementsMember_zVqA4zYi1orf" title="Accrued liabilities current"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2021-12-31_custom_MDAndersonSponsoredResearchAgreementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1191" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">411,773</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of accrued research and development expenses
pursuant to the agreements with MD Anderson, which are included within accrued expenses on the consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Litigation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but
which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities,
and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are
pending against the Company, or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of
any legal proceedings or unasserted claims, as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability
can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment
indicates that a potential material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated,
then the nature of the contingent liability and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2019, the holder of a promissory note in the principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20190131_zWrVPxYGUFH7" title="Debt instrument face amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2019-01-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1192" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">250,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">due on <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20190101__20190131_z1cAY5OG9EYc" title="Debt instrument maturity date"><span><ix:nonnumeric contextref="From2019-01-012019-01-31" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="false" id="fact-identifier-1193" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">March
16, 2016</ix:nonnumeric></span></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">instituted a collection action in the
Supreme Court of the State of New York, County of New York. On June 12, 2019, the plaintiff served a motion for summary judgment through
the Secretary of State which was heard on July 12, 2019 and granted. The Company contends that it was not given sufficient notice under
the applicable statute and did not have an opportunity to oppose the motion. Judgment was entered in October 2019 in the amount of $<span id="xdx_901_eus-gaap--LitigationSettlementAmountAwardedFromOtherParty_pp0p0_c20191001__20191031_zv1XB7DKSJTb" title="Litigation settlement, amount awarded from other party"><span><ix:nonfraction name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" contextref="From2019-10-012019-10-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1194" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">267,680</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company brought a motion to vacate based on the jurisdictional defect of the motion in not providing the required amount of time,
but that motion was denied in February 2021 without properly addressing the jurisdictional issues raised by the Company. The Company
has appealed the denial and then filed a motion to Renew and Reargue the motion to vacate based on the Court’s failure to address
critical issues. That motion was also denied on April 15, 2021 without addressing the Company’s arguments. The Company has appealed
the second denial as well and is pursuing both appeals in a consolidated manner so as to resolve all issues together. While the Company’s
motions were pending, the plaintiff has commenced steps to collect judgment. During the year ended December 31, 2021, $<span id="xdx_906_eus-gaap--RepaymentsOfNotesPayable_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--CourtOfficerMember_zsvkNzIzvUfl" title="Repayments of notes payable"><span><ix:nonfraction name="us-gaap:RepaymentsOfNotesPayable" contextref="From2021-01-012021-12-31_custom_CourtOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1195" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">103,088</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was released to an officer of the court and has
been accounted for as partial note repayment, such that, as of December 31, 2021, there was $<span id="xdx_909_eus-gaap--RepaymentsOfRelatedPartyDebt_pp0p0_c20210101__20211231_zwzkG82lzCUb" title="Repayments of related party debt"><span><ix:nonfraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1196" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">146,912</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding under the note. During the year ended
December 31, 2021, on behalf of the Company, a third party deposited the full amount of the unpaid judgment with the court, which created
an automatic stay of enforcement of this matter and which will be used to resolve the underlying note in the event of an adverse outcome
on appeal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
contingencies considered remote are generally not disclosed, unless they involve guarantees, in which case the guarantees would be disclosed.
There can be no assurance that such matters will not materially and adversely affect the Company’s business, financial position,
and results of operations or cash flows. As of December 31, 2021 and 2020, the Company had not accrued any amounts for contingencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-1197" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_znycUHxBBBji" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
12 – <span id="xdx_824_ztDiUGUgLe32">Related Party Transactions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 8, <i>Notes Payable</i> for details associated
with the issuance of a convertible note payable, the Soave Note, to a director of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and 2020, the Company was required to issue warrants to purchase an aggregate of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231__srt--TitleOfIndividualAxis__srt--DirectorMember_zzu0mXinM6F2" title="Warrants purchase for common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2021-12-31_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1198" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,356,500</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201231__srt--TitleOfIndividualAxis__srt--DirectorMember_zb4Ek32VGjx5" title="Warrants purchase for common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2020-12-31_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1199" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,056,500</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, shares of common stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__srt--TitleOfIndividualAxis__srt--DirectorMember_zvqlh4WEZohi" title="Warrant exercise price per share"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-12-31_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1200" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to directors of the Company in connection
with loans made to the Company in the aggregate amount of $<span id="xdx_908_ecustom--LoanPenaltiesAmount_iI_pp0p0_c20211231__srt--TitleOfIndividualAxis__srt--DirectorMember_zUcVDnthv5nf" title="Loan amount"><span><ix:nonfraction name="CLCS:LoanPenaltiesAmount" contextref="AsOf2021-12-31_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1201" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">459,000</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which required certain penalties in the form
of warrants. As a result, the Company had accrued $<span id="xdx_904_ecustom--FairValueOfAccruedLoanObligations_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__srt--DirectorMember_zFweOnJRpvTa" title="Accrued interest - related parties"><span><ix:nonfraction name="CLCS:FairValueOfAccruedLoanObligations" contextref="From2021-01-012021-12-31_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1202" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">249,389</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_903_ecustom--FairValueOfAccruedLoanObligations_pp0p0_c20200101__20201231__srt--TitleOfIndividualAxis__srt--DirectorMember_zg3044iBHd16" title="Accrued interest - related parties"><span><ix:nonfraction name="CLCS:FairValueOfAccruedLoanObligations" contextref="From2020-01-012020-12-31_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-1203" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">291,708</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">associated with the fair value of the obligations
as of December 31, 2021 and 2020, respectively, which amount is included in accrued interest – related parties on the consolidated
balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-1204" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_z3CLypj2r662" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
13 – <span id="xdx_82E_zo2WJhO1imq3">Subsequent Events</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Notes Payable Conversions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, an aggregate of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8GQJBrHrTga"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2022-03-31_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1205" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,375,698</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of principal outstanding under convertible
notes automatically converted into an aggregate of <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20220328__20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXPnE5fDpOhd"><span><ix:nonfraction name="us-gaap:ConversionOfStockSharesConverted1" contextref="From2022-03-282022-03-31_custom_SeriesCConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1206" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">183,422</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series C Convertible Preferred
Stock and the Company elected to convert an aggregate of $<span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zc41Nd183Po"><span><ix:nonfraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextref="AsOf2022-03-31_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1207" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57,399</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of interest accrued under such notes into
an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220328__20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zosrY43er5o"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2022-03-282022-03-31_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1208" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">76,530</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. The aggregate note
principal had a conversion price of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEKAJsIJmgad"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2022-03-31_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1209" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and the common stock was valued at
$<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMXnxEe5sCIb"><span><ix:nonfraction name="us-gaap:SharesIssuedPricePerShare" contextref="AsOf2022-03-31_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1210" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share for purposes of the interest payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 8, <i>Notes Payable </i>for details associated with past due notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Notes Payable and Appointment of Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 10, 2022, the Board of Directors of the Company appointed George Verstraete as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Verstraete agreed to make a loan of $<span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_c20220310__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MrVerstraeteMember_zWJwjl5eLh8b"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayable" contextref="AsOf2022-03-10_us-gaap_SubsequentEventMember_custom_MrVerstraeteMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1211" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,000,000</ix:nonfraction></span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
the Company pursuant to the terms of a convertible promissory note dated March 10, 2022. The note bears interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20220310__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MrVerstraeteMember_zJA54EwoKRS8"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextref="AsOf2022-03-10_us-gaap_SubsequentEventMember_custom_MrVerstraeteMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-1212" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
per annum and will mature twelve months from the date of issuance. The holder of the note has the right, at his option, to convert
the note into shares of the Company’s Series B Convertible Preferred Stock at a conversion price of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220310__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MrVerstraeteMember_zmOJUw3kybqa"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2022-03-10_us-gaap_SubsequentEventMember_custom_MrVerstraeteMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1213" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share at any time after the creation and sale of the Series B Convertible Preferred Stock. Interest accruing under the note will be
payable upon the maturity of the note and may be paid at the Company’s option in either cash or shares of the Company’s
common stock (calculated based upon $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20220310__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MrVerstraeteMember_z9SWOEO76eF2" title="Share price"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2022-03-10_us-gaap_SubsequentEventMember_custom_MrVerstraeteMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1214" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span></span> per share for purposes of calculating the number of shares of common stock to be
issued). </span>For each $<span id="xdx_90F_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220310__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MrVerstraeteMember_zBR0xO4GQBL9"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayableCurrent" contextref="AsOf2022-03-10_us-gaap_SubsequentEventMember_custom_MrVerstraeteMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1215" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advanced
under the note, Mr. Verstraete will be issued a warrant to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220310__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MrVerstraeteMember_zDVayh7UfRZ6"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2022-03-10_us-gaap_SubsequentEventMember_custom_MrVerstraeteMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1216" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">400,000</ix:nonfraction></span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of the Company’s Common Stock at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220310__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MrVerstraeteMember_zdwKHlpCBTI8"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2022-03-10_us-gaap_SubsequentEventMember_custom_MrVerstraeteMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1217" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. Each warrant will have a five year term. As of the date of filing, Mr. Verstraete had advanced $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20220415__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MrVerstraeteMember_z7gqzRDfXia9"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayableCurrent" contextref="AsOf2022-04-15_us-gaap_SubsequentEventMember_custom_MrVerstraeteMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1218" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,000,000</ix:nonfraction></span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
the note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to December 31, 2021, the Company issued aggregate convertible notes payable in the aggregate principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20220415__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zI4Qe1YOxig6" title="Principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2022-04-15_us-gaap_SubsequentEventMember_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-1219" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">245,000</ix:nonfraction></span></span> which have
maturity dates ranging from <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20220415__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zDsdy6x10kCk" title="Debt maturity date description"><span><ix:nonnumeric contextref="From2022-01-012022-04-15_us-gaap_SubsequentEventMember_us-gaap_ConvertibleNotesPayableMember" name="us-gaap:DebtInstrumentMaturityDateDescription" inside-table="false" id="fact-identifier-1220" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">August 2, 2022 through September 23, 2022</ix:nonnumeric></span></span>. The notes accrue interest at <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20220415__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zbz9JPdGuVb6" title="Interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2022-04-15_us-gaap_SubsequentEventMember_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-1221" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span></span>% per annum and are convertible
at any time at the option of the holder into the Company’s Series C Convertible Preferred Stock at a conversion price of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220415__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z0N8wqtO1I25" title="Conversion price per share"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2022-04-15_us-gaap_SubsequentEventMember_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1222" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.50</ix:nonfraction></span></span>
per share. The notes automatically convert into Series C Convertible Preferred Stock on the maturity date. In connection with the issuances,
the Company issued five-year immediately vested warrants to purchase an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220415__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z41iIgfh5P36" title="Warrants to purchase common stock"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2022-04-15_us-gaap_SubsequentEventMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-1223" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">196,000</ix:nonfraction></span></span> shares of common stock at an exercise price
$<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220415__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUXlNa1DTMkc" title="Warrants exercise price"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2022-04-15_us-gaap_SubsequentEventMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-1224" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.25</ix:nonfraction></span></span> per share.&nbsp;</span></p>

</ix:nonnumeric></span><p id="xdx_813_zc2u2lmPH9Z8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p>


<!-- Field: Page; Sequence: 100; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



</body>
</html>